{"PMC6402421": [["IntroductionThe porcine hemagglutinating encephalomyelitis virus (PHEV) is the causative agent of neurological and/or digestive disease in pigs.", [["neurological", "ANATOMY", 98, 110], ["digestive", "ANATOMY", 118, 127], ["porcine hemagglutinating encephalomyelitis", "DISEASE", 16, 58], ["neurological and/or digestive disease", "DISEASE", 98, 135], ["porcine hemagglutinating encephalomyelitis virus", "ORGANISM", 16, 64], ["PHEV", "ORGANISM", 66, 70], ["digestive", "ORGAN", 118, 127], ["pigs", "ORGANISM", 139, 143], ["porcine hemagglutinating encephalomyelitis virus", "SPECIES", 16, 64], ["pigs", "SPECIES", 139, 143], ["porcine hemagglutinating encephalomyelitis virus", "SPECIES", 16, 64], ["PHEV", "SPECIES", 66, 70], ["pigs", "SPECIES", 139, 143], ["The porcine hemagglutinating encephalomyelitis virus", "TREATMENT", 12, 64], ["digestive disease in pigs", "PROBLEM", 118, 143], ["porcine", "OBSERVATION_MODIFIER", 16, 23], ["hemagglutinating", "OBSERVATION_MODIFIER", 24, 40], ["encephalomyelitis", "OBSERVATION", 41, 58], ["digestive", "ANATOMY", 118, 127], ["disease", "OBSERVATION", 128, 135]]], ["PHEV was one of the first swine coronaviruses identified and isolated, and the only known neurotropic virus that affects pigs.", [["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["coronaviruses", "ORGANISM", 32, 45], ["neurotropic virus", "ORGANISM", 90, 107], ["pigs", "ORGANISM", 121, 125], ["swine", "SPECIES", 26, 31], ["pigs", "SPECIES", 121, 125], ["PHEV", "SPECIES", 0, 4], ["swine coronaviruses", "SPECIES", 26, 45], ["pigs", "SPECIES", 121, 125], ["the first swine coronaviruses", "PROBLEM", 16, 45], ["known neurotropic virus", "PROBLEM", 84, 107], ["neurotropic virus", "OBSERVATION", 90, 107]]], ["However, PHEV remains among the least studied of the swine coronaviruses because of its low clinical prevalence reported in the swine industry worldwide.", [["PHEV", "CHEMICAL", 9, 13], ["swine coronaviruses", "ORGANISM", 53, 72], ["swine", "SPECIES", 53, 58], ["swine", "SPECIES", 128, 133], ["PHEV", "SPECIES", 9, 13], ["swine coronaviruses", "SPECIES", 53, 72], ["swine", "SPECIES", 128, 133], ["PHEV", "TEST", 9, 13], ["the swine coronaviruses", "PROBLEM", 49, 72]]], ["PHEV can infect na\u00efve pigs of any age, but clinical disease is age-dependent.", [["PHEV", "CHEMICAL", 0, 4], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 22, 26], ["pigs", "SPECIES", 22, 26], ["PHEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 22, 26], ["clinical disease", "PROBLEM", 43, 59]]], ["Clinical manifestations, including vomiting and wasting and/or neurological signs, are age-related, and generally reported only in piglets under 4 weeks old.", [["neurological", "ANATOMY", 63, 75], ["vomiting", "DISEASE", 35, 43], ["wasting", "DISEASE", 48, 55], ["piglets", "ORGANISM", 131, 138], ["piglets", "SPECIES", 131, 138], ["Clinical manifestations", "PROBLEM", 0, 23], ["vomiting", "PROBLEM", 35, 43], ["wasting", "PROBLEM", 48, 55], ["neurological signs", "PROBLEM", 63, 81]]], ["Subclinical circulation of PHEV has been reported nearly worldwide in association with a high seroprevalence in swine herds.", [["PHEV", "CHEMICAL", 27, 31], ["PHEV", "GENE_OR_GENE_PRODUCT", 27, 31], ["PHEV", "PROTEIN", 27, 31], ["swine", "SPECIES", 112, 117], ["PHEV", "SPECIES", 27, 31], ["swine", "SPECIES", 112, 117], ["Subclinical circulation of PHEV", "PROBLEM", 0, 31]]], ["Protection from the disease could be provided through lactogenic immunity transferred from PHEV seropositive sows to their offspring in enzootically infected herds.", [["enzootically infected", "DISEASE", 136, 157], ["sows", "ORGANISM", 109, 113], ["PHEV", "SPECIES", 91, 95], ["Protection", "TREATMENT", 0, 10], ["the disease", "PROBLEM", 16, 27], ["disease", "OBSERVATION", 20, 27]]], ["However, PHEV still constitutes a potential threat to herds of high-health gilts, as evidenced by different outbreaks of vomiting and wasting syndrome and encephalomyelitis reported in neonatal pigs born from na\u00efve sows, with mortality rates reaching 100%.", [["PHEV", "CHEMICAL", 9, 13], ["vomiting", "DISEASE", 121, 129], ["wasting syndrome", "DISEASE", 134, 150], ["encephalomyelitis", "DISEASE", 155, 172], ["gilts", "ORGANISM", 75, 80], ["pigs", "ORGANISM", 194, 198], ["sows", "ORGANISM", 215, 219], ["pigs", "SPECIES", 194, 198], ["PHEV", "SPECIES", 9, 13], ["pigs", "SPECIES", 194, 198], ["vomiting", "PROBLEM", 121, 129], ["wasting syndrome", "PROBLEM", 134, 150], ["encephalomyelitis", "PROBLEM", 155, 172], ["mortality rates", "TEST", 226, 241], ["wasting syndrome", "OBSERVATION", 134, 150], ["encephalomyelitis", "OBSERVATION", 155, 172]]], ["In absence of effective vaccine, the best practice for preventing clinical disease in suckling piglets could be ensuring that gilts and sows are PHEV seropositive prior to farrowing.Taxonomy, Genomic Structure, and MorphologyCoronaviruses (CoVs) belong to the Nidovirales order, which includes the Coronaviridae, Arteriviridae, and Roniviridae families.", [["PHEV", "CHEMICAL", 145, 149], ["piglets", "ORGANISM", 95, 102], ["gilts", "ORGANISM", 126, 131], ["sows", "ORGANISM", 136, 140], ["MorphologyCoronaviruses", "GENE_OR_GENE_PRODUCT", 215, 238], ["CoVs", "GENE_OR_GENE_PRODUCT", 240, 244], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 313, 326], ["Roniviridae", "GENE_OR_GENE_PRODUCT", 332, 343], ["MorphologyCoronaviruses", "PROTEIN", 215, 238], ["CoVs", "PROTEIN", 240, 244], ["piglets", "SPECIES", 95, 102], ["PHEV", "SPECIES", 145, 149], ["effective vaccine", "TREATMENT", 14, 31], ["clinical disease in suckling piglets", "PROBLEM", 66, 102], ["PHEV seropositive", "PROBLEM", 145, 162], ["Genomic Structure", "PROBLEM", 192, 209], ["MorphologyCoronaviruses (CoVs)", "PROBLEM", 215, 245], ["the Coronaviridae", "TREATMENT", 294, 311], ["Arteriviridae", "TREATMENT", 313, 326], ["Genomic Structure", "OBSERVATION", 192, 209]]], ["The subfamily Cornavirinae is further divided into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus.", [["Cornavirinae", "GENE_OR_GENE_PRODUCT", 14, 26], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 64, 80], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 82, 97], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 99, 115], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 121, 137], ["The subfamily Cornavirinae", "TREATMENT", 0, 26], ["Alphacoronavirus", "TREATMENT", 64, 80], ["Betacoronavirus", "TREATMENT", 82, 97], ["Gammacoronavirus", "TREATMENT", 99, 115], ["Deltacoronavirus", "TREATMENT", 121, 137]]], ["Coronaviruses are enveloped and pleomorphic positive-sense RNA viruses, characterized by club-like spikes projected from their surface, a large RNA genome, and a unique replication strategy (1).", [["surface", "ANATOMY", 127, 134], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["surface", "CELLULAR_COMPONENT", 127, 134], ["RNA genome", "DNA", 144, 154], ["Coronaviruses", "PROBLEM", 0, 13], ["pleomorphic positive-sense RNA viruses", "PROBLEM", 32, 70], ["club-like spikes", "PROBLEM", 89, 105], ["a large RNA genome", "PROBLEM", 136, 154], ["a unique replication strategy", "TREATMENT", 160, 189], ["pleomorphic", "OBSERVATION_MODIFIER", 32, 43], ["sense RNA viruses", "OBSERVATION", 53, 70], ["club", "OBSERVATION_MODIFIER", 89, 93], ["spikes", "OBSERVATION_MODIFIER", 99, 105], ["large", "OBSERVATION_MODIFIER", 138, 143], ["RNA genome", "OBSERVATION", 144, 154]]], ["The overall diameter of CoVs can range from 60 to 160 nm as demonstrated by negative-staining electron microscopy (EM) (2).", [["CoVs", "SIMPLE_CHEMICAL", 24, 28], ["CoVs", "PROTEIN", 24, 28], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["diameter", "OBSERVATION_MODIFIER", 12, 20], ["CoVs", "OBSERVATION_MODIFIER", 24, 28]]], ["The phospholipids and glycolipids incorporated into the virus envelope are derived from the host cell cellular membranes, and therefore the envelope composition is host cell-dependent (3).", [["cell cellular membranes", "ANATOMY", 97, 120], ["cell", "ANATOMY", 169, 173], ["phospholipids", "SIMPLE_CHEMICAL", 4, 17], ["glycolipids", "SIMPLE_CHEMICAL", 22, 33], ["cell", "CELL", 97, 101], ["cellular membranes", "CELLULAR_COMPONENT", 102, 120], ["cell", "CELL", 169, 173], ["The phospholipids", "TREATMENT", 0, 17], ["glycolipids", "TREATMENT", 22, 33], ["the virus envelope", "PROBLEM", 52, 70], ["the envelope composition", "TREATMENT", 136, 160], ["virus", "OBSERVATION", 56, 61], ["host cell cellular membranes", "OBSERVATION", 92, 120], ["envelope", "OBSERVATION_MODIFIER", 140, 148], ["composition", "OBSERVATION_MODIFIER", 149, 160], ["host cell", "OBSERVATION", 164, 173]]], ["Most CoVs have a single layer of club-shaped spikes (S protein) 12\u201325 nm in length, but PHEV and some other betacoronaviruses have a second, shorter layer of surface spikes, the hemagglutinin-esterase (HE) protein (4).Taxonomy, Genomic Structure, and MorphologySwine CoVs present the same genomic organization, replication strategy, and expression of viral proteins as the rest of the members of the Nidovirales order (1, 3\u20136).", [["CoVs", "ANATOMY", 5, 9], ["surface", "ANATOMY", 158, 165], ["CoVs", "GENE_OR_GENE_PRODUCT", 5, 9], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 108, 125], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 178, 200], ["CoVs", "GENE_OR_GENE_PRODUCT", 267, 271], ["CoVs", "PROTEIN", 5, 9], ["S protein", "PROTEIN", 53, 62], ["PHEV", "PROTEIN", 88, 92], ["betacoronaviruses", "PROTEIN", 108, 125], ["hemagglutinin-esterase (HE) protein", "PROTEIN", 178, 213], ["viral proteins", "PROTEIN", 351, 365], ["Swine", "SPECIES", 261, 266], ["S protein", "TEST", 53, 62], ["length", "TEST", 76, 82], ["PHEV", "TEST", 88, 92], ["some other betacoronaviruses", "PROBLEM", 97, 125], ["surface spikes", "PROBLEM", 158, 172], ["the hemagglutinin-esterase", "TEST", 174, 200], ["Swine CoVs", "PROBLEM", 261, 271], ["replication strategy", "TREATMENT", 311, 331], ["viral proteins", "PROBLEM", 351, 365], ["single", "OBSERVATION_MODIFIER", 17, 23], ["layer", "OBSERVATION_MODIFIER", 24, 29], ["club", "OBSERVATION_MODIFIER", 33, 37], ["shaped", "OBSERVATION_MODIFIER", 38, 44], ["spikes", "OBSERVATION_MODIFIER", 45, 51], ["Genomic Structure", "OBSERVATION", 228, 245], ["Morphology", "OBSERVATION_MODIFIER", 251, 261], ["viral proteins", "OBSERVATION", 351, 365]]], ["Overall, the genomic RNA (25\u201330 kb) is large, of positive-sense polarity, and single-stranded with a large replicase gene followed by structural and non-structural or accessory genes.", [["genomic RNA", "RNA", 13, 24], ["replicase gene", "DNA", 107, 121], ["structural and non-structural or accessory genes", "DNA", 134, 182], ["the genomic RNA", "TEST", 9, 24], ["a large replicase gene", "TREATMENT", 99, 121], ["genomic RNA", "OBSERVATION", 13, 24], ["large", "OBSERVATION_MODIFIER", 39, 44], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["sense polarity", "OBSERVATION_MODIFIER", 58, 72], ["accessory genes", "OBSERVATION", 167, 182]]], ["The genome contains a 5\u2032 cap structure and a 3\u2032 poly (A) tail, acting as an mRNA for translation of the replicases.", [["5\u2032 cap structure", "DNA", 22, 38], ["poly (A) tail", "PROTEIN", 48, 61], ["mRNA", "RNA", 76, 80], ["a 5\u2032 cap structure", "PROBLEM", 20, 38], ["a 3\u2032 poly (A) tail", "TREATMENT", 43, 61], ["genome", "OBSERVATION", 4, 10], ["5\u2032 cap", "OBSERVATION_MODIFIER", 22, 28], ["tail", "ANATOMY", 57, 61]]], ["The non-structural proteins encoded by the replicase gene (~65 kDa) constitutes two-thirds of the genome, while the genes that encode the structural and accessory proteins compose approximately 10 kb of the viral genome.", [["non-structural proteins", "PROTEIN", 4, 27], ["replicase gene", "DNA", 43, 57], ["structural and accessory proteins", "PROTEIN", 138, 171], ["viral genome", "DNA", 207, 219], ["The non-structural proteins", "TEST", 0, 27], ["the viral genome", "PROBLEM", 203, 219], ["non-structural proteins", "OBSERVATION", 4, 27], ["viral genome", "OBSERVATION", 207, 219]]], ["The 5\u2032 end of the genome presents a leader sequence and untranslated region (UTR) required for replication and synthesis of viral RNA.", [["5\u2032 end", "DNA", 4, 10], ["leader sequence", "DNA", 36, 51], ["untranslated region", "DNA", 56, 75], ["UTR", "DNA", 77, 80], ["viral RNA", "RNA", 124, 133], ["a leader sequence and untranslated region (UTR)", "TREATMENT", 34, 81], ["replication", "TREATMENT", 95, 106], ["synthesis", "TREATMENT", 111, 120], ["viral RNA", "PROBLEM", 124, 133], ["genome", "OBSERVATION", 18, 24], ["viral RNA", "OBSERVATION", 124, 133]]], ["Additionally, there are transcriptional regulatory sequences (TRSs) in the 3\u2032 end of the structural and accessory genes that are required for gene expression.Taxonomy, Genomic Structure, and MorphologyMost CoVs contain four structural proteins: a large surface spike glycoprotein (S; 180\u2013200 kDa) visible as the corona, a small membrane protein (E; 8\u201310 kDa), a transmembrane glycoprotein (M; 20\u201330 kDa), and a nucleocapsid protein (N; 50\u201360 kDa).", [["surface", "ANATOMY", 253, 260], ["membrane", "ANATOMY", 328, 336], ["CoVs", "GENE_OR_GENE_PRODUCT", 206, 210], ["transcriptional regulatory sequences", "DNA", 24, 60], ["TRSs", "DNA", 62, 66], ["3\u2032 end", "DNA", 75, 81], ["structural and accessory genes", "DNA", 89, 119], ["CoVs", "PROTEIN", 206, 210], ["structural proteins", "PROTEIN", 224, 243], ["large surface spike glycoprotein", "PROTEIN", 247, 279], ["S", "PROTEIN", 281, 282], ["180\u2013200 kDa", "PROTEIN", 284, 295], ["small membrane protein", "PROTEIN", 322, 344], ["E", "PROTEIN", 346, 347], ["8\u201310 kDa", "PROTEIN", 349, 357], ["transmembrane glycoprotein", "PROTEIN", 362, 388], ["M", "PROTEIN", 390, 391], ["20\u201330 kDa", "PROTEIN", 393, 402], ["nucleocapsid protein", "PROTEIN", 411, 431], ["N", "PROTEIN", 433, 434], ["50\u201360 kDa", "PROTEIN", 436, 445], ["transcriptional regulatory sequences", "TEST", 24, 60], ["a small membrane protein", "TEST", 320, 344], ["a transmembrane glycoprotein", "TEST", 360, 388], ["a nucleocapsid protein", "TEST", 409, 431], ["accessory genes", "OBSERVATION", 104, 119], ["Genomic Structure", "OBSERVATION", 168, 185], ["Morphology", "OBSERVATION_MODIFIER", 191, 201], ["four structural", "OBSERVATION_MODIFIER", 219, 234], ["proteins", "OBSERVATION", 235, 243], ["large", "OBSERVATION_MODIFIER", 247, 252], ["corona", "ANATOMY_MODIFIER", 312, 318]]], ["The differences in the number, type, and sizes of the structural proteins are responsible for significant structural differences of the nucleocapsids and virions among Nidoviruses.", [["nucleocapsids", "ANATOMY", 136, 149], ["virions", "ANATOMY", 154, 161], ["nucleocapsids", "CELLULAR_COMPONENT", 136, 149], ["virions", "CELLULAR_COMPONENT", 154, 161], ["Nidoviruses", "GENE_OR_GENE_PRODUCT", 168, 179], ["structural proteins", "PROTEIN", 54, 73], ["Nidoviruses", "PROTEIN", 168, 179], ["the structural proteins", "PROBLEM", 50, 73], ["significant structural differences of the nucleocapsids and virions among Nidoviruses", "PROBLEM", 94, 179], ["differences", "OBSERVATION_MODIFIER", 4, 15], ["number", "OBSERVATION_MODIFIER", 23, 29], ["type", "OBSERVATION_MODIFIER", 31, 35], ["sizes", "OBSERVATION_MODIFIER", 41, 46], ["structural proteins", "OBSERVATION", 54, 73], ["responsible for", "UNCERTAINTY", 78, 93], ["nucleocapsids", "OBSERVATION", 136, 149]]], ["However, hemagglutinating coronaviruses like PHEV also possess an envelope-associated glycoprotein, the hemagglutinin-esterase (HE; ~140 kDa), which is made of two subunits (~65 kDa each) linked together by disulfide bonds (7, 8).Taxonomy, Genomic Structure, and MorphologyThe M protein is the most abundant structural envelope protein that contributes to the virion's shape (9).", [["disulfide", "CHEMICAL", 207, 216], ["hemagglutinating coronaviruses", "ORGANISM", 9, 39], ["PHEV", "GENE_OR_GENE_PRODUCT", 45, 49], ["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 104, 126], ["M protein", "GENE_OR_GENE_PRODUCT", 277, 286], ["PHEV", "PROTEIN", 45, 49], ["envelope-associated glycoprotein", "PROTEIN", 66, 98], ["hemagglutinin", "PROTEIN", 104, 117], ["esterase", "PROTEIN", 118, 126], ["HE", "PROTEIN", 128, 130], ["M protein", "PROTEIN", 277, 286], ["structural envelope protein", "PROTEIN", 308, 335], ["PHEV", "SPECIES", 45, 49], ["hemagglutinating coronaviruses", "PROBLEM", 9, 39], ["the hemagglutinin-esterase", "TEST", 100, 126], ["The M protein", "TEST", 273, 286], ["the virion's shape", "TEST", 356, 374], ["hemagglutinating coronaviruses", "OBSERVATION", 9, 39], ["Genomic Structure", "OBSERVATION", 240, 257], ["Morphology", "OBSERVATION_MODIFIER", 263, 273], ["most abundant", "OBSERVATION_MODIFIER", 294, 307], ["envelope protein", "OBSERVATION", 319, 335]]], ["Studies on severe acute respiratory syndrome-associated coronavirus (SARS-CoV) indicated that the M protein contains three transmembrane domains, a small N-terminal glycosylated ectodomain and a much larger C-terminal endodomain (10).", [["transmembrane", "ANATOMY", 123, 136], ["acute respiratory syndrome-associated coronavirus", "DISEASE", 18, 67], ["SARS", "DISEASE", 69, 73], ["N", "CHEMICAL", 154, 155], ["C", "CHEMICAL", 207, 208], ["M protein", "PROTEIN", 98, 107], ["transmembrane domains", "PROTEIN", 123, 144], ["N-terminal glycosylated ectodomain", "PROTEIN", 154, 188], ["C-terminal endodomain", "PROTEIN", 207, 228], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 11, 67], ["SARS-CoV", "SPECIES", 69, 77], ["severe acute respiratory syndrome", "PROBLEM", 11, 44], ["associated coronavirus", "PROBLEM", 45, 67], ["the M protein", "TEST", 94, 107], ["three transmembrane domains", "PROBLEM", 117, 144], ["a small N-terminal glycosylated ectodomain", "PROBLEM", 146, 188], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory syndrome", "OBSERVATION", 24, 44], ["coronavirus", "OBSERVATION", 56, 67], ["small", "OBSERVATION_MODIFIER", 148, 153], ["terminal", "OBSERVATION_MODIFIER", 156, 164], ["glycosylated ectodomain", "OBSERVATION", 165, 188], ["larger", "OBSERVATION_MODIFIER", 200, 206]]], ["More recent reports suggest the M protein has a dimeric conformation and adopt two different tridimensional morphologies that contribute to membrane curvature and nucleocapsid binding (11).", [["membrane", "ANATOMY", 140, 148], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["M protein", "PROTEIN", 32, 41], ["the M protein", "TEST", 28, 41], ["membrane curvature and nucleocapsid binding", "PROBLEM", 140, 183], ["membrane curvature", "OBSERVATION", 140, 158]]], ["In transmissible gastroenteritis virus (TGEV), the hydrophilic N terminus contain a single accessible glycosylation site that is responsible for interferon induction (12).", [["transmissible gastroenteritis", "DISEASE", 3, 32], ["N", "CHEMICAL", 63, 64], ["transmissible gastroenteritis virus", "ORGANISM", 3, 38], ["TGEV", "ORGANISM", 40, 44], ["interferon", "GENE_OR_GENE_PRODUCT", 145, 155], ["hydrophilic N terminus", "PROTEIN", 51, 73], ["glycosylation site", "PROTEIN", 102, 120], ["interferon", "PROTEIN", 145, 155], ["transmissible gastroenteritis virus", "SPECIES", 3, 38], ["transmissible gastroenteritis virus", "SPECIES", 3, 38], ["TGEV", "SPECIES", 40, 44], ["transmissible gastroenteritis virus", "PROBLEM", 3, 38], ["the hydrophilic N terminus", "TREATMENT", 47, 73], ["a single accessible glycosylation site", "PROBLEM", 82, 120], ["interferon induction", "TREATMENT", 145, 165], ["transmissible", "OBSERVATION_MODIFIER", 3, 16], ["gastroenteritis virus", "OBSERVATION", 17, 38], ["hydrophilic", "OBSERVATION_MODIFIER", 51, 62], ["glycosylation site", "OBSERVATION", 102, 120], ["responsible for", "UNCERTAINTY", 129, 144], ["interferon", "OBSERVATION", 145, 155]]], ["Epitopes on the protruding N- and C-terminal ends of the M protein of TGEV bind complement-dependent neutralizing monoclonal antibodies (MAbs) (13, 14).Taxonomy, Genomic Structure, and MorphologyThe trimeric S protein is a class I fusion protein (15) that, in most but not all CoVs, can be structurally or functionally divided into two subunits: S1 (N-terminal globular head), which is heavily N-linked glycosylated and has binding activity to the host cell receptors, and S2 (C-terminal membrane-bound stalk), which is responsible for membrane fusion (16\u201320).", [["cell", "ANATOMY", 453, 457], ["membrane", "ANATOMY", 488, 496], ["membrane", "ANATOMY", 536, 544], ["N", "CHEMICAL", 27, 28], ["C", "CHEMICAL", 34, 35], ["N", "CHEMICAL", 350, 351], ["N", "CHEMICAL", 394, 395], ["C", "CHEMICAL", 477, 478], ["TGEV", "ORGANISM", 70, 74], ["CoVs", "GENE_OR_GENE_PRODUCT", 277, 281], ["S1", "GENE_OR_GENE_PRODUCT", 346, 348], ["cell", "CELL", 453, 457], ["S2", "GENE_OR_GENE_PRODUCT", 473, 475], ["membrane", "CELLULAR_COMPONENT", 488, 496], ["membrane", "CELLULAR_COMPONENT", 536, 544], ["protruding N- and C-terminal ends", "DNA", 16, 49], ["M protein", "PROTEIN", 57, 66], ["complement-dependent neutralizing monoclonal antibodies", "PROTEIN", 80, 135], ["MAbs", "PROTEIN", 137, 141], ["trimeric S protein", "PROTEIN", 199, 217], ["class I fusion protein", "PROTEIN", 223, 245], ["CoVs", "PROTEIN", 277, 281], ["S1", "PROTEIN", 346, 348], ["N-terminal globular head", "PROTEIN", 350, 374], ["N-linked glycosylated", "PROTEIN", 394, 415], ["host cell receptors", "PROTEIN", 448, 467], ["S2", "PROTEIN", 473, 475], ["C-terminal membrane-bound stalk", "PROTEIN", 477, 508], ["TGEV", "SPECIES", 70, 74], ["the protruding N", "TEST", 12, 28], ["TGEV bind complement", "TEST", 70, 90], ["neutralizing monoclonal antibodies", "TEST", 101, 135], ["The trimeric S protein", "TEST", 195, 217], ["all CoVs", "PROBLEM", 273, 281], ["heavily N-linked glycosylated", "PROBLEM", 386, 415], ["S2 (C-terminal membrane-bound stalk", "PROBLEM", 473, 508], ["membrane fusion", "PROBLEM", 536, 551], ["dependent", "OBSERVATION_MODIFIER", 91, 100], ["neutralizing", "OBSERVATION_MODIFIER", 101, 113], ["monoclonal antibodies", "OBSERVATION", 114, 135], ["Genomic Structure", "OBSERVATION", 162, 179], ["Morphology", "OBSERVATION_MODIFIER", 185, 195], ["S1", "ANATOMY", 346, 348], ["terminal", "ANATOMY_MODIFIER", 352, 360], ["globular", "ANATOMY_MODIFIER", 361, 369], ["head", "ANATOMY", 370, 374], ["host cell receptors", "OBSERVATION", 448, 467], ["S2", "ANATOMY", 473, 475], ["responsible for", "UNCERTAINTY", 520, 535], ["membrane fusion", "OBSERVATION", 536, 551]]], ["Contrary to the conserved S2 subunit, the S1 subunit is the most heterogeneous among species of a single coronavirus, conferring host range specificity, whereas the S2 subunit is the most conserved region of the protein.", [["S2", "GENE_OR_GENE_PRODUCT", 26, 28], ["S1", "GENE_OR_GENE_PRODUCT", 42, 44], ["single coronavirus", "ORGANISM", 98, 116], ["S2", "GENE_OR_GENE_PRODUCT", 165, 167], ["conserved S2 subunit", "PROTEIN", 16, 36], ["S1 subunit", "PROTEIN", 42, 52], ["S2 subunit", "PROTEIN", 165, 175], ["a single coronavirus", "PROBLEM", 96, 116], ["S1", "ANATOMY", 42, 44], ["most heterogeneous", "OBSERVATION_MODIFIER", 60, 78]]], ["The homotrimeric structure of the S protein is responsible for the distinctive \u201ccorona-like\u201d spike structure of the virion (21).", [["virion", "CELLULAR_COMPONENT", 116, 122], ["S protein", "PROTEIN", 34, 43], ["the S protein", "TEST", 30, 43], ["responsible for", "UNCERTAINTY", 47, 62], ["distinctive", "OBSERVATION_MODIFIER", 67, 78], ["corona", "OBSERVATION_MODIFIER", 80, 86], ["\u201d spike", "OBSERVATION", 91, 98], ["virion", "OBSERVATION_MODIFIER", 116, 122]]], ["A small region of the PHEV S protein interacts with the neural cell adhesion molecule (NCAM, also known as CD56) expressed on the surface of the neurons (22), playing a role during the infection of PHEV neurons (23).", [["surface", "ANATOMY", 130, 137], ["neurons", "ANATOMY", 145, 152], ["PHEV neurons", "ANATOMY", 198, 210], ["infection", "DISEASE", 185, 194], ["PHEV S", "GENE_OR_GENE_PRODUCT", 22, 28], ["neural cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 56, 85], ["NCAM", "GENE_OR_GENE_PRODUCT", 87, 91], ["CD56", "GENE_OR_GENE_PRODUCT", 107, 111], ["surface", "CELLULAR_COMPONENT", 130, 137], ["neurons", "CELL", 145, 152], ["PHEV neurons", "CELL", 198, 210], ["PHEV S protein", "PROTEIN", 22, 36], ["neural cell adhesion molecule", "PROTEIN", 56, 85], ["NCAM", "PROTEIN", 87, 91], ["CD56", "PROTEIN", 107, 111], ["PHEV neurons", "CELL_TYPE", 198, 210], ["PHEV", "SPECIES", 198, 202], ["A small region of the PHEV S protein", "PROBLEM", 0, 36], ["the neural cell adhesion molecule", "PROBLEM", 52, 85], ["NCAM", "TEST", 87, 91], ["the infection of PHEV neurons", "PROBLEM", 181, 210], ["small", "OBSERVATION_MODIFIER", 2, 7], ["region", "OBSERVATION_MODIFIER", 8, 14], ["neural cell", "OBSERVATION", 56, 67], ["adhesion molecule", "OBSERVATION", 68, 85], ["neurons", "ANATOMY", 145, 152], ["infection", "OBSERVATION", 185, 194]]], ["Moreover, the S protein contains major antigenic and antiviral neutralizing determinants, which make it a potential target for development of vaccines and antibody-based diagnostic tools.Taxonomy, Genomic Structure, and MorphologyThe E protein is the less abundant protein of the virion, and it is highly divergent among CoVs.", [["E protein", "GENE_OR_GENE_PRODUCT", 234, 243], ["virion", "CELLULAR_COMPONENT", 280, 286], ["CoVs", "GENE_OR_GENE_PRODUCT", 321, 325], ["S protein", "PROTEIN", 14, 23], ["E protein", "PROTEIN", 234, 243], ["CoVs", "PROTEIN", 321, 325], ["the S protein", "TEST", 10, 23], ["major antigenic and antiviral neutralizing determinants", "PROBLEM", 33, 88], ["vaccines", "TREATMENT", 142, 150], ["antibody", "TEST", 155, 163], ["The E protein", "TEST", 230, 243], ["antiviral neutralizing", "OBSERVATION", 53, 75], ["Genomic Structure", "OBSERVATION", 197, 214], ["Morphology", "OBSERVATION_MODIFIER", 220, 230], ["E protein", "OBSERVATION_MODIFIER", 234, 243], ["less", "OBSERVATION_MODIFIER", 251, 255], ["abundant", "OBSERVATION_MODIFIER", 256, 264], ["protein", "OBSERVATION", 265, 272], ["divergent", "OBSERVATION_MODIFIER", 305, 314]]], ["These protein features could explain the lack of precise information related to its specific role during the infection and/or pathogenesis processes.", [["infection", "DISEASE", 109, 118], ["These protein features", "PROBLEM", 0, 22], ["the infection", "PROBLEM", 105, 118], ["pathogenesis processes", "PROBLEM", 126, 148], ["infection", "OBSERVATION", 109, 118]]], ["The protein E amino acid sequence is highly conserved among swine CoVs (24).", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["protein E amino acid sequence", "PROTEIN", 4, 33], ["swine", "SPECIES", 60, 65], ["swine CoVs", "SPECIES", 60, 70], ["The protein E amino acid sequence", "TEST", 0, 33]]], ["Fehr and Pelman (1) suggested that this protein is a transmembrane protein, with an N-terminal ectodomain, a C-terminal endodomain, and ion channel activity (25).", [["transmembrane", "ANATOMY", 53, 66], ["N", "CHEMICAL", 84, 85], ["C", "CHEMICAL", 109, 110], ["transmembrane", "CELLULAR_COMPONENT", 53, 66], ["transmembrane protein", "PROTEIN", 53, 74], ["N-terminal ectodomain", "PROTEIN", 84, 105], ["C-terminal endodomain", "PROTEIN", 109, 130], ["a transmembrane protein", "TEST", 51, 74]]], ["The E protein has a role in the assembling and releasing of the virions from infected cells (26).", [["virions", "ANATOMY", 64, 71], ["cells", "ANATOMY", 86, 91], ["E protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["cells", "CELL", 86, 91], ["E protein", "PROTEIN", 4, 13], ["infected cells", "CELL_TYPE", 77, 91], ["infected cells", "PROBLEM", 77, 91], ["E protein", "OBSERVATION_MODIFIER", 4, 13], ["infected cells", "OBSERVATION", 77, 91]]], ["Recent studies, compiled and reviewed by Ruch et al. (26), have expanded our knowledge on the role of the E protein beyond assembling, including viral nuclear egress and induction of the host stress response.", [["nuclear", "ANATOMY", 151, 158], ["E", "GENE_OR_GENE_PRODUCT", 106, 107], ["nuclear", "CELLULAR_COMPONENT", 151, 158], ["E protein", "PROTEIN", 106, 115], ["Recent studies", "TEST", 0, 14], ["the E protein", "TREATMENT", 102, 115], ["viral nuclear egress", "TREATMENT", 145, 165]]], ["However, recombinant viruses lacking the E protein (e.g., SARS-CoV) probed not to be lethal; although, this outcome could be virus type-dependent (27).Taxonomy, Genomic Structure, and MorphologyThe N protein is the most abundant coronavirus antigen produced during the course of the infection (28), and it is the only viral protein in the nucleocapsid that interacts with viral RNA to form a helical ribonucleoprotein complex.", [["infection", "DISEASE", 283, 292], ["recombinant viruses", "ORGANISM", 9, 28], ["E", "GENE_OR_GENE_PRODUCT", 41, 42], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["coronavirus", "ORGANISM", 229, 240], ["E protein", "PROTEIN", 41, 50], ["CoV", "PROTEIN", 63, 66], ["N protein", "PROTEIN", 198, 207], ["coronavirus antigen", "PROTEIN", 229, 248], ["viral protein", "PROTEIN", 318, 331], ["viral RNA", "RNA", 372, 381], ["helical ribonucleoprotein complex", "PROTEIN", 392, 425], ["SARS-CoV", "SPECIES", 58, 66], ["recombinant viruses", "PROBLEM", 9, 28], ["the E protein", "TEST", 37, 50], ["SARS", "PROBLEM", 58, 62], ["virus type-dependent", "PROBLEM", 125, 145], ["The N protein", "TEST", 194, 207], ["the most abundant coronavirus antigen", "PROBLEM", 211, 248], ["the infection", "PROBLEM", 279, 292], ["viral protein in the nucleocapsid", "PROBLEM", 318, 351], ["viral RNA", "PROBLEM", 372, 381], ["a helical ribonucleoprotein complex", "PROBLEM", 390, 425], ["viruses", "OBSERVATION", 21, 28], ["Genomic Structure", "OBSERVATION", 161, 178], ["Morphology", "OBSERVATION_MODIFIER", 184, 194], ["most abundant", "OBSERVATION_MODIFIER", 215, 228], ["coronavirus", "OBSERVATION", 229, 240], ["infection", "OBSERVATION", 283, 292], ["viral protein", "OBSERVATION", 318, 331], ["viral RNA", "OBSERVATION", 372, 381], ["ribonucleoprotein complex", "OBSERVATION", 400, 425]]], ["This structure, in association with the M protein, forms an internal icosahedral core within the virion helping the genome integration to the replicase-transcriptase complex during viral genome encapsidation, and subsequent formation of viral particles (29).", [["virion", "ANATOMY", 97, 103], ["virion", "CELLULAR_COMPONENT", 97, 103], ["replicase-transcriptase", "GENE_OR_GENE_PRODUCT", 142, 165], ["M protein", "PROTEIN", 40, 49], ["replicase-transcriptase complex", "PROTEIN", 142, 173], ["the M protein", "TEST", 36, 49], ["an internal icosahedral core", "PROBLEM", 57, 85], ["the virion", "TREATMENT", 93, 103], ["the replicase", "TREATMENT", 138, 151], ["transcriptase complex", "PROBLEM", 152, 173], ["viral genome encapsidation", "TREATMENT", 181, 207], ["viral particles", "PROBLEM", 237, 252], ["internal icosahedral", "OBSERVATION", 60, 80], ["genome integration", "OBSERVATION", 116, 134], ["viral genome encapsidation", "OBSERVATION", 181, 207], ["viral particles", "OBSERVATION", 237, 252]]], ["The soluble N protein is composed of two independent N- and C-terminal RNA-binding domains (1).", [["N", "CHEMICAL", 53, 54], ["C", "CHEMICAL", 60, 61], ["N protein", "PROTEIN", 12, 21], ["N- and C-terminal RNA-binding domains", "PROTEIN", 53, 90], ["The soluble N protein", "TREATMENT", 0, 21]]], ["The N protein phosphorylation has been associated with structural changes that enhance the affinity of viral RNA compared to non-viral RNA (1, 30).Taxonomy, Genomic Structure, and MorphologyRelated hemagglutinin-esterases (HEs) are also found in influenza C, toroviruses, and CoVs, likely because of relatively recent lateral gene transfer events (31).", [["MorphologyRelated hemagglutinin-esterases", "GENE_OR_GENE_PRODUCT", 180, 221], ["HEs", "GENE_OR_GENE_PRODUCT", 223, 226], ["influenza C", "ORGANISM", 246, 257], ["toroviruses", "GENE_OR_GENE_PRODUCT", 259, 270], ["CoVs", "GENE_OR_GENE_PRODUCT", 276, 280], ["N protein", "PROTEIN", 4, 13], ["viral RNA", "RNA", 103, 112], ["non-viral RNA", "RNA", 125, 138], ["MorphologyRelated hemagglutinin-esterases", "PROTEIN", 180, 221], ["HEs", "PROTEIN", 223, 226], ["The N protein phosphorylation", "TEST", 0, 29], ["structural changes", "PROBLEM", 55, 73], ["viral RNA", "PROBLEM", 103, 112], ["Genomic Structure", "PROBLEM", 157, 174], ["influenza C, toroviruses", "PROBLEM", 246, 270], ["CoVs", "PROBLEM", 276, 280], ["viral RNA", "OBSERVATION", 103, 112], ["non-viral RNA", "OBSERVATION_MODIFIER", 125, 138], ["Genomic Structure", "OBSERVATION", 157, 174]]], ["The HE protein, only present in a subset of betacoronaviruses, acts as a hemagglutinin, binds sialic acids on surface glycoproteins, and contains acetyl-esterase activity (32).", [["surface", "ANATOMY", 110, 117], ["sialic acids", "CHEMICAL", 94, 106], ["acetyl", "CHEMICAL", 146, 152], ["sialic acids", "CHEMICAL", 94, 106], ["acetyl", "CHEMICAL", 146, 152], ["HE", "GENE_OR_GENE_PRODUCT", 4, 6], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 44, 61], ["sialic acids", "SIMPLE_CHEMICAL", 94, 106], ["acetyl-esterase", "GENE_OR_GENE_PRODUCT", 146, 161], ["HE protein", "PROTEIN", 4, 14], ["betacoronaviruses", "PROTEIN", 44, 61], ["hemagglutinin", "PROTEIN", 73, 86], ["surface glycoproteins", "PROTEIN", 110, 131], ["acetyl-esterase", "PROTEIN", 146, 161], ["The HE protein", "TEST", 0, 14], ["a hemagglutinin", "TREATMENT", 71, 86], ["surface glycoproteins", "TREATMENT", 110, 131], ["acetyl-esterase activity", "TREATMENT", 146, 170]]], ["The HE protein is associated with granular projections located near the base of the typical large bulbous peplomers and displays hemagglutinating (HA), acetyl-esterase (AE) or receptor-destroying enzyme (RDE) activity (7).", [["granular projections", "ANATOMY", 34, 54], ["bulbous peplomers", "ANATOMY", 98, 115], ["acetyl", "CHEMICAL", 152, 158], ["acetyl", "CHEMICAL", 152, 158], ["HE", "GENE_OR_GENE_PRODUCT", 4, 6], ["granular projections", "CELLULAR_COMPONENT", 34, 54], ["acetyl-esterase", "GENE_OR_GENE_PRODUCT", 152, 167], ["AE", "SIMPLE_CHEMICAL", 169, 171], ["receptor-destroying enzyme", "GENE_OR_GENE_PRODUCT", 176, 202], ["RDE", "SIMPLE_CHEMICAL", 204, 207], ["HE protein", "PROTEIN", 4, 14], ["acetyl-esterase", "PROTEIN", 152, 167], ["AE", "PROTEIN", 169, 171], ["receptor-destroying enzyme", "PROTEIN", 176, 202], ["RDE", "PROTEIN", 204, 207], ["granular projections", "PROBLEM", 34, 54], ["hemagglutinating (HA)", "PROBLEM", 129, 150], ["acetyl-esterase", "TEST", 152, 167], ["associated with", "UNCERTAINTY", 18, 33], ["granular", "OBSERVATION_MODIFIER", 34, 42], ["base", "ANATOMY_MODIFIER", 72, 76], ["typical", "OBSERVATION_MODIFIER", 84, 91], ["large", "OBSERVATION_MODIFIER", 92, 97], ["bulbous", "OBSERVATION_MODIFIER", 98, 105], ["peplomers", "OBSERVATION", 106, 115], ["hemagglutinating", "OBSERVATION_MODIFIER", 129, 145]]], ["More specifically, the isolated HE-protein from PHEV and bovine coronavirus exhibits receptor-destroying and receptor-binding activity (33).", [["HE", "GENE_OR_GENE_PRODUCT", 32, 34], ["PHEV", "GENE_OR_GENE_PRODUCT", 48, 52], ["bovine coronavirus", "ORGANISM", 57, 75], ["HE-protein", "PROTEIN", 32, 42], ["PHEV", "PROTEIN", 48, 52], ["bovine", "SPECIES", 57, 63], ["coronavirus", "SPECIES", 64, 75], ["PHEV", "SPECIES", 48, 52], ["bovine coronavirus", "SPECIES", 57, 75], ["PHEV", "TEST", 48, 52], ["bovine coronavirus", "PROBLEM", 57, 75], ["bovine coronavirus", "OBSERVATION", 57, 75]]], ["The HE protein could facilitate viral cell entry and virus spreading through the interaction with S protein (34).", [["cell", "ANATOMY", 38, 42], ["HE", "GENE_OR_GENE_PRODUCT", 4, 6], ["cell", "CELL", 38, 42], ["S protein", "GENE_OR_GENE_PRODUCT", 98, 107], ["HE protein", "PROTEIN", 4, 14], ["S protein", "PROTEIN", 98, 107], ["The HE protein", "TEST", 0, 14], ["viral cell entry", "PROBLEM", 32, 48], ["virus spreading", "PROBLEM", 53, 68], ["S protein", "TEST", 98, 107], ["viral cell entry", "OBSERVATION", 32, 48]]], ["Interestingly, HE enhances the neurovirulence of the murine hepatitis virus (MHV) (35) but not in vitro (36).General Overview of Swine CoronavirusesSwine CoVs are represented within three genera of the Coronaviridae family.", [["murine hepatitis virus", "DISEASE", 53, 75], ["murine hepatitis virus", "ORGANISM", 53, 75], ["MHV)", "ORGANISM", 77, 81], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 202, 215], ["murine hepatitis virus", "SPECIES", 53, 75], ["Swine", "SPECIES", 148, 153], ["murine hepatitis virus", "SPECIES", 53, 75], ["MHV", "SPECIES", 77, 80], ["Swine CoronavirusesSwine CoVs", "SPECIES", 129, 158], ["the murine hepatitis virus", "PROBLEM", 49, 75], ["Swine CoronavirusesSwine CoVs", "PROBLEM", 129, 158]]], ["Five swine CoVs have been identified, including TGEV, first described in 1946 (37); PHEV, isolated in 1962 (38); porcine epidemic diarrhea virus (PEDV), isolated in 1977 (39); porcine respiratory coronavirus (PRCV), a spike (S) gene deletion mutant of TGEV isolated in 1984 (40); and porcine deltacoronavirus, detected in 2012 (41).", [["porcine epidemic diarrhea", "DISEASE", 113, 138], ["respiratory coronavirus", "DISEASE", 184, 207], ["swine", "ORGANISM", 5, 10], ["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["TGEV", "ORGANISM", 48, 52], ["porcine epidemic diarrhea virus", "ORGANISM", 113, 144], ["porcine respiratory coronavirus", "ORGANISM", 176, 207], ["TGEV", "ORGANISM", 252, 256], ["porcine", "ORGANISM", 284, 291], ["spike (S) gene deletion mutant", "DNA", 218, 248], ["swine", "SPECIES", 5, 10], ["porcine epidemic diarrhea virus", "SPECIES", 113, 144], ["porcine respiratory coronavirus", "SPECIES", 176, 207], ["TGEV", "SPECIES", 252, 256], ["porcine", "SPECIES", 284, 291], ["swine", "SPECIES", 5, 10], ["TGEV", "SPECIES", 48, 52], ["porcine epidemic diarrhea virus", "SPECIES", 113, 144], ["PEDV", "SPECIES", 146, 150], ["porcine respiratory coronavirus", "SPECIES", 176, 207], ["PRCV", "SPECIES", 209, 213], ["TGEV", "SPECIES", 252, 256], ["Five swine CoVs", "PROBLEM", 0, 15], ["TGEV", "PROBLEM", 48, 52], ["PHEV", "TEST", 84, 88], ["porcine epidemic diarrhea virus (PEDV", "PROBLEM", 113, 150], ["porcine respiratory coronavirus", "PROBLEM", 176, 207], ["a spike (S) gene deletion mutant of TGEV", "PROBLEM", 216, 256], ["porcine deltacoronavirus", "PROBLEM", 284, 308], ["respiratory coronavirus", "ANATOMY", 184, 207]]], ["In addition, a TGEV/PEDV recombinant virus has been identified in swine in Europe (42\u201344), and a bat-HKU2-like Alphacoronavirus has been identified in swine in China (45, 46).", [["Alphacoronavirus", "CHEMICAL", 111, 127], ["TGEV", "ORGANISM", 15, 19], ["PEDV recombinant virus", "ORGANISM", 20, 42], ["swine", "ORGANISM", 66, 71], ["bat-HKU2", "ORGANISM", 97, 105], ["Alphacoronavirus", "ORGANISM", 111, 127], ["swine", "SPECIES", 66, 71], ["swine", "SPECIES", 151, 156], ["TGEV", "SPECIES", 15, 19], ["swine", "SPECIES", 66, 71], ["swine", "SPECIES", 151, 156], ["a TGEV/PEDV recombinant virus", "PROBLEM", 13, 42], ["a bat", "TEST", 95, 100], ["Alphacoronavirus", "PROBLEM", 111, 127], ["swine", "OBSERVATION_MODIFIER", 66, 71], ["bat", "ANATOMY", 97, 100]]], ["For each swine CoV, only a single serotype is recognized (Table 1).General Overview of Swine CoronavirusesSwine coronaviruses show different tissue tropisms, including the gastrointestinal and respiratory tracts, the peripheral and central nervous systems, and the mammary glands (Table 1).", [["tissue", "ANATOMY", 141, 147], ["gastrointestinal", "ANATOMY", 172, 188], ["respiratory tracts", "ANATOMY", 193, 211], ["peripheral", "ANATOMY", 217, 227], ["central nervous systems", "ANATOMY", 232, 255], ["mammary glands", "ANATOMY", 265, 279], ["swine CoV", "ORGANISM", 9, 18], ["Swine coronaviruses", "ORGANISM", 106, 125], ["tissue", "TISSUE", 141, 147], ["gastrointestinal", "ORGAN", 172, 188], ["peripheral", "ANATOMICAL_SYSTEM", 217, 227], ["central nervous systems", "ANATOMICAL_SYSTEM", 232, 255], ["mammary glands", "ORGAN", 265, 279], ["swine", "SPECIES", 9, 14], ["Swine", "SPECIES", 106, 111], ["swine CoV", "SPECIES", 9, 18], ["Swine Coronaviruses", "SPECIES", 87, 106], ["Swine coronaviruses", "SPECIES", 106, 125], ["each swine CoV", "PROBLEM", 4, 18], ["a single serotype", "PROBLEM", 25, 42], ["Swine Coronaviruses", "PROBLEM", 87, 106], ["Swine coronaviruses", "PROBLEM", 106, 125], ["different tissue tropisms", "PROBLEM", 131, 156], ["different tissue tropisms", "OBSERVATION", 131, 156], ["gastrointestinal", "ANATOMY", 172, 188], ["respiratory tracts", "ANATOMY", 193, 211], ["peripheral", "ANATOMY_MODIFIER", 217, 227], ["central", "ANATOMY_MODIFIER", 232, 239], ["nervous systems", "ANATOMY", 240, 255], ["mammary glands", "ANATOMY", 265, 279]]], ["The alphacoronaviruses TGEV and PEDV and deltacoronavirus produce mild to severe or fatal enteric disease (47).", [["enteric disease", "DISEASE", 90, 105], ["alphacoronaviruses TGEV", "ORGANISM", 4, 27], ["PEDV", "GENE_OR_GENE_PRODUCT", 32, 36], ["TGEV", "SPECIES", 23, 27], ["TGEV", "SPECIES", 23, 27], ["PEDV", "SPECIES", 32, 36], ["The alphacoronaviruses TGEV", "PROBLEM", 0, 27], ["PEDV", "PROBLEM", 32, 36], ["deltacoronavirus", "PROBLEM", 41, 57], ["mild to severe or fatal enteric disease", "PROBLEM", 66, 105], ["alphacoronaviruses TGEV", "OBSERVATION", 4, 27], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["fatal", "OBSERVATION_MODIFIER", 84, 89], ["enteric disease", "OBSERVATION", 90, 105]]], ["The alphacoronavirus PRCV infects the upper respiratory tract, trachea, tonsils, or lungs, with limited intestinal replication, but the asymptomatic or subclinical form occurs most frequently (48).", [["upper respiratory tract", "ANATOMY", 38, 61], ["trachea", "ANATOMY", 63, 70], ["tonsils", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 84, 89], ["intestinal", "ANATOMY", 104, 114], ["alphacoronavirus PRCV", "ORGANISM", 4, 25], ["upper", "ORGANISM_SUBDIVISION", 38, 43], ["respiratory tract", "ORGANISM_SUBDIVISION", 44, 61], ["trachea", "ORGAN", 63, 70], ["tonsils", "ORGAN", 72, 79], ["lungs", "ORGAN", 84, 89], ["intestinal", "ORGAN", 104, 114], ["The alphacoronavirus PRCV infects the upper respiratory tract, trachea, tonsils, or lungs", "PROBLEM", 0, 89], ["limited intestinal replication", "TREATMENT", 96, 126], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61], ["trachea", "ANATOMY", 63, 70], ["tonsils", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 84, 89], ["intestinal", "ANATOMY", 104, 114], ["replication", "OBSERVATION", 115, 126]]], ["The betacoronavirus PHEV produces vomiting and wasting disease (VWD) and/or encephalomyelitis (4).History of the Emergence of PHEVIn the fall of 1957, a disease affecting nursery pigs characterized by high morbidity, vomiting, anorexia, constipation, and severe progressive emaciation was reported in Ontario, Canada (49).", [["PHEV", "CHEMICAL", 20, 24], ["vomiting", "DISEASE", 34, 42], ["wasting disease", "DISEASE", 47, 62], ["VWD", "DISEASE", 64, 67], ["encephalomyelitis", "DISEASE", 76, 93], ["vomiting", "DISEASE", 217, 225], ["anorexia", "DISEASE", 227, 235], ["constipation", "DISEASE", 237, 249], ["emaciation", "DISEASE", 274, 284], ["betacoronavirus PHEV", "ORGANISM", 4, 24], ["pigs", "ORGANISM", 179, 183], ["pigs", "SPECIES", 179, 183], ["vomiting", "PROBLEM", 34, 42], ["wasting disease (VWD)", "PROBLEM", 47, 68], ["encephalomyelitis", "PROBLEM", 76, 93], ["high morbidity", "PROBLEM", 201, 215], ["vomiting", "PROBLEM", 217, 225], ["anorexia", "PROBLEM", 227, 235], ["constipation", "PROBLEM", 237, 249], ["severe progressive emaciation", "PROBLEM", 255, 284], ["wasting disease", "OBSERVATION", 47, 62], ["encephalomyelitis", "OBSERVATION", 76, 93], ["high", "OBSERVATION_MODIFIER", 201, 205], ["morbidity", "OBSERVATION", 206, 215], ["constipation", "OBSERVATION", 237, 249], ["severe", "OBSERVATION_MODIFIER", 255, 261], ["progressive", "OBSERVATION_MODIFIER", 262, 273], ["emaciation", "OBSERVATION", 274, 284]]], ["Subsequently, different outbreaks of a virus-like encephalomyelitis affecting neonatal pigs were systematically reported in Ontario between 1958 and 1961 (50, 51).", [["encephalomyelitis", "DISEASE", 50, 67], ["pigs", "ORGANISM", 87, 91], ["pigs", "SPECIES", 87, 91], ["pigs", "SPECIES", 87, 91], ["a virus-like encephalomyelitis", "PROBLEM", 37, 67], ["different", "OBSERVATION_MODIFIER", 14, 23], ["outbreaks", "OBSERVATION_MODIFIER", 24, 33], ["virus", "OBSERVATION", 39, 44], ["encephalomyelitis", "OBSERVATION", 50, 67]]], ["Piglets remained clinically normal until 6 or 7 days of age, when animals started to show clinical signs, including reluctance to nurse, shivering, huddling, and squealing, followed by neurological signs including vomiting, ataxia, hyperesthesia, incoordination, and paddling.", [["neurological", "ANATOMY", 185, 197], ["shivering", "DISEASE", 137, 146], ["vomiting", "DISEASE", 214, 222], ["ataxia", "DISEASE", 224, 230], ["hyperesthesia", "DISEASE", 232, 245], ["incoordination", "DISEASE", 247, 261], ["Piglets", "ORGANISM", 0, 7], ["Piglets", "SPECIES", 0, 7], ["clinical signs", "PROBLEM", 90, 104], ["shivering", "PROBLEM", 137, 146], ["neurological signs", "PROBLEM", 185, 203], ["vomiting", "PROBLEM", 214, 222], ["ataxia", "PROBLEM", 224, 230], ["hyperesthesia", "PROBLEM", 232, 245], ["incoordination", "PROBLEM", 247, 261], ["paddling", "PROBLEM", 267, 275], ["normal", "OBSERVATION", 28, 34], ["hyperesthesia", "OBSERVATION", 232, 245]]], ["These symptoms were followed by death 2\u20133 days after the onset of the clinical signs.", [["death", "DISEASE", 32, 37], ["These symptoms", "PROBLEM", 0, 14], ["the clinical signs", "PROBLEM", 66, 84]]], ["The etiologic agent of this clinical syndrome was named \u201chemagglutinating encephalomyelitis virus\u201d because of its hemagglutinating properties.", [["hemagglutinating encephalomyelitis", "DISEASE", 57, 91], ["hemagglutinating encephalomyelitis virus", "ORGANISM", 57, 97], ["hemagglutinating encephalomyelitis virus", "SPECIES", 57, 97], ["hemagglutinating encephalomyelitis virus", "SPECIES", 57, 97], ["this clinical syndrome", "PROBLEM", 23, 45], ["hemagglutinating encephalomyelitis virus", "PROBLEM", 57, 97], ["its hemagglutinating properties", "PROBLEM", 110, 141], ["hemagglutinating encephalomyelitis", "OBSERVATION", 57, 91]]], ["This virus was first isolated in primary pig kidney (PK) cells from the brains of 7\u20138 days old piglets showing histopathological evidence of viral polioencephalomyelitis, including perivascular cuffing with mononuclear cells, neuronal degeneration, and gliosis (38).", [["primary pig kidney (PK) cells", "ANATOMY", 33, 62], ["brains", "ANATOMY", 72, 78], ["perivascular", "ANATOMY", 181, 193], ["mononuclear cells", "ANATOMY", 207, 224], ["neuronal", "ANATOMY", 226, 234], ["viral polioencephalomyelitis", "DISEASE", 141, 169], ["neuronal degeneration", "DISEASE", 226, 247], ["gliosis", "DISEASE", 253, 260], ["pig", "ORGANISM", 41, 44], ["kidney", "ORGAN", 45, 51], ["PK) cells", "CELL", 53, 62], ["brains", "ORGAN", 72, 78], ["piglets", "ORGANISM", 95, 102], ["mononuclear cells", "CELL", 207, 224], ["neuronal", "CELL", 226, 234], ["primary pig kidney (PK) cells", "CELL_TYPE", 33, 62], ["mononuclear cells", "CELL_TYPE", 207, 224], ["pig", "SPECIES", 41, 44], ["piglets", "SPECIES", 95, 102], ["pig", "SPECIES", 41, 44], ["This virus", "PROBLEM", 0, 10], ["the brains", "TEST", 68, 78], ["viral polioencephalomyelitis", "PROBLEM", 141, 169], ["perivascular cuffing", "PROBLEM", 181, 201], ["mononuclear cells", "PROBLEM", 207, 224], ["neuronal degeneration", "PROBLEM", 226, 247], ["gliosis", "PROBLEM", 253, 260], ["kidney", "ANATOMY", 45, 51], ["brains", "ANATOMY", 72, 78], ["evidence of", "UNCERTAINTY", 129, 140], ["viral polioencephalomyelitis", "OBSERVATION", 141, 169], ["perivascular", "ANATOMY_MODIFIER", 181, 193], ["cuffing", "OBSERVATION", 194, 201], ["mononuclear cells", "OBSERVATION", 207, 224], ["neuronal degeneration", "OBSERVATION", 226, 247], ["gliosis", "OBSERVATION", 253, 260]]], ["Milder transient clinical signs such as anorexia, shivering, loss of body condition and vomiting without signs of encephalomyelitis were reported in 4 weeks old piglets from the same farms.", [["body", "ANATOMY", 69, 73], ["anorexia", "DISEASE", 40, 48], ["shivering", "DISEASE", 50, 59], ["loss of body condition", "DISEASE", 61, 83], ["vomiting", "DISEASE", 88, 96], ["encephalomyelitis", "DISEASE", 114, 131], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["piglets", "ORGANISM", 161, 168], ["piglets", "SPECIES", 161, 168], ["Milder transient clinical signs", "PROBLEM", 0, 31], ["anorexia", "PROBLEM", 40, 48], ["shivering", "PROBLEM", 50, 59], ["loss of body condition", "PROBLEM", 61, 83], ["vomiting", "PROBLEM", 88, 96], ["encephalomyelitis", "PROBLEM", 114, 131], ["anorexia", "OBSERVATION", 40, 48], ["encephalomyelitis", "OBSERVATION", 114, 131]]], ["This alternative clinical presentation was named \u201cvomiting and wasting disease\u201d (VWD).", [["vomiting", "DISEASE", 50, 58], ["wasting disease", "DISEASE", 63, 78], ["VWD", "DISEASE", 81, 84], ["vomiting", "PROBLEM", 50, 58], ["wasting disease\u201d (VWD)", "PROBLEM", 63, 85]]], ["Shortly thereafter, it was determined that the same virus was the cause of the disease characterized by vomiting and wasting concurrently reported in Europe (52\u201354) and other regions in Canada (55).", [["vomiting", "DISEASE", 104, 112], ["wasting", "DISEASE", 117, 124], ["the same virus", "PROBLEM", 43, 57], ["the disease", "PROBLEM", 75, 86], ["vomiting", "PROBLEM", 104, 112], ["disease", "OBSERVATION", 79, 86]]], ["During the first investigations, the viral diagnosis was based on three criteria: formation of multinucleated giant cells in PK cells, hemagglutination of chicken erythrocytes in culture fluids, and inhibition of hemagglutination in hyper-immune anti-serum.History of the Emergence of PHEVOriginally, the virus was mistakenly associated with a Myxovirus/Paramyxovirus group (55).", [["multinucleated giant cells", "ANATOMY", 95, 121], ["PK cells", "ANATOMY", 125, 133], ["erythrocytes", "ANATOMY", 163, 175], ["culture fluids", "ANATOMY", 179, 193], ["multinucleated giant cells", "CELL", 95, 121], ["PK cells", "CELL", 125, 133], ["chicken", "ORGANISM", 155, 162], ["erythrocytes", "CELL", 163, 175], ["multinucleated giant cells", "CELL_TYPE", 95, 121], ["PK cells", "CELL_TYPE", 125, 133], ["chicken erythrocytes", "CELL_TYPE", 155, 175], ["chicken", "SPECIES", 155, 162], ["chicken", "SPECIES", 155, 162], ["multinucleated giant cells", "PROBLEM", 95, 121], ["PK cells", "TEST", 125, 133], ["hemagglutination", "TEST", 135, 151], ["chicken erythrocytes", "PROBLEM", 155, 175], ["culture fluids", "TEST", 179, 193], ["hemagglutination", "PROBLEM", 213, 229], ["hyper-immune anti-serum", "PROBLEM", 233, 256], ["the virus", "PROBLEM", 301, 310], ["a Myxovirus/Paramyxovirus group", "TREATMENT", 342, 373], ["multinucleated giant cells", "OBSERVATION", 95, 121], ["PK cells", "OBSERVATION", 125, 133], ["chicken erythrocytes", "OBSERVATION", 155, 175]]], ["The virus was finally classified as a coronavirus in 1971 (56, 57).", [["coronavirus", "DISEASE", 38, 49], ["The virus", "PROBLEM", 0, 9], ["a coronavirus", "TEST", 36, 49], ["virus", "OBSERVATION", 4, 9]]], ["Specifically, PHEV belongs to the genus Betacoronavirus of the family Coronaviridae (group 2a) in the order Nidovirales (58).", [["PHEV", "CHEMICAL", 14, 18], ["PHEV", "GENE_OR_GENE_PRODUCT", 14, 18], ["PHEV", "PROTEIN", 14, 18], ["PHEV", "SPECIES", 14, 18]]], ["PHEV is closely related to canine, bovine, murine, human and equine coronaviruses, as well as rat sialolodacryoadenitis coronaviruses (6).", [["sialolodacryoadenitis coronaviruses", "DISEASE", 98, 133], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["canine", "ORGANISM", 27, 33], ["bovine", "ORGANISM", 35, 41], ["murine", "ORGANISM", 43, 49], ["human", "ORGANISM", 51, 56], ["equine coronaviruses", "ORGANISM", 61, 81], ["rat", "ORGANISM", 94, 97], ["sialolodacryoadenitis coronaviruses", "ORGANISM", 98, 133], ["PHEV", "PROTEIN", 0, 4], ["canine", "SPECIES", 27, 33], ["bovine", "SPECIES", 35, 41], ["murine", "SPECIES", 43, 49], ["human", "SPECIES", 51, 56], ["equine", "SPECIES", 61, 67], ["rat", "SPECIES", 94, 97], ["PHEV", "SPECIES", 0, 4], ["canine", "SPECIES", 27, 33], ["bovine", "SPECIES", 35, 41], ["human", "SPECIES", 51, 56], ["equine coronaviruses", "SPECIES", 61, 81], ["rat sialolodacryoadenitis coronaviruses", "SPECIES", 94, 133], ["human and equine coronaviruses", "PROBLEM", 51, 81], ["rat sialolodacryoadenitis coronaviruses", "PROBLEM", 94, 133]]], ["The virus agglutinates the erythrocytes of mice, rats, chickens, and several other animals (59).", [["erythrocytes", "ANATOMY", 27, 39], ["erythrocytes", "CELL", 27, 39], ["mice", "ORGANISM", 43, 47], ["rats", "ORGANISM", 49, 53], ["chickens", "ORGANISM", 55, 63], ["erythrocytes", "CELL_TYPE", 27, 39], ["mice", "SPECIES", 43, 47], ["rats", "SPECIES", 49, 53], ["chickens", "SPECIES", 55, 63], ["mice", "SPECIES", 43, 47], ["chickens", "SPECIES", 55, 63], ["virus", "OBSERVATION", 4, 9], ["erythrocytes", "ANATOMY", 27, 39]]], ["Pigs are the only species naturally infected by PHEV, which do not constitute a hazard to human health.", [["Pigs", "ORGANISM", 0, 4], ["human", "ORGANISM", 90, 95], ["Pigs", "SPECIES", 0, 4], ["human", "SPECIES", 90, 95], ["Pigs", "SPECIES", 0, 4], ["PHEV", "SPECIES", 48, 52], ["human", "SPECIES", 90, 95], ["species", "OBSERVATION_MODIFIER", 18, 25], ["naturally", "OBSERVATION_MODIFIER", 26, 35], ["infected", "OBSERVATION", 36, 44]]], ["PHEV is the only known neurotropic coronavirus affecting pigs and is a potential threat to herds of high-health gilts.", [["PHEV", "CHEMICAL", 0, 4], ["neurotropic coronavirus", "DISEASE", 23, 46], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["neurotropic coronavirus", "ORGANISM", 23, 46], ["pigs", "ORGANISM", 57, 61], ["gilts", "ORGANISM", 112, 117], ["coronavirus", "SPECIES", 35, 46], ["pigs", "SPECIES", 57, 61], ["PHEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 57, 61], ["neurotropic", "OBSERVATION_MODIFIER", 23, 34], ["coronavirus", "OBSERVATION", 35, 46]]], ["Likewise, the virus displays neurotropism in mice and Wistar rats (60, 61).", [["mice", "ORGANISM", 45, 49], ["Wistar rats", "ORGANISM", 54, 65], ["mice", "SPECIES", 45, 49], ["rats", "SPECIES", 61, 65], ["mice", "SPECIES", 45, 49], ["virus", "OBSERVATION", 14, 19], ["neurotropism", "OBSERVATION_MODIFIER", 29, 41]]], ["Although PHEV-related diseases have different clinical manifestations, only one PHEV serotype has been described to date.", [["PHEV", "CHEMICAL", 9, 13], ["PHEV", "GENE_OR_GENE_PRODUCT", 9, 13], ["PHEV", "CANCER", 80, 84], ["PHEV", "SPECIES", 9, 13], ["PHEV", "SPECIES", 80, 84], ["PHEV-related diseases", "PROBLEM", 9, 30], ["different clinical manifestations", "PROBLEM", 36, 69], ["one PHEV serotype", "PROBLEM", 76, 93]]], ["PHEV can infect na\u00efve pigs of any age, but clinical disease, morbidity, and mortality are age-dependent.", [["PHEV", "CHEMICAL", 0, 4], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 22, 26], ["pigs", "SPECIES", 22, 26], ["PHEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 22, 26], ["clinical disease", "PROBLEM", 43, 59], ["morbidity", "PROBLEM", 61, 70]]], ["Age-related susceptibility of the pigs, possible strain differences in virulence, and variation in pathogenesis may influence clinical signs (4).Global Distribution and Epidemiology of PHEV InfectionSerologic surveys (1960\u20131990) have demonstrated that PHEV is highly prevalent and circulates subclinically in most swine herds worldwide.", [["PHEV", "CHEMICAL", 252, 256], ["pigs", "ORGANISM", 34, 38], ["pigs", "SPECIES", 34, 38], ["swine", "SPECIES", 314, 319], ["pigs", "SPECIES", 34, 38], ["PHEV", "SPECIES", 252, 256], ["swine", "SPECIES", 314, 319], ["the pigs", "PROBLEM", 30, 38], ["strain differences in virulence", "PROBLEM", 49, 80], ["susceptibility", "OBSERVATION_MODIFIER", 12, 26], ["possible", "UNCERTAINTY", 40, 48], ["strain", "OBSERVATION_MODIFIER", 49, 55], ["differences", "OBSERVATION_MODIFIER", 56, 67], ["virulence", "OBSERVATION_MODIFIER", 71, 80], ["Distribution", "OBSERVATION_MODIFIER", 152, 164]]], ["Viral circulation is maintained in herd populations by continuous flow management, and pigs can be infected vertically from sows to neonates or by comingling at weaning (4).", [["pigs", "ORGANISM", 87, 91], ["sows", "ORGANISM_SUBDIVISION", 124, 128], ["pigs", "SPECIES", 87, 91], ["pigs", "SPECIES", 87, 91], ["Viral circulation", "PROBLEM", 0, 17], ["continuous flow management", "TREATMENT", 55, 81], ["pigs", "TREATMENT", 87, 91], ["circulation", "OBSERVATION", 6, 17]]], ["However, there have been only a few reports of clinical outbreaks of VWD or PHEV-associated mortality since the virus's 1958 discovery in Canada (49).", [["VWD", "DISEASE", 69, 72], ["PHEV", "CHEMICAL", 76, 80], ["VWD", "PROBLEM", 69, 72], ["PHEV", "PROBLEM", 76, 80], ["the virus", "PROBLEM", 108, 117], ["few", "OBSERVATION_MODIFIER", 32, 35]]], ["Additionally, PHEV circulation in Japan was demonstrated through serological surveys (70).Global Distribution and Epidemiology of PHEV InfectionThe current worldwide seroprevalence of PHEV is mostly unknown.", [["PHEV Infection", "DISEASE", 130, 144], ["PHEV", "DISEASE", 184, 188], ["PHEV", "SIMPLE_CHEMICAL", 14, 18], ["PHEV", "CANCER", 184, 188], ["PHEV", "SPECIES", 14, 18], ["PHEV", "SPECIES", 130, 134], ["PHEV", "SPECIES", 184, 188], ["PHEV circulation in Japan", "PROBLEM", 14, 39], ["serological surveys", "TEST", 65, 84], ["Global Distribution", "PROBLEM", 90, 109], ["PHEV Infection", "PROBLEM", 130, 144], ["Distribution", "OBSERVATION_MODIFIER", 97, 109], ["PHEV Infection", "OBSERVATION", 130, 144]]], ["A recent seroprevalence study determined the seroprevalence of PHEV in sow herds in the US (71).", [["PHEV", "CHEMICAL", 63, 67], ["sow", "SPECIES", 71, 74], ["PHEV", "SPECIES", 63, 67], ["A recent seroprevalence study", "TEST", 0, 29]]], ["A total of 2,756 serum samples of reproductive animals (>28 weeks-old) from farms with no history of neonatal VWD or outbreaks of neurological signs during 2016 were included in this study.", [["serum samples", "ANATOMY", 17, 30], ["neurological", "ANATOMY", 130, 142], ["VWD", "DISEASE", 110, 113], ["neurological signs", "DISEASE", 130, 148], ["serum samples", "ORGANISM_SUBSTANCE", 17, 30], ["serum samples", "TEST", 17, 30], ["reproductive animals", "PROBLEM", 34, 54], ["neonatal VWD", "PROBLEM", 101, 113], ["outbreaks of neurological signs", "PROBLEM", 117, 148], ["this study", "TEST", 178, 188], ["total", "OBSERVATION_MODIFIER", 2, 7], ["no", "UNCERTAINTY", 87, 89]]], ["Samples represented 104 farms from 19 swine production states.", [["swine", "SPECIES", 38, 43], ["swine", "SPECIES", 38, 43], ["Samples", "TEST", 0, 7]]], ["The overall seroprevalence detected was 53.34% (CI \u00b1 1.86).", [["The overall seroprevalence", "TEST", 0, 26], ["CI", "TEST", 48, 50]]], ["The between-farm prevalence was 96.15% (CI \u00b1 3.70).", [["CI", "TEST", 40, 42]]], ["This study further demonstrated that PHEV is circulating subclinically in the U.S. swine population.Global Distribution and Epidemiology of PHEV InfectionLikewise, a serological survey was performed on farms with different grades of biosecurity in Argentina (67).", [["PHEV", "CHEMICAL", 37, 41], ["PHEV", "GENE_OR_GENE_PRODUCT", 37, 41], ["PHEV", "PROTEIN", 37, 41], ["swine", "SPECIES", 83, 88], ["PHEV", "SPECIES", 37, 41], ["PHEV", "SPECIES", 140, 144], ["This study", "TEST", 0, 10], ["PHEV InfectionLikewise", "PROBLEM", 140, 162], ["a serological survey", "TEST", 164, 184], ["Distribution", "OBSERVATION_MODIFIER", 107, 119]]], ["A total of 961 serum samples collected from 14 breeding herds and three farrow-to-finish farms were evaluated.", [["serum samples", "ANATOMY", 15, 28], ["serum samples", "ORGANISM_SUBSTANCE", 15, 28], ["serum samples", "TEST", 15, 28]]], ["Samples were collected from 30 randomly selected gilts, sows or growing/fattener pigs.", [["Samples", "ANATOMY", 0, 7], ["sows", "ORGANISM", 56, 60], ["pigs", "ORGANISM", 81, 85], ["sows", "SPECIES", 56, 60], ["pigs", "SPECIES", 81, 85], ["Samples", "TEST", 0, 7], ["fattener pigs", "OBSERVATION", 72, 85]]], ["The overall seroprevalence was 41.62% (CI \u00b1 3.12).", [["CI", "TEST", 39, 41]]], ["Among positive farms, the within herd prevalence varied from 12.5 to 86.6% for sows, 25 to 85.7% for gilts, and 3.7 to 90% for grower/fattener pigs.", [["pigs", "ORGANISM", 143, 147], ["pigs", "SPECIES", 143, 147], ["gilts", "TEST", 101, 106], ["positive farms", "OBSERVATION", 6, 20]]], ["No statistical differences in seroprevalence as it pertained to age category or biosecurity status were observed.", [["statistical", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26]]], ["The presence of antibodies in grower/finisher pigs suggested that colostral antibodies may persist for more than 6 weeks or, alternatively, that the animals were subclinically infected during the grower-finisher stage.", [["pigs", "ORGANISM", 46, 50], ["colostral antibodies", "GENE_OR_GENE_PRODUCT", 66, 86], ["animals", "ORGANISM", 149, 156], ["antibodies", "PROTEIN", 16, 26], ["colostral antibodies", "PROTEIN", 66, 86], ["pigs", "SPECIES", 46, 50], ["antibodies", "PROBLEM", 16, 26], ["colostral antibodies", "PROBLEM", 66, 86], ["antibodies", "OBSERVATION", 16, 26], ["subclinically", "OBSERVATION_MODIFIER", 162, 175], ["infected", "OBSERVATION", 176, 184]]], ["This survey demonstrated that PHEV is widespread and is undergone subclinically in Argentina.Global Distribution and Epidemiology of PHEV InfectionIt is generally accepted that only piglets under 3\u20134 weeks of age born from PHEV na\u00efve dams are susceptible to PHEV-associated disease (72).", [["PHEV", "CHEMICAL", 30, 34], ["PHEV", "CHEMICAL", 258, 262], ["piglets", "ORGANISM", 182, 189], ["dams", "ORGANISM", 234, 238], ["piglets", "SPECIES", 182, 189], ["PHEV", "SPECIES", 30, 34], ["PHEV", "SPECIES", 133, 137], ["PHEV", "SPECIES", 223, 227], ["PHEV", "SPECIES", 258, 262], ["This survey", "TEST", 0, 11], ["Global Distribution", "PROBLEM", 93, 112], ["PHEV InfectionIt", "PROBLEM", 133, 149], ["PHEV-associated disease", "PROBLEM", 258, 281], ["widespread", "OBSERVATION_MODIFIER", 38, 48], ["subclinically", "OBSERVATION_MODIFIER", 66, 79], ["Distribution", "OBSERVATION_MODIFIER", 100, 112], ["PHEV InfectionIt", "OBSERVATION", 133, 149]]], ["Older pigs do not usually develop clinical disease.", [["pigs", "ORGANISM", 6, 10], ["pigs", "SPECIES", 6, 10], ["pigs", "SPECIES", 6, 10], ["clinical disease", "PROBLEM", 34, 50]]], ["The presence of persistently infected subclinical carriers has not been fully demonstrated.", [["persistently infected subclinical carriers", "PROBLEM", 16, 58], ["persistently", "OBSERVATION_MODIFIER", 16, 28], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["subclinical", "OBSERVATION", 38, 49]]], ["Since PHEV is endemic in most swine populations, most dams are immune to PHEV and can confer passive immunity to their offspring.", [["PHEV", "CHEMICAL", 6, 10], ["PHEV", "CHEMICAL", 73, 77], ["PHEV", "GENE_OR_GENE_PRODUCT", 6, 10], ["dams", "ORGANISM", 54, 58], ["PHEV", "CANCER", 73, 77], ["swine", "SPECIES", 30, 35], ["PHEV", "SPECIES", 6, 10], ["swine", "SPECIES", 30, 35], ["PHEV", "SPECIES", 73, 77], ["endemic", "PROBLEM", 14, 21], ["endemic", "OBSERVATION_MODIFIER", 14, 21], ["most swine", "OBSERVATION_MODIFIER", 25, 35]]], ["Thus, clinical outbreaks are rare and limited to litters from PHEV naive gilts or low-parity sows.", [["sows", "ORGANISM", 93, 97], ["clinical outbreaks", "PROBLEM", 6, 24]]], ["In fact, there are only three major outbreaks described to date.", [["major", "OBSERVATION_MODIFIER", 30, 35], ["outbreaks", "OBSERVATION", 36, 45]]], ["In 2001, PHEV was isolated from newborn and early-weaned pigs with vomiting and posterior paralysis in Quebec (62), and in 2002 a 650-sow genetic nucleus in Ontario suffered an outbreak of VWD (73).", [["nucleus", "ANATOMY", 146, 153], ["vomiting", "DISEASE", 67, 75], ["paralysis", "DISEASE", 90, 99], ["VWD", "DISEASE", 189, 192], ["PHEV", "CANCER", 9, 13], ["pigs", "ORGANISM", 57, 61], ["pigs", "SPECIES", 57, 61], ["PHEV", "SPECIES", 9, 13], ["vomiting", "PROBLEM", 67, 75], ["posterior paralysis", "PROBLEM", 80, 99], ["VWD", "PROBLEM", 189, 192], ["posterior", "ANATOMY_MODIFIER", 80, 89], ["paralysis", "OBSERVATION", 90, 99], ["nucleus", "ANATOMY", 146, 153]]], ["In 2006 a VWD outbreak with motor disorders and high mortality, affecting a three-site herd with 6,000 sows and 55% replacement rate, was reported for the first time in Argentina (66).Clinical DiseasePHEV can infect na\u00efve pigs of any age, but clinical disease is variable and dependent on age, possible differences in virus virulence (74), and the course of viral pathogenesis.", [["VWD", "DISEASE", 10, 13], ["motor disorders", "DISEASE", 28, 43], ["pigs", "ORGANISM", 222, 226], ["pigs", "SPECIES", 222, 226], ["pigs", "SPECIES", 222, 226], ["motor disorders", "PROBLEM", 28, 43], ["high mortality", "PROBLEM", 48, 62], ["55% replacement rate", "TREATMENT", 112, 132], ["clinical disease", "PROBLEM", 243, 259], ["differences in virus virulence", "PROBLEM", 303, 333], ["viral pathogenesis", "PROBLEM", 358, 376], ["viral pathogenesis", "OBSERVATION", 358, 376]]], ["In growing pigs and adults, PHEV infection is subclinical, and animals develop a robust humoral immune response against the virus (66, 75).", [["infection", "DISEASE", 33, 42], ["pigs", "ORGANISM", 11, 15], ["adults", "ORGANISM", 20, 26], ["PHEV", "ORGANISM", 28, 32], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 11, 15], ["PHEV", "SPECIES", 28, 32], ["PHEV infection", "PROBLEM", 28, 42], ["the virus", "PROBLEM", 120, 129], ["growing", "OBSERVATION_MODIFIER", 3, 10], ["pigs", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 33, 42]]], ["Exceptionally, transient anorexia (1\u20132 days) was reported in PHEV-infected sows in absence of other clinical signs (55).", [["anorexia", "DISEASE", 25, 33], ["sows", "ORGANISM", 75, 79], ["transient anorexia", "PROBLEM", 15, 33], ["transient", "OBSERVATION_MODIFIER", 15, 24], ["anorexia", "OBSERVATION", 25, 33], ["infected", "OBSERVATION", 66, 74]]], ["An experimental study performed on 7 weeks old pigs reported transient mild neuromotor signs, including tremor and generalized muscle fasciculation in 17% (2/12) of pigs between 4 and 6 days after oronasal inoculation (75).", [["muscle", "ANATOMY", 127, 133], ["neuromotor signs", "DISEASE", 76, 92], ["tremor", "DISEASE", 104, 110], ["muscle fasciculation", "DISEASE", 127, 147], ["pigs", "ORGANISM", 47, 51], ["muscle", "ORGAN", 127, 133], ["pigs", "ORGANISM", 165, 169], ["oronasal", "ORGANISM_SUBDIVISION", 197, 205], ["pigs", "SPECIES", 47, 51], ["pigs", "SPECIES", 165, 169], ["pigs", "SPECIES", 47, 51], ["An experimental study", "TEST", 0, 21], ["transient mild neuromotor signs", "PROBLEM", 61, 92], ["tremor", "PROBLEM", 104, 110], ["generalized muscle fasciculation", "PROBLEM", 115, 147], ["oronasal inoculation", "TEST", 197, 217], ["mild", "OBSERVATION_MODIFIER", 71, 75], ["neuromotor signs", "OBSERVATION", 76, 92], ["generalized", "OBSERVATION_MODIFIER", 115, 126], ["muscle", "ANATOMY", 127, 133], ["fasciculation", "OBSERVATION", 134, 147]]], ["Acute outbreaks of VWD and encephalomyelitis have been reported in piglets under 3\u20134 weeks of age born from na\u00efve sows, with mortality rates reaching 100%.", [["VWD", "DISEASE", 19, 22], ["encephalomyelitis", "DISEASE", 27, 44], ["piglets", "ORGANISM", 67, 74], ["sows", "ORGANISM", 114, 118], ["piglets", "SPECIES", 67, 74], ["Acute outbreaks of VWD", "PROBLEM", 0, 22], ["encephalomyelitis", "PROBLEM", 27, 44], ["mortality rates", "TEST", 125, 140], ["VWD", "OBSERVATION", 19, 22], ["encephalomyelitis", "OBSERVATION", 27, 44]]], ["The first signs of infection are generally non-specific and may include sneezing and/or coughing because of virus replication primarily occur in the upper respiratory tract; followed by transient fever that may last for 1\u20132 days.", [["upper respiratory tract", "ANATOMY", 149, 172], ["infection", "DISEASE", 19, 28], ["sneezing", "DISEASE", 72, 80], ["coughing", "DISEASE", 88, 96], ["fever", "DISEASE", 196, 201], ["upper", "ORGANISM_SUBDIVISION", 149, 154], ["respiratory tract", "ORGANISM_SUBDIVISION", 155, 172], ["infection", "PROBLEM", 19, 28], ["sneezing", "PROBLEM", 72, 80], ["coughing", "PROBLEM", 88, 96], ["virus replication", "PROBLEM", 108, 125], ["transient fever", "PROBLEM", 186, 201], ["infection", "OBSERVATION", 19, 28], ["may include", "UNCERTAINTY", 60, 71], ["sneezing", "OBSERVATION", 72, 80], ["upper", "ANATOMY_MODIFIER", 149, 154], ["respiratory tract", "ANATOMY", 155, 172], ["transient", "OBSERVATION_MODIFIER", 186, 195], ["fever", "OBSERVATION", 196, 201]]], ["More specific clinical manifestations may appear between 4 and 7 days after infection and are characterized by (1) VWD and (2) neurological signs including tremor, recumbency, padding opisthotonus, and finally death.", [["neurological", "ANATOMY", 127, 139], ["infection", "DISEASE", 76, 85], ["VWD", "DISEASE", 115, 118], ["tremor", "DISEASE", 156, 162], ["opisthotonus", "DISEASE", 184, 196], ["death", "DISEASE", 210, 215], ["infection", "PROBLEM", 76, 85], ["1) VWD and (2) neurological signs", "PROBLEM", 112, 145], ["tremor", "PROBLEM", 156, 162], ["recumbency", "PROBLEM", 164, 174], ["padding opisthotonus", "PROBLEM", 176, 196], ["finally death", "PROBLEM", 202, 215], ["infection", "OBSERVATION", 76, 85], ["tremor", "OBSERVATION", 156, 162]]], ["Both clinical forms can be observed concurrently in the same herd during an acute outbreak.", [["an acute outbreak", "PROBLEM", 73, 90], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["outbreak", "OBSERVATION", 82, 90]]], ["More recently, PHEV was associated with a case of influenza-like respiratory illness in a swine exhibition in Michigan, USA, in 2015 (76).", [["respiratory", "ANATOMY", 65, 76], ["influenza-like respiratory illness", "DISEASE", 50, 84], ["PHEV", "CANCER", 15, 19], ["swine", "SPECIES", 90, 95], ["PHEV", "SPECIES", 15, 19], ["swine", "SPECIES", 90, 95], ["influenza", "PROBLEM", 50, 59], ["respiratory illness", "PROBLEM", 65, 84], ["influenza", "OBSERVATION", 50, 59], ["respiratory illness", "OBSERVATION", 65, 84]]], ["Although PEHV can replicate in the respiratory epithelium, the role of PHEV as respiratory pathogen has not yet been confirmed and needs further investigation.Clinical DiseaseThe VWD was experimentally reproduced and reported for the first time in 1974 (59) in colostrum-deprived (CD) pigs by oronasal and intracranial inoculation.", [["respiratory epithelium", "ANATOMY", 35, 57], ["intracranial", "ANATOMY", 306, 318], ["VWD", "DISEASE", 179, 182], ["PEHV", "GENE_OR_GENE_PRODUCT", 9, 13], ["respiratory epithelium", "TISSUE", 35, 57], ["PHEV", "GENE_OR_GENE_PRODUCT", 71, 75], ["colostrum", "ORGANISM", 261, 270], ["pigs", "ORGANISM", 285, 289], ["oronasal", "ORGANISM_SUBDIVISION", 293, 301], ["PEHV", "PROTEIN", 9, 13], ["pigs", "SPECIES", 285, 289], ["PEHV", "SPECIES", 9, 13], ["PHEV", "SPECIES", 71, 75], ["pigs", "SPECIES", 285, 289], ["respiratory pathogen", "PROBLEM", 79, 99], ["further investigation", "TEST", 137, 158], ["Clinical Disease", "PROBLEM", 159, 175], ["oronasal and intracranial inoculation", "PROBLEM", 293, 330], ["respiratory epithelium", "ANATOMY", 35, 57], ["VWD", "OBSERVATION", 179, 182], ["oronasal", "ANATOMY", 293, 301], ["intracranial", "ANATOMY", 306, 318], ["inoculation", "OBSERVATION", 319, 330]]], ["Mengeling et al. (74) experimentally reproduced both clinical forms of the disease in neonatal pigs inoculated with a field virus isolate.", [["pigs", "ORGANISM", 95, 99], ["pigs", "SPECIES", 95, 99], ["pigs", "SPECIES", 95, 99], ["the disease", "PROBLEM", 71, 82], ["neonatal pigs", "TREATMENT", 86, 99], ["a field virus isolate", "TREATMENT", 116, 137], ["disease", "OBSERVATION", 75, 82]]], ["Later, Andries et al. (77) evaluated the clinical and pathogenic outcomes with different routes of inoculation.", [["inoculation", "PROBLEM", 99, 110]]], ["In this experiment, all piglets inoculated oronasally or via the infraorbital nerve showed signs of VWD 5 days after the inoculation.", [["oronasally", "ANATOMY", 43, 53], ["infraorbital nerve", "ANATOMY", 65, 83], ["VWD", "DISEASE", 100, 103], ["piglets", "ORGANISM", 24, 31], ["infraorbital nerve", "MULTI-TISSUE_STRUCTURE", 65, 83], ["piglets", "SPECIES", 24, 31], ["piglets", "SPECIES", 24, 31], ["VWD", "PROBLEM", 100, 103], ["the inoculation", "TREATMENT", 117, 132], ["infraorbital nerve", "ANATOMY", 65, 83]]], ["However, a high percentage of animals inoculated through the stomach wall, intramuscularly, and intracerebrally showed VWD signs 3 days after inoculation.", [["stomach wall", "ANATOMY", 61, 73], ["intramuscularly", "ANATOMY", 75, 90], ["VWD", "DISEASE", 119, 122], ["stomach wall", "MULTI-TISSUE_STRUCTURE", 61, 73], ["VWD signs", "PROBLEM", 119, 128], ["inoculation", "PROBLEM", 142, 153], ["high", "OBSERVATION_MODIFIER", 11, 15], ["percentage", "OBSERVATION_MODIFIER", 16, 26], ["stomach", "ANATOMY", 61, 68], ["wall", "ANATOMY_MODIFIER", 69, 73], ["VWD", "OBSERVATION", 119, 122]]], ["Pigs inoculated intravenously, intraperitoneal or in the stomach lumen did not show PHEV-associated VDW signs.Clinical DiseaseSuckling piglets experiencing PHEV-associated VWD show repeated retching and vomiting, which could be centrally induced (4, 49, 59, 73).", [["intravenously", "ANATOMY", 16, 29], ["intraperitoneal", "ANATOMY", 31, 46], ["stomach lumen", "ANATOMY", 57, 70], ["PHEV", "CHEMICAL", 84, 88], ["PHEV", "CHEMICAL", 156, 160], ["VWD", "DISEASE", 172, 175], ["retching", "DISEASE", 190, 198], ["vomiting", "DISEASE", 203, 211], ["Pigs", "ORGANISM", 0, 4], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 29], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 46], ["stomach", "ORGANISM_SUBDIVISION", 57, 64], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 70], ["piglets", "ORGANISM", 135, 142], ["Pigs", "SPECIES", 0, 4], ["piglets", "SPECIES", 135, 142], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["intraperitoneal or in the stomach lumen", "TEST", 31, 70], ["PHEV", "TEST", 84, 88], ["associated VDW signs", "PROBLEM", 89, 109], ["Clinical DiseaseSuckling piglets", "PROBLEM", 110, 142], ["PHEV", "TEST", 156, 160], ["VWD", "PROBLEM", 172, 175], ["repeated retching", "PROBLEM", 181, 198], ["vomiting", "PROBLEM", 203, 211], ["stomach", "ANATOMY", 57, 64], ["lumen", "ANATOMY_MODIFIER", 65, 70], ["VDW signs", "OBSERVATION", 100, 109], ["retching", "OBSERVATION", 190, 198]]], ["The persistent vomiting and decreased food intake result in dehydration, constipation, and therefore a rapid loss of body condition.", [["body", "ANATOMY", 117, 121], ["vomiting", "DISEASE", 15, 23], ["dehydration", "DISEASE", 60, 71], ["constipation", "DISEASE", 73, 85], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["The persistent vomiting", "PROBLEM", 0, 23], ["decreased food intake", "PROBLEM", 28, 49], ["dehydration", "PROBLEM", 60, 71], ["constipation", "PROBLEM", 73, 85], ["a rapid loss of body condition", "PROBLEM", 101, 131], ["persistent", "OBSERVATION_MODIFIER", 4, 14], ["vomiting", "OBSERVATION", 15, 23], ["decreased", "OBSERVATION_MODIFIER", 28, 37], ["food intake", "OBSERVATION", 38, 49], ["dehydration", "OBSERVATION", 60, 71], ["constipation", "OBSERVATION", 73, 85]]], ["PHEV-infected neonates become severely dehydrated after few days, exhibit dyspnea, cyanosis, lapse into a coma, and die.", [["PHEV", "CHEMICAL", 0, 4], ["dyspnea", "DISEASE", 74, 81], ["cyanosis", "DISEASE", 83, 91], ["coma", "DISEASE", 106, 110], ["PHEV", "ORGANISM", 0, 4], ["neonates", "ORGANISM", 14, 22], ["PHEV", "SPECIES", 0, 4], ["infected neonates", "PROBLEM", 5, 22], ["severely dehydrated", "PROBLEM", 30, 49], ["dyspnea", "PROBLEM", 74, 81], ["cyanosis", "PROBLEM", 83, 91], ["infected", "OBSERVATION", 5, 13], ["severely", "OBSERVATION_MODIFIER", 30, 38], ["dehydrated", "OBSERVATION", 39, 49], ["dyspnea", "OBSERVATION", 74, 81], ["cyanosis", "OBSERVATION", 83, 91]]], ["During the acute stage of VWD outbreaks, some pigs may also display neurologic signs, including muscle tremors, hyperesthesia, excess physical sensitivity, incoordination, paddling, paralysis, and dullness (68).", [["neurologic", "ANATOMY", 68, 78], ["muscle", "ANATOMY", 96, 102], ["VWD", "DISEASE", 26, 29], ["neurologic signs", "DISEASE", 68, 84], ["muscle tremors", "DISEASE", 96, 110], ["hyperesthesia", "DISEASE", 112, 125], ["excess physical sensitivity", "DISEASE", 127, 154], ["incoordination", "DISEASE", 156, 170], ["paralysis", "DISEASE", 182, 191], ["dullness", "DISEASE", 197, 205], ["pigs", "ORGANISM", 46, 50], ["muscle", "ORGAN", 96, 102], ["pigs", "SPECIES", 46, 50], ["pigs", "SPECIES", 46, 50], ["VWD outbreaks", "PROBLEM", 26, 39], ["neurologic signs", "PROBLEM", 68, 84], ["muscle tremors", "PROBLEM", 96, 110], ["hyperesthesia", "PROBLEM", 112, 125], ["excess physical sensitivity", "PROBLEM", 127, 154], ["incoordination", "PROBLEM", 156, 170], ["paddling", "PROBLEM", 172, 180], ["paralysis", "PROBLEM", 182, 191], ["dullness", "PROBLEM", 197, 205], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["VWD", "OBSERVATION", 26, 29], ["muscle", "ANATOMY", 96, 102], ["tremors", "OBSERVATION", 103, 110], ["hyperesthesia", "OBSERVATION", 112, 125], ["paralysis", "OBSERVATION", 182, 191], ["dullness", "OBSERVATION_MODIFIER", 197, 205]]], ["When the infection occurs in older pigs, there is anorexia followed by emaciation (Figure 1).", [["infection", "DISEASE", 9, 18], ["anorexia", "DISEASE", 50, 58], ["emaciation", "DISEASE", 71, 81], ["pigs", "ORGANISM", 35, 39], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 35, 39], ["the infection", "PROBLEM", 5, 18], ["anorexia", "PROBLEM", 50, 58], ["emaciation", "PROBLEM", 71, 81], ["infection", "OBSERVATION", 9, 18], ["anorexia", "OBSERVATION", 50, 58]]], ["They continue to vomit, although less frequently than in the acute stage.", [["vomit", "PROBLEM", 17, 22]]], ["After the acute stage, animals start showing emaciation (\u201cwasting disease\u201d) and often present distension of the cranial abdomen.", [["cranial abdomen", "ANATOMY", 112, 127], ["emaciation", "DISEASE", 45, 55], ["wasting", "DISEASE", 58, 65], ["cranial abdomen", "ORGAN", 112, 127], ["the acute stage", "PROBLEM", 6, 21], ["emaciation (\u201cwasting disease\u201d", "PROBLEM", 45, 74], ["distension of the cranial abdomen", "PROBLEM", 94, 127], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["distension", "OBSERVATION", 94, 104], ["cranial", "ANATOMY_MODIFIER", 112, 119], ["abdomen", "ANATOMY", 120, 127]]], ["This \u201cwasting\u201d state may persist for several weeks after weaning, which in most cases requires euthanasia.Clinical DiseasePre-weaning morbidity varies depending on the immune status of neonatal litters at the time of PHEV infection (4, 74).", [["wasting", "DISEASE", 6, 13], ["infection", "DISEASE", 222, 231], ["litters", "ORGAN", 194, 201], ["PHEV", "SPECIES", 217, 221], ["euthanasia", "PROBLEM", 95, 105], ["Clinical DiseasePre-weaning morbidity", "PROBLEM", 106, 143], ["neonatal litters", "PROBLEM", 185, 201], ["PHEV infection", "PROBLEM", 217, 231], ["euthanasia", "OBSERVATION", 95, 105], ["infection", "OBSERVATION", 222, 231]]], ["In piglets without lactogenic immunity against PHEV, morbidity is litter-dependent and may approach 100% when the infection occurs near birth.", [["PHEV", "CHEMICAL", 47, 51], ["infection", "DISEASE", 114, 123], ["piglets", "ORGANISM", 3, 10], ["piglets", "SPECIES", 3, 10], ["PHEV", "SPECIES", 47, 51], ["lactogenic immunity", "TREATMENT", 19, 38], ["morbidity", "PROBLEM", 53, 62], ["the infection", "PROBLEM", 110, 123], ["infection", "OBSERVATION", 114, 123]]], ["Overall, morbidity decreases markedly as the pig's age increases at the time of PHEV infection.", [["infection", "DISEASE", 85, 94], ["pig", "ORGANISM", 45, 48], ["pig", "SPECIES", 45, 48], ["PHEV", "SPECIES", 80, 84], ["morbidity", "PROBLEM", 9, 18], ["PHEV infection", "PROBLEM", 80, 94], ["morbidity", "OBSERVATION", 9, 18], ["decreases", "OBSERVATION_MODIFIER", 19, 28], ["markedly", "OBSERVATION_MODIFIER", 29, 37], ["infection", "OBSERVATION", 85, 94]]], ["Mortality is variable, reaching up to 100% in neonatal litters born from PHEV na\u00efve dams.", [["PHEV", "SPECIES", 73, 77], ["variable", "OBSERVATION_MODIFIER", 13, 21]]], ["However, a different epidemiological picture was observed in the outbreak reported during the winter of 2006 in Argentina (66) where only suckling pigs born from an isolated pool of non-immune gilts were affected.", [["pigs", "ORGANISM", 147, 151], ["gilts", "ORGANISM", 193, 198], ["pigs", "SPECIES", 147, 151], ["pigs", "SPECIES", 147, 151], ["a different epidemiological picture", "PROBLEM", 9, 44], ["non-immune gilts", "PROBLEM", 182, 198], ["different", "OBSERVATION_MODIFIER", 11, 20], ["non-immune gilts", "OBSERVATION", 182, 198]]], ["The severity of the main clinical signs reported, including vomiting, emaciation, wasting, and death was unexpected according to previous reports in the field (73).", [["vomiting", "DISEASE", 60, 68], ["emaciation", "DISEASE", 70, 80], ["wasting", "DISEASE", 82, 89], ["death", "DISEASE", 95, 100], ["the main clinical signs", "PROBLEM", 16, 39], ["vomiting", "PROBLEM", 60, 68], ["emaciation", "PROBLEM", 70, 80], ["wasting", "PROBLEM", 82, 89], ["death", "PROBLEM", 95, 100], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["main", "OBSERVATION_MODIFIER", 20, 24]]], ["The morbidity was 27.6% in 1 week old pigs and declined to 1.6% in 3 weeks old pigs.", [["pigs", "ORGANISM", 38, 42], ["pigs", "ORGANISM", 79, 83], ["pigs", "SPECIES", 38, 42], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 38, 42], ["pigs", "SPECIES", 79, 83], ["The morbidity", "TEST", 0, 13], ["morbidity", "OBSERVATION_MODIFIER", 4, 13]]], ["After weaning, 15\u201340% of the pigs coming from affected farrowing units showed wasting disease.", [["wasting disease", "DISEASE", 78, 93], ["pigs", "ORGANISM", 29, 33], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 29, 33], ["the pigs", "TREATMENT", 25, 33], ["wasting disease", "PROBLEM", 78, 93], ["wasting disease", "OBSERVATION", 78, 93]]], ["An estimated 12.6% (3,683) pigs died or were euthanized (66).Clinical DiseaseThe first clinical signs observed during neurological PHEV outbreaks include sneezing, coughing, and vomiting 4\u20137 days after birth, with a morbidity rate of approximately 100% (4, 78, 79).", [["neurological", "ANATOMY", 118, 130], ["sneezing", "DISEASE", 154, 162], ["coughing", "DISEASE", 164, 172], ["vomiting", "DISEASE", 178, 186], ["pigs", "ORGANISM", 27, 31], ["pigs", "SPECIES", 27, 31], ["Clinical Disease", "PROBLEM", 61, 77], ["sneezing", "PROBLEM", 154, 162], ["coughing", "PROBLEM", 164, 172], ["vomiting", "PROBLEM", 178, 186], ["a morbidity rate", "TEST", 214, 230], ["12.6%", "OBSERVATION_MODIFIER", 13, 18]]], ["Mild vomiting may continue intermittently for 1\u20132 days.", [["vomiting", "DISEASE", 5, 13], ["Mild vomiting", "PROBLEM", 0, 13], ["vomiting", "OBSERVATION", 5, 13]]], ["In some outbreaks, the first sign is acute depression and huddling.", [["depression", "DISEASE", 43, 53], ["acute depression and huddling", "PROBLEM", 37, 66], ["some", "OBSERVATION_MODIFIER", 3, 7], ["outbreaks", "OBSERVATION", 8, 17], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["depression", "OBSERVATION", 43, 53]]], ["After 1\u20133 days, pigs exhibit various combinations of neurological disorders.", [["neurological", "ANATOMY", 53, 65], ["neurological disorders", "DISEASE", 53, 75], ["pigs", "ORGANISM", 16, 20], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["pigs", "TREATMENT", 16, 20], ["neurological disorders", "PROBLEM", 53, 75]]], ["Generalized muscle tremors and hyperesthesia are common.", [["muscle", "ANATOMY", 12, 18], ["muscle tremors", "DISEASE", 12, 26], ["hyperesthesia", "DISEASE", 31, 44], ["muscle", "ORGAN", 12, 18], ["Generalized muscle tremors", "PROBLEM", 0, 26], ["hyperesthesia", "PROBLEM", 31, 44], ["muscle", "ANATOMY", 12, 18], ["tremors", "OBSERVATION", 19, 26], ["hyperesthesia", "OBSERVATION", 31, 44]]], ["Pigs may have a jerky gait and walk backwards, ending in a dog-sitting position.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4]]], ["They become weak and unable to rise, and they paddle their limbs.", [["limbs", "ANATOMY", 59, 64], ["limbs", "ORGANISM_SUBDIVISION", 59, 64], ["weak", "PROBLEM", 12, 16], ["weak", "OBSERVATION", 12, 16], ["limbs", "ANATOMY", 59, 64]]], ["Blindness, opisthotonus, and nystagmus may also occur.", [["Blindness", "DISEASE", 0, 9], ["opisthotonus", "DISEASE", 11, 23], ["nystagmus", "DISEASE", 29, 38], ["Blindness", "PROBLEM", 0, 9], ["opisthotonus", "PROBLEM", 11, 23], ["nystagmus", "PROBLEM", 29, 38], ["nystagmus", "OBSERVATION", 29, 38]]], ["Finally, the animals become dyspneic and lie in lateral recumbency.", [["dyspneic", "DISEASE", 28, 36], ["dyspneic", "PROBLEM", 28, 36], ["lie in lateral recumbency", "PROBLEM", 41, 66], ["dyspneic", "OBSERVATION", 28, 36], ["lateral", "ANATOMY_MODIFIER", 48, 55], ["recumbency", "OBSERVATION_MODIFIER", 56, 66]]], ["In most cases, coma precedes death, with a mortality rate of 100% in neonatal pigs (4).", [["coma", "DISEASE", 15, 19], ["death", "DISEASE", 29, 34], ["pigs", "ORGANISM", 78, 82], ["pigs", "SPECIES", 78, 82], ["a mortality rate", "TEST", 41, 57]]], ["Older pigs show mild transient neurological signs, including generalized muscle fasciculation and posterior paralysis.", [["neurological", "ANATOMY", 31, 43], ["muscle", "ANATOMY", 73, 79], ["neurological signs", "DISEASE", 31, 49], ["muscle fasciculation", "DISEASE", 73, 93], ["paralysis", "DISEASE", 108, 117], ["pigs", "ORGANISM", 6, 10], ["muscle", "ORGAN", 73, 79], ["pigs", "SPECIES", 6, 10], ["mild transient neurological signs", "PROBLEM", 16, 49], ["generalized muscle fasciculation", "PROBLEM", 61, 93], ["posterior paralysis", "PROBLEM", 98, 117], ["mild", "OBSERVATION_MODIFIER", 16, 20], ["transient", "OBSERVATION_MODIFIER", 21, 30], ["neurological signs", "OBSERVATION", 31, 49], ["generalized", "OBSERVATION_MODIFIER", 61, 72], ["muscle", "ANATOMY", 73, 79], ["fasciculation", "OBSERVATION", 80, 93], ["posterior", "ANATOMY_MODIFIER", 98, 107], ["paralysis", "OBSERVATION", 108, 117]]], ["Outbreaks described in Taiwan (65) in 30\u201350 days old pigs were characterized by fever, constipation, hyperesthesia, muscular tremor, progressive anterior paresis, posterior paresis, prostration, recumbency, and paddling movements with a morbidity of 4% and a mortality of 100% at 4\u20135 days after the onset of clinical signs.Clinical DiseaseIn non-swine species, PHEV-related disease only has been induced experimentally.", [["muscular", "ANATOMY", 116, 124], ["fever", "DISEASE", 80, 85], ["constipation", "DISEASE", 87, 99], ["hyperesthesia", "DISEASE", 101, 114], ["muscular tremor", "DISEASE", 116, 131], ["anterior paresis", "DISEASE", 145, 161], ["paresis", "DISEASE", 173, 180], ["prostration", "DISEASE", 182, 193], ["PHEV", "CHEMICAL", 361, 365], ["pigs", "ORGANISM", 53, 57], ["pigs", "SPECIES", 53, 57], ["pigs", "SPECIES", 53, 57], ["fever", "PROBLEM", 80, 85], ["constipation", "PROBLEM", 87, 99], ["hyperesthesia", "PROBLEM", 101, 114], ["muscular tremor", "PROBLEM", 116, 131], ["progressive anterior paresis", "PROBLEM", 133, 161], ["posterior paresis", "PROBLEM", 163, 180], ["prostration", "PROBLEM", 182, 193], ["recumbency", "PROBLEM", 195, 205], ["paddling movements", "PROBLEM", 211, 229], ["clinical signs", "PROBLEM", 308, 322], ["Clinical DiseaseIn non-swine species", "PROBLEM", 323, 359], ["disease", "PROBLEM", 374, 381], ["fever", "OBSERVATION", 80, 85], ["hyperesthesia", "OBSERVATION", 101, 114], ["muscular", "ANATOMY", 116, 124], ["tremor", "OBSERVATION", 125, 131], ["progressive", "OBSERVATION_MODIFIER", 133, 144], ["anterior", "ANATOMY_MODIFIER", 145, 153], ["paresis", "OBSERVATION", 154, 161], ["posterior", "ANATOMY_MODIFIER", 163, 172], ["paresis", "OBSERVATION", 173, 180], ["recumbency", "OBSERVATION_MODIFIER", 195, 205], ["disease", "OBSERVATION", 374, 381]]], ["It was also demonstrated that suckling mice (3 days old) were susceptible in a dose- and age-dependent manner to PHEV infection through intracranial inoculation, showing neurological signs and dying (80).Pathogenesis and Gross and Histological LesionsThe primary site of replication of PHEV in pigs is the respiratory tract, which may result in mild or subclinical disease (76, 77, 81\u201383).", [["intracranial", "ANATOMY", 136, 148], ["neurological", "ANATOMY", 170, 182], ["respiratory tract", "ANATOMY", 306, 323], ["PHEV", "CHEMICAL", 113, 117], ["infection", "DISEASE", 118, 127], ["PHEV", "CHEMICAL", 286, 290], ["suckling mice", "ORGANISM", 30, 43], ["PHEV", "ORGANISM", 113, 117], ["PHEV", "ORGANISM", 286, 290], ["pigs", "ORGANISM", 294, 298], ["respiratory tract", "ORGANISM_SUBDIVISION", 306, 323], ["mice", "SPECIES", 39, 43], ["pigs", "SPECIES", 294, 298], ["mice", "SPECIES", 39, 43], ["PHEV", "SPECIES", 113, 117], ["PHEV", "SPECIES", 286, 290], ["pigs", "SPECIES", 294, 298], ["PHEV infection", "PROBLEM", 113, 127], ["intracranial inoculation", "PROBLEM", 136, 160], ["neurological signs", "PROBLEM", 170, 188], ["Pathogenesis", "PROBLEM", 204, 216], ["Gross and Histological Lesions", "PROBLEM", 221, 251], ["replication of PHEV in pigs", "TREATMENT", 271, 298], ["mild or subclinical disease", "PROBLEM", 345, 372], ["infection", "OBSERVATION", 118, 127], ["intracranial", "ANATOMY", 136, 148], ["inoculation", "OBSERVATION", 149, 160], ["Gross", "OBSERVATION_MODIFIER", 221, 226], ["Histological", "OBSERVATION_MODIFIER", 231, 243], ["Lesions", "OBSERVATION", 244, 251], ["replication", "OBSERVATION", 271, 282], ["respiratory tract", "ANATOMY", 306, 323], ["mild", "OBSERVATION_MODIFIER", 345, 349], ["subclinical", "OBSERVATION_MODIFIER", 353, 364], ["disease", "OBSERVATION", 365, 372]]], ["Immunofluorescence testing revealed that epithelial cells of nasal mucosa, tonsils, lungs, and some unidentified cells in the small intestine can be infected (63).", [["epithelial cells", "ANATOMY", 41, 57], ["nasal mucosa", "ANATOMY", 61, 73], ["tonsils", "ANATOMY", 75, 82], ["lungs", "ANATOMY", 84, 89], ["cells", "ANATOMY", 113, 118], ["small intestine", "ANATOMY", 126, 141], ["epithelial cells", "CELL", 41, 57], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 61, 73], ["tonsils", "ORGAN", 75, 82], ["lungs", "ORGAN", 84, 89], ["cells", "CELL", 113, 118], ["small intestine", "ORGAN", 126, 141], ["epithelial cells", "CELL_TYPE", 41, 57], ["Immunofluorescence testing", "TEST", 0, 26], ["epithelial cells of nasal mucosa, tonsils, lungs", "PROBLEM", 41, 89], ["some unidentified cells in the small intestine", "PROBLEM", 95, 141], ["epithelial cells", "OBSERVATION", 41, 57], ["nasal mucosa", "ANATOMY", 61, 73], ["tonsils", "ANATOMY", 75, 82], ["lungs", "ANATOMY", 84, 89], ["cells", "OBSERVATION", 113, 118], ["small intestine", "ANATOMY", 126, 141], ["infected", "OBSERVATION", 149, 157]]], ["Experimental studies using CD piglets, inoculated oronasally with PHEV, provided relevant information regarding PHEV pathogenesis (59, 77, 84).", [["oronasally", "ANATOMY", 50, 60], ["piglets", "ORGANISM", 30, 37], ["PHEV", "CANCER", 112, 116], ["piglets", "SPECIES", 30, 37], ["PHEV", "SPECIES", 66, 70], ["PHEV", "SPECIES", 112, 116], ["Experimental studies", "TEST", 0, 20], ["CD piglets", "TREATMENT", 27, 37], ["PHEV pathogenesis", "PROBLEM", 112, 129]]], ["PHEV can spread from the primary sites of replication through the peripheral nervous system to the central nervous system.", [["primary sites", "ANATOMY", 25, 38], ["peripheral nervous system", "ANATOMY", 66, 91], ["central nervous system", "ANATOMY", 99, 121], ["PHEV", "CHEMICAL", 0, 4], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 66, 91], ["central nervous system", "ANATOMICAL_SYSTEM", 99, 121], ["PHEV", "PROTEIN", 0, 4], ["PHEV", "SPECIES", 0, 4], ["PHEV", "TREATMENT", 0, 4], ["replication", "OBSERVATION", 42, 53], ["peripheral", "ANATOMY_MODIFIER", 66, 76], ["nervous system", "ANATOMY", 77, 91], ["central", "ANATOMY_MODIFIER", 99, 106], ["nervous system", "ANATOMY", 107, 121]]], ["Primary viral replication in the nasal mucosa and tonsils allows the virus to spread to the trigeminal ganglion and brainstem trigeminal sensory nucleus.", [["nasal mucosa", "ANATOMY", 33, 45], ["tonsils", "ANATOMY", 50, 57], ["trigeminal ganglion", "ANATOMY", 92, 111], ["brainstem trigeminal sensory nucleus", "ANATOMY", 116, 152], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 33, 45], ["tonsils", "ORGAN", 50, 57], ["trigeminal ganglion", "MULTI-TISSUE_STRUCTURE", 92, 111], ["brainstem trigeminal sensory nucleus", "MULTI-TISSUE_STRUCTURE", 116, 152], ["Primary viral replication in the nasal mucosa and tonsils", "PROBLEM", 0, 57], ["the virus", "PROBLEM", 65, 74], ["viral replication", "OBSERVATION", 8, 25], ["nasal mucosa", "ANATOMY", 33, 45], ["tonsils", "ANATOMY", 50, 57], ["virus", "OBSERVATION", 69, 74], ["trigeminal ganglion", "ANATOMY", 92, 111], ["brainstem", "ANATOMY_MODIFIER", 116, 125], ["trigeminal sensory nucleus", "ANATOMY", 126, 152]]], ["Viral spreading through the vagal nerve also allows the virus to infect the vagal sensory ganglion and brainstem vagal sensory nucleus.", [["vagal nerve", "ANATOMY", 28, 39], ["vagal sensory ganglion", "ANATOMY", 76, 98], ["brainstem vagal sensory nucleus", "ANATOMY", 103, 134], ["vagal nerve", "MULTI-TISSUE_STRUCTURE", 28, 39], ["vagal sensory ganglion", "TISSUE", 76, 98], ["brainstem vagal sensory nucleus", "MULTI-TISSUE_STRUCTURE", 103, 134], ["Viral spreading", "PROBLEM", 0, 15], ["the vagal nerve", "PROBLEM", 24, 39], ["the virus", "PROBLEM", 52, 61], ["vagal nerve", "ANATOMY", 28, 39], ["vagal sensory ganglion", "ANATOMY", 76, 98], ["brainstem vagal", "ANATOMY", 103, 118], ["sensory nucleus", "OBSERVATION", 119, 134]]], ["The virus can also spread peripherally from the intestinal myenteric plexuses to the local sensory ganglia of the spinal cord.", [["intestinal myenteric plexuses", "ANATOMY", 48, 77], ["sensory ganglia", "ANATOMY", 91, 106], ["spinal cord", "ANATOMY", 114, 125], ["intestinal myenteric plexuses", "MULTI-TISSUE_STRUCTURE", 48, 77], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 91, 106], ["spinal cord", "ORGAN", 114, 125], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["intestinal myenteric", "ANATOMY", 48, 68], ["plexuses", "ANATOMY_MODIFIER", 69, 77], ["local", "ANATOMY_MODIFIER", 85, 90], ["sensory", "ANATOMY_MODIFIER", 91, 98], ["ganglia", "ANATOMY_MODIFIER", 99, 106], ["spinal cord", "ANATOMY", 114, 125]]], ["Electron microscopy yielded the discovery of viral particles within nerve cells, moving from the periphery through the cell cytoplasm to reach the axon (85).", [["nerve cells", "ANATOMY", 68, 79], ["cell cytoplasm", "ANATOMY", 119, 133], ["axon", "ANATOMY", 147, 151], ["nerve cells", "CELL", 68, 79], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 119, 133], ["axon", "CELLULAR_COMPONENT", 147, 151], ["nerve cells", "CELL_TYPE", 68, 79], ["Electron microscopy", "TEST", 0, 19], ["viral particles within nerve cells", "PROBLEM", 45, 79], ["viral particles", "OBSERVATION", 45, 60], ["nerve cells", "OBSERVATION", 68, 79], ["periphery", "ANATOMY_MODIFIER", 97, 106], ["cell cytoplasm", "OBSERVATION", 119, 133]]], ["However, viral particles could not be found in surrounding glial or in inflammatory cells (85).Pathogenesis and Gross and Histological LesionsAfter peripheral viral spreading, the virus infects well-defined nuclei of the medulla oblongata progressing to the brainstem, spinal cord, and occasionally cerebrum and cerebellum.", [["glial", "ANATOMY", 59, 64], ["inflammatory cells", "ANATOMY", 71, 89], ["nuclei", "ANATOMY", 207, 213], ["medulla oblongata", "ANATOMY", 221, 238], ["brainstem", "ANATOMY", 258, 267], ["spinal cord", "ANATOMY", 269, 280], ["cerebrum", "ANATOMY", 299, 307], ["cerebellum", "ANATOMY", 312, 322], ["peripheral viral spreading", "DISEASE", 148, 174], ["glial", "CELL", 59, 64], ["inflammatory cells", "CELL", 71, 89], ["nuclei", "CELLULAR_COMPONENT", 207, 213], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 221, 238], ["brainstem", "ORGAN", 258, 267], ["spinal cord", "ORGAN", 269, 280], ["cerebrum", "ORGAN", 299, 307], ["cerebellum", "ORGAN", 312, 322], ["inflammatory cells", "CELL_TYPE", 71, 89], ["viral particles", "PROBLEM", 9, 24], ["Pathogenesis", "PROBLEM", 95, 107], ["Gross and Histological Lesions", "PROBLEM", 112, 142], ["peripheral viral spreading", "PROBLEM", 148, 174], ["the virus infects", "PROBLEM", 176, 193], ["the brainstem, spinal cord, and occasionally cerebrum and cerebellum", "PROBLEM", 254, 322], ["viral particles", "OBSERVATION", 9, 24], ["could not be found", "UNCERTAINTY", 25, 43], ["glial", "ANATOMY_MODIFIER", 59, 64], ["inflammatory cells", "OBSERVATION", 71, 89], ["Gross", "OBSERVATION_MODIFIER", 112, 117], ["Histological", "OBSERVATION_MODIFIER", 122, 134], ["Lesions", "OBSERVATION", 135, 142], ["peripheral", "ANATOMY_MODIFIER", 148, 158], ["viral spreading", "OBSERVATION", 159, 174], ["virus infects", "OBSERVATION", 180, 193], ["well-defined", "OBSERVATION_MODIFIER", 194, 206], ["nuclei", "ANATOMY_MODIFIER", 207, 213], ["medulla oblongata", "ANATOMY", 221, 238], ["brainstem", "ANATOMY_MODIFIER", 258, 267], ["spinal cord", "ANATOMY", 269, 280], ["occasionally", "ANATOMY_MODIFIER", 286, 298], ["cerebrum", "ANATOMY", 299, 307], ["cerebellum", "ANATOMY", 312, 322]]], ["Immunofluorescence staining in the brain revealed that the infection is always restricted to the perikaryon and processes of neurons (81).", [["brain", "ANATOMY", 35, 40], ["perikaryon", "ANATOMY", 97, 107], ["neurons", "ANATOMY", 125, 132], ["infection", "DISEASE", 59, 68], ["brain", "ORGAN", 35, 40], ["neurons", "CELL", 125, 132], ["Immunofluorescence staining", "TEST", 0, 27], ["the infection", "PROBLEM", 55, 68], ["brain", "ANATOMY", 35, 40], ["infection", "OBSERVATION", 59, 68]]], ["Vomiting is induced by viral replication in the vagal sensory ganglion (ganglion distale vagi) or by impulses of the vomiting center induced by vagal ganglia infected neurons (77).", [["vagal sensory ganglion", "ANATOMY", 48, 70], ["ganglion distale vagi", "ANATOMY", 72, 93], ["vagal ganglia", "ANATOMY", 144, 157], ["neurons", "ANATOMY", 167, 174], ["Vomiting", "DISEASE", 0, 8], ["vomiting", "DISEASE", 117, 125], ["vagal sensory ganglion", "TISSUE", 48, 70], ["ganglion distale vagi", "TISSUE", 72, 93], ["vagal ganglia infected neurons", "CELL", 144, 174], ["vagal ganglia infected neurons", "CELL_TYPE", 144, 174], ["Vomiting", "PROBLEM", 0, 8], ["viral replication", "PROBLEM", 23, 40], ["ganglion distale vagi)", "PROBLEM", 72, 94], ["the vomiting center", "PROBLEM", 113, 132], ["vagal ganglia infected neurons", "PROBLEM", 144, 174], ["viral replication", "OBSERVATION", 23, 40], ["vagal", "ANATOMY_MODIFIER", 48, 53], ["sensory ganglion", "ANATOMY", 54, 70], ["vagal ganglia", "ANATOMY", 144, 157]]], ["It has been suggested that virus-induced lesions in the myenteric plexus of the stomach that may contribute to gastric stasis and delayed stomach emptying (77).Pathogenesis and Gross and Histological LesionsDespite the fact that swine is the only species susceptible to PHEV natural infection, laboratory rodents such as mice (80, 86\u201391) and rats (92, 93) have been used as an alternative animal model for PHEV pathogenesis investigation.", [["lesions", "ANATOMY", 41, 48], ["myenteric plexus", "ANATOMY", 56, 72], ["stomach", "ANATOMY", 80, 87], ["gastric", "ANATOMY", 111, 118], ["stomach", "ANATOMY", 138, 145], ["gastric stasis", "DISEASE", 111, 125], ["delayed stomach emptying", "DISEASE", 130, 154], ["natural infection", "DISEASE", 275, 292], ["lesions", "PATHOLOGICAL_FORMATION", 41, 48], ["myenteric plexus", "MULTI-TISSUE_STRUCTURE", 56, 72], ["stomach", "ORGAN", 80, 87], ["gastric", "ORGAN", 111, 118], ["stomach", "ORGAN", 138, 145], ["swine", "ORGANISM", 229, 234], ["mice", "ORGANISM", 321, 325], ["rats", "ORGANISM", 342, 346], ["PHEV", "CANCER", 406, 410], ["swine", "SPECIES", 229, 234], ["mice", "SPECIES", 321, 325], ["rats", "SPECIES", 342, 346], ["swine", "SPECIES", 229, 234], ["PHEV", "SPECIES", 270, 274], ["mice", "SPECIES", 321, 325], ["PHEV", "SPECIES", 406, 410], ["virus-induced lesions in the myenteric plexus of the stomach", "PROBLEM", 27, 87], ["gastric stasis", "PROBLEM", 111, 125], ["delayed stomach emptying", "PROBLEM", 130, 154], ["Pathogenesis", "PROBLEM", 160, 172], ["Gross and Histological LesionsDespite", "PROBLEM", 177, 214], ["PHEV natural infection", "PROBLEM", 270, 292], ["rats", "TEST", 342, 346], ["PHEV pathogenesis investigation", "TEST", 406, 437], ["virus", "OBSERVATION", 27, 32], ["lesions", "OBSERVATION", 41, 48], ["myenteric plexus", "ANATOMY", 56, 72], ["stomach", "ANATOMY", 80, 87], ["may contribute to", "UNCERTAINTY", 93, 110], ["gastric", "ANATOMY", 111, 118], ["stasis", "OBSERVATION", 119, 125], ["stomach", "ANATOMY", 138, 145], ["Gross", "OBSERVATION_MODIFIER", 177, 182], ["Histological", "OBSERVATION_MODIFIER", 187, 199], ["LesionsDespite", "OBSERVATION", 200, 214], ["infection", "OBSERVATION", 283, 292]]], ["Ultrastructural studies in rats provided insights into neural pathogenesis, in which PHEV antigen was found in the ipsilateral dorsal root ganglions (DRGs) 3 days after peripheral inoculation into the rats' footpads (94, 95).", [["neural", "ANATOMY", 55, 61], ["ipsilateral dorsal root ganglions", "ANATOMY", 115, 148], ["DRGs", "ANATOMY", 150, 154], ["footpads", "ANATOMY", 207, 215], ["rats", "ORGANISM", 27, 31], ["PHEV antigen", "GENE_OR_GENE_PRODUCT", 85, 97], ["dorsal root ganglions", "MULTI-TISSUE_STRUCTURE", 127, 148], ["rats", "ORGANISM", 201, 205], ["footpads", "ORGANISM_SUBDIVISION", 207, 215], ["PHEV antigen", "PROTEIN", 85, 97], ["rats", "SPECIES", 27, 31], ["rats", "SPECIES", 201, 205], ["Ultrastructural studies", "TEST", 0, 23], ["PHEV antigen", "TEST", 85, 97], ["peripheral inoculation", "TREATMENT", 169, 191], ["ipsilateral", "ANATOMY_MODIFIER", 115, 126], ["dorsal", "ANATOMY_MODIFIER", 127, 133], ["root ganglions", "ANATOMY", 134, 148], ["footpads", "ANATOMY", 207, 215]]], ["Additional studies demonstrated that PHEV budded from endoplasmic reticulum-Golgi intermediate compartments in the cell bodies of infected neurons, and the assembled progeny viruses were vesicle-mediated, secreted, and taken up by the adjacent satellite cells (92).", [["endoplasmic reticulum-Golgi intermediate compartments", "ANATOMY", 54, 107], ["cell bodies", "ANATOMY", 115, 126], ["neurons", "ANATOMY", 139, 146], ["vesicle", "ANATOMY", 187, 194], ["satellite cells", "ANATOMY", 244, 259], ["PHEV", "GENE_OR_GENE_PRODUCT", 37, 41], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 54, 75], ["Golgi intermediate compartments", "CELLULAR_COMPONENT", 76, 107], ["cell bodies", "CELLULAR_COMPONENT", 115, 126], ["neurons", "CELL", 139, 146], ["vesicle", "CELLULAR_COMPONENT", 187, 194], ["satellite cells", "CELL", 244, 259], ["infected neurons", "CELL_TYPE", 130, 146], ["adjacent satellite cells", "CELL_TYPE", 235, 259], ["PHEV", "SPECIES", 37, 41], ["Additional studies", "TEST", 0, 18], ["PHEV budded", "PROBLEM", 37, 48], ["endoplasmic reticulum", "TEST", 54, 75], ["infected neurons", "PROBLEM", 130, 146], ["endoplasmic reticulum", "OBSERVATION", 54, 75], ["Golgi", "OBSERVATION", 76, 81], ["intermediate compartments", "OBSERVATION", 82, 107], ["cell bodies", "ANATOMY_MODIFIER", 115, 126], ["infected neurons", "OBSERVATION", 130, 146], ["progeny viruses", "OBSERVATION", 166, 181], ["satellite cells", "OBSERVATION", 244, 259]]], ["Cell damage surrounding satellite cells could be observed later during infection, with viral particles contained in vesicles and lysosomes.", [["Cell", "ANATOMY", 0, 4], ["satellite cells", "ANATOMY", 24, 39], ["vesicles", "ANATOMY", 116, 124], ["lysosomes", "ANATOMY", 129, 138], ["infection", "DISEASE", 71, 80], ["Cell", "CELL", 0, 4], ["satellite cells", "CELL", 24, 39], ["vesicles", "CELLULAR_COMPONENT", 116, 124], ["lysosomes", "CELLULAR_COMPONENT", 129, 138], ["satellite cells", "CELL_TYPE", 24, 39], ["Cell damage surrounding satellite cells", "PROBLEM", 0, 39], ["infection", "PROBLEM", 71, 80], ["viral particles", "PROBLEM", 87, 102], ["satellite cells", "OBSERVATION", 24, 39], ["infection", "OBSERVATION", 71, 80], ["viral particles", "OBSERVATION", 87, 102], ["vesicles", "ANATOMY", 116, 124], ["lysosomes", "OBSERVATION_MODIFIER", 129, 138]]], ["It has been demonstrated that PHEV replicates only in the cytoplasm of sensory neurons (93).", [["cytoplasm", "ANATOMY", 58, 67], ["sensory neurons", "ANATOMY", 71, 86], ["PHEV", "GENE_OR_GENE_PRODUCT", 30, 34], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["sensory neurons", "CELL", 71, 86], ["PHEV", "PROTEIN", 30, 34], ["sensory neurons", "CELL_TYPE", 71, 86], ["sensory neurons", "ANATOMY", 71, 86]]], ["Progeny virions were released through an exocytic pathway, and PHEV viral particles accumulate in dilated extracellular spaces between satellite cells.", [["virions", "ANATOMY", 8, 15], ["exocytic", "ANATOMY", 41, 49], ["extracellular spaces", "ANATOMY", 106, 126], ["satellite cells", "ANATOMY", 135, 150], ["Progeny", "ORGANISM", 0, 7], ["PHEV", "GENE_OR_GENE_PRODUCT", 63, 67], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["satellite cells", "CELL", 135, 150], ["satellite cells", "CELL_TYPE", 135, 150], ["PHEV", "SPECIES", 63, 67], ["Progeny virions", "TREATMENT", 0, 15], ["an exocytic pathway", "TEST", 38, 57], ["PHEV viral particles", "TEST", 63, 83], ["dilated extracellular spaces between satellite cells", "PROBLEM", 98, 150], ["viral particles", "OBSERVATION", 68, 83], ["dilated", "OBSERVATION", 98, 105], ["extracellular spaces", "OBSERVATION", 106, 126], ["satellite cells", "OBSERVATION", 135, 150]]], ["The non-neuronal cells can engulf these released virions; however, no viral particles were observed in their cytoplasm (93).Pathogenesis and Gross and Histological LesionsIn mice, intracranial inoculation with PHEV produced multifocal cortical necrosis in the cerebral (80).", [["non-neuronal cells", "ANATOMY", 4, 22], ["virions", "ANATOMY", 49, 56], ["cytoplasm", "ANATOMY", 109, 118], ["intracranial", "ANATOMY", 180, 192], ["cortical", "ANATOMY", 235, 243], ["cerebral", "ANATOMY", 260, 268], ["PHEV", "CHEMICAL", 210, 214], ["cortical necrosis", "DISEASE", 235, 252], ["non-neuronal cells", "CELL", 4, 22], ["cytoplasm", "ORGANISM_SUBSTANCE", 109, 118], ["mice", "ORGANISM", 174, 178], ["cerebral", "ORGAN", 260, 268], ["non-neuronal cells", "CELL_TYPE", 4, 22], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 174, 178], ["PHEV", "SPECIES", 210, 214], ["viral particles", "PROBLEM", 70, 85], ["Pathogenesis", "PROBLEM", 124, 136], ["Gross and Histological LesionsIn mice", "PROBLEM", 141, 178], ["intracranial inoculation", "PROBLEM", 180, 204], ["PHEV", "PROBLEM", 210, 214], ["multifocal cortical necrosis in the cerebral", "PROBLEM", 224, 268], ["non-neuronal cells", "OBSERVATION", 4, 22], ["no", "UNCERTAINTY", 67, 69], ["viral particles", "OBSERVATION", 70, 85], ["Gross", "OBSERVATION_MODIFIER", 141, 146], ["intracranial", "ANATOMY", 180, 192], ["inoculation", "OBSERVATION", 193, 204], ["multifocal", "OBSERVATION_MODIFIER", 224, 234], ["cortical", "OBSERVATION_MODIFIER", 235, 243], ["necrosis", "OBSERVATION", 244, 252], ["cerebral", "ANATOMY", 260, 268]]], ["Virus replication occurs in the neuron's cytoplasm (96), and specific immunofluorescence and electron microscopy the supported detection of viral particles.", [["neuron", "ANATOMY", 32, 38], ["cytoplasm", "ANATOMY", 41, 50], ["Virus", "ORGANISM", 0, 5], ["neuron", "CELLULAR_COMPONENT", 32, 38], ["cytoplasm", "ORGANISM_SUBSTANCE", 41, 50], ["Virus replication", "TREATMENT", 0, 17], ["specific immunofluorescence", "TEST", 61, 88], ["electron microscopy", "TEST", 93, 112], ["viral particles", "PROBLEM", 140, 155], ["viral particles", "OBSERVATION", 140, 155]]], ["The virion is assembled in the rough endoplasmic reticulum and Golgi body before utilizing a membranous coating mechanism to spread through trans-synaptic communication (96).", [["endoplasmic reticulum", "ANATOMY", 37, 58], ["Golgi body", "ANATOMY", 63, 73], ["virion", "CELLULAR_COMPONENT", 4, 10], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 37, 58], ["Golgi body", "CELLULAR_COMPONENT", 63, 73], ["a membranous coating mechanism", "TREATMENT", 91, 121], ["virion", "OBSERVATION", 4, 10], ["rough", "ANATOMY_MODIFIER", 31, 36], ["endoplasmic reticulum", "OBSERVATION", 37, 58], ["Golgi body", "OBSERVATION", 63, 73], ["membranous", "OBSERVATION_MODIFIER", 93, 103], ["coating", "OBSERVATION", 104, 111]]], ["Neurological signs and fatal PHEV infection could be prevented after injection into the footpad by cutting the ipsilateral sciatic nerve 1 h after infection (93).", [["Neurological", "ANATOMY", 0, 12], ["footpad", "ANATOMY", 88, 95], ["ipsilateral sciatic nerve", "ANATOMY", 111, 136], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 147, 156], ["footpad", "ORGANISM_SUBDIVISION", 88, 95], ["sciatic nerve", "MULTI-TISSUE_STRUCTURE", 123, 136], ["PHEV", "SPECIES", 29, 33], ["Neurological signs", "TEST", 0, 18], ["fatal PHEV infection", "PROBLEM", 23, 43], ["infection", "PROBLEM", 147, 156], ["fatal", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 34, 43], ["footpad", "ANATOMY", 88, 95], ["ipsilateral", "ANATOMY_MODIFIER", 111, 122], ["sciatic nerve", "ANATOMY", 123, 136]]], ["Like the rabies virus, PHEV viral particles were found in peripheral axons and trans-synaptic spread between neurons through endo- and exocytosis, allowing PHEV to move from the periphery to the central nervous system (93).", [["peripheral axons", "ANATOMY", 58, 74], ["synaptic", "ANATOMY", 85, 93], ["neurons", "ANATOMY", 109, 116], ["periphery", "ANATOMY", 178, 187], ["central nervous system", "ANATOMY", 195, 217], ["rabies virus", "ORGANISM", 9, 21], ["PHEV viral", "ORGANISM", 23, 33], ["peripheral axons", "MULTI-TISSUE_STRUCTURE", 58, 74], ["trans-synaptic", "CELLULAR_COMPONENT", 79, 93], ["neurons", "CELL", 109, 116], ["PHEV", "GENE_OR_GENE_PRODUCT", 156, 160], ["central nervous system", "ANATOMICAL_SYSTEM", 195, 217], ["PHEV", "PROTEIN", 156, 160], ["rabies virus", "SPECIES", 9, 21], ["rabies virus", "SPECIES", 9, 21], ["PHEV", "SPECIES", 23, 27], ["the rabies virus", "PROBLEM", 5, 21], ["PHEV viral particles", "PROBLEM", 23, 43], ["endo", "TEST", 125, 129], ["exocytosis", "PROBLEM", 135, 145], ["PHEV", "TREATMENT", 156, 160], ["rabies virus", "OBSERVATION", 9, 21], ["viral particles", "OBSERVATION", 28, 43], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["axons", "ANATOMY", 69, 74], ["periphery", "ANATOMY_MODIFIER", 178, 187], ["central", "ANATOMY_MODIFIER", 195, 202], ["nervous system", "ANATOMY", 203, 217]]], ["More recent studies in mice demonstrated that PHEV is involved in post-transcriptional regulation, and contributed to central nervous system dysfunction by spatiotemporal control of host microRNAs (97).Pathogenesis and Gross and Histological LesionsIn vitro studies indicated that PHEV enters nerve cells via clathrin-mediated endocytosis in a dynamin-, cholesterol-, and pH-dependent manner that requires the GTPases Rab5 and Rab7, which are the primary regulators of the vesicular trafficking pathways (97).", [["central nervous system", "ANATOMY", 118, 140], ["nerve cells", "ANATOMY", 293, 304], ["vesicular", "ANATOMY", 473, 482], ["cholesterol", "CHEMICAL", 354, 365], ["cholesterol", "CHEMICAL", 354, 365], ["mice", "ORGANISM", 23, 27], ["PHEV", "GENE_OR_GENE_PRODUCT", 46, 50], ["nervous system", "ANATOMICAL_SYSTEM", 126, 140], ["PHEV", "SIMPLE_CHEMICAL", 281, 285], ["nerve cells", "CELL", 293, 304], ["clathrin", "GENE_OR_GENE_PRODUCT", 309, 317], ["dynamin-", "SIMPLE_CHEMICAL", 344, 352], ["cholesterol", "SIMPLE_CHEMICAL", 354, 365], ["Rab5", "GENE_OR_GENE_PRODUCT", 418, 422], ["Rab7", "GENE_OR_GENE_PRODUCT", 427, 431], ["vesicular", "MULTI-TISSUE_STRUCTURE", 473, 482], ["PHEV", "PROTEIN", 46, 50], ["host microRNAs", "DNA", 182, 196], ["PHEV", "PROTEIN", 281, 285], ["nerve cells", "CELL_TYPE", 293, 304], ["clathrin", "PROTEIN", 309, 317], ["GTPases", "PROTEIN", 410, 417], ["Rab5", "PROTEIN", 418, 422], ["Rab7", "PROTEIN", 427, 431], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["PHEV", "SPECIES", 46, 50], ["PHEV", "SPECIES", 281, 285], ["central nervous system dysfunction", "PROBLEM", 118, 152], ["Pathogenesis", "PROBLEM", 202, 214], ["Gross and Histological LesionsIn vitro studies", "TEST", 219, 265], ["PHEV enters nerve cells", "PROBLEM", 281, 304], ["clathrin", "TEST", 309, 317], ["mediated endocytosis", "PROBLEM", 318, 338], ["cholesterol", "TEST", 354, 365], ["the GTPases Rab5", "TEST", 406, 422], ["Rab7", "TEST", 427, 431], ["central", "ANATOMY_MODIFIER", 118, 125], ["nervous system", "ANATOMY", 126, 140], ["host microRNAs", "OBSERVATION", 182, 196], ["Gross", "OBSERVATION_MODIFIER", 219, 224], ["nerve cells", "OBSERVATION", 293, 304], ["endocytosis", "OBSERVATION", 327, 338], ["vesicular", "ANATOMY_MODIFIER", 473, 482]]], ["The cytopathic effect and mechanism-inducing cellular death in PHEV-infected pig kidney (PK)-15 cells could be attributed to a caspase-dependent pathway (98).", [["cellular", "ANATOMY", 45, 53], ["kidney (PK)-15 cells", "ANATOMY", 81, 101], ["death", "DISEASE", 54, 59], ["cellular", "CELL", 45, 53], ["PHEV", "ORGANISM", 63, 67], ["pig", "ORGANISM", 77, 80], ["kidney", "ORGAN", 81, 87], ["PK)-15 cells", "CELL", 89, 101], ["caspase", "GENE_OR_GENE_PRODUCT", 127, 134], ["PHEV-infected pig kidney (PK)-15 cells", "CELL_LINE", 63, 101], ["caspase", "PROTEIN", 127, 134], ["pig", "SPECIES", 77, 80], ["PHEV", "SPECIES", 63, 67], ["pig", "SPECIES", 77, 80], ["The cytopathic effect", "PROBLEM", 0, 21], ["cellular death", "PROBLEM", 45, 59], ["PHEV", "TEST", 63, 67], ["infected pig kidney", "PROBLEM", 68, 87], ["a caspase-dependent pathway", "PROBLEM", 125, 152], ["cytopathic effect", "OBSERVATION", 4, 21], ["cellular death", "OBSERVATION", 45, 59], ["infected", "OBSERVATION", 68, 76], ["pig kidney", "ANATOMY", 77, 87]]], ["During its replication, PHEV induces enzymatic activity of cellular proteases, cysteine-dependent proteinase, or caspase activation by enzymatic cleavage, allowing spread to neighboring cells and limiting host response.", [["cellular", "ANATOMY", 59, 67], ["cells", "ANATOMY", 186, 191], ["PHEV", "CHEMICAL", 24, 28], ["cysteine", "CHEMICAL", 79, 87], ["PHEV", "SIMPLE_CHEMICAL", 24, 28], ["cellular", "CELL", 59, 67], ["cysteine-dependent proteinase", "GENE_OR_GENE_PRODUCT", 79, 108], ["caspase", "GENE_OR_GENE_PRODUCT", 113, 120], ["cells", "CELL", 186, 191], ["PHEV", "PROTEIN", 24, 28], ["cellular proteases", "PROTEIN", 59, 77], ["cysteine-dependent proteinase", "PROTEIN", 79, 108], ["caspase", "PROTEIN", 113, 120], ["neighboring cells", "CELL_TYPE", 174, 191], ["PHEV", "SPECIES", 24, 28], ["its replication", "TREATMENT", 7, 22], ["PHEV", "TREATMENT", 24, 28], ["cellular proteases", "TREATMENT", 59, 77], ["cysteine-dependent proteinase", "TREATMENT", 79, 108], ["caspase activation", "TREATMENT", 113, 131], ["enzymatic cleavage", "PROBLEM", 135, 153], ["cellular proteases", "OBSERVATION", 59, 77]]], ["However, the specific mechanisms of caspase activation remain unknown.", [["caspase", "GENE_OR_GENE_PRODUCT", 36, 43], ["caspase", "PROTEIN", 36, 43], ["caspase activation", "PROBLEM", 36, 54]]], ["In addition, PHEV infection can block the phagosome and lysosomes fusion, inducing an atypical autophagy response necessary for viral replication in neurons (99).", [["phagosome", "ANATOMY", 42, 51], ["lysosomes", "ANATOMY", 56, 65], ["neurons", "ANATOMY", 149, 156], ["PHEV", "CHEMICAL", 13, 17], ["infection", "DISEASE", 18, 27], ["PHEV", "GENE_OR_GENE_PRODUCT", 13, 17], ["phagosome", "CELLULAR_COMPONENT", 42, 51], ["lysosomes", "CELLULAR_COMPONENT", 56, 65], ["neurons", "CELL", 149, 156], ["PHEV", "SPECIES", 13, 17], ["PHEV infection", "PROBLEM", 13, 27], ["the phagosome", "TREATMENT", 38, 51], ["lysosomes fusion", "TREATMENT", 56, 72], ["an atypical autophagy response", "PROBLEM", 83, 113], ["viral replication in neurons", "PROBLEM", 128, 156], ["infection", "OBSERVATION", 18, 27], ["lysosomes fusion", "OBSERVATION", 56, 72]]], ["Furthermore, PHEV genome replication in PK-15 cells and; therefore, the production of infectious virus in vitro can be inhibited through small interfering RNAs (siRNA) that target different regions of the PHEV spike glycoprotein (100) or nucleocapsid genes (101).Pathogenesis and Gross and Histological LesionsA post-mortem examination of PHEV-affected animals revealed cachexia, a dilatated stomach containing abundant non-digested milk, and distension of the abdomen in some chronically affected piglets (54) (Figure 2).", [["PK-15 cells", "ANATOMY", 40, 51], ["cachexia", "ANATOMY", 370, 378], ["stomach", "ANATOMY", 392, 399], ["milk", "ANATOMY", 433, 437], ["abdomen", "ANATOMY", 461, 468], ["cachexia", "DISEASE", 370, 378], ["PK-15 cells", "CELL", 40, 51], ["infectious virus", "ORGANISM", 86, 102], ["PHEV spike glycoprotein (100)", "GENE_OR_GENE_PRODUCT", 205, 234], ["animals", "ORGANISM", 353, 360], ["cachexia", "CANCER", 370, 378], ["stomach", "ORGAN", 392, 399], ["milk", "ORGANISM_SUBSTANCE", 433, 437], ["abdomen", "ORGAN", 461, 468], ["piglets", "ORGANISM", 498, 505], ["PHEV genome", "DNA", 13, 24], ["PK-15 cells", "CELL_LINE", 40, 51], ["small interfering RNAs", "RNA", 137, 159], ["PHEV spike glycoprotein (100) or nucleocapsid genes", "DNA", 205, 256], ["piglets", "SPECIES", 498, 505], ["PHEV", "SPECIES", 13, 17], ["PHEV", "SPECIES", 339, 343], ["PHEV genome replication", "TREATMENT", 13, 36], ["PK", "TEST", 40, 42], ["infectious virus", "PROBLEM", 86, 102], ["small interfering RNAs (siRNA)", "PROBLEM", 137, 167], ["the PHEV spike glycoprotein", "PROBLEM", 201, 228], ["Pathogenesis", "PROBLEM", 263, 275], ["post-mortem examination", "TEST", 312, 335], ["PHEV", "TEST", 339, 343], ["affected animals", "PROBLEM", 344, 360], ["cachexia", "PROBLEM", 370, 378], ["a dilatated stomach", "PROBLEM", 380, 399], ["distension of the abdomen", "PROBLEM", 443, 468], ["infectious virus", "OBSERVATION", 86, 102], ["small", "OBSERVATION_MODIFIER", 137, 142], ["interfering RNAs", "OBSERVATION", 143, 159], ["Gross", "OBSERVATION_MODIFIER", 280, 285], ["cachexia", "OBSERVATION", 370, 378], ["stomach", "ANATOMY", 392, 399], ["abundant", "OBSERVATION_MODIFIER", 411, 419], ["non-digested milk", "OBSERVATION", 420, 437], ["distension", "OBSERVATION", 443, 453], ["abdomen", "ANATOMY", 461, 468], ["chronically", "OBSERVATION_MODIFIER", 477, 488], ["affected", "OBSERVATION", 489, 497]]], ["Otherwise, no other significant gross findings were normally observed.Pathogenesis and Gross and Histological LesionsMicroscopic examination of brains of clinically affected piglets showed a non-suppurative viral-type encephalomyelitis, characterized by lymphoplasmacytic perivascular cuffing (Figure 3), mononuclear cells' infiltration in the gray matter of the cerebrum and neuronal degeneration, affecting the mesencephalon, pons, medulla oblongata, horns of the proximal spinal cord, and trigeminal ganglia (Figure 4) (69, 85, 102).", [["brains", "ANATOMY", 144, 150], ["lymphoplasmacytic perivascular", "ANATOMY", 254, 284], ["mononuclear cells", "ANATOMY", 305, 322], ["gray matter", "ANATOMY", 344, 355], ["cerebrum", "ANATOMY", 363, 371], ["neuronal", "ANATOMY", 376, 384], ["mesencephalon", "ANATOMY", 413, 426], ["pons", "ANATOMY", 428, 432], ["medulla oblongata", "ANATOMY", 434, 451], ["horns", "ANATOMY", 453, 458], ["proximal spinal cord", "ANATOMY", 466, 486], ["trigeminal ganglia", "ANATOMY", 492, 510], ["viral-type encephalomyelitis", "DISEASE", 207, 235], ["neuronal degeneration", "DISEASE", 376, 397], ["brains", "ORGAN", 144, 150], ["piglets", "ORGANISM", 174, 181], ["mononuclear cells", "CELL", 305, 322], ["cerebrum", "ORGAN", 363, 371], ["neuronal", "CELL", 376, 384], ["mesencephalon", "ORGAN", 413, 426], ["pons", "MULTI-TISSUE_STRUCTURE", 428, 432], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 434, 451], ["horns", "ORGANISM_SUBDIVISION", 453, 458], ["spinal cord", "ORGAN", 475, 486], ["trigeminal ganglia", "MULTI-TISSUE_STRUCTURE", 492, 510], ["mononuclear cells", "CELL_TYPE", 305, 322], ["piglets", "SPECIES", 174, 181], ["non-suppurative viral-type encephalomyelitis", "SPECIES", 191, 235], ["other significant gross findings", "PROBLEM", 14, 46], ["Pathogenesis", "PROBLEM", 70, 82], ["Gross and Histological Lesions", "PROBLEM", 87, 117], ["Microscopic examination", "TEST", 117, 140], ["clinically affected piglets", "PROBLEM", 154, 181], ["a non-suppurative viral-type encephalomyelitis", "PROBLEM", 189, 235], ["lymphoplasmacytic perivascular cuffing", "PROBLEM", 254, 292], ["mononuclear cells' infiltration", "PROBLEM", 305, 336], ["neuronal degeneration", "PROBLEM", 376, 397], ["the mesencephalon, pons, medulla oblongata, horns of the proximal spinal cord", "PROBLEM", 409, 486], ["no other", "UNCERTAINTY", 11, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["Gross", "OBSERVATION_MODIFIER", 87, 92], ["Histological", "OBSERVATION_MODIFIER", 97, 109], ["Lesions", "OBSERVATION", 110, 117], ["non-suppurative", "OBSERVATION_MODIFIER", 191, 206], ["type encephalomyelitis", "OBSERVATION", 213, 235], ["lymphoplasmacytic", "OBSERVATION_MODIFIER", 254, 271], ["perivascular cuffing", "OBSERVATION", 272, 292], ["mononuclear cells' infiltration", "OBSERVATION", 305, 336], ["gray matter", "ANATOMY_MODIFIER", 344, 355], ["cerebrum", "ANATOMY", 363, 371], ["neuronal degeneration", "OBSERVATION", 376, 397], ["mesencephalon", "ANATOMY", 413, 426], ["pons", "ANATOMY", 428, 432], ["medulla oblongata", "ANATOMY", 434, 451], ["horns", "ANATOMY_MODIFIER", 453, 458], ["proximal", "ANATOMY_MODIFIER", 466, 474], ["spinal cord", "ANATOMY", 475, 486], ["trigeminal ganglia", "ANATOMY", 492, 510]]], ["These lesions were found in 70\u2013100% or 20\u201360% of animals showing neurological signs or VWD, respectively (65, 103, 104).", [["lesions", "ANATOMY", 6, 13], ["neurological", "ANATOMY", 65, 77], ["VWD", "DISEASE", 87, 90], ["lesions", "CANCER", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["neurological signs", "TEST", 65, 83], ["VWD", "PROBLEM", 87, 90], ["lesions", "OBSERVATION", 6, 13]]], ["Microscopic changes in the stomach wall were found only in pigs showing VWD.", [["stomach wall", "ANATOMY", 27, 39], ["VWD", "DISEASE", 72, 75], ["stomach wall", "MULTI-TISSUE_STRUCTURE", 27, 39], ["pigs", "ORGANISM", 59, 63], ["pigs", "SPECIES", 59, 63], ["pigs", "SPECIES", 59, 63], ["Microscopic changes in the stomach wall", "PROBLEM", 0, 39], ["VWD", "PROBLEM", 72, 75], ["stomach", "ANATOMY", 27, 34], ["wall", "ANATOMY_MODIFIER", 35, 39], ["VWD", "OBSERVATION", 72, 75]]], ["The lesions were most pronounced in the pyloric gland area (54).", [["lesions", "ANATOMY", 4, 11], ["pyloric gland area", "ANATOMY", 40, 58], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["pyloric gland", "ORGAN", 40, 53], ["The lesions", "PROBLEM", 0, 11], ["lesions", "OBSERVATION", 4, 11], ["most pronounced", "OBSERVATION_MODIFIER", 17, 32], ["pyloric gland", "ANATOMY", 40, 53]]], ["Degeneration of the ganglia of the stomach wall and lymphoplasmacytic perivascular cuffing were present in 15\u201385% of affected animals (Figure 5).", [["ganglia", "ANATOMY", 20, 27], ["stomach wall", "ANATOMY", 35, 47], ["lymphoplasmacytic perivascular", "ANATOMY", 52, 82], ["ganglia", "ORGAN", 20, 27], ["stomach wall", "MULTI-TISSUE_STRUCTURE", 35, 47], ["lymphoplasmacytic perivascular cuffing", "PATHOLOGICAL_FORMATION", 52, 90], ["Degeneration of the ganglia of the stomach wall", "PROBLEM", 0, 47], ["lymphoplasmacytic perivascular cuffing", "PROBLEM", 52, 90], ["ganglia", "ANATOMY_MODIFIER", 20, 27], ["stomach", "ANATOMY", 35, 42], ["wall", "ANATOMY_MODIFIER", 43, 47], ["lymphoplasmacytic", "OBSERVATION_MODIFIER", 52, 69], ["perivascular", "ANATOMY_MODIFIER", 70, 82], ["cuffing", "OBSERVATION", 83, 90], ["15\u201385", "OBSERVATION_MODIFIER", 107, 112]]], ["However, no pathognomonic or histologic examination of acutely affected piglets revealed epithelial degeneration and mononuclear inflammation in the tonsils and respiratory tract (69, 105).DiagnosticsA diagnosis of PHEV can be achieved by a combination of direct and indirect detection methods.", [["piglets", "ANATOMY", 72, 79], ["epithelial", "ANATOMY", 89, 99], ["mononuclear", "ANATOMY", 117, 128], ["tonsils", "ANATOMY", 149, 156], ["respiratory tract", "ANATOMY", 161, 178], ["mononuclear inflammation", "DISEASE", 117, 141], ["PHEV", "DISEASE", 215, 219], ["piglets", "ORGANISM", 72, 79], ["epithelial", "TISSUE", 89, 99], ["mononuclear", "TISSUE", 117, 128], ["tonsils", "ORGAN", 149, 156], ["respiratory tract", "ORGANISM_SUBDIVISION", 161, 178], ["PHEV", "CANCER", 215, 219], ["piglets", "SPECIES", 72, 79], ["PHEV", "SPECIES", 215, 219], ["histologic examination", "TEST", 29, 51], ["acutely affected piglets", "PROBLEM", 55, 79], ["epithelial degeneration", "PROBLEM", 89, 112], ["mononuclear inflammation in the tonsils and respiratory tract", "PROBLEM", 117, 178], ["PHEV", "PROBLEM", 215, 219], ["direct and indirect detection methods", "TEST", 256, 293], ["no", "UNCERTAINTY", 9, 11], ["epithelial degeneration", "OBSERVATION", 89, 112], ["mononuclear inflammation", "OBSERVATION", 117, 141], ["tonsils", "ANATOMY", 149, 156], ["respiratory tract", "ANATOMY", 161, 178]]], ["Methods for the direct detection of PHEV in the tissues of clinically affected animals include immunohistochemistry in sections of the brain, spinal cord and myenteric plexus (64, 66, 106).", [["tissues", "ANATOMY", 48, 55], ["sections", "ANATOMY", 119, 127], ["brain", "ANATOMY", 135, 140], ["spinal cord", "ANATOMY", 142, 153], ["myenteric plexus", "ANATOMY", 158, 174], ["PHEV", "GENE_OR_GENE_PRODUCT", 36, 40], ["tissues", "TISSUE", 48, 55], ["brain", "ORGAN", 135, 140], ["spinal cord", "ORGAN", 142, 153], ["myenteric plexus", "MULTI-TISSUE_STRUCTURE", 158, 174], ["PHEV", "PROTEIN", 36, 40], ["PHEV", "SPECIES", 36, 40], ["the direct detection", "TEST", 12, 32], ["PHEV", "PROBLEM", 36, 40], ["immunohistochemistry in sections of the brain", "TEST", 95, 140], ["tissues", "ANATOMY", 48, 55], ["brain", "ANATOMY", 135, 140], ["spinal cord", "ANATOMY", 142, 153], ["myenteric plexus", "ANATOMY", 158, 174]]], ["Tonsils and lungs dissected aseptically from young acutely affected piglets can be also used for testing the presence of PHEV.", [["Tonsils", "ANATOMY", 0, 7], ["lungs", "ANATOMY", 12, 17], ["lungs", "ORGAN", 12, 17], ["piglets", "ORGANISM", 68, 75], ["PHEV", "CANCER", 121, 125], ["piglets", "SPECIES", 68, 75], ["PHEV", "SPECIES", 121, 125], ["lungs", "ANATOMY", 12, 17]]], ["Detection of viral RNA by real-time reverse transcription polymerase chain reaction (RT-PCR) and/or nested PCR in different tissues including brainstem, trigeminal ganglia and spinal cord (64, 66, 107).", [["tissues", "ANATOMY", 124, 131], ["brainstem", "ANATOMY", 142, 151], ["trigeminal ganglia", "ANATOMY", 153, 171], ["spinal cord", "ANATOMY", 176, 187], ["tissues", "TISSUE", 124, 131], ["brainstem", "MULTI-TISSUE_STRUCTURE", 142, 151], ["trigeminal ganglia", "MULTI-TISSUE_STRUCTURE", 153, 171], ["spinal cord", "ORGAN", 176, 187], ["viral RNA", "RNA", 13, 22], ["viral RNA", "PROBLEM", 13, 22], ["chain reaction", "TEST", 69, 83], ["RT-PCR", "TEST", 85, 91], ["nested PCR in different tissues including brainstem, trigeminal ganglia and spinal cord", "PROBLEM", 100, 187], ["viral RNA", "OBSERVATION", 13, 22], ["brainstem", "ANATOMY_MODIFIER", 142, 151], ["trigeminal ganglia", "ANATOMY", 153, 171], ["spinal cord", "ANATOMY", 176, 187]]], ["Viral isolation is normally coupled to direct immunofluorescence and hemadsorption to detect viral growth (108).DiagnosticsPCR-based methods are useful to identify and subsequently isolate animals that are actively shedding the virus.", [["Viral isolation", "PROBLEM", 0, 15], ["direct immunofluorescence", "TEST", 39, 64], ["hemadsorption", "TEST", 69, 82], ["viral growth", "PROBLEM", 93, 105], ["DiagnosticsPCR", "TEST", 112, 126], ["actively shedding the virus", "PROBLEM", 206, 233], ["isolation", "OBSERVATION", 6, 15]]], ["Rauh et al. (109) described the development of a dry room temperature-stable real-time RT-PCR assay for the specific detection of PHEV.", [["PHEV", "CANCER", 130, 134], ["PHEV", "PROTEIN", 130, 134], ["PHEV", "SPECIES", 130, 134], ["a dry room temperature", "PROBLEM", 47, 69], ["PCR assay", "TEST", 90, 99], ["stable", "OBSERVATION_MODIFIER", 70, 76]]], ["This RT-PCR was used to describe and compare the patterns of PHEV shedding and the dynamic of the infection in pen-based feces and oral fluid specimens collected from PHEV experimentally inoculated 7 weeks old pigs over the course of a clinical/subclinical infection.", [["feces", "ANATOMY", 121, 126], ["oral fluid specimens", "ANATOMY", 131, 151], ["infection", "DISEASE", 98, 107], ["infection", "DISEASE", 257, 266], ["PHEV", "GENE_OR_GENE_PRODUCT", 61, 65], ["feces", "ORGANISM", 121, 126], ["oral fluid specimens", "ORGANISM_SUBSTANCE", 131, 151], ["pigs", "ORGANISM", 210, 214], ["pigs", "SPECIES", 210, 214], ["PHEV", "SPECIES", 61, 65], ["PHEV", "SPECIES", 167, 171], ["pigs", "SPECIES", 210, 214], ["This RT-PCR", "TEST", 0, 11], ["PHEV shedding", "PROBLEM", 61, 74], ["the infection", "PROBLEM", 94, 107], ["oral fluid specimens", "TEST", 131, 151], ["a clinical/subclinical infection", "PROBLEM", 234, 266], ["infection", "OBSERVATION", 98, 107], ["subclinical", "OBSERVATION_MODIFIER", 245, 256], ["infection", "OBSERVATION", 257, 266]]], ["In this experiment, virus shedding was consistently detected by real-time RT-PCR in pen-based oral fluids collected from grow-finishers between 1 and 28 days post-inoculation (DPI) and feces between 1 and 10 DPI, however, viremia was not detected throughout the observation period (75).", [["oral fluids", "ANATOMY", 94, 105], ["DPI", "CHEMICAL", 208, 211], ["viremia", "DISEASE", 222, 229], ["oral", "ORGANISM_SUBDIVISION", 94, 98], ["virus shedding", "PROBLEM", 20, 34], ["PCR", "TEST", 77, 80], ["viremia", "PROBLEM", 222, 229], ["virus", "OBSERVATION", 20, 25], ["viremia", "OBSERVATION", 222, 229]]], ["Previous reports indicated that viremia had little effect during the infection and the pathogenesis of the disease (81).", [["viremia", "DISEASE", 32, 39], ["infection", "DISEASE", 69, 78], ["viremia", "PROBLEM", 32, 39], ["the infection", "PROBLEM", 65, 78], ["the disease", "PROBLEM", 103, 114], ["viremia", "OBSERVATION", 32, 39], ["infection", "OBSERVATION", 69, 78]]], ["Oral fluids are a suitable specimen for routine PHEV diagnosis and surveillance.DiagnosticsAlthough, the virus was first isolated in primary PK cells (38), the virus was also demonstrated to grow on other PK cell lines, including PK-15, FS-L3, SK-6, IBRS2 cell lines (83, 110\u2013112), secondary pig thyroid (SPTh) cells (113), pig embryonic pulmonary cells, and the swine testicle (ST) cell line (14, 114).", [["Oral fluids", "ANATOMY", 0, 11], ["specimen", "ANATOMY", 27, 35], ["primary PK cells", "ANATOMY", 133, 149], ["PK cell lines", "ANATOMY", 205, 218], ["PK-15", "ANATOMY", 230, 235], ["FS-L3", "ANATOMY", 237, 242], ["SK-6", "ANATOMY", 244, 248], ["IBRS2 cell lines", "ANATOMY", 250, 266], ["thyroid (SPTh) cells", "ANATOMY", 296, 316], ["embryonic pulmonary cells", "ANATOMY", 328, 353], ["testicle (ST) cell line", "ANATOMY", 369, 392], ["PK cells", "CELL", 141, 149], ["PK cell lines", "CELL", 205, 218], ["PK-15", "CELL", 230, 235], ["FS-L3", "CELL", 237, 242], ["SK-6", "CELL", 244, 248], ["IBRS2 cell lines", "CELL", 250, 266], ["110\u2013112", "CELL", 272, 279], ["pig", "ORGANISM", 292, 295], ["thyroid (SPTh) cells", "CELL", 296, 316], ["pig", "ORGANISM", 324, 327], ["embryonic pulmonary cells", "CELL", 328, 353], ["swine", "ORGANISM", 363, 368], ["testicle (ST) cell line", "CELL", 369, 392], ["primary PK cells", "CELL_LINE", 133, 149], ["PK cell lines", "CELL_LINE", 205, 218], ["PK-15", "CELL_LINE", 230, 235], ["FS-L3, SK-6", "CELL_LINE", 237, 248], ["IBRS2 cell lines", "CELL_LINE", 250, 266], ["secondary pig thyroid (SPTh) cells", "CELL_LINE", 282, 316], ["pig embryonic pulmonary cells", "CELL_TYPE", 324, 353], ["swine testicle (ST) cell line", "CELL_LINE", 363, 392], ["pig", "SPECIES", 292, 295], ["pig", "SPECIES", 324, 327], ["swine", "SPECIES", 363, 368], ["PHEV", "SPECIES", 48, 52], ["pig", "SPECIES", 292, 295], ["pig", "SPECIES", 324, 327], ["swine", "SPECIES", 363, 368], ["Oral fluids", "TREATMENT", 0, 11], ["routine PHEV diagnosis", "TEST", 40, 62], ["surveillance", "TEST", 67, 79], ["the virus", "PROBLEM", 101, 110], ["primary PK cells", "TEST", 133, 149], ["the virus", "PROBLEM", 156, 165], ["PK cell lines", "TEST", 205, 218], ["PK", "TEST", 230, 232], ["FS", "TEST", 237, 239], ["SK", "TEST", 244, 246], ["IBRS2 cell lines", "TEST", 250, 266], ["secondary pig thyroid (SPTh) cells", "PROBLEM", 282, 316], ["pig embryonic pulmonary cells", "PROBLEM", 324, 353], ["the swine testicle (ST) cell line", "PROBLEM", 359, 392], ["fluids", "OBSERVATION", 5, 11], ["PK cells", "OBSERVATION", 141, 149], ["PK cell lines", "OBSERVATION", 205, 218], ["L3", "ANATOMY", 240, 242], ["SK", "ANATOMY", 244, 246], ["cell lines", "OBSERVATION", 256, 266], ["thyroid", "ANATOMY", 296, 303], ["pig embryonic", "OBSERVATION", 324, 337], ["pulmonary cells", "ANATOMY", 338, 353], ["swine testicle", "ANATOMY", 363, 377], ["cell line", "OBSERVATION", 383, 392]]], ["It has been demonstrated that both SPTh and PK cells were most susceptible to cultivation and virus titration (115).", [["PK cells", "ANATOMY", 44, 52], ["SPTh", "GENE_OR_GENE_PRODUCT", 35, 39], ["PK cells", "CELL", 44, 52], ["SPTh", "CELL_TYPE", 35, 39], ["PK cells", "CELL_LINE", 44, 52], ["both SPTh and PK cells", "PROBLEM", 30, 52], ["virus titration", "TREATMENT", 94, 109], ["PK cells", "OBSERVATION", 44, 52]]], ["PHEV can be consistently isolated from the tonsils and respiratory tract (nasal and pharyngeal swabs, nasal mucosal, and lungs) but irregularly from the pons and medulla, hindbrains, and stomach wall (59, 77, 82).", [["tonsils", "ANATOMY", 43, 50], ["respiratory tract", "ANATOMY", 55, 72], ["nasal", "ANATOMY", 74, 79], ["pharyngeal swabs", "ANATOMY", 84, 100], ["nasal mucosal", "ANATOMY", 102, 115], ["lungs", "ANATOMY", 121, 126], ["pons", "ANATOMY", 153, 157], ["medulla", "ANATOMY", 162, 169], ["hindbrains", "ANATOMY", 171, 181], ["stomach wall", "ANATOMY", 187, 199], ["PHEV", "CHEMICAL", 0, 4], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["tonsils", "ORGAN", 43, 50], ["respiratory tract", "ORGANISM_SUBDIVISION", 55, 72], ["nasal", "ORGANISM_SUBDIVISION", 74, 79], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 84, 100], ["nasal mucosal", "MULTI-TISSUE_STRUCTURE", 102, 115], ["lungs", "ORGAN", 121, 126], ["pons", "MULTI-TISSUE_STRUCTURE", 153, 157], ["medulla", "MULTI-TISSUE_STRUCTURE", 162, 169], ["hindbrains", "CANCER", 171, 181], ["stomach wall", "MULTI-TISSUE_STRUCTURE", 187, 199], ["PHEV", "PROTEIN", 0, 4], ["PHEV", "SPECIES", 0, 4], ["PHEV", "TREATMENT", 0, 4], ["respiratory tract", "TEST", 55, 72], ["nasal and pharyngeal swabs, nasal mucosal, and lungs", "TEST", 74, 126], ["irregularly from the pons and medulla, hindbrains, and stomach wall", "PROBLEM", 132, 199], ["tonsils", "ANATOMY", 43, 50], ["respiratory tract", "ANATOMY", 55, 72], ["nasal", "ANATOMY", 74, 79], ["pharyngeal swabs", "ANATOMY", 84, 100], ["nasal mucosal", "ANATOMY", 102, 115], ["lungs", "ANATOMY", 121, 126], ["irregularly", "OBSERVATION_MODIFIER", 132, 143], ["pons", "ANATOMY", 153, 157], ["medulla", "ANATOMY", 162, 169], ["hindbrains", "ANATOMY_MODIFIER", 171, 181], ["stomach", "ANATOMY", 187, 194], ["wall", "ANATOMY_MODIFIER", 195, 199]]], ["PHEV can be also isolated from the nasal cavity of healthy pigs (83).", [["nasal cavity", "ANATOMY", 35, 47], ["PHEV", "CHEMICAL", 0, 4], ["PHEV", "GENE_OR_GENE_PRODUCT", 0, 4], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 35, 47], ["pigs", "ORGANISM", 59, 63], ["PHEV", "PROTEIN", 0, 4], ["pigs", "SPECIES", 59, 63], ["PHEV", "SPECIES", 0, 4], ["PHEV", "TREATMENT", 0, 4], ["nasal cavity", "ANATOMY", 35, 47]]], ["Virus isolation can be difficult after 2\u20133 days after the onset of clinical signs or more than 8 days after experimental inoculation (59).", [["Virus", "ORGANISM", 0, 5], ["Virus isolation", "TREATMENT", 0, 15], ["clinical signs", "PROBLEM", 67, 81], ["experimental inoculation", "TEST", 108, 132]]], ["PHEV in a culture can be detected by the formation of syncytia.", [["syncytia", "ANATOMY", 54, 62], ["PHEV", "CHEMICAL", 0, 4], ["PHEV", "SIMPLE_CHEMICAL", 0, 4], ["syncytia", "CELL", 54, 62], ["PHEV", "PROTEIN", 0, 4], ["PHEV", "SPECIES", 0, 4], ["a culture", "TEST", 8, 17], ["syncytia", "PROBLEM", 54, 62], ["syncytia", "OBSERVATION", 54, 62]]], ["Hemadsorption and/or hemagglutination tests were also used to demonstrate viral growth.", [["Hemadsorption and/or hemagglutination tests", "TEST", 0, 43], ["viral growth", "PROBLEM", 74, 86], ["viral", "OBSERVATION", 74, 79]]], ["One or more blind passages may be needed since specimens often contain small amounts of infectious viral particles.", [["specimens", "ANATOMY", 47, 56], ["specimens", "TEST", 47, 56], ["small amounts of infectious viral particles", "PROBLEM", 71, 114], ["small", "OBSERVATION_MODIFIER", 71, 76], ["amounts", "OBSERVATION_MODIFIER", 77, 84], ["infectious", "OBSERVATION_MODIFIER", 88, 98], ["viral particles", "OBSERVATION", 99, 114]]], ["Although a virus grown in cell culture can still infect pigs, it can be less virulent than an isolated field strain1.DiagnosticsNon-porcine cell culture has been shown to have little susceptibility to PHEV growth (112, 114).", [["cell culture", "ANATOMY", 26, 38], ["cell", "ANATOMY", 140, 144], ["cell culture", "CELL", 26, 38], ["pigs", "ORGANISM", 56, 60], ["Non-porcine cell", "CELL", 128, 144], ["Non-porcine cell culture", "CELL_LINE", 128, 152], ["pigs", "SPECIES", 56, 60], ["pigs", "SPECIES", 56, 60], ["PHEV", "SPECIES", 201, 205], ["a virus", "PROBLEM", 9, 16], ["cell culture", "TEST", 26, 38], ["an isolated field strain1", "PROBLEM", 91, 116], ["DiagnosticsNon-porcine cell culture", "TEST", 117, 152], ["PHEV growth", "TEST", 201, 212], ["virus", "OBSERVATION", 11, 16], ["field strain1", "OBSERVATION", 103, 116], ["growth", "OBSERVATION_MODIFIER", 206, 212]]], ["However, PHEV can grow in mice's brain cells (97, 116, 117), dorsal root ganglia cells from newborn mice (96), and in Madin-Darby canine kidney \u201clow passage\u201d (MDCK I) cells without prior adaptation (33).DiagnosticsCurrent indirect methods for detection of PHEV antibodies include hemagglutination (HA) and hemagglutination inhibition (HI) assays, virus neutralization (VN) tests, enzyme-linked immune-sorbent assays (ELISA), and rapid immunochromatographic strip tests (55, 71, 87, 106, 108, 113).", [["brain cells", "ANATOMY", 33, 44], ["dorsal root ganglia cells", "ANATOMY", 61, 86], ["kidney", "ANATOMY", 137, 143], ["MDCK I) cells", "ANATOMY", 159, 172], ["PHEV", "CHEMICAL", 9, 13], ["PHEV", "GENE_OR_GENE_PRODUCT", 9, 13], ["mice", "ORGANISM", 26, 30], ["brain cells", "CELL", 33, 44], ["dorsal root ganglia cells", "CELL", 61, 86], ["mice", "ORGANISM", 100, 104], ["kidney", "ORGAN", 137, 143], ["low passage\u201d (MDCK I) cells", "CELL", 145, 172], ["PHEV antibodies", "GENE_OR_GENE_PRODUCT", 256, 271], ["PHEV", "PROTEIN", 9, 13], ["brain cells", "CELL_TYPE", 33, 44], ["dorsal root ganglia cells", "CELL_TYPE", 61, 86], ["Madin-Darby canine kidney \u201clow passage\u201d (MDCK I) cells", "CELL_LINE", 118, 172], ["PHEV antibodies", "PROTEIN", 256, 271], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 100, 104], ["PHEV", "SPECIES", 9, 13], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 100, 104], ["PHEV", "SPECIES", 256, 260], ["PHEV", "TEST", 9, 13], ["mice's brain cells", "TEST", 26, 44], ["dorsal root ganglia cells", "PROBLEM", 61, 86], ["Madin", "TEST", 118, 123], ["low passage", "PROBLEM", 145, 156], ["PHEV antibodies", "TEST", 256, 271], ["hemagglutination (HA)", "PROBLEM", 280, 301], ["hemagglutination inhibition (HI) assays", "PROBLEM", 306, 345], ["virus neutralization (VN) tests", "TEST", 347, 378], ["enzyme", "TEST", 380, 386], ["sorbent assays", "TEST", 401, 415], ["ELISA", "TEST", 417, 422], ["rapid immunochromatographic strip tests", "TEST", 429, 468], ["brain cells", "ANATOMY", 33, 44], ["dorsal", "ANATOMY_MODIFIER", 61, 67], ["root ganglia", "ANATOMY", 68, 80], ["kidney", "ANATOMY", 137, 143], ["low passage", "OBSERVATION", 145, 156]]], ["Unlike other coronaviruses, PHEV readily agglutinates a variety of red blood cells.", [["red blood cells", "ANATOMY", 67, 82], ["PHEV", "CHEMICAL", 28, 32], ["coronaviruses", "ORGANISM", 13, 26], ["PHEV", "SIMPLE_CHEMICAL", 28, 32], ["red blood cells", "CELL", 67, 82], ["red blood cells", "CELL_TYPE", 67, 82], ["PHEV", "SPECIES", 28, 32], ["other coronaviruses", "PROBLEM", 7, 26], ["red blood cells", "TEST", 67, 82], ["coronaviruses", "OBSERVATION", 13, 26]]], ["Specifically, PHEV attaches to N-acetyl-9-O-acetylneuraminic acid-containing receptors on erythrocytes (33).", [["erythrocytes", "ANATOMY", 90, 102], ["PHEV", "CHEMICAL", 14, 18], ["N-acetyl-9-O-acetylneuraminic acid-", "CHEMICAL", 31, 66], ["N-acetyl-9-O-acetylneuraminic acid-", "CHEMICAL", 31, 66], ["PHEV", "SIMPLE_CHEMICAL", 14, 18], ["N-acetyl-9-O-acetylneuraminic acid-", "SIMPLE_CHEMICAL", 31, 66], ["erythrocytes", "CELL", 90, 102], ["PHEV", "PROTEIN", 14, 18], ["N-acetyl-9-O-acetylneuraminic acid-containing receptors", "PROTEIN", 31, 86], ["erythrocytes", "CELL_TYPE", 90, 102], ["PHEV", "TEST", 14, 18], ["N-acetyl", "TEST", 31, 39], ["O-acetylneuraminic acid-", "TREATMENT", 42, 66], ["erythrocytes", "TEST", 90, 102]]], ["Girard et al. (118) originally used this feature for a differential diagnosis of PHEV-related disease from Teschen/Talfan disease and pseudorabies (Aujeszky's) disease.", [["PHEV", "CHEMICAL", 81, 85], ["Teschen/Talfan disease", "DISEASE", 107, 129], ["pseudorabies (Aujeszky's) disease", "DISEASE", 134, 167], ["PHEV", "CANCER", 81, 85], ["pseudorabies", "ORGANISM", 134, 146], ["pseudorabies", "SPECIES", 134, 146], ["Aujeszky", "SPECIES", 148, 156], ["Aujeszky", "SPECIES", 148, 156], ["PHEV", "PROBLEM", 81, 85], ["related disease", "PROBLEM", 86, 101], ["Teschen/Talfan disease", "PROBLEM", 107, 129], ["pseudorabies (Aujeszky's) disease", "PROBLEM", 134, 167], ["Talfan disease", "OBSERVATION", 115, 129]]], ["The HI test was adapted from the procedure suggested by the Committee on Standard Serological Procedures in Influenza Studies.", [["The HI test", "TEST", 0, 11], ["the procedure", "TREATMENT", 29, 42], ["Influenza Studies", "TEST", 108, 125]]], ["Hemagglutinin-inhibiting and hemagglutinin-neutralizing antibodies can be detected in sera at 6 or 9 days, respectively, after experimental inoculation (59).", [["sera", "ANATOMY", 86, 90], ["Hemagglutinin", "CHEMICAL", 0, 13], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 13], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["Hemagglutinin", "PROTEIN", 0, 13], ["hemagglutinin", "PROTEIN", 29, 42], ["neutralizing antibodies", "PROTEIN", 43, 66], ["Hemagglutinin", "TREATMENT", 0, 13], ["hemagglutinin-neutralizing antibodies", "TREATMENT", 29, 66]]], ["Neither HI titer nor SN titers can be used for PHEV serodiagnosis or to assess degrees of antigenic relationship between isolates (55); however, the VN assay has been described as more specific than HI (110).", [["VN", "PROTEIN", 149, 151], ["PHEV", "SPECIES", 47, 51], ["PHEV serodiagnosis", "TEST", 47, 65], ["antigenic relationship between isolates", "PROBLEM", 90, 129], ["the VN assay", "TEST", 145, 157]]], ["Moreover, the ability to detect specific PHEV antibodies allows the determination of the status of first-litter gilts and evaluation of their risk of tier offspring to infection.", [["infection", "DISEASE", 168, 177], ["PHEV antibodies", "GENE_OR_GENE_PRODUCT", 41, 56], ["PHEV antibodies", "PROTEIN", 41, 56], ["PHEV", "SPECIES", 41, 45], ["specific PHEV antibodies", "TEST", 32, 56], ["first-litter gilts", "TREATMENT", 99, 117], ["evaluation", "TEST", 122, 132], ["infection", "PROBLEM", 168, 177], ["infection", "OBSERVATION", 168, 177]]], ["However, serology results must be interpreted with caution as PHEV is highly prevalent, circulating subclinically in most swine herds.", [["swine", "SPECIES", 122, 127], ["PHEV", "SPECIES", 62, 66], ["swine", "SPECIES", 122, 127], ["serology", "TEST", 9, 17], ["PHEV", "TEST", 62, 66]]], ["The development of specific monoclonal antibodies against PHEV and their utility for diagnosis and antibody-based treatment of the disease has also been reported (86).DiagnosticsThe ability to detect antibodies allows producers to know the status of first-litter gilts and evaluate their risk of tier offspring to infection.", [["infection", "DISEASE", 314, 323], ["PHEV", "CANCER", 58, 62], ["gilts", "ORGANISM", 263, 268], ["monoclonal antibodies", "PROTEIN", 28, 49], ["PHEV", "PROTEIN", 58, 62], ["antibodies", "PROTEIN", 200, 210], ["PHEV", "SPECIES", 58, 62], ["specific monoclonal antibodies", "TEST", 19, 49], ["diagnosis", "TEST", 85, 94], ["antibody", "TEST", 99, 107], ["the disease", "PROBLEM", 127, 138], ["first-litter gilts", "TREATMENT", 250, 268], ["infection", "PROBLEM", 314, 323], ["monoclonal antibodies", "OBSERVATION", 28, 49], ["disease", "OBSERVATION", 131, 138], ["infection", "OBSERVATION", 314, 323]]], ["However, in commercial swine farms, pigs are exposed to different coronaviruses with common genetic and antigenic features.", [["pigs", "ORGANISM", 36, 40], ["coronaviruses", "ORGANISM", 66, 79], ["swine", "SPECIES", 23, 28], ["pigs", "SPECIES", 36, 40], ["swine", "SPECIES", 23, 28], ["pigs", "SPECIES", 36, 40], ["different coronaviruses", "PROBLEM", 56, 79], ["common genetic and antigenic features", "PROBLEM", 85, 122], ["antigenic features", "OBSERVATION", 104, 122]]], ["The N-terminal portion (S1) of the spike protein is the only antigenic region that allows for antibody-based differential diagnosis of porcine coronaviruses, based on a complete absence of detectable cross-reactivity (24).", [["porcine coronaviruses", "DISEASE", 135, 156], ["porcine coronaviruses", "ORGANISM", 135, 156], ["N-terminal portion", "PROTEIN", 4, 22], ["S1", "PROTEIN", 24, 26], ["spike protein", "PROTEIN", 35, 48], ["porcine coronaviruses", "SPECIES", 135, 156], ["the spike protein", "PROBLEM", 31, 48], ["antibody", "TEST", 94, 102], ["porcine coronaviruses", "PROBLEM", 135, 156], ["N-terminal", "OBSERVATION_MODIFIER", 4, 14], ["portion", "OBSERVATION_MODIFIER", 15, 22], ["S1", "ANATOMY", 24, 26], ["spike protein", "OBSERVATION", 35, 48], ["porcine coronaviruses", "OBSERVATION", 135, 156]]], ["Contrary, the N protein and especially the M protein are highly conserved among porcine coronaviruses and, therefore, should not be used for differential serodiagnosis of CoV-related diseases in pigs (24).", [["porcine coronaviruses", "ORGANISM", 80, 101], ["CoV", "ORGANISM", 171, 174], ["pigs", "ORGANISM", 195, 199], ["N protein", "PROTEIN", 14, 23], ["M protein", "PROTEIN", 43, 52], ["porcine", "SPECIES", 80, 87], ["pigs", "SPECIES", 195, 199], ["porcine coronaviruses", "SPECIES", 80, 101], ["pigs", "SPECIES", 195, 199], ["the N protein", "TEST", 10, 23], ["the M protein", "TEST", 39, 52], ["porcine coronaviruses", "PROBLEM", 80, 101], ["differential serodiagnosis", "TEST", 141, 167], ["CoV", "PROBLEM", 171, 174], ["related diseases", "PROBLEM", 175, 191], ["porcine coronaviruses", "OBSERVATION", 80, 101]]], ["Mora-D\u00edaz et al. (75) developed a PHEV S1-based indirect ELISA for isotype-specific (IgG, IgA, IgM) antibody detection.", [["IgG", "GENE_OR_GENE_PRODUCT", 85, 88], ["IgA", "GENE_OR_GENE_PRODUCT", 90, 93], ["IgM", "GENE_OR_GENE_PRODUCT", 95, 98], ["PHEV S1", "PROTEIN", 34, 41], ["IgG", "PROTEIN", 85, 88], ["IgA", "PROTEIN", 90, 93], ["IgM", "PROTEIN", 95, 98], ["PHEV", "SPECIES", 34, 38], ["Mora", "TEST", 0, 4], ["a PHEV S1", "TEST", 32, 41], ["indirect ELISA", "TEST", 48, 62], ["isotype-specific", "TEST", 67, 83], ["IgG", "TEST", 85, 88], ["IgA", "TEST", 90, 93], ["IgM", "TEST", 95, 98], ["antibody detection", "TEST", 100, 118]]], ["Experimental data showed that PHEV infected-pigs develop detectable antibody responses by 7 days after infection, coincident with the onset of clinical signs.", [["infection", "DISEASE", 103, 112], ["PHEV", "ORGANISM", 30, 34], ["pigs", "ORGANISM", 44, 48], ["pigs", "SPECIES", 44, 48], ["PHEV", "SPECIES", 30, 34], ["pigs", "SPECIES", 44, 48], ["Experimental data", "TEST", 0, 17], ["PHEV infected", "PROBLEM", 30, 43], ["infection", "PROBLEM", 103, 112], ["clinical signs", "PROBLEM", 143, 157]]], ["Specifically, the isotype-specific antibody responses in serum showed a strong IgM response at 7 DPI that declined quickly after 14 DPI.", [["serum", "ANATOMY", 57, 62], ["DPI", "CHEMICAL", 132, 135], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["IgM", "GENE_OR_GENE_PRODUCT", 79, 82], ["isotype-specific antibody", "PROTEIN", 18, 43], ["IgM", "PROTEIN", 79, 82], ["the isotype-specific antibody responses", "TEST", 14, 53], ["serum", "TEST", 57, 62], ["strong", "OBSERVATION_MODIFIER", 72, 78], ["IgM response", "OBSERVATION", 79, 91]]], ["Strong IgA and IgG responses were detected by DPI 10 and declined gradually after 28 DPI.ImmunityIt has been proposed but not yet fully demonstrated that the transference of lactogenic passive immunity might protect piglets from PHEV infection during the first few weeks of life.", [["DPI", "CHEMICAL", 46, 49], ["DPI", "CHEMICAL", 85, 88], ["PHEV", "CHEMICAL", 229, 233], ["infection", "DISEASE", 234, 243], ["IgA", "GENE_OR_GENE_PRODUCT", 7, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["piglets", "ORGANISM", 216, 223], ["IgA", "PROTEIN", 7, 10], ["IgG", "PROTEIN", 15, 18], ["piglets", "SPECIES", 216, 223], ["piglets", "SPECIES", 216, 223], ["PHEV", "SPECIES", 229, 233], ["lactogenic passive immunity", "TREATMENT", 174, 201], ["PHEV infection", "PROBLEM", 229, 243], ["IgA", "OBSERVATION", 7, 10], ["infection", "OBSERVATION", 234, 243]]], ["Previous in vivo studies demonstrated that animals with high hemagglutination inhibition (HI) antibody titers were not susceptible to PHEV infection (55).", [["infection", "DISEASE", 139, 148], ["PHEV", "SPECIES", 134, 138], ["Previous in vivo studies", "TEST", 0, 24], ["high hemagglutination inhibition", "PROBLEM", 56, 88], ["HI) antibody titers", "TEST", 90, 109], ["PHEV infection", "PROBLEM", 134, 148]]], ["Pigs develop a detectable circulating antibody response to PHEV between 7 and 10 days after exposure.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["PHEV", "SPECIES", 59, 63], ["a detectable circulating antibody response", "PROBLEM", 13, 55], ["PHEV", "TEST", 59, 63], ["detectable", "OBSERVATION_MODIFIER", 15, 25], ["circulating", "OBSERVATION_MODIFIER", 26, 37], ["antibody response", "OBSERVATION", 38, 55]]], ["The immune response against PHEV has been recently characterized in grow-finisher pigs under experimental conditions (75).", [["PHEV", "CHEMICAL", 28, 32], ["PHEV", "GENE_OR_GENE_PRODUCT", 28, 32], ["pigs", "ORGANISM", 82, 86], ["PHEV", "PROTEIN", 28, 32], ["pigs", "SPECIES", 82, 86], ["PHEV", "SPECIES", 28, 32]]], ["In this study, the isotype-specific antibody responses in serum showed a strong IgM response at 7 days post-inoculation (DPI) that declined after 14 DPI.", [["serum", "ANATOMY", 58, 63], ["DPI", "CHEMICAL", 149, 152], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["IgM", "GENE_OR_GENE_PRODUCT", 80, 83], ["isotype-specific antibody", "PROTEIN", 19, 44], ["IgM", "PROTEIN", 80, 83], ["this study", "TEST", 3, 13], ["the isotype-specific antibody responses", "TEST", 15, 54], ["serum", "TEST", 58, 63]]], ["A strong IgA and IgG responses were detected by 10 DPI, peaked at 28 DPI, and declined gradually thereafter.", [["DPI", "CHEMICAL", 51, 54], ["IgA", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgA", "PROTEIN", 9, 12], ["IgG", "PROTEIN", 17, 20], ["IgG responses", "TEST", 17, 30], ["strong", "OBSERVATION_MODIFIER", 2, 8], ["IgA", "OBSERVATION", 9, 12]]], ["Increasing levels of systemic INF-\u03b1 (DPI 3), TNF-\u03b1 (DPI 10-17), and IL-8 (DPI 14) were detected by multiplex microbead-based immunoassay (Luminex\u00ae) over the course of the infection.", [["DPI", "CHEMICAL", 37, 40], ["infection", "DISEASE", 171, 180], ["INF-\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["DPI 3", "GENE_OR_GENE_PRODUCT", 37, 42], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 45, 50], ["DPI 10-17", "SIMPLE_CHEMICAL", 52, 61], ["IL-8", "GENE_OR_GENE_PRODUCT", 68, 72], ["DPI 14", "SIMPLE_CHEMICAL", 74, 80], ["TNF", "PROTEIN", 45, 48], ["Increasing levels of systemic INF", "PROBLEM", 0, 33], ["DPI", "TEST", 37, 40], ["TNF", "TEST", 45, 48], ["DPI", "TEST", 52, 55], ["IL", "TEST", 68, 70], ["Luminex\u00ae", "TREATMENT", 138, 146], ["the infection", "PROBLEM", 167, 180], ["systemic INF", "ANATOMY", 21, 33], ["infection", "OBSERVATION", 171, 180]]], ["In addition, flow cytometry analysis revealed an increase in both monocytes (DPI 10) and cytotoxic T cell (DPI 21) populations in response to PHEV infection (75).", [["monocytes", "ANATOMY", 66, 75], ["cytotoxic T cell", "ANATOMY", 89, 105], ["infection", "DISEASE", 147, 156], ["monocytes", "CELL", 66, 75], ["cytotoxic T cell", "CELL", 89, 105], ["DPI 21) populations", "CELL", 107, 126], ["PHEV", "ORGANISM", 142, 146], ["monocytes", "CELL_TYPE", 66, 75], ["cytotoxic T cell", "CELL_TYPE", 89, 105], ["PHEV", "SPECIES", 142, 146], ["flow cytometry analysis", "TEST", 13, 36], ["an increase in both monocytes", "PROBLEM", 46, 75], ["DPI", "TEST", 77, 80], ["cytotoxic T cell (DPI", "TREATMENT", 89, 110], ["PHEV infection", "PROBLEM", 142, 156], ["flow cytometry", "OBSERVATION", 13, 27], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["both monocytes", "OBSERVATION", 61, 75], ["cytotoxic T cell", "OBSERVATION", 89, 105], ["infection", "OBSERVATION", 147, 156]]], ["The duration of PHEV-specific antibodies has not been determined under field conditions.", [["PHEV", "GENE_OR_GENE_PRODUCT", 16, 20], ["PHEV", "PROTEIN", 16, 20], ["PHEV", "SPECIES", 16, 20], ["PHEV", "TEST", 16, 20], ["specific antibodies", "TEST", 21, 40]]], ["Sows that were exposed to PHEV rapidly developed detectable levels of antibodies (55).", [["PHEV", "CHEMICAL", 26, 30], ["PHEV", "CHEMICAL", 26, 30], ["antibodies", "PROTEIN", 70, 80], ["PHEV", "SPECIES", 26, 30], ["detectable levels of antibodies", "PROBLEM", 49, 80]]], ["The duration of anti-PHEV immunity is not a critical factor as piglets become resistant to PHEV infection with age.", [["infection", "DISEASE", 96, 105], ["anti-PHEV", "CANCER", 16, 25], ["piglets", "ORGANISM", 63, 70], ["PHEV", "CANCER", 91, 95], ["piglets", "SPECIES", 63, 70], ["anti-PHEV", "SPECIES", 16, 25], ["PHEV", "SPECIES", 91, 95], ["anti-PHEV immunity", "TREATMENT", 16, 34], ["PHEV infection", "PROBLEM", 91, 105], ["infection", "OBSERVATION", 96, 105]]], ["Neonatal pigs born from immune dams, previously exposed to PHEV, are fully protected by maternally-derived antibodies that persist until the age of 4\u201318 weeks (119).", [["pigs", "ORGANISM", 9, 13], ["dams", "ORGANISM", 31, 35], ["antibodies", "PROTEIN", 107, 117], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["Neonatal pigs", "TREATMENT", 0, 13], ["immune dams", "PROBLEM", 24, 35], ["maternally-derived antibodies", "PROBLEM", 88, 117]]], ["More recent field studies carried out in Argentina demonstrated the presence of antibodies in grower/finisher pigs, suggesting that colostral antibodies may persist for more than 6 weeks (67).ImmunityIn rats, the intravenous or intraperitoneal administration of PHEV antiserum provided partial protection against PHEV infection, evidenced by the absence of viral detection in the brain and spinal cord and the absence of PHEV-related neurological clinical signs (120).Prevention and ControlSubclinical circulation of PHEV has been reported nearly worldwide.", [["intravenous", "ANATOMY", 213, 224], ["intraperitoneal", "ANATOMY", 228, 243], ["brain", "ANATOMY", 380, 385], ["spinal cord", "ANATOMY", 390, 401], ["neurological", "ANATOMY", 434, 446], ["PHEV", "CHEMICAL", 262, 266], ["PHEV infection", "DISEASE", 313, 327], ["PHEV", "CHEMICAL", 517, 521], ["pigs", "ORGANISM", 110, 114], ["colostral antibodies", "GENE_OR_GENE_PRODUCT", 132, 152], ["ImmunityIn rats", "ORGANISM", 192, 207], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 213, 224], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 228, 243], ["PHEV antiserum", "GENE_OR_GENE_PRODUCT", 262, 276], ["PHEV", "CANCER", 313, 317], ["brain", "ORGAN", 380, 385], ["spinal cord", "ORGAN", 390, 401], ["PHEV", "GENE_OR_GENE_PRODUCT", 421, 425], ["antibodies", "PROTEIN", 80, 90], ["colostral antibodies", "PROTEIN", 132, 152], ["pigs", "SPECIES", 110, 114], ["rats", "SPECIES", 203, 207], ["pigs", "SPECIES", 110, 114], ["PHEV", "SPECIES", 262, 266], ["PHEV", "SPECIES", 313, 317], ["PHEV", "SPECIES", 517, 521], ["recent field studies", "TEST", 5, 25], ["antibodies", "PROBLEM", 80, 90], ["colostral antibodies", "PROBLEM", 132, 152], ["ImmunityIn rats", "TREATMENT", 192, 207], ["the intravenous", "TREATMENT", 209, 224], ["intraperitoneal administration", "TREATMENT", 228, 258], ["PHEV antiserum", "TREATMENT", 262, 276], ["partial protection", "TREATMENT", 286, 304], ["PHEV infection", "PROBLEM", 313, 327], ["viral detection in the brain and spinal cord", "PROBLEM", 357, 401], ["PHEV", "PROBLEM", 421, 425], ["ControlSubclinical circulation of PHEV", "PROBLEM", 483, 521], ["colostral antibodies", "OBSERVATION", 132, 152], ["infection", "OBSERVATION", 318, 327], ["viral", "OBSERVATION", 357, 362], ["brain", "ANATOMY", 380, 385], ["spinal cord", "ANATOMY", 390, 401]]], ["PHEV persists endemically in most breeding farms by pig-to-pig transmission and subclinical infections with colonization of the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 128, 151], ["PHEV", "CHEMICAL", 0, 4], ["infections", "DISEASE", 92, 102], ["colonization of the upper respiratory tract", "DISEASE", 108, 151], ["pig", "ORGANISM", 52, 55], ["pig", "ORGANISM", 59, 62], ["upper respiratory", "ORGANISM_SUBDIVISION", 128, 145], ["tract", "ORGANISM_SUBDIVISION", 146, 151], ["pig", "SPECIES", 52, 55], ["-pig", "SPECIES", 58, 62], ["PHEV", "SPECIES", 0, 4], ["pig", "SPECIES", 52, 55], ["pig", "SPECIES", 59, 62], ["subclinical infections", "PROBLEM", 80, 102], ["colonization of the upper respiratory tract", "PROBLEM", 108, 151], ["subclinical", "OBSERVATION_MODIFIER", 80, 91], ["infections", "OBSERVATION", 92, 102], ["colonization", "OBSERVATION", 108, 120], ["upper", "ANATOMY_MODIFIER", 128, 133], ["respiratory tract", "ANATOMY", 134, 151]]], ["Protection from the disease may be provided by lactogenic immunity transferred from PHEV seropositive dams to their offspring in enzootically infected herds.", [["enzootically infected", "DISEASE", 129, 150], ["dams", "ORGANISM", 102, 106], ["PHEV", "SPECIES", 84, 88], ["Protection", "TREATMENT", 0, 10], ["the disease", "PROBLEM", 16, 27], ["disease", "OBSERVATION", 20, 27]]], ["PHEV-related disease is a concern mainly in litters of young gilts that may not have been previously exposed to PHEV.", [["PHEV", "CHEMICAL", 0, 4], ["gilts", "ORGANISM", 61, 66], ["PHEV", "SPECIES", 0, 4], ["disease", "PROBLEM", 13, 20], ["disease", "OBSERVATION", 13, 20]]], ["PHEV na\u00efve swine herds (i.e., replacement or isolated gilts and small farms) can be at risk if breaks in biosecurity allow the virus entry to the nursery in farms with low or no passive immunity (68).", [["swine", "SPECIES", 11, 16], ["PHEV", "SPECIES", 0, 4], ["swine", "SPECIES", 11, 16], ["PHEV na\u00efve swine herds", "TREATMENT", 0, 22], ["replacement or isolated gilts and small farms", "TREATMENT", 30, 75]]], ["However, if non-immune dams are infected 2\u20133 weeks before farrowing they become immune, and newborn piglets are usually protected through lactogenic immunity.", [["non-immune dams", "ORGANISM", 12, 27], ["piglets", "ORGANISM", 100, 107], ["piglets", "SPECIES", 100, 107], ["piglets", "SPECIES", 100, 107], ["non-immune dams", "PROBLEM", 12, 27], ["infected", "PROBLEM", 32, 40]]], ["Moreover, it has been demonstrated that circulating anti-PHEV antibodies (hyper-immune serum), administered parentally, or intraperitoneally, protect neonatal piglets against PHEV infection.", [["serum", "ANATOMY", 87, 92], ["intraperitoneally", "ANATOMY", 123, 140], ["PHEV infection", "DISEASE", 175, 189], ["anti-PHEV antibodies", "GENE_OR_GENE_PRODUCT", 52, 72], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["piglets", "ORGANISM", 159, 166], ["PHEV", "CANCER", 175, 179], ["anti-PHEV antibodies", "PROTEIN", 52, 72], ["piglets", "SPECIES", 159, 166], ["anti-PHEV", "SPECIES", 52, 61], ["PHEV", "SPECIES", 175, 179], ["circulating anti-PHEV antibodies", "TEST", 40, 72], ["hyper-immune serum)", "TREATMENT", 74, 93], ["neonatal piglets", "TREATMENT", 150, 166], ["PHEV infection", "PROBLEM", 175, 189], ["infection", "OBSERVATION", 180, 189]]], ["In addition, neutralizing monoclonal antibodies specifically against PHEV could be useful for antibody-based treatment of the disease (86).", [["PHEV", "CHEMICAL", 69, 73], ["PHEV", "SIMPLE_CHEMICAL", 69, 73], ["neutralizing monoclonal antibodies", "PROTEIN", 13, 47], ["PHEV", "PROTEIN", 69, 73], ["PHEV", "SPECIES", 69, 73], ["neutralizing monoclonal antibodies", "TEST", 13, 47], ["PHEV", "TEST", 69, 73], ["antibody", "TEST", 94, 102], ["the disease", "PROBLEM", 122, 133]]], ["Despite some isolated efforts to develop a PHEV vaccine (87), overall, PHEV-related disease is not clinically relevant in most of the swine-producing countries.", [["PHEV", "CHEMICAL", 43, 47], ["PHEV", "CHEMICAL", 71, 75], ["PHEV", "SPECIES", 43, 47], ["PHEV", "SPECIES", 71, 75], ["swine", "SPECIES", 134, 139], ["a PHEV vaccine", "TREATMENT", 41, 55], ["PHEV-related disease", "PROBLEM", 71, 91], ["disease", "OBSERVATION", 84, 91]]], ["Thus, in the absence of current PHEV vaccines, promoting virus circulation on farms with early exposure to gilts and young sows could induce maternal immunity and prevent disease in piglets.ConclusionsPHEV should be considered a major source of economic loss because of the high mortality on farms with high gilt replacement rates, specific pathogen-free animals, and gnotobiotic swine herds.", [["ConclusionsPHEV", "CHEMICAL", 190, 205], ["gilts", "ORGANISM", 107, 112], ["sows", "ORGANISM", 123, 127], ["piglets", "ORGANISM", 182, 189], ["gilt", "ORGANISM_SUBDIVISION", 308, 312], ["piglets", "SPECIES", 182, 189], ["swine", "SPECIES", 380, 385], ["PHEV", "SPECIES", 32, 36], ["ConclusionsPHEV", "SPECIES", 190, 205], ["swine", "SPECIES", 380, 385], ["current PHEV vaccines", "TREATMENT", 24, 45], ["promoting virus circulation", "PROBLEM", 47, 74], ["disease in piglets", "PROBLEM", 171, 189], ["economic loss", "PROBLEM", 245, 258], ["the high mortality", "PROBLEM", 270, 288], ["high gilt replacement rates", "TREATMENT", 303, 330], ["gnotobiotic swine herds", "TREATMENT", 368, 391], ["high", "OBSERVATION_MODIFIER", 274, 278]]], ["Swine-breeding herds with low biosecurity or high pathogen loads may also be at risk of high piglet mortality because of PHEV.", [["piglet", "ANATOMY", 93, 99], ["PHEV", "CHEMICAL", 121, 125], ["herds", "ORGANISM", 15, 20], ["piglet", "ORGANISM_SUBDIVISION", 93, 99], ["Swine", "SPECIES", 0, 5], ["PHEV", "SPECIES", 121, 125], ["low biosecurity", "TREATMENT", 26, 41], ["high pathogen loads", "PROBLEM", 45, 64], ["high piglet mortality", "PROBLEM", 88, 109]]], ["A better understanding of the mechanisms of viral infection and replication would assist in the development of better measures of prevention and treatment.Conflict of Interest Statement ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["viral infection", "DISEASE", 44, 59], ["viral infection", "PROBLEM", 44, 59], ["treatment", "TREATMENT", 145, 154], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59]]]], "PMC7177122": [["Corona virus disease 2019 (COVID-19), as named by World Health Organisation (WHO), has emerged as one of the biggest threats to mankind.", [["Corona virus disease", "DISEASE", 0, 20], ["COVID-19", "CHEMICAL", 27, 35], ["Corona virus", "ORGANISM", 0, 12], ["Corona virus disease 2019 (COVID-19", "SPECIES", 0, 35], ["Corona virus disease", "PROBLEM", 0, 20], ["COVID", "TEST", 27, 32], ["virus disease", "OBSERVATION", 7, 20]]], ["Due to rapid spread among health care workers (HCW), management of airway has become a colossal task for the HCWs.", [["airway", "ANATOMY", 67, 73], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["spread", "OBSERVATION_MODIFIER", 13, 19], ["airway", "ANATOMY", 67, 73]]], ["Not only adequate personal protective equipment (PPE) is necessary, additional measures are being instituted to secure the airway whilst minimising the aerosol generation and transmission.", [["airway", "ANATOMY", 123, 129], ["airway", "MULTI-TISSUE_STRUCTURE", 123, 129], ["additional measures", "TREATMENT", 68, 87], ["the aerosol generation", "TREATMENT", 148, 170], ["airway", "ANATOMY", 123, 129]]]], "8523880d2a0416da7c1296f5e1e1702df9c96bbe": [["and Hoffmann et al. (Cell) identify ACE2 as a SARS-CoV-2 receptor, and the latter show its entry mechanism depends on cellular serine protease TMPRSS2.", [["Cell", "ANATOMY", 21, 25], ["cellular", "ANATOMY", 118, 126], ["serine", "CHEMICAL", 127, 133], ["Cell", "CELL", 21, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["SARS-CoV-2 receptor", "GENE_OR_GENE_PRODUCT", 46, 65], ["cellular", "CELL", 118, 126], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 143, 150], ["ACE2", "PROTEIN", 36, 40], ["SARS-CoV-2 receptor", "PROTEIN", 46, 65], ["cellular serine protease", "PROTEIN", 118, 142], ["TMPRSS2", "PROTEIN", 143, 150], ["ACE2", "TEST", 36, 40], ["a SARS", "TEST", 44, 50], ["cellular serine protease TMPRSS2", "TREATMENT", 118, 150]]], ["These results may explain proinflammatory cytokine release via the associated angiotestin II pathway and a possible therapeutic target via the IL-6-STAT3 axis.", [["angiotestin II", "GENE_OR_GENE_PRODUCT", 78, 92], ["IL-6", "GENE_OR_GENE_PRODUCT", 143, 147], ["STAT3", "GENE_OR_GENE_PRODUCT", 148, 153], ["proinflammatory cytokine", "PROTEIN", 26, 50], ["angiotestin II", "PROTEIN", 78, 92], ["IL-6", "PROTEIN", 143, 147], ["STAT3", "PROTEIN", 148, 153], ["proinflammatory cytokine release", "PROBLEM", 26, 58], ["the IL", "TEST", 139, 145]]]], "PMC7087647": [["IntroductionAs of May 2010, 214 countries worldwide have reported laboratory-confirmed cases of pandemic influenza H1N1 including 18,036 deaths.", [["influenza H1N1", "DISEASE", 105, 119], ["deaths", "DISEASE", 137, 143], ["pandemic influenza H1N1", "SPECIES", 96, 119], ["pandemic influenza H1N1", "SPECIES", 96, 119], ["pandemic influenza H1N1", "PROBLEM", 96, 119]]], ["According to WHO, the case count was likely to be significantly lower than the actual number of cases that have occurred as many countries stopped counting individual cases, particularly of milder illness (WHO 2010).IntroductionIn October 2009, nearly all states reported geographically widespread influenza activity.", [["influenza", "DISEASE", 298, 307], ["the case count", "TEST", 18, 32], ["geographically", "OBSERVATION_MODIFIER", 272, 286], ["widespread", "OBSERVATION_MODIFIER", 287, 297], ["influenza activity", "OBSERVATION", 298, 316]]], ["Nationwide, the percentage of visits to health care providers for influenza-like illness (ILI) was higher than that observed at the peak of any seasonal influenza season since ILINet (Influenza-like Illness Surveillance Network) was implemented in its current form in 1997 (CDC 2010).", [["influenza-like illness", "DISEASE", 66, 88], ["ILI", "DISEASE", 90, 93], ["influenza", "DISEASE", 153, 162], ["Influenza-like Illness", "DISEASE", 184, 206], ["influenza", "PROBLEM", 66, 75], ["Influenza", "PROBLEM", 184, 193]]], ["By April 2010 the US Centers for Disease Control and Prevention (CDC) estimated 12,470 deaths (CDC 2009a, b, c, d, e, f, g).IntroductionSince April 2009, pandemic H1N1 became the dominant circulating influenza strain (CDC 2009a, b, c, d, e, f, g).", [["deaths", "DISEASE", 87, 93], ["H1N1", "DISEASE", 163, 167], ["influenza", "DISEASE", 200, 209], ["Disease Control", "TREATMENT", 33, 48], ["CDC", "TEST", 95, 98], ["pandemic H1N1", "PROBLEM", 154, 167], ["the dominant circulating influenza strain", "PROBLEM", 175, 216], ["CDC", "TEST", 218, 221], ["dominant", "OBSERVATION_MODIFIER", 179, 187], ["circulating", "OBSERVATION_MODIFIER", 188, 199], ["influenza", "OBSERVATION", 200, 209]]], ["According to CDC of the 48,483 (99.8%) specimens positive for influenza A, 32,867 (68%) were subtyped by real-time reverse transcription polymerase chain reaction (rRT-PCR).", [["specimens", "ANATOMY", 39, 48], ["influenza A", "DISEASE", 62, 73], ["specimens", "CANCER", 39, 48], ["influenza A", "SPECIES", 62, 73], ["CDC", "TEST", 13, 16], ["specimens", "TEST", 39, 48], ["influenza", "PROBLEM", 62, 71], ["reverse transcription polymerase chain reaction", "PROBLEM", 115, 162], ["rRT", "TEST", 164, 167]]], ["The result was 99.8% for 2009 pandemic influenza A (H1N1) viruses, 18 (0.1%) were seasonal influenza A (H1), and 35 (0.1%) were influenza A (H3) viruses (CDC 2009a, b, c, d, e, f, g).", [["influenza A (H1N1) viruses", "DISEASE", 39, 65], ["influenza A", "DISEASE", 91, 102], ["influenza", "DISEASE", 128, 137], ["influenza A (H1N1) viruses", "ORGANISM", 39, 65], ["influenza A (H3) viruses", "ORGANISM", 128, 152], ["pandemic influenza A (H1N1", "SPECIES", 30, 56], ["2009 pandemic influenza A (H1N1) viruses", "SPECIES", 25, 65], ["H1", "SPECIES", 104, 106], ["The result", "TEST", 0, 10], ["pandemic influenza A (H1N1) viruses", "PROBLEM", 30, 65], ["seasonal influenza A", "TEST", 82, 102], ["influenza", "PROBLEM", 128, 137], ["viruses", "TEST", 145, 152], ["CDC", "TEST", 154, 157], ["b", "TEST", 165, 166]]], ["Due to the prevalence of H1N1 type strain, the CDC stopped widespread testing for the H1N1 influenza virus (CDC 2009a, b, c, d, e, f, g).", [["influenza", "DISEASE", 91, 100], ["H1N1 type strain", "ORGANISM", 25, 41], ["H1N1 influenza virus", "ORGANISM", 86, 106], ["H1N1 influenza virus", "SPECIES", 86, 106], ["H1N1 influenza virus", "SPECIES", 86, 106], ["H1N1 type strain", "PROBLEM", 25, 41], ["the CDC", "TEST", 43, 50], ["widespread testing", "TEST", 59, 77], ["the H1N1 influenza virus", "PROBLEM", 82, 106], ["CDC", "TEST", 108, 111], ["H1N1", "OBSERVATION", 25, 29]]], ["On 24 October 2009, the US government declared the swine flu outbreak a national emergency, thereby allowing hospital and local governments to speedily set up alternate sites for treatment and triage procedures if needed to handle any surge of patients (Calmes and McNeil 2009).IntroductionThe information analyzed by the CDC supports the conclusion that novel H1N1 flu has caused greater disease burden on people younger than 25 years of age than older people (CDC 2009a, b, c, d, e, f, g).", [["H1N1 flu", "DISEASE", 361, 369], ["patients", "ORGANISM", 244, 252], ["H1N1 flu", "ORGANISM", 361, 369], ["people", "ORGANISM", 407, 413], ["people", "ORGANISM", 454, 460], ["swine", "SPECIES", 51, 56], ["patients", "SPECIES", 244, 252], ["people", "SPECIES", 407, 413], ["people", "SPECIES", 454, 460], ["swine flu", "SPECIES", 51, 60], ["H1N1 flu", "SPECIES", 361, 369], ["treatment", "TREATMENT", 179, 188], ["triage procedures", "TREATMENT", 193, 210], ["novel H1N1 flu", "PROBLEM", 355, 369], ["greater disease burden", "PROBLEM", 381, 403], ["CDC", "TEST", 462, 465]]], ["One study done earlier in 2009 among US military beneficiaries about the epidemiologic characteristics of novel H1N1 clearly showed that the strain appeared to preferentially affect adolescent and young adults between 15 and 24 years of age (Crum-Cianflone et al. 2009).", [["One study", "TEST", 0, 9], ["novel H1N1", "PROBLEM", 106, 116], ["the strain", "PROBLEM", 137, 147]]], ["At the inception of the epidemic, there were no vaccines available.", [["vaccines", "TREATMENT", 48, 56], ["no", "UNCERTAINTY", 45, 47]]], ["Later, there were vaccines available free of charge for H1N1 influenza, and the CDC recommended the vaccine as the best preventive measure against H1N1 (CDC 2009a, b, c, d, e, f, g).", [["influenza", "DISEASE", 61, 70], ["H1N1", "DISEASE", 147, 151], ["vaccines", "TREATMENT", 18, 26], ["H1N1 influenza", "PROBLEM", 56, 70], ["the vaccine", "TREATMENT", 96, 107], ["H1N1", "PROBLEM", 147, 151], ["CDC", "TEST", 153, 156]]], ["Transmissibility of the H1N1 virus has been shown to be substantially higher than that of seasonal flu (Fraser et al. 2009).", [["H1N1 virus", "ORGANISM", 24, 34], ["H1N1 virus", "SPECIES", 24, 34], ["H1N1 virus", "SPECIES", 24, 34], ["the H1N1 virus", "PROBLEM", 20, 34], ["seasonal flu", "PROBLEM", 90, 102], ["H1N1", "OBSERVATION", 24, 28], ["substantially", "OBSERVATION_MODIFIER", 56, 69], ["higher", "OBSERVATION_MODIFIER", 70, 76]]], ["Thus, it has become imperative to educate the public about measures of prevention of transmission of the H1N1 virus in order to mitigate its impact on the population.IntroductionEncouraging the public to undertake specific behaviors related to hygiene has proved useful in containing previous outbreaks of infectious diseases (Fung and Cairncross 2006).", [["infectious diseases", "DISEASE", 306, 325], ["H1N1 virus", "ORGANISM", 105, 115], ["H1N1 virus", "SPECIES", 105, 115], ["the H1N1 virus", "PROBLEM", 101, 115], ["infectious diseases", "PROBLEM", 306, 325], ["H1N1", "OBSERVATION", 105, 109], ["infectious", "OBSERVATION", 306, 316]]], ["Studies of how people responded to the outbreak of severe acute respiratory syndrome (SARS) in 2002 suggest that perceptions or beliefs about an outbreak may be important in determining compliance with official advice.", [["acute respiratory syndrome", "DISEASE", 58, 84], ["SARS", "DISEASE", 86, 90], ["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["severe acute respiratory syndrome", "PROBLEM", 51, 84], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["Different authors have cited the Health Belief Model (Lau et al. 2003; Tang and Wong 2003; Janz and Becker 1984; Rosenstock et al. 1988; Tang and Wong 2004; Lau et al. 2007) and the public\u2019s response during the outbreak of SARS (Lau et al. 2003; Tang and Wong 2003; Tang and Wong 2004; Lau et al. 2007) to suggest that people may be more likely to comply with health-related recommendations if they believe the following: the effects of the disease are severe; the recommended behaviors are effective (Tang and Wong 2004; Lau et al. 2007; Janz and Becker 1984); they are susceptible (Janz and Becker 1984; Rosenstock et al. 1988; Tang and Wong 2004); the illness is difficult to treat (Lau et al. 2007); the government is providing clear and sufficient information about the outbreak and can be trusted to control the spread of infection (Tang and Wong 2003); and there are few barriers to action (Janz and Becker 1984; Rosenstock et al. 1988).", [["SARS", "DISEASE", 223, 227], ["illness", "DISEASE", 655, 662], ["infection", "DISEASE", 828, 837], ["people", "ORGANISM", 319, 325], ["people", "SPECIES", 319, 325], ["SARS", "PROBLEM", 223, 227], ["the disease", "PROBLEM", 437, 448], ["the illness", "PROBLEM", 651, 662], ["infection", "PROBLEM", 828, 837], ["infection", "OBSERVATION", 828, 837]]], ["In addition, a higher level of anxiety or worry may be associated with an increase in behavior changes (Leung et al. 2005).", [["anxiety", "DISEASE", 31, 38], ["worry", "DISEASE", 42, 47], ["anxiety", "PROBLEM", 31, 38], ["an increase in behavior changes", "PROBLEM", 71, 102], ["increase", "OBSERVATION_MODIFIER", 74, 82]]], ["Thus, understanding the role of specific perceptions in motivating people to engage in precautionary behavior may help health communicators improve their messages about outbreaks of new infectious disease generally and H1N1 specifically (Rubin et al. 2009).IntroductionThe four main objectives of this study were to determine (1) knowledge, beliefs, and misconception about the 2009 swine flu, (2) perception about the efficacy of swine flu immunization and governmental actions to contain the H1N1 epidemic, (3) perceived efficacy of preventive behavior, and (4) prevalence of anxiety in relation to swine flu (H1N1) among a sample of college students aged 18\u201324 years.", [["infectious disease", "DISEASE", 186, 204], ["anxiety", "DISEASE", 578, 585], ["swine flu", "DISEASE", 601, 610], ["people", "ORGANISM", 67, 73], ["swine flu", "ORGANISM", 601, 610], ["people", "SPECIES", 67, 73], ["swine", "SPECIES", 383, 388], ["swine", "SPECIES", 431, 436], ["swine", "SPECIES", 601, 606], ["2009 swine flu", "SPECIES", 378, 392], ["swine", "SPECIES", 431, 436], ["swine flu (H1N1", "SPECIES", 601, 616], ["new infectious disease", "PROBLEM", 182, 204], ["H1N1", "PROBLEM", 219, 223], ["this study", "TEST", 297, 307], ["swine flu immunization", "TREATMENT", 431, 453], ["governmental actions", "TREATMENT", 458, 478], ["the H1N1 epidemic", "PROBLEM", 490, 507], ["preventive behavior", "PROBLEM", 535, 554], ["anxiety", "PROBLEM", 578, 585], ["new", "OBSERVATION_MODIFIER", 182, 185], ["infectious", "OBSERVATION", 186, 196]]], ["This age group has been shown to be more at risk of getting swine flu than the older population and was in priority consideration in the initial stages of vaccination due to shortages.Data analysis ::: Subjects and methodsThe data were analyzed using SPSS version 16 (SPSS Inc., Chicago, IL, USA).", [["swine", "SPECIES", 60, 65], ["swine", "SPECIES", 60, 65], ["vaccination", "TREATMENT", 155, 166], ["Data analysis", "TEST", 184, 197], ["The data", "TEST", 222, 230], ["SPSS version", "TEST", 251, 263], ["SPSS Inc.", "TEST", 268, 277]]], ["Descriptive statistics (frequencies, means, and standard deviations) were used to describe demographic characteristics, knowledge of swine flu, risk reduction, and prevention.Data analysis ::: Subjects and methodsItems on knowledge were scaled on a \u201cyes-no-don\u2019t know\u201d format options.", [["swine flu", "DISEASE", 133, 142], ["swine", "SPECIES", 133, 138], ["swine", "SPECIES", 133, 138], ["swine flu", "PROBLEM", 133, 142], ["risk reduction", "TREATMENT", 144, 158], ["Data analysis", "TEST", 175, 188]]], ["The \u201cdon\u2019t know\u201d as an option was included to reduce the probability of guessing, as guessing causes some variation in performance from item to item, which tends to lower the test reliability (Nunnally 1967).Data analysis ::: Subjects and methodsItems subscale assessing perceived self-efficacy or preventive behavior (washing hands, cleaning or disinfecting contaminated inanimate objects) utilized a 5-point Likert format ranging from 1 (strongly disagree/very unlikely) to 5 (strongly agree/most likely) with the midpoints representing ambivalent responses.Data analysis ::: Subjects and methodsPersonal risk reduction was determined with questions relating to hand washing.", [["hand", "ANATOMY", 664, 668], ["hand", "ORGANISM_SUBDIVISION", 664, 668], ["Data analysis", "TEST", 208, 221], ["preventive behavior", "PROBLEM", 298, 317], ["Data analysis", "TEST", 560, 573], ["Personal risk reduction", "PROBLEM", 598, 621], ["hand washing", "TREATMENT", 664, 676]]], ["The anxiety indicator was measured through closed format questions assessing personal worries about catching the virus (on a 4-point scale from 4 = \u201cvery concerned\u201d to 1 = \u201cnot at all concerned\u201d).Data analysis ::: Subjects and methodsBivariate data were analyzed by contingency table analysis except for t tests as appropriate for continuous data (for example, anxiety scale).", [["anxiety", "DISEASE", 4, 11], ["anxiety", "DISEASE", 361, 368], ["The anxiety indicator", "PROBLEM", 0, 21], ["the virus", "PROBLEM", 109, 118], ["a 4-point scale", "TREATMENT", 123, 138], ["Data analysis", "TEST", 196, 209], ["methodsBivariate data", "TEST", 227, 248], ["contingency table analysis", "TEST", 266, 292], ["t tests", "TEST", 304, 311], ["continuous data", "TEST", 331, 346], ["anxiety scale", "TEST", 361, 374]]], ["The chi-square test was used to assess the bivariate relationship between differences in proportions and for other categorical variables.", [["The chi-square test", "TEST", 0, 19]]], ["Cross-tabulations were run on demographic variables and risk reduction to determine associations between race and risk reduction.", [["demographic variables", "TEST", 30, 51], ["risk reduction", "TREATMENT", 56, 70], ["risk reduction", "TREATMENT", 114, 128]]], ["All statistical tests were two-tailed and alpha = 0.05 or less was considered statistically significant.Knowledge, beliefs, and misconceptions ::: ResultsRespondents overwhelmingly agreed that washing hands with soap and water (95.1%) and cleaning or disinfecting things one might touch could reduce the possible transmission of the swine flu virus (87.8%).", [["swine flu virus", "ORGANISM", 333, 348], ["swine flu virus", "SPECIES", 333, 348], ["swine flu virus", "SPECIES", 333, 348], ["All statistical tests", "TEST", 0, 21], ["alpha", "TEST", 42, 47], ["soap and water", "TREATMENT", 212, 226], ["cleaning", "TREATMENT", 239, 247], ["the swine flu virus", "PROBLEM", 329, 348]]], ["Table 1 shows the respondents\u2019 knowledge, beliefs, and misconceptions about swine flu.", [["swine", "ORGANISM", 76, 81], ["swine", "SPECIES", 76, 81], ["swine flu", "SPECIES", 76, 85]]]], "29a2661db09a1b742b1c72d0a7c28614e745ba02": [["In BriefRabies-related viruses cause a similar disease as rabies virus, but protection is not always induced by current vaccines.", [["BriefRabies", "CHEMICAL", 3, 14], ["rabies virus", "DISEASE", 58, 70], ["BriefRabies-related viruses", "ORGANISM", 3, 30], ["rabies virus", "ORGANISM", 58, 70], ["rabies virus", "SPECIES", 58, 70], ["related viruses", "PROBLEM", 15, 30], ["a similar disease", "PROBLEM", 37, 54], ["rabies virus", "PROBLEM", 58, 70], ["current vaccines", "TREATMENT", 112, 128], ["viruses", "OBSERVATION", 23, 30], ["similar", "OBSERVATION_MODIFIER", 39, 46], ["disease", "OBSERVATION", 47, 54]]], ["Fisher et al. design a vaccine featuring a functional, chimeric envelope protein that combines parts of two highly divergent viruses.", [["chimeric envelope protein", "PROTEIN", 55, 80], ["a vaccine", "TREATMENT", 21, 30], ["a functional, chimeric envelope protein", "PROBLEM", 41, 80], ["divergent", "OBSERVATION_MODIFIER", 115, 124], ["viruses", "OBSERVATION", 125, 132]]], ["The vaccine generates robust immune responses and protects against disease in mice.INTRODUCTIONEmerging infectious diseases are on the rise (Smith et al., 2014) .", [["infectious diseases", "DISEASE", 104, 123], ["mice", "ORGANISM", 78, 82], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["The vaccine", "TREATMENT", 0, 11], ["disease in mice", "PROBLEM", 67, 82], ["INTRODUCTIONEmerging infectious diseases", "PROBLEM", 83, 123]]], ["The recent outbreaks of Ebola virus, Zika virus, and SARS-CoV-2 highlight our lack of preparedness: despite their relation to known diseases, few therapeutics were available for rapid distribution.", [["Ebola virus, Zika virus", "DISEASE", 24, 47], ["SARS", "DISEASE", 53, 57], ["Ebola virus", "ORGANISM", 24, 35], ["Zika virus", "ORGANISM", 37, 47], ["SARS-CoV-2", "ORGANISM", 53, 63], ["Ebola virus", "SPECIES", 24, 35], ["Zika virus", "SPECIES", 37, 47], ["Ebola virus", "SPECIES", 24, 35], ["Zika virus", "SPECIES", 37, 47], ["SARS-CoV", "SPECIES", 53, 61], ["Ebola virus", "PROBLEM", 24, 35], ["Zika virus", "PROBLEM", 37, 47], ["SARS", "PROBLEM", 53, 57], ["known diseases", "PROBLEM", 126, 140], ["Ebola virus", "OBSERVATION", 24, 35], ["diseases", "OBSERVATION", 132, 140]]], ["Zoonotic diseases are particularly threatening, because they often move to new hosts opportunistically and can rarely be eradicated on a global scale (Cutler et al., 2010; Welburn et al., 2015) .INTRODUCTIONRabies is a neglected infectious disease that is responsible for an estimated 59,000 global human deaths annually (Hampson et al., 2015; World Health Organization, 2017a) , roughly the same number of deaths caused annually by influenza in the United States (Kochanek et al., 2011) .", [["Zoonotic diseases", "DISEASE", 0, 17], ["infectious disease", "DISEASE", 229, 247], ["deaths", "DISEASE", 305, 311], ["deaths", "DISEASE", 407, 413], ["influenza", "DISEASE", 433, 442], ["human", "ORGANISM", 299, 304], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 299, 304], ["Zoonotic diseases", "PROBLEM", 0, 17], ["a neglected infectious disease", "PROBLEM", 217, 247], ["influenza", "PROBLEM", 433, 442], ["infectious", "OBSERVATION", 229, 239]]], ["Whereas millions of people survive influenza each year, fewer than 30 cases of human rabies survival have been documented (Fooks et al., 2017; Mani et al., 2019) .", [["influenza", "DISEASE", 35, 44], ["rabies", "DISEASE", 85, 91], ["people", "ORGANISM", 20, 26], ["human", "ORGANISM", 79, 84], ["people", "SPECIES", 20, 26], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["human rabies survival", "TREATMENT", 79, 100]]], ["The number of human rabies deaths is likely underestimated, as studies in developing countries with poor health infrastructure suggest (Fooks et al., 2014; Mallewa et al., 2007) .", [["rabies deaths", "DISEASE", 20, 33], ["human", "ORGANISM", 14, 19], ["rabies", "ORGANISM", 20, 26], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19]]], ["Rabies virus (RABV)-induced encephalitis is the most lethal viral infection known to humankind when no intervention is applied prior to symptoms.", [["Rabies virus", "DISEASE", 0, 12], ["encephalitis", "DISEASE", 28, 40], ["viral infection", "DISEASE", 60, 75], ["Rabies virus", "ORGANISM", 0, 12], ["RABV", "ORGANISM", 14, 18], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["RABV", "SPECIES", 14, 18], ["Rabies virus (RABV)", "PROBLEM", 0, 19], ["encephalitis", "PROBLEM", 28, 40], ["the most lethal viral infection", "PROBLEM", 44, 75], ["intervention", "TREATMENT", 103, 115], ["symptoms", "PROBLEM", 136, 144], ["encephalitis", "OBSERVATION", 28, 40], ["infection", "OBSERVATION", 66, 75]]], ["Less known is that RABVrelated lyssaviruses cause the same zoonotic disease, have similar mortality rates as RABV, but are far less studied (Banyard et al., 2014; Evans et al., 2012) .", [["zoonotic disease", "DISEASE", 59, 75], ["RABVrelated lyssaviruses", "ORGANISM", 19, 43], ["RABV", "ORGANISM", 109, 113], ["RABV", "SPECIES", 109, 113], ["the same zoonotic disease", "PROBLEM", 50, 75], ["zoonotic", "OBSERVATION_MODIFIER", 59, 67], ["disease", "OBSERVATION", 68, 75]]], ["The lyssavirus genus is comprised of 17 single-stranded, negative-sense RNA viruses divided into at least three phylogroups (RABV being categorized in phylogroup I) (Markotter and Coertse, 2018) .", [["lyssavirus genus", "ORGANISM", 4, 20], ["RABV", "ORGANISM", 125, 129], ["RABV", "SPECIES", 125, 129], ["The lyssavirus genus", "TEST", 0, 20], ["sense RNA viruses", "PROBLEM", 66, 83], ["lyssavirus genus", "OBSERVATION", 4, 20]]], ["Classical RABV circulates on all continents but Antarctica; non-RABV lyssaviruses are endemic in Europe, Africa, Asia, and Australia (Fisher et al., 2018) .INTRODUCTIONRabies is highly survivable with prompt administration of vaccines and antiserum.", [["RABV", "ORGANISM", 10, 14], ["non-RABV lyssaviruses", "ORGANISM", 60, 81], ["antiserum", "ORGANISM_SUBSTANCE", 239, 248], ["RABV", "SPECIES", 10, 14], ["Classical RABV circulates", "PROBLEM", 0, 25], ["vaccines", "TREATMENT", 226, 234], ["antiserum", "TREATMENT", 239, 248], ["RABV", "OBSERVATION", 10, 14], ["endemic", "OBSERVATION_MODIFIER", 86, 93]]], ["RABV vaccines are touted as one of the lowest cost but highest impact tradeoffs among vaccine-preventable infectious diseases (comparing procurement cost to Gavi, the Vaccine Alliance, and governments per death averted) (Gavi, 2018) .", [["infectious diseases", "DISEASE", 106, 125], ["death", "DISEASE", 205, 210], ["RABV", "ORGANISM", 0, 4], ["RABV", "SPECIES", 0, 4], ["RABV vaccines", "TREATMENT", 0, 13], ["preventable infectious diseases", "PROBLEM", 94, 125], ["infectious", "OBSERVATION", 106, 116]]], ["Critically, disease from other lyssaviruses is not always prevented by RABV-based vaccines and biologics: protection against phylogroup II and III viruses is minimal (Weyer et al., 2008) , and lapses in coverage by post-exposure prophylaxis (PEP) have even been shown within phylogroup I, despite phylogenic proximity to RABV (Liu et al., 2013) .", [["lyssaviruses", "DISEASE", 31, 43], ["RABV", "ORGANISM", 71, 75], ["phylogroup II", "ORGANISM", 125, 138], ["phylogroup I", "GENE_OR_GENE_PRODUCT", 275, 287], ["RABV", "ORGANISM", 321, 325], ["phylogroup I", "PROTEIN", 275, 287], ["RABV", "SPECIES", 71, 75], ["RABV", "SPECIES", 321, 325], ["Critically, disease from other lyssaviruses", "PROBLEM", 0, 43], ["RABV-based vaccines", "TREATMENT", 71, 90], ["protection", "TREATMENT", 106, 116], ["phylogroup II and III viruses", "PROBLEM", 125, 154], ["post-exposure prophylaxis", "TREATMENT", 215, 240], ["PEP", "TEST", 242, 245], ["disease", "OBSERVATION", 12, 19], ["minimal", "OBSERVATION_MODIFIER", 158, 165]]], ["Despite this, the available vaccines were developed solely against RABV (Liu et al., 2013; Nel, 2001) .", [["RABV", "ORGANISM", 67, 71], ["RABV", "SPECIES", 67, 71], ["the available vaccines", "TREATMENT", 14, 36]]], ["Investment in studying lyssaviruses and development of a pan-lyssavirus vaccine is currently lacking but would have a profound impact if or when a divergent lyssavirus emerges.INTRODUCTIONThe fraction of disease burden shared by non-RABV lyssaviruses is unknown: the viral encephalitis and resulting symptoms from lyssaviruses are indistinguishable from RABV infections, and current diagnostic reagents based on the highly conserved nucleoprotein (N) cannot differentiate between lyssaviruses (von Teichman et al., 1998; World Health Organization, 2018) .", [["lyssaviruses", "DISEASE", 238, 250], ["viral encephalitis", "DISEASE", 267, 285], ["lyssaviruses", "DISEASE", 314, 326], ["RABV infections", "DISEASE", 354, 369], ["lyssavirus", "CANCER", 157, 167], ["RABV", "ORGANISM", 354, 358], ["RABV", "SPECIES", 354, 358], ["a pan-lyssavirus vaccine", "TREATMENT", 55, 79], ["a divergent lyssavirus emerges", "PROBLEM", 145, 175], ["disease burden", "PROBLEM", 204, 218], ["non-RABV lyssaviruses", "PROBLEM", 229, 250], ["the viral encephalitis", "PROBLEM", 263, 285], ["resulting symptoms", "PROBLEM", 290, 308], ["lyssaviruses", "PROBLEM", 314, 326], ["RABV infections", "PROBLEM", 354, 369], ["fraction", "OBSERVATION_MODIFIER", 192, 200], ["disease", "OBSERVATION", 204, 211], ["viral encephalitis", "OBSERVATION", 267, 285], ["RABV infections", "OBSERVATION", 354, 369]]], ["Discriminatory diagnostics are rarely available for either human cases or surveillance in animal populations (Evans et al., 2012; Mallewa et al., 2007) .", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["Discriminatory diagnostics", "TEST", 0, 26]]], ["Definitive evidence of a non-RABV lyssavirus infection can only be made in post-mortem analysis, and the methods (sequencing the viral genome or probing with speciesspecific antibodies) are not yet standardized.", [["lyssavirus infection", "DISEASE", 34, 54], ["viral genome", "DNA", 129, 141], ["speciesspecific antibodies", "PROTEIN", 158, 184], ["non-RABV", "SPECIES", 25, 33], ["a non-RABV lyssavirus infection", "PROBLEM", 23, 54], ["post-mortem analysis", "TEST", 75, 95], ["the methods", "TEST", 101, 112], ["speciesspecific antibodies", "TEST", 158, 184], ["evidence of", "UNCERTAINTY", 11, 22], ["non-RABV lyssavirus", "OBSERVATION", 25, 44], ["infection", "OBSERVATION", 45, 54]]], ["Seroprevalence studies in wildlife suggest lyssaviruses circulate in low but steady proportions compared with RABV (M\u00e9 lade et al., 2016; Or1owska et al., 2020; Suu-Ire et al., 2017) .", [["RABV", "ORGANISM", 110, 114], ["RABV", "SPECIES", 110, 114], ["Seroprevalence studies", "TEST", 0, 22]]], ["A small number of human deaths caused by six non-RABV lyssaviruses has been confirmed, but the actual number is likely higher (Evans et al., 2012) .INTRODUCTIONSporadic outbreaks of RABV (Feng et al., 2016; Kuzmin et al., 2012) and the consistent discovery of new lyssaviruses (Ar\u00e9chiga Ceballos et al., 2013; Hu et al., 2018; Nokireki et al., 2018) challenge our understanding of lyssavirus evolution and host switching (Fisher et al., 2018) .", [["deaths", "DISEASE", 24, 30], ["lyssaviruses", "DISEASE", 54, 66], ["human", "ORGANISM", 18, 23], ["RABV", "ORGANISM", 182, 186], ["lyssavirus", "CANCER", 381, 391], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["RABV", "SPECIES", 182, 186], ["human deaths", "PROBLEM", 18, 30], ["six non-RABV lyssaviruses", "PROBLEM", 41, 66], ["lyssavirus", "PROBLEM", 381, 391], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["human deaths", "OBSERVATION", 18, 30], ["likely", "UNCERTAINTY", 112, 118], ["higher", "OBSERVATION_MODIFIER", 119, 125], ["lyssavirus", "OBSERVATION", 381, 391]]], ["RABV likely originated as a bat-derived virus, then spread to terrestrial mammal reservoirs, notably dogs, numerous times (Badrane and Tordo, 2001) .", [["RABV", "ORGANISM", 0, 4], ["dogs", "ORGANISM", 101, 105], ["dogs", "SPECIES", 101, 105], ["RABV", "SPECIES", 0, 4], ["RABV", "PROBLEM", 0, 4], ["a bat-derived virus", "PROBLEM", 26, 45], ["terrestrial mammal reservoirs", "OBSERVATION", 62, 91]]], ["Canine RABV is now responsible for 95% of human RABV fatalities (Hampson et al., 2015; World Health Organization, 2017a) .", [["RABV fatalities", "DISEASE", 48, 63], ["Canine RABV", "ORGANISM", 0, 11], ["human", "ORGANISM", 42, 47], ["RABV", "ORGANISM", 48, 52], ["Canine", "SPECIES", 0, 6], ["human", "SPECIES", 42, 47], ["Canine", "SPECIES", 0, 6], ["RABV", "SPECIES", 7, 11], ["human", "SPECIES", 42, 47], ["RABV", "SPECIES", 48, 52], ["Canine RABV", "TREATMENT", 0, 11]]], ["Lyssaviruses circulate in bats with two notable exceptions where the reservoirs have not been identified: Ikoma virus (IKOV) (Marston et al., 2012) and Mokola virus (MOKV) (Coertse et al., 2017; Sabeta et al., 2007) .", [["Ikoma virus", "ORGANISM", 106, 117], ["Mokola virus", "ORGANISM", 152, 164], ["Mokola virus", "SPECIES", 152, 164], ["Ikoma virus", "SPECIES", 106, 117], ["IKOV", "SPECIES", 119, 123], ["Mokola virus", "SPECIES", 152, 164], ["Ikoma virus", "PROBLEM", 106, 117], ["notable", "OBSERVATION_MODIFIER", 40, 47], ["reservoirs", "OBSERVATION", 69, 79]]], ["The possibility of further terrestrial adaptation and consequent increased risk to humans is of concern.", [["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["further terrestrial adaptation", "PROBLEM", 19, 49], ["terrestrial adaptation", "OBSERVATION", 27, 49], ["increased", "OBSERVATION_MODIFIER", 65, 74]]], ["MOKV, a divergent member of phylogroup II, was one of the first non-RABV lyssaviruses to be discovered (Shope et al., 1970) , and lack of protection from RABV-based vaccines in animals has been well documented: for example, MOKV has been isolated from rabies-vaccinated domestic cats multiple times (Nel et al., 2000; Sabeta et al., 2010 Sabeta et al., , 2007 von Teichman et al., 1998) .", [["MOKV", "CHEMICAL", 0, 4], ["MOKV", "CHEMICAL", 224, 228], ["MOKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["phylogroup II", "GENE_OR_GENE_PRODUCT", 28, 41], ["RABV", "ORGANISM", 154, 158], ["MOKV", "GENE_OR_GENE_PRODUCT", 224, 228], ["rabies", "ORGANISM", 252, 258], ["cats", "ORGANISM", 279, 283], ["MOKV", "PROTEIN", 0, 4], ["phylogroup II", "PROTEIN", 28, 41], ["MOKV", "PROTEIN", 224, 228], ["cats", "SPECIES", 279, 283], ["MOKV", "SPECIES", 0, 4], ["RABV", "SPECIES", 154, 158], ["MOKV", "SPECIES", 224, 228], ["RABV-based vaccines", "TREATMENT", 154, 173]]], ["Although rare cross-reactivity between RABV and MOKV has been observed, the current RABV vaccine is unlikely to provide protection against MOKV (De Benedictis et al., 2016; Hanlon et al., 2005) .INTRODUCTIONThe unique attributes of rabies and its epidemiology call for economic factors to be considered during vaccine development.", [["rabies", "DISEASE", 232, 238], ["RABV", "ORGANISM", 39, 43], ["MOKV", "CANCER", 48, 52], ["RABV", "ORGANISM", 84, 88], ["rabies", "ORGANISM", 232, 238], ["MOKV", "PROTEIN", 48, 52], ["RABV", "SPECIES", 39, 43], ["MOKV", "SPECIES", 48, 52], ["RABV", "SPECIES", 84, 88], ["MOKV", "SPECIES", 139, 143], ["rabies", "SPECIES", 232, 238], ["rare cross-reactivity between RABV", "PROBLEM", 9, 43], ["the current RABV vaccine", "TREATMENT", 72, 96], ["economic factors", "TREATMENT", 269, 285], ["cross-reactivity", "OBSERVATION", 14, 30]]], ["Despite its favorable cost-to-impact tradeoff, the current rabies vaccine is expensive, especially for rural populations in developing countries where transmission most often occurs.", [["rabies", "ORGANISM", 59, 65], ["rabies", "SPECIES", 59, 65], ["the current rabies vaccine", "TREATMENT", 47, 73], ["favorable", "OBSERVATION_MODIFIER", 12, 21]]], ["Therefore, in crafting a vaccine with broadened protection, we aimed for a vaccine similar to current vaccines in composition and formulation: inactivated virions of a single strain.", [["a vaccine", "TREATMENT", 23, 32], ["broadened protection", "TREATMENT", 38, 58], ["a vaccine", "TREATMENT", 73, 82], ["current vaccines", "TREATMENT", 94, 110], ["a single strain", "PROBLEM", 166, 181]]], ["The glycoprotein (G) is the sole protein on the surface of the lyssavirus virions, and serum virus neutralizing antibodies (VNAs) against G are considered the primary correlate of protection against rabies disease.", [["surface", "ANATOMY", 48, 55], ["lyssavirus virions", "ANATOMY", 63, 81], ["serum", "ANATOMY", 87, 92], ["rabies disease", "DISEASE", 199, 213], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 4, 20], ["surface", "CELLULAR_COMPONENT", 48, 55], ["lyssavirus virions", "ORGANISM", 63, 81], ["serum virus", "ORGANISM", 87, 98], ["G", "GENE_OR_GENE_PRODUCT", 138, 139], ["rabies", "ORGANISM", 199, 205], ["glycoprotein (G)", "PROTEIN", 4, 20], ["serum virus neutralizing antibodies", "PROTEIN", 87, 122], ["VNAs", "PROTEIN", 124, 128], ["rabies", "SPECIES", 199, 205], ["The glycoprotein (G)", "TREATMENT", 0, 20], ["the lyssavirus virions", "TREATMENT", 59, 81], ["serum virus neutralizing antibodies", "TEST", 87, 122], ["rabies disease", "PROBLEM", 199, 213], ["lyssavirus virions", "OBSERVATION", 63, 81]]], ["Our proposed vaccine therefore focuses on engineering the G.INTRODUCTIONCreating chimeric protein antigens is a well-established technique for modulating immune responses.", [["G.INTRODUCTIONCreating chimeric protein antigens", "PROTEIN", 58, 106], ["Our proposed vaccine", "TREATMENT", 0, 20]]], ["The move toward ''epitope-based'' vaccines is an attractive approach in many efforts to make vaccines with increased safety, potency, and breadth (Bogdanoff et al., 2017; Wei et al., 2010; Xu et al., 2011; Zhou et al., 2009) .", [["''epitope-based'' vaccines", "TREATMENT", 16, 42], ["an attractive approach", "TREATMENT", 46, 68], ["vaccines", "TREATMENT", 93, 101]]], ["Previous attempts by other groups to create a chimeric G of RABV G and MOKV G, whether swapping antigenic sites or entire domains, were inconclusive or unsuccessful (Bahloul et al., 1998; Evans et al., 2018a; Jallet et al., 1999; Mebatsion et al., 1995) .", [["RABV G", "GENE_OR_GENE_PRODUCT", 60, 66], ["MOKV G", "GENE_OR_GENE_PRODUCT", 71, 77], ["chimeric G", "PROTEIN", 46, 56], ["MOKV G", "PROTEIN", 71, 77], ["RABV", "SPECIES", 60, 64], ["a chimeric G of RABV G", "TREATMENT", 44, 66], ["MOKV G", "TREATMENT", 71, 77], ["swapping antigenic sites", "PROBLEM", 87, 111]]], ["Site switching is necessarily based on the known antigenic sites of RABV G. Five antigenic regions where VNAs bind were empirically mapped on RABV G, enabling deep understanding of neutralization mechanisms and the humoral response against RABV (Benmansour et al., 1991; Cai et al., 2010; Marissen et al., 2005) .", [["VNAs", "GENE_OR_GENE_PRODUCT", 105, 109], ["RABV G", "ORGANISM", 142, 148], ["RABV", "ORGANISM", 240, 244], ["VNAs", "PROTEIN", 105, 109], ["RABV", "SPECIES", 68, 72], ["RABV", "SPECIES", 142, 146], ["RABV", "SPECIES", 240, 244], ["RABV G", "TREATMENT", 142, 148], ["neutralization mechanisms", "TREATMENT", 181, 206]]], ["However, detailed study of other lyssavirus Gs has not been carried out, so swapping these short regions may miss other important sites.", [["lyssavirus", "ORGANISM", 33, 43], ["Gs", "GENE_OR_GENE_PRODUCT", 44, 46], ["Gs", "PROTEIN", 44, 46], ["detailed study", "TEST", 9, 23]]], ["This is evident from recent work in which antigenic sites were swapped between the Gs of RABV and Lagos bat virus (LBV): site II, considered a major site on RABV G, appears to also be immunodominant on LBV G, but the results of other sites are largely inconclusive (Evans et al., 2018a) .", [["Gs", "GENE_OR_GENE_PRODUCT", 83, 85], ["RABV", "ORGANISM", 89, 93], ["Lagos bat virus", "ORGANISM", 98, 113], ["LBV", "CANCER", 115, 118], ["RABV G", "GENE_OR_GENE_PRODUCT", 157, 163], ["LBV G", "GENE_OR_GENE_PRODUCT", 202, 207], ["Gs", "PROTEIN", 83, 85], ["site II", "DNA", 121, 128], ["bat virus", "SPECIES", 104, 113], ["RABV", "SPECIES", 89, 93], ["Lagos bat virus", "SPECIES", 98, 113], ["LBV", "SPECIES", 115, 118], ["RABV", "SPECIES", 157, 161], ["antigenic sites", "PROBLEM", 42, 57], ["a major site", "PROBLEM", 141, 153], ["RABV G", "TREATMENT", 157, 163], ["LBV G", "TEST", 202, 207], ["RABV", "OBSERVATION", 157, 161], ["immunodominant", "OBSERVATION", 184, 198]]], ["Swapping entire domains did not reliably produce infectious particles (Bahloul et al., 1998; Jallet et al., 1999; Mebatsion et al., 1995) , likely because of the imperfect protein engineering caused by the lack of structural information at the time.", [["infectious", "OBSERVATION", 49, 59]]], ["Although transported to the cell surface and incorporated into budding virions, the chimeras failed to support viral replication, consistent with the lack of important structural determinants.INTRODUCTIONThe vaccine described here is based on a RABV vaccine strain and features a structurally designed chimeric lyssavirus glycoprotein containing domains from both RABV G and the highly divergent MOKV G. In mice, the inactivated vaccine elicits high titers of antibodies, which neutralize a panel of lyssaviruses, and protects against challenge with RABV and a recombinant MOKV.Structure-Based Design of Chimeric Lyssavirus GlycoproteinsIn designing a more broadly protective lyssavirus vaccine, we initially inserted MOKV G into a RABV vector already containing a native RABV G (BNSP333; Figure S1A ).", [["cell surface", "ANATOMY", 28, 40], ["virions", "ANATOMY", 71, 78], ["chimeras", "ANATOMY", 84, 92], ["cell surface", "CELLULAR_COMPONENT", 28, 40], ["budding virions", "CELLULAR_COMPONENT", 63, 78], ["RABV", "ORGANISM", 245, 249], ["RABV G", "ORGANISM", 364, 370], ["MOKV G.", "ORGANISM", 396, 403], ["mice", "ORGANISM", 407, 411], ["RABV", "ORGANISM", 550, 554], ["MOKV", "GENE_OR_GENE_PRODUCT", 573, 577], ["lyssavirus", "CANCER", 676, 686], ["MOKV G", "GENE_OR_GENE_PRODUCT", 718, 724], ["RABV", "ORGANISM", 732, 736], ["RABV G (BNSP333; Figure S1A", "GENE_OR_GENE_PRODUCT", 772, 799], ["chimeric lyssavirus glycoprotein", "PROTEIN", 302, 334], ["RABV G", "PROTEIN", 364, 370], ["antibodies", "PROTEIN", 460, 470], ["recombinant MOKV", "PROTEIN", 561, 577], ["Chimeric Lyssavirus Glycoproteins", "PROTEIN", 604, 637], ["MOKV G", "DNA", 718, 724], ["mice", "SPECIES", 407, 411], ["RABV", "SPECIES", 245, 249], ["RABV", "SPECIES", 364, 368], ["mice", "SPECIES", 407, 411], ["RABV", "SPECIES", 550, 554], ["RABV", "SPECIES", 732, 736], ["RABV", "SPECIES", 772, 776], ["the chimeras", "PROBLEM", 80, 92], ["viral replication", "PROBLEM", 111, 128], ["The vaccine", "TREATMENT", 204, 215], ["a RABV vaccine strain", "PROBLEM", 243, 264], ["chimeric lyssavirus glycoprotein", "TREATMENT", 302, 334], ["the inactivated vaccine", "TREATMENT", 413, 436], ["high titers of antibodies", "PROBLEM", 445, 470], ["lyssaviruses", "TREATMENT", 500, 512], ["RABV", "TREATMENT", 550, 554], ["a recombinant MOKV", "TREATMENT", 559, 577], ["Chimeric Lyssavirus Glycoproteins", "TREATMENT", 604, 637], ["a more broadly protective lyssavirus vaccine", "TREATMENT", 650, 694], ["a RABV vector", "TREATMENT", 730, 743], ["a native RABV G", "TREATMENT", 763, 778], ["budding virions", "OBSERVATION", 63, 78], ["consistent with", "UNCERTAINTY", 130, 145], ["Lyssavirus Glycoproteins", "OBSERVATION", 613, 637]]], ["This strategy has been successfully employed with various foreign viral Gs in the BNSP333 vector (Abreu-Mota et al., 2018; Johnson et al., 2016; Kurup et al., 2015) .", [["Gs", "GENE_OR_GENE_PRODUCT", 72, 74], ["BNSP333", "GENE_OR_GENE_PRODUCT", 82, 89], ["various foreign viral", "TREATMENT", 50, 71], ["foreign viral", "OBSERVATION", 58, 71]]], ["However, the virus containing both Gs lost expression of MOKV G rapidly, as indicated by immunofluorescence ( Figure S1B) .", [["Gs", "GENE_OR_GENE_PRODUCT", 35, 37], ["MOKV G", "GENE_OR_GENE_PRODUCT", 57, 63], ["Gs", "PROTEIN", 35, 37], ["MOKV G", "PROTEIN", 57, 63], ["the virus", "PROBLEM", 9, 18], ["MOKV G", "TREATMENT", 57, 63], ["immunofluorescence", "TEST", 89, 107], ["virus", "OBSERVATION", 13, 18]]], ["Furthermore, MOKV G alone or in addition to the native RABV G caused the vector to grow significantly slower ( Figure S1C ).", [["G", "GENE_OR_GENE_PRODUCT", 18, 19], ["RABV G", "GENE_OR_GENE_PRODUCT", 55, 61], ["RABV G", "PROTEIN", 55, 61], ["RABV", "SPECIES", 55, 59]]], ["Therefore, we pursued a more technical strategy to create a single chimeric G, which would serve as the only glycoprotein supporting viral entry.Structure-Based Design of Chimeric Lyssavirus GlycoproteinsTo design a chimeric G, we generated structural models of lyssavirus Gs by threading their amino acid sequences onto the most closely related structure available at the time, that of the vesicular stomatitis virus (VSV) pre-fusion G. We used three structural modeling programs: I-TASSER (Zhang, 2008) , SWISS-MODEL (Waterhouse et al., 2018) , and Phyre2 (Kelley et al., 2015) ( Figure 1A ).", [["amino acid", "CHEMICAL", 295, 305], ["vesicular stomatitis", "DISEASE", 391, 411], ["amino acid", "CHEMICAL", 295, 305], ["G", "GENE_OR_GENE_PRODUCT", 76, 77], ["lyssavirus", "ORGANISM", 262, 272], ["Gs", "GENE_OR_GENE_PRODUCT", 273, 275], ["amino acid", "AMINO_ACID", 295, 305], ["vesicular stomatitis virus", "ORGANISM", 391, 417], ["VSV", "ORGANISM", 419, 422], ["chimeric G", "PROTEIN", 67, 77], ["glycoprotein", "PROTEIN", 109, 121], ["Chimeric Lyssavirus Glycoproteins", "PROTEIN", 171, 204], ["chimeric G", "PROTEIN", 216, 226], ["Gs", "PROTEIN", 273, 275], ["lyssavirus", "SPECIES", 262, 272], ["stomatitis virus", "SPECIES", 401, 417], ["VSV", "SPECIES", 419, 422], ["a single chimeric G", "TREATMENT", 58, 77], ["Chimeric Lyssavirus Glycoproteins", "TREATMENT", 171, 204], ["a chimeric G", "TREATMENT", 214, 226], ["threading their amino acid sequences", "TEST", 279, 315], ["the vesicular stomatitis virus", "PROBLEM", 387, 417], ["Lyssavirus Glycoproteins", "OBSERVATION", 180, 204], ["vesicular stomatitis", "ANATOMY", 391, 411]]], ["Despite sharing only~18% sequence identity, VSV and RABV Gs appear to share conserved structural features, such as disulfide bonds (Yang et al., 2020) , and VSV has previously been used to model RABV G (Fernando et al.,Structure-Based Design of Chimeric Lyssavirus Glycoproteins2 Cell Reports 32, 107920, July 21, 2020 Article ll OPEN ACCESS 2016) .", [["disulfide", "CHEMICAL", 115, 124], ["VSV", "ORGANISM", 44, 47], ["RABV Gs", "GENE_OR_GENE_PRODUCT", 52, 59], ["VSV", "ORGANISM", 157, 160], ["RABV", "ORGANISM", 195, 199], ["VSV and RABV Gs", "PROTEIN", 44, 59], ["VSV", "SPECIES", 44, 47], ["RABV", "SPECIES", 52, 56], ["VSV", "SPECIES", 157, 160], ["RABV", "SPECIES", 195, 199], ["VSV and RABV Gs", "TEST", 44, 59], ["VSV", "TREATMENT", 157, 160]]], ["In all of the models, we identified three subdomains in the ectodomain: a ''clip'' that consists of a small hairpin-shaped region near the amino (N) terminus (yellow); a ''core'' that forms a large region containing a globular portion, beta sheets, and the putative fusion domain (orange); and a ''flap,'' the region near the transmembrane (TM) domain that associates closely with the clip and that contains the receptor binding domain (red) (Figures 1A and 1D) .", [["transmembrane", "ANATOMY", 326, 339], ["amino", "CHEMICAL", 139, 144], ["transmembrane", "CELLULAR_COMPONENT", 326, 339], ["ectodomain", "PROTEIN", 60, 70], ["small hairpin-shaped region", "PROTEIN", 102, 129], ["amino (N) terminus", "PROTEIN", 139, 157], ["globular portion", "PROTEIN", 218, 234], ["beta sheets", "PROTEIN", 236, 247], ["putative fusion domain", "PROTEIN", 257, 279], ["transmembrane (TM) domain", "PROTEIN", 326, 351], ["clip", "PROTEIN", 385, 389], ["receptor binding domain", "PROTEIN", 412, 435], ["red", "PROTEIN", 437, 440], ["1D", "PROTEIN", 458, 460], ["a ''clip''", "TREATMENT", 72, 82], ["a small hairpin-shaped region", "PROBLEM", 100, 129], ["a ''core''", "PROBLEM", 168, 178], ["a ''flap", "TREATMENT", 294, 302], ["the clip", "TREATMENT", 381, 389], ["three", "OBSERVATION_MODIFIER", 36, 41], ["subdomains", "OBSERVATION_MODIFIER", 42, 52], ["ectodomain", "ANATOMY", 60, 70], ["small", "OBSERVATION_MODIFIER", 102, 107], ["hairpin", "OBSERVATION", 108, 115], ["shaped", "OBSERVATION_MODIFIER", 116, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["amino", "ANATOMY_MODIFIER", 139, 144], ["yellow", "OBSERVATION_MODIFIER", 159, 165], ["large", "OBSERVATION_MODIFIER", 192, 197], ["globular", "OBSERVATION_MODIFIER", 218, 226], ["portion", "OBSERVATION_MODIFIER", 227, 234], ["clip", "OBSERVATION", 385, 389]]], ["The structure of RABV G was recently solved at both low and high pH levels (Yang et al., 2020) .", [["RABV", "ORGANISM", 17, 21], ["G", "GENE_OR_GENE_PRODUCT", 22, 23], ["RABV G", "PROTEIN", 17, 23], ["RABV", "SPECIES", 17, 21], ["RABV G", "TREATMENT", 17, 23], ["RABV G", "OBSERVATION", 17, 23], ["low", "OBSERVATION_MODIFIER", 52, 55]]], ["Comparison between the high pH (pre-fusion) structure and our model shows similar positioning of the clip, core, and flap ( Figure S2 ), validating the use of structural modeling for designing chimeric proteins.Structure-Based Design of Chimeric Lyssavirus GlycoproteinsThe clip, core, and flap subdomains formed the basis for building Chimeric G 1 and Chimeric G 2, which are comprised of alternating subdomains from RABV G (blue) and MOKV G (red) (Figures 1B, 1C, 1E, and 1F) .", [["flap subdomains", "ANATOMY", 290, 305], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 336, 348], ["Chimeric G 2", "GENE_OR_GENE_PRODUCT", 353, 365], ["RABV G (blue)", "GENE_OR_GENE_PRODUCT", 418, 431], ["MOKV G", "GENE_OR_GENE_PRODUCT", 436, 442], ["chimeric proteins", "PROTEIN", 193, 210], ["Chimeric Lyssavirus Glycoproteins", "PROTEIN", 237, 270], ["clip, core, and flap subdomains", "PROTEIN", 274, 305], ["Chimeric G 1", "PROTEIN", 336, 348], ["Chimeric G 2", "PROTEIN", 353, 365], ["alternating subdomains", "PROTEIN", 390, 412], ["MOKV G", "PROTEIN", 436, 442], ["red", "PROTEIN", 444, 447], ["1E", "PROTEIN", 466, 468], ["the high pH (pre-fusion) structure", "PROBLEM", 19, 53], ["the clip", "TREATMENT", 97, 105], ["structural modeling", "TREATMENT", 159, 178], ["designing chimeric proteins", "PROBLEM", 183, 210], ["Chimeric Lyssavirus Glycoproteins", "TREATMENT", 237, 270], ["The clip", "TREATMENT", 270, 278], ["building Chimeric G", "TREATMENT", 327, 346], ["Chimeric G 2", "PROBLEM", 353, 365], ["alternating subdomains", "PROBLEM", 390, 412], ["MOKV G", "TEST", 436, 442], ["Figures", "TEST", 450, 457], ["1C", "TEST", 462, 464], ["similar", "OBSERVATION_MODIFIER", 74, 81], ["positioning", "OBSERVATION_MODIFIER", 82, 93], ["clip", "OBSERVATION", 101, 105], ["flap", "ANATOMY", 117, 121], ["Lyssavirus Glycoproteins", "OBSERVATION", 246, 270], ["clip", "OBSERVATION", 274, 278], ["core", "OBSERVATION_MODIFIER", 280, 284], ["flap", "OBSERVATION", 290, 294]]], ["We hypothesized that the design of a functional G protein requires the amino acid sequences of the clip and the flap to be derived from the same virus to reproduce optimal bonding interactions between these two moieties.Structure-Based Design of Chimeric Lyssavirus GlycoproteinsOther important features known about the well-studied RABV G were incorporated in the chimeric G designs.", [["amino acid", "CHEMICAL", 71, 81], ["amino acid", "CHEMICAL", 71, 81], ["G protein", "GENE_OR_GENE_PRODUCT", 48, 57], ["amino acid", "AMINO_ACID", 71, 81], ["RABV", "ORGANISM", 333, 337], ["G", "GENE_OR_GENE_PRODUCT", 338, 339], ["G protein", "PROTEIN", 48, 57], ["amino acid sequences", "PROTEIN", 71, 91], ["RABV G", "PROTEIN", 333, 339], ["RABV", "SPECIES", 333, 337], ["a functional G protein", "TREATMENT", 35, 57], ["the amino acid sequences", "TREATMENT", 67, 91], ["the clip", "TREATMENT", 95, 103], ["the flap", "TREATMENT", 108, 116], ["the same virus", "PROBLEM", 136, 150], ["Chimeric Lyssavirus GlycoproteinsOther", "TREATMENT", 246, 284], ["the chimeric G designs", "TREATMENT", 361, 383], ["flap", "ANATOMY", 112, 116]]], ["Extensive studies have mapped the majority of potently neutralizing monoclonal antibodies (mAbs) to five antigenic sites on RABV G (Benmansour et al., 1991; Dietzschold et al., 1988; Prehaud et al., 1988) ( Figure 1D ).", [["RABV", "ORGANISM", 124, 128], ["potently neutralizing monoclonal antibodies", "PROTEIN", 46, 89], ["mAbs", "PROTEIN", 91, 95], ["RABV", "SPECIES", 124, 128], ["Extensive studies", "TEST", 0, 17], ["potently neutralizing monoclonal antibodies", "TREATMENT", 46, 89]]], ["The chimeric Gs share sites I and II from the same donor G, and sites III, IV, and minor site ''a'' from the other donor G, resulting in relatively balanced immunogenicity.", [["Gs", "GENE_OR_GENE_PRODUCT", 13, 15], ["G", "GENE_OR_GENE_PRODUCT", 57, 58], ["chimeric Gs", "PROTEIN", 4, 15], ["I and II", "PROTEIN", 28, 36], ["donor G, and sites III, IV, and minor site", "DNA", 51, 93], ["balanced immunogenicity", "OBSERVATION", 148, 171]]], ["The short, intracellular carboxy (C) terminal of RABV G interacts with the matrix protein (M) during viral budding and does not contribute to antigenicity (Wirblich et al., 2008) , so it was maintained as RABV in both Chimeric G 1 and 2.Structure-Based Design of Chimeric Lyssavirus GlycoproteinsAn immunofluorescence assay showed the chimeric Gs to successfully traffic to the cell surface and exhibit the anticipated antibody staining patterns ( Figure S3 ).", [["intracellular", "ANATOMY", 11, 24], ["cell surface", "ANATOMY", 378, 390], ["carboxy", "CHEMICAL", 25, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["RABV G", "GENE_OR_GENE_PRODUCT", 49, 55], ["matrix", "CELLULAR_COMPONENT", 75, 81], ["RABV", "ORGANISM", 205, 209], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 218, 230], ["Gs", "GENE_OR_GENE_PRODUCT", 344, 346], ["cell surface", "CELLULAR_COMPONENT", 378, 390], ["intracellular carboxy (C) terminal", "PROTEIN", 11, 45], ["RABV G", "PROTEIN", 49, 55], ["matrix protein", "PROTEIN", 75, 89], ["Chimeric Lyssavirus Glycoproteins", "PROTEIN", 263, 296], ["Gs", "PROTEIN", 344, 346], ["RABV", "SPECIES", 49, 53], ["RABV", "SPECIES", 205, 209], ["The short, intracellular carboxy (C) terminal of RABV G", "PROBLEM", 0, 55], ["the matrix protein", "TEST", 71, 89], ["viral budding", "PROBLEM", 101, 114], ["Chimeric Lyssavirus Glycoproteins", "TREATMENT", 263, 296], ["An immunofluorescence assay", "TEST", 296, 323], ["the anticipated antibody staining patterns", "PROBLEM", 403, 445], ["short", "OBSERVATION_MODIFIER", 4, 9], ["Lyssavirus Glycoproteins", "OBSERVATION", 272, 296]]], ["Cells transiently expressing Chimeric G 1 or 2 were positively stained by polyclonal sera generated against RABV G or MOKV G, whereas cells expressing a wild-type (WT) G were stained only by their cognate sera.", [["Cells", "ANATOMY", 0, 5], ["sera", "ANATOMY", 85, 89], ["cells", "ANATOMY", 134, 139], ["sera", "ANATOMY", 205, 209], ["Cells", "CELL", 0, 5], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 29, 41], ["2", "GENE_OR_GENE_PRODUCT", 45, 46], ["sera", "ORGANISM_SUBSTANCE", 85, 89], ["RABV G", "GENE_OR_GENE_PRODUCT", 108, 114], ["MOKV G", "GENE_OR_GENE_PRODUCT", 118, 124], ["cells", "CELL", 134, 139], ["wild-type (WT) G", "GENE_OR_GENE_PRODUCT", 153, 169], ["sera", "ORGANISM_SUBSTANCE", 205, 209], ["Chimeric G 1", "PROTEIN", 29, 41], ["MOKV G", "PROTEIN", 118, 124], ["RABV", "SPECIES", 108, 112], ["Cells", "TEST", 0, 5], ["Chimeric G 1", "TEST", 29, 41], ["polyclonal sera", "TEST", 74, 89], ["RABV G", "TEST", 108, 114]]], ["The human anti-RABV G mAb 4C12 binds in the flap region of RABV G and thus stains only Chimeric G 1.Chimeric Glycoprotein Is Functional and Supports Viral ReplicationFour vaccines were then constructed in the BNSP RABV vector lacking its native G in the fourth position (BNSPDG; Figure 2A ).", [["flap region", "ANATOMY", 44, 55], ["human", "ORGANISM", 4, 9], ["anti-RABV G mAb 4C12", "GENE_OR_GENE_PRODUCT", 10, 30], ["RABV G", "GENE_OR_GENE_PRODUCT", 59, 65], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 87, 99], ["RABV", "ORGANISM", 214, 218], ["human anti-RABV G mAb 4C12", "PROTEIN", 4, 30], ["Chimeric G 1", "PROTEIN", 87, 99], ["BNSP RABV vector", "DNA", 209, 225], ["native G", "PROTEIN", 238, 246], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["RABV", "SPECIES", 59, 63], ["RABV", "SPECIES", 214, 218], ["The human anti-RABV G mAb", "TREATMENT", 0, 25], ["RABV G", "TEST", 59, 65], ["Chimeric Glycoprotein", "TREATMENT", 100, 121], ["Viral ReplicationFour vaccines", "TREATMENT", 149, 179], ["the BNSP RABV vector", "TREATMENT", 205, 225], ["flap", "ANATOMY", 44, 48], ["RABV", "OBSERVATION", 59, 63]]], ["The G gene of interest was inserted into the second position: the vaccines rRABV and rMOKV contain the codon-optimized genes of RABV G or MOKV G, respectively, and the vaccines rChimera1 and rChimera2 contain the respective chimeric Gs 1 and 2 ( Figure 2A ).", [["G", "GENE_OR_GENE_PRODUCT", 4, 5], ["rRABV", "GENE_OR_GENE_PRODUCT", 75, 80], ["rMOKV", "GENE_OR_GENE_PRODUCT", 85, 90], ["RABV G", "GENE_OR_GENE_PRODUCT", 128, 134], ["MOKV G", "GENE_OR_GENE_PRODUCT", 138, 144], ["rChimera1", "GENE_OR_GENE_PRODUCT", 177, 186], ["rChimera2", "GENE_OR_GENE_PRODUCT", 191, 200], ["Gs 1", "GENE_OR_GENE_PRODUCT", 233, 237], ["Figure 2A", "GENE_OR_GENE_PRODUCT", 246, 255], ["G gene", "DNA", 4, 10], ["vaccines rRABV", "DNA", 66, 80], ["rMOKV", "DNA", 85, 90], ["codon-optimized genes", "DNA", 103, 124], ["RABV G", "DNA", 128, 134], ["MOKV G", "DNA", 138, 144], ["vaccines rChimera1", "DNA", 168, 186], ["rChimera2", "DNA", 191, 200], ["chimeric Gs 1 and 2", "DNA", 224, 243], ["RABV", "SPECIES", 128, 132], ["the vaccines rRABV", "TREATMENT", 62, 80], ["rMOKV", "TREATMENT", 85, 90], ["the codon", "TREATMENT", 99, 108], ["RABV G", "TREATMENT", 128, 134], ["the vaccines rChimera1", "TREATMENT", 164, 186], ["rChimera2", "TREATMENT", 191, 200], ["the respective chimeric Gs", "TEST", 209, 235]]], ["Placing of G in the second position of the genome instead of its native fourth position increases expression levels because of the transcription gradient exhibited by rhabdoviruses (McGettigan et al., 2003) .", [["G", "GENE_OR_GENE_PRODUCT", 11, 12], ["G", "TREATMENT", 11, 12], ["expression levels", "PROBLEM", 98, 115], ["the transcription gradient", "PROBLEM", 127, 153]]], ["This increase in expression also contributes attenuation, which, despite proposed administration in an inactivated form, renders the vaccine safer to work with.Chimeric Glycoprotein Is Functional and Supports Viral ReplicationMultiple attempts to recover rChimera2 did not yield appreciable titers of infectious virus, suggesting that the chimeric G did not efficiently support viral spread.", [["rChimera2", "GENE_OR_GENE_PRODUCT", 255, 264], ["infectious virus", "ORGANISM", 301, 317], ["rChimera2", "PROTEIN", 255, 264], ["chimeric G", "PROTEIN", 339, 349], ["infectious virus", "SPECIES", 301, 317], ["the vaccine", "TREATMENT", 129, 140], ["infectious virus", "PROBLEM", 301, 317], ["the chimeric G", "PROBLEM", 335, 349], ["viral spread", "PROBLEM", 378, 390], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["attenuation", "OBSERVATION_MODIFIER", 45, 56], ["infectious", "OBSERVATION", 301, 311], ["viral", "OBSERVATION", 378, 383]]], ["By contrast, rChimera1 was successfully recovered, demonstrating the functionality of this G. An immunofluorescence assay confirmed that only cells infected with rChimera1, but not with either rRABV or rMOKV, exhibited dual staining with both anti-RABV G and anti-MOKV G reagents ( Figure 2B ).", [["cells", "ANATOMY", 142, 147], ["rChimera1", "GENE_OR_GENE_PRODUCT", 13, 22], ["cells", "CELL", 142, 147], ["rChimera1", "GENE_OR_GENE_PRODUCT", 162, 171], ["rRABV", "GENE_OR_GENE_PRODUCT", 193, 198], ["rMOKV", "GENE_OR_GENE_PRODUCT", 202, 207], ["anti-RABV G", "GENE_OR_GENE_PRODUCT", 243, 254], ["anti-MOKV G reagents", "SIMPLE_CHEMICAL", 259, 279], ["rChimera1", "PROTEIN", 13, 22], ["rChimera1", "PROTEIN", 162, 171], ["rRABV", "PROTEIN", 193, 198], ["rMOKV", "PROTEIN", 202, 207], ["anti-RABV G", "PROTEIN", 243, 254], ["anti-RABV", "SPECIES", 243, 252], ["this G.", "TEST", 86, 93], ["An immunofluorescence assay", "TEST", 94, 121], ["rChimera1", "TREATMENT", 162, 171], ["dual staining", "PROBLEM", 219, 232], ["both anti-RABV G", "TREATMENT", 238, 254], ["anti-MOKV G reagents", "TREATMENT", 259, 279]]], ["Furthermore, the presence of foci indicates the virus's ability to spread from cell to cell mediated solely by the Chimeric G. Purified virions were analyzed by SDS-PAGE, which shows comparable incorporation of Chimeric G 1 into virions as compared with the control vaccines ( Figure 2C ). rChi-mera1 is henceforth referred to as LyssaVax.LyssaVax Is Apathogenic by Intramuscular and Intranasal RoutesEven though rabies vaccines are administered in an inactivated (killed) form to humans, safety is a necessary priority during production when the virus is live and concentrated.", [["foci", "ANATOMY", 29, 33], ["cell", "ANATOMY", 79, 83], ["cell", "ANATOMY", 87, 91], ["virions", "ANATOMY", 136, 143], ["virions", "ANATOMY", 229, 236], ["cell", "CELL", 79, 83], ["cell", "CELL", 87, 91], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 211, 223], ["rChi-mera1", "GENE_OR_GENE_PRODUCT", 290, 300], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 330, 338], ["rabies", "ORGANISM", 413, 419], ["humans", "ORGANISM", 481, 487], ["Chimeric G 1", "PROTEIN", 211, 223], ["rChi-mera1", "PROTEIN", 290, 300], ["LyssaVax", "PROTEIN", 330, 338], ["humans", "SPECIES", 481, 487], ["rabies", "SPECIES", 413, 419], ["humans", "SPECIES", 481, 487], ["foci", "PROBLEM", 29, 33], ["the virus's ability", "PROBLEM", 44, 63], ["Chimeric G 1 into virions", "TREATMENT", 211, 236], ["the control vaccines", "TREATMENT", 254, 274], ["LyssaVax", "TREATMENT", 339, 347], ["Apathogenic", "PROBLEM", 351, 362], ["Intramuscular and Intranasal Routes", "TREATMENT", 366, 401], ["rabies vaccines", "TREATMENT", 413, 428], ["the virus", "PROBLEM", 543, 552], ["foci", "OBSERVATION", 29, 33]]], ["We therefore analyzed live LyssaVax for any pathogenicity, comparing it with similar vectors containing the wild-type (WT) G protein from RABV or MOKV.", [["LyssaVax", "CHEMICAL", 27, 35], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 27, 35], ["wild-type (WT) G protein", "GENE_OR_GENE_PRODUCT", 108, 132], ["RABV", "ORGANISM", 138, 142], ["live LyssaVax", "PROTEIN", 22, 35], ["wild-type (WT) G protein", "PROTEIN", 108, 132], ["RABV", "SPECIES", 138, 142], ["MOKV", "SPECIES", 146, 150], ["any pathogenicity", "PROBLEM", 40, 57]]], ["LyssaVax was administered live by two Figure S4B ).LyssaVax Elicits High Titers of Antibodies against Both RABV and MOKVTo assess immunogenicity, we administered inactivated Lyssa-Vax to groups of 10 Swiss Webster mice.", [["LyssaVax", "CHEMICAL", 0, 8], ["LyssaVax", "SIMPLE_CHEMICAL", 0, 8], ["LyssaVax", "SIMPLE_CHEMICAL", 51, 59], ["RABV", "ORGANISM", 107, 111], ["Swiss Webster mice", "ORGANISM", 200, 218], ["Antibodies", "PROTEIN", 83, 93], ["MOKVTo", "PROTEIN", 116, 122], ["mice", "SPECIES", 214, 218], ["RABV", "SPECIES", 107, 111], ["Swiss Webster mice", "SPECIES", 200, 218], ["LyssaVax", "TREATMENT", 0, 8], ["LyssaVax", "TREATMENT", 51, 59], ["High Titers of Antibodies", "PROBLEM", 68, 93]]], ["Inactivated rRABV and rMOKV were administered individually as control vaccines.", [["rRABV", "GENE_OR_GENE_PRODUCT", 12, 17], ["rMOKV", "GENE_OR_GENE_PRODUCT", 22, 27], ["Inactivated rRABV", "PROTEIN", 0, 17], ["rMOKV", "PROTEIN", 22, 27], ["rRABV", "SPECIES", 12, 17], ["Inactivated rRABV", "TREATMENT", 0, 17], ["rMOKV", "TREATMENT", 22, 27]]], ["Figure 3A displays the immunization and blood draw schedule (including challenge, discussed in the next section).", [["blood", "ANATOMY", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["the immunization", "TREATMENT", 19, 35], ["blood draw schedule", "TREATMENT", 40, 59]]], ["Sera were analyzed by enzyme-linked immunosorbent assay (ELISA) against RABV G and MOKV G antigens.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["RABV", "ORGANISM", 72, 76], ["G", "GENE_OR_GENE_PRODUCT", 77, 78], ["MOKV G antigens", "GENE_OR_GENE_PRODUCT", 83, 98], ["RABV G and MOKV G antigens", "PROTEIN", 72, 98], ["RABV", "SPECIES", 72, 76], ["Sera", "TEST", 0, 4], ["enzyme", "TEST", 22, 28], ["immunosorbent assay", "TEST", 36, 55], ["ELISA", "TEST", 57, 62], ["RABV G", "TEST", 72, 78]]], ["To avoid cross-reactivity with other RABV proteins, soluble Gs were produced, stripped, and purified from a recombinant VSV, which either expressed RABV G instead of VSV G or which lacked a G gene and was trans-complemented with MOKV G. mAbs against each protein were used to validate the antigen: the mouse anti-RABV G mAb 1C5 and the mouse mAb 1409-7, which cross-reacts with MOKV G (Dietzschold et al., 1988) ( Figure S5 ).", [["RABV", "ORGANISM", 37, 41], ["Gs", "GENE_OR_GENE_PRODUCT", 60, 62], ["VSV", "ORGANISM", 120, 123], ["RABV G", "GENE_OR_GENE_PRODUCT", 148, 154], ["VSV G", "ORGANISM", 166, 171], ["G", "GENE_OR_GENE_PRODUCT", 190, 191], ["mAbs", "GENE_OR_GENE_PRODUCT", 237, 241], ["mouse", "ORGANISM", 302, 307], ["anti-RABV G mAb 1C5", "GENE_OR_GENE_PRODUCT", 308, 327], ["mouse", "ORGANISM", 336, 341], ["RABV proteins", "PROTEIN", 37, 50], ["soluble Gs", "PROTEIN", 52, 62], ["RABV G", "PROTEIN", 148, 154], ["VSV G", "PROTEIN", 166, 171], ["G gene", "DNA", 190, 196], ["MOKV", "PROTEIN", 229, 233], ["mAbs", "PROTEIN", 237, 241], ["mouse anti-RABV G mAb 1C5", "PROTEIN", 302, 327], ["mouse mAb 1409-7", "PROTEIN", 336, 352], ["mouse", "SPECIES", 302, 307], ["mouse", "SPECIES", 336, 341], ["RABV", "SPECIES", 37, 41], ["VSV", "SPECIES", 120, 123], ["RABV", "SPECIES", 148, 152], ["VSV", "SPECIES", 166, 169], ["mouse", "SPECIES", 302, 307], ["mouse", "SPECIES", 336, 341], ["a recombinant VSV", "TREATMENT", 106, 123], ["VSV G", "TREATMENT", 166, 171], ["MOKV G. mAbs", "TREATMENT", 229, 241], ["the mouse anti-RABV G mAb", "TREATMENT", 298, 323], ["the mouse mAb", "TEST", 332, 345]]], ["Sera were tested to assess immunogenicity before immunization (day 0), 7 days following each immunization (days 7, 14, and 35) and just prior to challenge (day 56).", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Sera", "TEST", 0, 4], ["immunization", "TREATMENT", 49, 61]]], ["Individual mouse halfmaximal responses (EC 50 s) are compared against RABV G ( Figure 3B ) and MOKV G ( Figure 3C ).", [["mouse", "ORGANISM", 11, 16], ["MOKV G", "GENE_OR_GENE_PRODUCT", 95, 101], ["MOKV G", "PROTEIN", 95, 101], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["RABV", "SPECIES", 70, 74], ["RABV G", "TEST", 70, 76]]], ["Dilution curves of group av-erages are displayed in Figure S5 .", [["Dilution curves of group av-erages", "TEST", 0, 34], ["Figure S5", "OBSERVATION", 52, 61]]], ["Sera from mice immunized with LyssaVax reacted strongly against both RABV and MOKV G antigens, nearly matching sera from cognate immunizations.", [["sera", "ANATOMY", 111, 115], ["LyssaVax", "CHEMICAL", 30, 38], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 10, 14], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 30, 38], ["RABV", "ORGANISM", 69, 73], ["MOKV G antigens", "GENE_OR_GENE_PRODUCT", 78, 93], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["LyssaVax", "PROTEIN", 30, 38], ["RABV and MOKV G antigens", "PROTEIN", 69, 93], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["RABV", "SPECIES", 69, 73], ["MOKV", "SPECIES", 78, 82], ["Sera", "TEST", 0, 4], ["LyssaVax", "TREATMENT", 30, 38], ["cognate immunizations", "TREATMENT", 121, 142]]], ["EC 50 s of RABV G-specific antibodies were not significantly different between LyssaVax and rRABV immune sera ( Figure 3B ).", [["EC", "ANATOMY", 0, 2], ["sera", "ANATOMY", 105, 109], ["EC", "CELL", 0, 2], ["RABV", "ORGANISM", 11, 15], ["G", "GENE_OR_GENE_PRODUCT", 16, 17], ["LyssaVax", "SIMPLE_CHEMICAL", 79, 87], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["RABV G-specific antibodies", "PROTEIN", 11, 37], ["RABV", "SPECIES", 11, 15], ["rRABV", "SPECIES", 92, 97], ["EC", "TEST", 0, 2], ["RABV G", "TEST", 11, 17], ["specific antibodies", "TEST", 18, 37], ["LyssaVax", "TEST", 79, 87]]], ["EC 50 s of MOKV G-specific antibodies from LyssaVax-immunized mice were significantly lower than rMOKV only at day 7 (p = 0.0412; Figure 3C ).", [["EC", "ANATOMY", 0, 2], ["EC", "CELL", 0, 2], ["MOKV G-specific antibodies", "GENE_OR_GENE_PRODUCT", 11, 37], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 43, 51], ["mice", "ORGANISM", 62, 66], ["MOKV G-specific antibodies", "PROTEIN", 11, 37], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["EC", "TEST", 0, 2], ["MOKV G", "TEST", 11, 17], ["specific antibodies", "TEST", 18, 37], ["LyssaVax", "TEST", 43, 51]]], ["Sera from mock-immunized mice did not seroconvert to either antigen ( Figure S5 ).", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mock", "ORGANISM", 10, 14], ["mice", "ORGANISM", 25, 29], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["Sera from mock", "TEST", 0, 14]]], ["Together, these data suggest that the chimeric G in LyssaVax is highly immunogenic and broadens the antigenicity of a single lyssavirus glycoprotein.LyssaVax Elicits High Titers of Antibodies against Both RABV and MOKVInterestingly, sera from rMOKV immune mice reacted to RABV G (red dots/bars in Figure 3B ) and sera from rRABV-immune mice reacted to MOKV G (blue dots/bars in Figure 3C ), although both at significantly lower levels than LyssaVax sera.", [["sera", "ANATOMY", 233, 237], ["sera", "ANATOMY", 313, 317], ["sera", "ANATOMY", 449, 453], ["G", "GENE_OR_GENE_PRODUCT", 47, 48], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 52, 60], ["LyssaVax", "SIMPLE_CHEMICAL", 149, 157], ["RABV", "ORGANISM", 205, 209], ["sera", "ORGANISM_SUBSTANCE", 233, 237], ["rMOKV immune mice", "ORGANISM", 243, 260], ["RABV G", "ORGANISM", 272, 278], ["red dots", "ORGANISM", 280, 288], ["sera", "ORGANISM_SUBSTANCE", 313, 317], ["rRABV-immune", "ORGANISM", 323, 335], ["mice", "ORGANISM", 336, 340], ["blue dots", "ORGANISM", 360, 369], ["sera", "ORGANISM_SUBSTANCE", 449, 453], ["chimeric G", "PROTEIN", 38, 48], ["LyssaVax", "PROTEIN", 52, 60], ["lyssavirus glycoprotein", "PROTEIN", 125, 148], ["Antibodies", "PROTEIN", 181, 191], ["mice", "SPECIES", 256, 260], ["mice", "SPECIES", 336, 340], ["RABV", "SPECIES", 205, 209], ["rMOKV", "SPECIES", 243, 248], ["mice", "SPECIES", 256, 260], ["RABV", "SPECIES", 272, 276], ["rRABV", "SPECIES", 323, 328], ["mice", "SPECIES", 336, 340], ["these data", "TEST", 10, 20], ["the chimeric G in LyssaVax", "TREATMENT", 34, 60], ["a single lyssavirus glycoprotein", "TREATMENT", 116, 148], ["LyssaVax", "TREATMENT", 149, 157], ["High Titers of Antibodies", "PROBLEM", 166, 191], ["sera", "TEST", 233, 237], ["RABV G", "TEST", 272, 278], ["red dots", "TEST", 280, 288], ["sera", "TEST", 313, 317], ["rRABV", "TEST", 323, 328], ["immune mice", "PROBLEM", 329, 340], ["MOKV G (blue dots/bars in Figure 3C", "TREATMENT", 352, 387]]], ["In both cases, titers increased over time (compared with mock-immunized sera), suggesting that these antibody responses were specific and being boosted by each subsequent immunization.LyssaVax Elicits RABV Neutralizing AntibodiesSera from mice immunized with LyssaVax neutralized RABV strain CVS-11 at comparable levels with rRABV control immune sera, as determined by the rapid fluorescent focus inhibition test (RFFIT) (Figure 4 ; Table S1 ).", [["sera", "ANATOMY", 72, 76], ["sera", "ANATOMY", 346, 350], ["sera", "ORGANISM_SUBSTANCE", 72, 76], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 184, 192], ["RABV", "ORGANISM", 201, 205], ["mice", "ORGANISM", 239, 243], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 259, 267], ["RABV", "ORGANISM", 280, 284], ["CVS-11", "ORGANISM", 292, 298], ["sera", "ORGANISM_SUBSTANCE", 346, 350], ["mice", "SPECIES", 239, 243], ["RABV", "SPECIES", 201, 205], ["mice", "SPECIES", 239, 243], ["RABV strain CVS-11", "SPECIES", 280, 298], ["rRABV", "SPECIES", 325, 330], ["these antibody responses", "PROBLEM", 95, 119], ["LyssaVax", "TREATMENT", 184, 192], ["RABV Neutralizing Antibodies", "TEST", 201, 229], ["Sera", "TEST", 229, 233], ["LyssaVax", "TREATMENT", 259, 267], ["CVS", "TEST", 292, 295], ["titers", "OBSERVATION_MODIFIER", 15, 21], ["increased", "OBSERVATION_MODIFIER", 22, 31]]], ["When normalized to a rabies immunoglobulin standard, serum containing greater than 0.5 international units per milliliter (IU/mL) VNAs is considered adequate for protection (Bogel, 1978; Keates, 2010) .", [["serum", "ANATOMY", 53, 58], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 28, 42], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["rabies", "SPECIES", 21, 27], ["a rabies immunoglobulin standard", "TREATMENT", 19, 51], ["serum", "TEST", 53, 58]]], ["Neutralizing titers in all 10 LyssaVaximmunized mice reached >4 IU/mL by day 14 post-immunization (p.i.; after two vaccine inoculations on days 0 and 7).", [["mice", "ORGANISM", 48, 52], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["Neutralizing titers", "TREATMENT", 0, 19], ["immunization", "TREATMENT", 85, 97], ["two vaccine inoculations", "TREATMENT", 111, 135]]], ["Titers 4 Cell Reports 32, 107920, July 21, 2020LyssaVax Elicits RABV Neutralizing AntibodiesArticle ll OPEN ACCESS continued to climb after the final immunization on day 28, peaking at an average of 57.2 IU/mL on day 56 p.i.", [["Cell", "ANATOMY", 9, 13], ["Cell", "CELL", 9, 13], ["RABV", "SPECIES", 64, 68], ["Neutralizing AntibodiesArticle ll OPEN ACCESS", "TREATMENT", 69, 114]]], ["Sera from mice immunized with the control vaccine, rRABV, yielded higher titers at each time point, but differed significantly (p = 0.0342) only on day 35 p.i., when titers peaked, averaging 103.5 IU/mL.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 10, 14], ["rRABV", "ORGANISM", 51, 56], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["rRABV", "SPECIES", 51, 56], ["Sera", "TREATMENT", 0, 4], ["the control vaccine", "TREATMENT", 30, 49], ["rRABV", "TREATMENT", 51, 56], ["titers", "TEST", 166, 172]]], ["None of the mock-immunized groups exhibited virus neutralization capability, as determined by assaying pooled sera.", [["sera", "ANATOMY", 110, 114], ["sera", "ORGANISM_SUBSTANCE", 110, 114], ["the mock", "TEST", 8, 16], ["virus neutralization capability", "PROBLEM", 44, 75]]], ["These data demonstrate the potency of the chimeric G vaccine, because VNA titers are considered the most important correlate of protection (Both et al., 2012; World Health Organization, 2017b) . rMOKV immune sera did not neutralize CVS-11 above the 4 IU/ mL level of detection initially used in the RFFIT, despite the high titers of cross-reactive antibodies observed in the RABV G ELISA.", [["sera", "ANATOMY", 208, 212], ["VNA", "GENE_OR_GENE_PRODUCT", 70, 73], ["rMOKV", "GENE_OR_GENE_PRODUCT", 195, 200], ["sera", "ORGANISM_SUBSTANCE", 208, 212], ["RABV G ELISA", "GENE_OR_GENE_PRODUCT", 375, 387], ["cross-reactive antibodies", "PROTEIN", 333, 358], ["rMOKV", "SPECIES", 195, 200], ["RABV", "SPECIES", 375, 379], ["the chimeric G vaccine", "TREATMENT", 38, 60], ["VNA titers", "TREATMENT", 70, 80], ["immune sera", "TEST", 201, 212], ["CVS", "TEST", 232, 235], ["detection", "TEST", 267, 276], ["cross-reactive antibodies", "PROBLEM", 333, 358]]], ["To address the possibility of VNA titers below 4 IU/mL, we performed a follow-up assay with larger dilutions of sera from days 28, 56, and 96 p.i., enabling a 0.2 IU/mL level of detection ( Figure S6 ).", [["sera", "ANATOMY", 112, 116], ["VNA", "CANCER", 30, 33], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["sera", "TEST", 112, 116]]], ["At day 28, only two mice exhibited titers above this new level of detection at 0.6 and 2 IU/mL, respectively.", [["mice", "ORGANISM", 20, 24], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24]]], ["At day 56, 9/10 sera exhibited low levels of neutralization, with four mice achieving titers above the 0.5 IU/mL threshold for protection.Antibodies Elicited by LyssaVax Neutralize MOKV G PseudotypesUnlike RABV, neither reference assays nor standards have been established for non-RABV lyssaviruses.", [["sera", "ANATOMY", 16, 20], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["mice", "ORGANISM", 71, 75], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["RABV", "SPECIES", 206, 210], ["non-RABV", "SPECIES", 277, 285], ["low levels of neutralization", "PROBLEM", 31, 59], ["Antibodies", "TEST", 138, 148], ["non-RABV lyssaviruses", "PROBLEM", 277, 298], ["neutralization", "OBSERVATION", 45, 59]]], ["Therefore, to assess the functionality of anti-MOKV G VNAs within the immunized mouse sera, we tested sera in a pseudotype neutralization assay.", [["sera", "ANATOMY", 86, 90], ["sera", "ANATOMY", 102, 106], ["anti-MOKV G VNAs", "GENE_OR_GENE_PRODUCT", 42, 58], ["mouse", "ORGANISM", 80, 85], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["sera", "ORGANISM_SUBSTANCE", 102, 106], ["anti-MOKV G VNAs", "PROTEIN", 42, 58], ["mouse", "SPECIES", 80, 85], ["mouse", "SPECIES", 80, 85], ["anti-MOKV G VNAs", "TREATMENT", 42, 58], ["the immunized mouse sera", "TREATMENT", 66, 90], ["a pseudotype neutralization assay", "TEST", 110, 143]]], ["VSV lacking G and expressing NanoLuciferase and EGFP (VSVDG-NanoLuc-EGFP) was trans-complemented with MOKV G to create MOKV G pseudotype viruses (MOKV G PTVs; see Figure S7 for schematic).", [["VSV", "ORGANISM", 0, 3], ["G", "GENE_OR_GENE_PRODUCT", 12, 13], ["NanoLuciferase", "GENE_OR_GENE_PRODUCT", 29, 43], ["EGFP", "GENE_OR_GENE_PRODUCT", 48, 52], ["VSVDG-NanoLuc-EGFP", "GENE_OR_GENE_PRODUCT", 54, 72], ["MOKV G", "GENE_OR_GENE_PRODUCT", 102, 108], ["MOKV G pseudotype", "ORGANISM", 119, 136], ["NanoLuciferase", "PROTEIN", 29, 43], ["EGFP", "PROTEIN", 48, 52], ["VSVDG", "PROTEIN", 54, 59], ["NanoLuc", "PROTEIN", 60, 67], ["EGFP", "PROTEIN", 68, 72], ["MOKV G", "PROTEIN", 102, 108], ["VSV", "SPECIES", 0, 3], ["NanoLuciferase", "TEST", 29, 43], ["EGFP", "TEST", 48, 52], ["VSVDG", "TEST", 54, 59], ["MOKV G", "TREATMENT", 102, 108], ["G pseudotype viruses", "PROBLEM", 124, 144], ["MOKV G PTVs", "TREATMENT", 146, 157]]], ["Cells express NanoLuc and EGFP when infected with these single round infectious particles; thus, neutralization was measured as a reduction in luminescence.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["NanoLuc", "GENE_OR_GENE_PRODUCT", 14, 21], ["EGFP", "GENE_OR_GENE_PRODUCT", 26, 30], ["NanoLuc", "PROTEIN", 14, 21], ["EGFP", "PROTEIN", 26, 30], ["NanoLuc and EGFP", "TREATMENT", 14, 30], ["these single round infectious particles", "PROBLEM", 50, 89], ["neutralization", "TREATMENT", 97, 111], ["a reduction in luminescence", "TREATMENT", 128, 155], ["round", "OBSERVATION_MODIFIER", 63, 68], ["infectious", "OBSERVATION", 69, 79]]], ["To account for background, we normalized luminescence to day 0 sera.", [["sera", "ANATOMY", 63, 67], ["sera", "ORGANISM_SUBSTANCE", 63, 67]]], ["Similar to the RFFIT, Lyssa-Vax-immune sera neutralized MOKV G PTVs at low concentrations, nearly as low as the control rMOKV.", [["sera", "ANATOMY", 39, 43], ["Lyssa", "GENE_OR_GENE_PRODUCT", 22, 27], ["Vax", "GENE_OR_GENE_PRODUCT", 28, 31], ["sera", "ORGANISM_SUBSTANCE", 39, 43], ["MOKV G PTVs", "SIMPLE_CHEMICAL", 56, 67], ["rMOKV", "PROTEIN", 120, 125], ["the RFFIT", "TEST", 11, 20], ["Lyssa", "TEST", 22, 27], ["Vax", "TREATMENT", 28, 31], ["immune sera neutralized MOKV G PTVs at low concentrations", "TREATMENT", 32, 89]]], ["Of the two time points for which half-maximal inhibitory concentrations (IC 50 ) could be calculated, LyssaVax differed from rMOKV significantly only at day 35 (p = 0.0133) ( Figure 5D ).", [["LyssaVax", "SIMPLE_CHEMICAL", 102, 110], ["rMOKV", "PROTEIN", 125, 130], ["half-maximal inhibitory concentrations (IC", "TREATMENT", 33, 75]]], ["Sera from mice immunized with rRABV did not neutralize the MOKV G PTVs.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 10, 14], ["MOKV G PTVs", "GENE_OR_GENE_PRODUCT", 59, 70], ["MOKV G PTVs", "DNA", 59, 70], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["rRABV", "SPECIES", 30, 35], ["Sera", "TEST", 0, 4], ["rRABV", "TREATMENT", 30, 35]]], ["Similar to the rMOKV sera in the RFFIT assay, high titers of cross-reactive sera seen in the ELISA did not correlate with functional VNA by day 35.", [["sera", "ANATOMY", 21, 25], ["sera", "ANATOMY", 76, 80], ["rMOKV", "ORGANISM", 15, 20], ["sera", "ORGANISM_SUBSTANCE", 21, 25], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["rMOKV", "SPECIES", 15, 20], ["the rMOKV sera", "TEST", 11, 25], ["the RFFIT assay", "TEST", 29, 44], ["high titers of cross-reactive sera", "PROBLEM", 46, 80]]], ["Pooled sera from mock-immunized mice showed no neutralization.LyssaVax Protects against Lethal Challenge of Both RABV and rMOKVThe vaccinated mice were challenged at 58 days p.i. (see schedule in Figure 3A ).", [["sera", "ANATOMY", 7, 11], ["LyssaVax", "CHEMICAL", 62, 70], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["mice", "ORGANISM", 32, 36], ["LyssaVax", "SIMPLE_CHEMICAL", 62, 70], ["RABV", "ORGANISM", 113, 117], ["mice", "ORGANISM", 142, 146], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 32, 36], ["RABV", "SPECIES", 113, 117], ["mice", "SPECIES", 142, 146], ["Pooled sera from mock", "TEST", 0, 21], ["neutralization", "PROBLEM", 47, 61], ["LyssaVax", "TREATMENT", 62, 70], ["rMOKVThe vaccinated mice", "TREATMENT", 122, 146], ["no", "UNCERTAINTY", 44, 46], ["neutralization", "OBSERVATION", 47, 61]]], ["The 10 mice per immunization group (B and C) Development of antibodies over time in groups of mice (n = 10 mice per group, analyzed in triplicate, mean \u00b1 SD) immunized three times with either LyssaVax (purple), rRABV (blue), or rMOKV (red).", [["mice", "ORGANISM", 7, 11], ["mice", "ORGANISM", 94, 98], ["mice", "ORGANISM", 107, 111], ["LyssaVax", "SIMPLE_CHEMICAL", 192, 200], ["rRABV (blue)", "GENE_OR_GENE_PRODUCT", 211, 223], ["antibodies", "PROTEIN", 60, 70], ["rMOKV", "PROTEIN", 228, 233], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 107, 111], ["The 10 mice per immunization group (B and C)", "TREATMENT", 0, 44], ["antibodies", "PROBLEM", 60, 70], ["mean \u00b1 SD)", "TREATMENT", 147, 157], ["rRABV (blue", "TREATMENT", 211, 222]]], ["Graphs compare halfmaximal responses (EC 50 s) between sera from immune mice probed against RABV G (B) or MOKV G (C) antigens in ELISA format.", [["sera", "ANATOMY", 55, 59], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["mice", "ORGANISM", 72, 76], ["RABV G (B)", "GENE_OR_GENE_PRODUCT", 92, 102], ["MOKV G (C) antigens", "GENE_OR_GENE_PRODUCT", 106, 125], ["RABV G", "PROTEIN", 92, 98], ["MOKV G (C) antigens", "PROTEIN", 106, 125], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["RABV", "SPECIES", 92, 96], ["Graphs", "TEST", 0, 6], ["halfmaximal responses", "TEST", 15, 36], ["EC", "TEST", 38, 40], ["sera", "TEST", 55, 59], ["immune mice", "TREATMENT", 65, 76], ["RABV G", "TEST", 92, 98], ["MOKV G (C) antigens in ELISA format", "PROBLEM", 106, 141]]], ["Day 0 samples did not seroconvert, so EC 50 values were not calculated.", [["samples", "ANATOMY", 6, 13], ["EC", "CELL", 38, 40]]], ["Analysis within time points by Kruskal-Wallis test and Dunn's multiple comparisons test (p < 0.001, ****p < 0.0001 for adjusted p values; n.s. is not significant).", [["Analysis", "TEST", 0, 8], ["Kruskal-Wallis test", "TEST", 31, 50], ["Dunn's multiple comparisons test", "TEST", 55, 87], ["adjusted p values", "TEST", 119, 136]]], ["RABV Neutralizing Titers over TimeDevelopment of RABV neutralizing antibodies over time, averaged from mice in groups of mice (n = 10 mice per group, analyzed in duplicate, mean \u00b1 SD) immunized on days 0, 7, and 28 with either rRABV (blue), rMOKV (red), or LyssaVax (purple), or mock immunized (gray).", [["RABV", "ORGANISM", 0, 4], ["RABV", "ORGANISM", 49, 53], ["mice", "ORGANISM", 103, 107], ["mice", "ORGANISM", 121, 125], ["mice", "ORGANISM", 134, 138], ["LyssaVax", "SIMPLE_CHEMICAL", 257, 265], ["RABV neutralizing antibodies", "PROTEIN", 49, 77], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 134, 138], ["RABV", "SPECIES", 0, 4], ["RABV", "SPECIES", 49, 53], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 134, 138], ["RABV Neutralizing Titers", "TREATMENT", 0, 24], ["RABV neutralizing antibodies", "TREATMENT", 49, 77]]], ["See Figure 3A for full immunization scheme.", [["full immunization scheme", "TREATMENT", 18, 42]]], ["Titers were calculated in international units (IU) per milliliter by comparison with the US standard rabies immune globulin.", [["immune globulin", "GENE_OR_GENE_PRODUCT", 108, 123], ["rabies immune globulin", "PROTEIN", 101, 123], ["rabies", "SPECIES", 101, 107], ["Titers", "TEST", 0, 6], ["the US", "TEST", 85, 91]]], ["Two-way ANOVA and Tukey's multiple comparisons tests were performed. p < 0.05, ***p < 0.0001 for adjusted p values; n.s. is not significant).Vaccine-Generated Antibody Responses8 Cell Reports 32, 107920, July 21, 2020 Article ll OPEN ACCESS necessary for neutralizing non-RABV phylogroup I viruses (Hanlon et al., 2005) , so the RABV G-specific titers from LyssaVax may not have been high enough.", [["RABV", "ORGANISM", 329, 333], ["G", "GENE_OR_GENE_PRODUCT", 334, 335], ["LyssaVax", "SIMPLE_CHEMICAL", 357, 365], ["RABV", "SPECIES", 329, 333], ["Tukey's multiple comparisons tests", "TEST", 18, 52], ["adjusted p values", "TEST", 97, 114], ["Article ll OPEN ACCESS", "TREATMENT", 218, 240], ["neutralizing non-RABV phylogroup I viruses", "PROBLEM", 255, 297], ["the RABV G", "TEST", 325, 335], ["LyssaVax", "TREATMENT", 357, 365]]], ["The ability of GLA-SE to boost phylogroup I VNA titers when added to LyssaVax supports this.Vaccine-Generated Antibody ResponsesAlthough division of the lyssavirus genus into phylogroups is based on genetic and antigenic clustering, there are many examples of less discrete patterns of antigenicity.", [["GLA-", "CHEMICAL", 15, 19], ["SE", "DISEASE", 19, 21], ["GLA", "SIMPLE_CHEMICAL", 15, 18], ["phylogroup I VNA", "GENE_OR_GENE_PRODUCT", 31, 47], ["LyssaVax", "PROTEIN", 69, 77], ["LyssaVax", "TREATMENT", 69, 77], ["Vaccine", "TREATMENT", 92, 99], ["less discrete", "OBSERVATION_MODIFIER", 260, 273]]], ["For example, interphylogroup neutralization has been observed in RABV-vaccinated laboratory workers with exceptionally high titers (De Benedictis et al., 2016; Hanlon et al., 2005) , and there are at least two examples of anti-RABV G mAbs reported to cross-neutralize MOKV: 1409 -7 (Dietzschold et al., 1988 and JA-3.3A5 (Hanlon et al., 2001) .", [["RABV", "ORGANISM", 65, 69], ["anti-RABV G mAbs", "GENE_OR_GENE_PRODUCT", 222, 238], ["anti-RABV G mAbs", "PROTEIN", 222, 238], ["RABV", "SPECIES", 65, 69], ["interphylogroup neutralization", "PROBLEM", 13, 43], ["anti-RABV G mAbs", "TREATMENT", 222, 238], ["JA", "TEST", 312, 314]]], ["Furthermore, antigenic cartography studies have determined that only 67% of antigenic differences among lyssavirus Gs are predictable from the amino acid sequence (Horton et al., 2010) .Vaccine-Generated Antibody ResponsesIn the cases where LyssaVax is cross-neutralizing, it is unknown whether the sera contain individual cross-reactive antibodies or whether discrete populations of antibodies bind to each antigen; both possibilities likely contribute.", [["sera", "ANATOMY", 299, 303], ["amino acid", "CHEMICAL", 143, 153], ["LyssaVax", "CHEMICAL", 241, 249], ["amino acid", "CHEMICAL", 143, 153], ["lyssavirus", "ORGANISM", 104, 114], ["Gs", "GENE_OR_GENE_PRODUCT", 115, 117], ["amino acid", "AMINO_ACID", 143, 153], ["LyssaVax", "SIMPLE_CHEMICAL", 241, 249], ["sera", "ORGANISM_SUBSTANCE", 299, 303], ["Gs", "PROTEIN", 115, 117], ["cross-reactive antibodies", "PROTEIN", 323, 348], ["antibodies", "PROTEIN", 384, 394], ["antigenic cartography studies", "TEST", 13, 42], ["antigenic differences", "PROBLEM", 76, 97], ["the amino acid sequence", "TEST", 139, 162], ["Vaccine", "TREATMENT", 186, 193], ["the sera", "TEST", 295, 303], ["individual cross-reactive antibodies", "PROBLEM", 312, 348], ["discrete populations of antibodies bind", "PROBLEM", 360, 399]]], ["This question can be answered only by isolating and characterizing mAbs, a goal of future studies.", [["mAbs", "PROTEIN", 67, 71], ["future studies", "TEST", 83, 97]]], ["Knowledge of where physiologically relevant antibodies bind on non-RABV lyssavirus Gs will be important for detailed study of how LyssaVax elicits protective antibodies against multiple lyssaviruses.Protection from Rabies DiseaseBased on the high titers of VNAs against the two component viruses, which contributed to the chimeric G, we anticipated full protection.", [["LyssaVax", "CHEMICAL", 130, 138], ["Gs", "GENE_OR_GENE_PRODUCT", 83, 85], ["LyssaVax", "SIMPLE_CHEMICAL", 130, 138], ["Rabies", "ORGANISM", 215, 221], ["VNAs", "GENE_OR_GENE_PRODUCT", 257, 261], ["LyssaVax", "PROTEIN", 130, 138], ["protective antibodies", "PROTEIN", 147, 168], ["VNAs", "PROTEIN", 257, 261], ["chimeric G", "PROTEIN", 322, 332], ["physiologically relevant antibodies bind", "PROBLEM", 19, 59], ["non-RABV lyssavirus", "TREATMENT", 63, 82], ["detailed study", "TEST", 108, 122], ["protective antibodies", "TREATMENT", 147, 168], ["multiple lyssaviruses", "PROBLEM", 177, 198], ["Protection", "TREATMENT", 199, 209], ["VNAs", "TREATMENT", 257, 261], ["the two component viruses", "PROBLEM", 270, 295], ["the chimeric G", "TREATMENT", 318, 332], ["Rabies DiseaseBased", "OBSERVATION", 215, 234], ["component", "OBSERVATION_MODIFIER", 278, 287], ["viruses", "OBSERVATION", 288, 295]]], ["LyssaVax indeed protected all mice challenged with either RABV or rMOKV, with no weight loss or clinical symptoms observed.", [["LyssaVax", "CHEMICAL", 0, 8], ["weight loss", "DISEASE", 81, 92], ["LyssaVax", "SIMPLE_CHEMICAL", 0, 8], ["mice", "ORGANISM", 30, 34], ["RABV", "ORGANISM", 58, 62], ["rMOKV", "GENE_OR_GENE_PRODUCT", 66, 71], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["RABV", "SPECIES", 58, 62], ["LyssaVax", "TREATMENT", 0, 8], ["weight loss", "PROBLEM", 81, 92], ["clinical symptoms", "PROBLEM", 96, 113]]], ["Although lyssaviruses are typically administered intracranially, the i.n. route was chosen in this study for several reasons.", [["lyssaviruses", "SIMPLE_CHEMICAL", 9, 21], ["lyssaviruses", "PROBLEM", 9, 21], ["this study", "TEST", 94, 104]]], ["First, we observed uniform pathogenicity in female mice during pathogenicity studies ( Figure S4 ).", [["mice", "ORGANISM", 51, 55], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["pathogenicity studies", "TEST", 63, 84], ["uniform", "OBSERVATION_MODIFIER", 19, 26], ["pathogenicity", "OBSERVATION", 27, 40]]], ["Second, rMOKV is not pathogenic by the i.m. route ( Figure S4 ), consistent with WT MOKV studies (Badrane et al., 2001; Percy et al., 1973; Perrin et al., 1996) .", [["rMOKV", "GENE_OR_GENE_PRODUCT", 8, 13], ["rMOKV", "PROTEIN", 8, 13], ["pathogenic", "PROBLEM", 21, 31], ["not", "UNCERTAINTY", 17, 20], ["pathogenic", "OBSERVATION", 21, 31], ["consistent with", "UNCERTAINTY", 65, 80]]], ["Third, the i.n. route has been shown to be an acceptable alternative to intracranial injection for RABV challenge (Lafay et al., 1991; Lewis et al., 2013; Rosseels et al., 2011) .", [["intracranial", "ANATOMY", 72, 84], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 84], ["RABV", "ORGANISM", 99, 103], ["RABV", "SPECIES", 99, 103], ["intracranial injection", "TREATMENT", 72, 94]]], ["Finally, i.n. inoculation poses a lesser risk to laboratory personnel.Protection from Rabies DiseaseAmong the control groups, mice immunized and challenged with homologous vaccines/viruses survived, as expected ( Figures S8C and S8H ), whereas some mice survived challenge with heterologous virus (Figures S8D and S8G) .", [["Rabies DiseaseAmong", "DISEASE", 86, 105], ["Rabies", "ORGANISM", 86, 92], ["mice", "ORGANISM", 126, 130], ["mice", "ORGANISM", 249, 253], ["heterologous virus", "ORGANISM", 278, 296], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 249, 253], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 249, 253], ["Protection", "TREATMENT", 70, 80], ["Rabies DiseaseAmong the control groups", "TREATMENT", 86, 124], ["homologous vaccines", "TREATMENT", 161, 180], ["viruses", "PROBLEM", 181, 188], ["heterologous virus", "PROBLEM", 278, 296]]], ["This was surprising because, despite appreciable titers of antibodies against heterologous Gs detected in the ELISA (Figure 3 ), mice immunized with rMOKV had marginal RABV-neutralizing titers ( Figure 4 ) and rRABV did not neutralize MOKV G pseudotypes ( Figure 6 ).", [["Gs", "GENE_OR_GENE_PRODUCT", 91, 93], ["mice", "ORGANISM", 129, 133], ["rMOKV", "GENE_OR_GENE_PRODUCT", 149, 154], ["RABV", "ORGANISM", 168, 172], ["antibodies", "PROTEIN", 59, 69], ["Gs", "PROTEIN", 91, 93], ["rMOKV", "PROTEIN", 149, 154], ["rRABV", "PROTEIN", 210, 215], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["rMOKV", "SPECIES", 149, 154], ["RABV", "SPECIES", 168, 172], ["rRABV", "SPECIES", 210, 215], ["appreciable titers of antibodies", "PROBLEM", 37, 69], ["heterologous", "TREATMENT", 78, 90], ["Gs", "TEST", 91, 93], ["the ELISA", "TEST", 106, 115], ["marginal RABV", "TREATMENT", 159, 172], ["rRABV", "TREATMENT", 210, 215]]], ["However, in light of the cross-neutralization of other phylogroup I viruses that rMOKV sera exhibited in Figure 7 , the survival is less exceptional.Protection from Rabies DiseaseIt is notable that two mice immunized with rMOKV lost weight and were euthanized, and two mice immunized with rRABV lost weight after rMOKV challenge and recovered ( Figure S8) .", [["sera", "ANATOMY", 87, 91], ["Rabies DiseaseIt", "DISEASE", 165, 181], ["phylogroup I viruses", "ORGANISM", 55, 75], ["rMOKV", "ORGANISM", 81, 86], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["Rabies", "ORGANISM", 165, 171], ["mice", "ORGANISM", 202, 206], ["mice", "ORGANISM", 269, 273], ["rRABV", "ORGANISM", 289, 294], ["rRABV", "PROTEIN", 289, 294], ["mice", "SPECIES", 202, 206], ["mice", "SPECIES", 269, 273], ["rMOKV", "SPECIES", 81, 86], ["mice", "SPECIES", 202, 206], ["mice", "SPECIES", 269, 273], ["rRABV", "SPECIES", 289, 294], ["rMOKV sera", "TEST", 81, 91], ["rMOKV challenge", "TREATMENT", 313, 328], ["less exceptional", "OBSERVATION_MODIFIER", 132, 148], ["Rabies DiseaseIt", "OBSERVATION", 165, 181]]], ["The atypical challenge model (attenuated strains administered i.n.) may be responsible; this would be addressed by the WT challenge experiment.", [["The atypical challenge model (attenuated strains", "TREATMENT", 0, 48], ["atypical", "OBSERVATION_MODIFIER", 4, 12]]], ["Given that 9/10 mock-immunized mice were euthanized ( Figure S8A ) and the 10 th mouse indeed survived after infection, as evidenced by RABV VNAs detected at necropsy (Table S1 , mouse ID 1-4), we are confident that the mice in Figures S8D and S8G were successfully infected.Protection from Rabies DiseaseThe mechanism for developing broadly neutralizing lyssavirus VNAs has not been studied and raises important questions about the antigenic relationships between lyssaviruses and how protection is conferred.", [["infection", "DISEASE", 109, 118], ["Rabies Disease", "DISEASE", 291, 305], ["mice", "ORGANISM", 31, 35], ["mouse", "ORGANISM", 81, 86], ["RABV", "ORGANISM", 136, 140], ["mouse", "ORGANISM", 179, 184], ["mice", "ORGANISM", 220, 224], ["S8G", "ORGANISM", 244, 247], ["RABV VNAs", "PROTEIN", 136, 145], ["lyssavirus VNAs", "PROTEIN", 355, 370], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 179, 184], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 31, 35], ["mouse", "SPECIES", 81, 86], ["RABV", "SPECIES", 136, 140], ["mice", "SPECIES", 220, 224], ["Rabies Disease", "SPECIES", 291, 305], ["infection", "PROBLEM", 109, 118], ["RABV VNAs", "TEST", 136, 145], ["S8G", "TREATMENT", 244, 247], ["Rabies Disease", "PROBLEM", 291, 305], ["lyssaviruses", "TREATMENT", 465, 477], ["infection", "OBSERVATION", 109, 118], ["Rabies Disease", "OBSERVATION", 291, 305], ["neutralizing lyssavirus", "OBSERVATION", 342, 365]]], ["There may be additional, uncharacterized immune mechanisms that contribute to protection in the absence of neutralizing antibodies.", [["neutralizing antibodies", "PROTEIN", 107, 130], ["uncharacterized immune mechanisms", "PROBLEM", 25, 58], ["neutralizing antibodies", "PROBLEM", 107, 130], ["may be", "UNCERTAINTY", 6, 12], ["immune mechanisms", "OBSERVATION", 41, 58], ["neutralizing antibodies", "OBSERVATION", 107, 130]]], ["This possibility warrants further investigation.ConclusionsWe present a lyssavirus vaccine featuring a single chimeric glycoprotein that was designed based on observations of predicted lyssavirus G structures.", [["lyssavirus G", "GENE_OR_GENE_PRODUCT", 185, 197], ["chimeric glycoprotein", "PROTEIN", 110, 131], ["further investigation", "TEST", 26, 47], ["a lyssavirus vaccine", "TREATMENT", 70, 90], ["a single chimeric glycoprotein", "TREATMENT", 101, 131]]], ["The chimeric G retains antigenic qualities of component Gs (RABV and MOKV) and cell-infecting functionality.", [["cell", "ANATOMY", 79, 83], ["chimeric G", "GENE_OR_GENE_PRODUCT", 4, 14], ["Gs", "GENE_OR_GENE_PRODUCT", 56, 58], ["RABV", "ORGANISM", 60, 64], ["MOKV", "GENE_OR_GENE_PRODUCT", 69, 73], ["cell", "CELL", 79, 83], ["chimeric G", "PROTEIN", 4, 14], ["component Gs", "PROTEIN", 46, 58], ["MOKV", "PROTEIN", 69, 73], ["RABV", "SPECIES", 60, 64], ["component Gs", "TEST", 46, 58], ["infecting functionality", "OBSERVATION", 84, 107]]], ["When administered as an inactivated vaccine formulation, it stimulates high titers of neutralizing antibodies against component viral Gs and some additional lyssaviruses.", [["Gs", "GENE_OR_GENE_PRODUCT", 134, 136], ["neutralizing antibodies", "PROTEIN", 86, 109], ["an inactivated vaccine formulation", "TREATMENT", 21, 55], ["neutralizing antibodies", "TREATMENT", 86, 109], ["some additional lyssaviruses", "PROBLEM", 141, 169]]], ["Finally, LyssaVax was shown to protect against challenge with RABV and a recombinant MOKV.", [["LyssaVax", "CHEMICAL", 9, 17], ["LyssaVax", "SIMPLE_CHEMICAL", 9, 17], ["RABV", "ORGANISM", 62, 66], ["MOKV", "GENE_OR_GENE_PRODUCT", 85, 89], ["LyssaVax", "PROTEIN", 9, 17], ["recombinant MOKV", "PROTEIN", 73, 89], ["RABV", "SPECIES", 62, 66], ["LyssaVax", "TREATMENT", 9, 17], ["RABV", "TREATMENT", 62, 66], ["a recombinant MOKV", "TREATMENT", 71, 89]]], ["Development is needed to improve VNA titer responses against phylogroup I viruses.", [["VNA", "CANCER", 33, 36], ["phylogroup I viruses", "ORGANISM", 61, 81], ["phylogroup I viruses", "SPECIES", 61, 81]]], ["We propose that, with further development, this vaccine could be employed during a lyssavirus outbreak or supplant current rabies vaccines in areas where non-RABV lyssaviruses are endemic.STAR+METHODSDetailed methods are provided in the online version of this paper and include the following: Nel, L., Jacobs, J., Jaftha, J., von Teichman, B., Bingham, J., and Olivier, M. (2000) .", [["rabies", "ORGANISM", 123, 129], ["non-RABV lyssaviruses", "ORGANISM", 154, 175], ["lyssavirus", "SPECIES", 83, 93], ["rabies", "SPECIES", 123, 129], ["non-RABV", "SPECIES", 154, 162], ["this vaccine", "TREATMENT", 43, 55], ["a lyssavirus outbreak", "TREATMENT", 81, 102], ["supplant current rabies vaccines", "TREATMENT", 106, 138]]], ["New cases of Mokola virus infection in South Africa: a genotypic comparison of Southern African virus isolates.", [["Mokola virus infection", "DISEASE", 13, 35], ["Mokola virus", "ORGANISM", 13, 25], ["Southern African virus", "ORGANISM", 79, 101], ["Mokola virus", "SPECIES", 13, 25], ["African virus", "SPECIES", 88, 101], ["Mokola virus infection", "PROBLEM", 13, 35], ["Southern African virus isolates", "TREATMENT", 79, 110], ["Mokola virus infection", "OBSERVATION", 13, 35]]], ["Virus Genes 20, 103-106.STAR+METHODSNi, Y., Tominaga, Y., Honda, Y., Morimoto, K., Sakamoto, S., and Kawai, A. (1995) .", [["Virus Genes", "TEST", 0, 11]]], ["Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719.", [["rabies virus glycoprotein", "ORGANISM", 60, 85], ["RG719", "SIMPLE_CHEMICAL", 145, 150], ["rabies virus glycoprotein", "PROTEIN", 60, 85], ["neutralizing monoclonal antibody", "PROTEIN", 111, 143], ["RG719", "PROTEIN", 145, 150], ["rabies virus", "SPECIES", 60, 72], ["rabies virus", "SPECIES", 60, 72], ["Mapping", "TEST", 0, 7], ["a sequential epitope", "PROBLEM", 32, 52], ["the rabies virus glycoprotein", "PROBLEM", 56, 85], ["a neutralizing monoclonal antibody", "TEST", 109, 143]]], ["Microbiol.", [["Microbiol", "CHEMICAL", 0, 9], ["Microbiol", "SIMPLE_CHEMICAL", 0, 9]]], ["Immunol.", [["Immunol", "CHEMICAL", 0, 7], ["Immunol", "SIMPLE_CHEMICAL", 0, 7], ["Immunol", "TREATMENT", 0, 7]]], ["Tentative novel lyssavirus in a bat in Finland.", [["Tentative novel lyssavirus", "PROBLEM", 0, 26], ["lyssavirus", "OBSERVATION", 16, 26]]], ["Serological Survey of Lyssaviruses in Polish Bats in the Frame of Passive Rabies Surveillance Using an Enzyme-Linked Immunosorbent Assay.", [["an Enzyme", "TEST", 100, 109], ["Immunosorbent Assay", "TEST", 117, 136]]], ["Viruses 12, 271.STAR+METHODSPapaneri, A.B., Wirblich, C., Marissen, W.E., and Schnell, M.J. (2013) .", [["Viruses", "TEST", 0, 7]]], ["Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.", [["Alanine", "CHEMICAL", 0, 7], ["rabies virus", "DISEASE", 87, 99], ["Alanine", "CHEMICAL", 0, 7], ["Alanine", "AMINO_ACID", 0, 7], ["rabies virus", "ORGANISM", 24, 36], ["recombinant", "ORGANISM", 75, 86], ["rabies virus", "ORGANISM", 87, 99], ["rabies virus glycoprotein antigenic site III", "DNA", 24, 68], ["rabies virus", "SPECIES", 24, 36], ["rabies virus", "SPECIES", 87, 99], ["rabies virus", "SPECIES", 24, 36], ["rabies virus", "SPECIES", 87, 99], ["Alanine scanning", "TEST", 0, 16], ["the rabies virus glycoprotein antigenic", "TREATMENT", 20, 59], ["post-exposure treatment", "TREATMENT", 117, 140]]], ["Vaccine 31, 5897-5902.STAR+METHODSPatton, K., Aslam, S., Shambaugh, C., Lin, R., Heeke, D., Frantz, C., Zuo, F., Esser, M.T., Paliard, X., and Lambert, S.L. (2015) .", [["31, 5897-5902", "CHEMICAL", 8, 21], ["Lin", "ANATOMY", 72, 75], ["R.", "ANATOMY", 77, 79], ["Zuo", "ANATOMY", 104, 107]]], ["Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.", [["respiratory syncytial virus", "DISEASE", 29, 56], ["GLA", "CHEMICAL", 110, 113], ["SE", "DISEASE", 114, 116], ["respiratory syncytial virus", "ORGANISM", 29, 56], ["RSV", "ORGANISM", 58, 61], ["GLA", "SIMPLE_CHEMICAL", 110, 113], ["cynomolgus macaques", "ORGANISM", 120, 139], ["respiratory syncytial virus", "SPECIES", 29, 56], ["cynomolgus macaques", "SPECIES", 120, 139], ["respiratory syncytial virus", "SPECIES", 29, 56], ["RSV", "SPECIES", 58, 61], ["cynomolgus macaques", "SPECIES", 120, 139], ["a respiratory syncytial virus (RSV) F subunit vaccine", "TREATMENT", 27, 80], ["the adjuvant GLA", "TREATMENT", 97, 113], ["respiratory syncytial virus", "OBSERVATION", 29, 56], ["cynomolgus macaques", "OBSERVATION", 120, 139]]], ["Vaccine 33, 4472-4478.", [["Vaccine", "TREATMENT", 0, 7]]], ["Experimental infection of dogs and monkeys with two rabies serogroup viruses, Lagos bat and Mokola (IbAn 27377).", [["infection", "DISEASE", 13, 22], ["rabies serogroup viruses", "DISEASE", 52, 76], ["IbAn 27377", "CHEMICAL", 100, 110], ["dogs", "ORGANISM", 26, 30], ["monkeys", "ORGANISM", 35, 42], ["rabies serogroup viruses", "ORGANISM", 52, 76], ["dogs", "SPECIES", 26, 30], ["rabies serogroup viruses", "SPECIES", 52, 76], ["rabies serogroup viruses", "SPECIES", 52, 76], ["Lagos bat", "SPECIES", 78, 87], ["Experimental infection of dogs and monkeys", "PROBLEM", 0, 42], ["two rabies serogroup viruses", "PROBLEM", 48, 76], ["infection", "OBSERVATION", 13, 22]]], ["Gross pathologic and histopathologic changes.", [["Gross pathologic and histopathologic changes", "PROBLEM", 0, 44], ["pathologic", "OBSERVATION", 6, 16], ["histopathologic", "OBSERVATION", 21, 36]]], ["The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic Lyssoviruses.", [["cell", "ANATOMY", 21, 25], ["infection", "DISEASE", 76, 85], ["antigen", "GENE_OR_GENE_PRODUCT", 4, 11], ["cell", "CELL", 21, 25], ["mice", "ORGANISM", 54, 58], ["Lyssoviruses", "GENE_OR_GENE_PRODUCT", 102, 114], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["The antigen", "TEST", 0, 11], ["infection", "PROBLEM", 76, 85], ["pathogenic Lyssoviruses", "PROBLEM", 91, 114], ["infection", "OBSERVATION", 76, 85]]], ["147, 289-299.Lead ContactFurther information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matthias Schnell (Matthias.Schnell@jefferson.edu).Materials AvailabilityUpon request, further information, resources, and reagents are available from the authors pending an executed MTA as well as biosafety approval of the requesting institution(s).Data and Code AvailabilityAll data are available upon request to the lead contact author.", [["reagents", "TREATMENT", 76, 84]]], ["No proprietary software was used in the data analysis.EXPERIMENTAL MODEL AND SUBJECT DETAILSSwiss Webster mice (Charles River), age 6-10 weeks, were used in this study.", [["Webster mice", "ORGANISM", 98, 110], ["Charles River", "ORGANISM", 112, 125], ["mice", "SPECIES", 106, 110], ["the data analysis", "TEST", 36, 53], ["this study", "TEST", 157, 167]]], ["All mice used were female except where noted.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Mice used in this study were handled in adherence to the recommendations described in the Guide for the Care and Use of Laboratory Animals, and work was approved by the Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University (TJU) under protocols 01886 and 01940.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["this study", "TEST", 13, 23]]], ["Mice were housed with up to five individuals per cage, under controlled conditions of humidity, temperature, and light (12 h light, 12 h dark cycles).", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["temperature", "TEST", 96, 107]]], ["Animal procedures were conducted under 3% isoflurane/O 2 gas anesthesia.EXPERIMENTAL MODEL AND SUBJECT DETAILSThe following cell lines and their culture conditions were used in this work: mouse neuroblastoma (NA) cells were grown in RPMI (Corning) with 5% fetal bovine serum (FBS, Atlanta Biologicals) and 1X Penicillin/Streptomycin (Corning).", [["cell lines", "ANATOMY", 124, 134], ["neuroblastoma (NA) cells", "ANATOMY", 194, 218], ["fetal bovine serum", "ANATOMY", 256, 274], ["FBS", "ANATOMY", 276, 279], ["isoflurane", "CHEMICAL", 42, 52], ["neuroblastoma", "DISEASE", 194, 207], ["Penicillin", "CHEMICAL", 309, 319], ["Streptomycin", "CHEMICAL", 320, 332], ["isoflurane", "CHEMICAL", 42, 52], ["O 2", "CHEMICAL", 53, 56], ["Penicillin", "CHEMICAL", 309, 319], ["Streptomycin", "CHEMICAL", 320, 332], ["isoflurane", "SIMPLE_CHEMICAL", 42, 52], ["cell lines", "CELL", 124, 134], ["mouse", "ORGANISM", 188, 193], ["neuroblastoma (NA) cells", "CELL", 194, 218], ["bovine", "ORGANISM", 262, 268], ["serum", "ORGANISM_SUBSTANCE", 269, 274], ["FBS", "ORGANISM_SUBSTANCE", 276, 279], ["1X Penicillin", "SIMPLE_CHEMICAL", 306, 319], ["Streptomycin", "SIMPLE_CHEMICAL", 320, 332], ["cell lines", "CELL_LINE", 124, 134], ["mouse neuroblastoma (NA) cells", "CELL_LINE", 188, 218], ["mouse", "SPECIES", 188, 193], ["bovine", "SPECIES", 262, 268], ["mouse", "SPECIES", 188, 193], ["bovine", "SPECIES", 262, 268], ["Animal procedures", "TREATMENT", 0, 17], ["3% isoflurane", "TREATMENT", 39, 52], ["2 gas anesthesia", "TREATMENT", 55, 71], ["cell lines", "TREATMENT", 124, 134], ["their culture conditions", "TEST", 139, 163], ["mouse neuroblastoma (NA) cells", "PROBLEM", 188, 218], ["RPMI", "TEST", 233, 237], ["fetal bovine serum", "TEST", 256, 274], ["FBS", "TEST", 276, 279], ["Atlanta Biologicals", "TREATMENT", 281, 300], ["1X Penicillin", "TREATMENT", 306, 319], ["Streptomycin", "TREATMENT", 320, 332], ["cell lines", "OBSERVATION", 124, 134]]], ["The other cell lines were grown in DMEM (Corning) with 5% FBS and 1X Penicillin/Streptomycin: BSR cells (a derivative of the baby hamster kidney cell line BHK-21), the African green monkey cell line VERO, and the human lung cell line BEAS-2b.", [["cell lines", "ANATOMY", 10, 20], ["BSR cells", "ANATOMY", 94, 103], ["hamster kidney cell line BHK-21", "ANATOMY", 130, 161], ["green monkey cell line VERO", "ANATOMY", 176, 203], ["lung cell line BEAS-2b", "ANATOMY", 219, 241], ["Penicillin", "CHEMICAL", 69, 79], ["Streptomycin", "CHEMICAL", 80, 92], ["Penicillin", "CHEMICAL", 69, 79], ["Streptomycin", "CHEMICAL", 80, 92], ["cell lines", "CELL", 10, 20], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["Penicillin", "SIMPLE_CHEMICAL", 69, 79], ["Streptomycin", "SIMPLE_CHEMICAL", 80, 92], ["BSR cells", "CELL", 94, 103], ["hamster", "ORGANISM", 130, 137], ["kidney cell line BHK-21", "CELL", 138, 161], ["green monkey cell line VERO", "CELL", 176, 203], ["human", "ORGANISM", 213, 218], ["lung cell line BEAS-2b", "CELL", 219, 241], ["cell lines", "CELL_LINE", 10, 20], ["BSR cells", "CELL_LINE", 94, 103], ["baby hamster kidney cell line BHK-21", "CELL_LINE", 125, 161], ["African green monkey cell line VERO", "CELL_LINE", 168, 203], ["human lung cell line", "CELL_LINE", 213, 233], ["BEAS-2b", "CELL_LINE", 234, 241], ["hamster", "SPECIES", 130, 137], ["human", "SPECIES", 213, 218], ["hamster", "SPECIES", 130, 137], ["African green monkey", "SPECIES", 168, 188], ["human", "SPECIES", 213, 218], ["5% FBS", "TREATMENT", 55, 61], ["1X Penicillin", "TREATMENT", 66, 79], ["Streptomycin", "TREATMENT", 80, 92], ["BSR cells", "PROBLEM", 94, 103], ["BHK", "TEST", 155, 158], ["the human lung cell line BEAS", "TEST", 209, 238], ["cell lines", "OBSERVATION", 10, 20], ["kidney", "ANATOMY", 138, 144], ["cell line", "OBSERVATION", 145, 154], ["monkey cell line", "OBSERVATION", 182, 198], ["lung", "ANATOMY", 219, 223], ["cell line", "OBSERVATION", 224, 233]]], ["Cells were kept at 37 C and 5% CO 2 during non-infectious growth and 34 C with 5% CO 2 during infectious growth.", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 31, 35], ["CO 2", "CHEMICAL", 82, 86], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["% CO", "TEST", 29, 33], ["non-infectious growth", "TEST", 43, 64], ["infectious growth", "PROBLEM", 94, 111]]], ["Infected cell cultures were cultured in OptiPRO SFM (Life Technologies) unless otherwise noted.Structural modeling and chimeric glycoprotein designTo generate structural models of RABV and MOKV G, their amino acid sequences were threaded onto the pre-fusion structure of vesicular stomatitis virus (VSV) G (Roche et al., 2007) .", [["cell cultures", "ANATOMY", 9, 22], ["amino acid", "CHEMICAL", 203, 213], ["vesicular stomatitis", "DISEASE", 271, 291], ["amino acid", "CHEMICAL", 203, 213], ["cell cultures", "CELL", 9, 22], ["RABV", "ORGANISM", 180, 184], ["MOKV G", "GENE_OR_GENE_PRODUCT", 189, 195], ["amino acid", "AMINO_ACID", 203, 213], ["vesicular stomatitis virus", "ORGANISM", 271, 297], ["VSV", "ORGANISM", 299, 302], ["Infected cell cultures", "CELL_LINE", 0, 22], ["chimeric glycoprotein designTo", "PROTEIN", 119, 149], ["MOKV G", "PROTEIN", 189, 195], ["stomatitis virus", "SPECIES", 281, 297], ["RABV", "SPECIES", 180, 184], ["stomatitis virus", "SPECIES", 281, 297], ["VSV", "SPECIES", 299, 302], ["Infected cell cultures", "TEST", 0, 22], ["MOKV G", "TREATMENT", 189, 195], ["their amino acid sequences", "TEST", 197, 223], ["vesicular stomatitis virus", "PROBLEM", 271, 297], ["cell cultures", "OBSERVATION", 9, 22], ["chimeric glycoprotein", "OBSERVATION", 119, 140], ["vesicular stomatitis virus", "OBSERVATION", 271, 297]]], ["After analysis and delineation of the clip, core, and flap regions of the glycoproteins, the proposed chimeric G were also threaded onto VSV G to confirm the placement of the ectodomain regions.cDNA construction of vaccine vectorsTo make the rRABV vector, we inserted a human codon-optimized RABV G (SAD B19 strain with R333E mutation, synthesized by Genscript USA) into the BNSPDG vector (Blaney et al., 2011) using the BsiWI and NheI restriction sites.", [["G", "GENE_OR_GENE_PRODUCT", 111, 112], ["VSV", "ORGANISM", 137, 140], ["rRABV", "GENE_OR_GENE_PRODUCT", 242, 247], ["human", "ORGANISM", 270, 275], ["RABV G", "ORGANISM", 292, 298], ["SAD B19", "ORGANISM", 300, 307], ["strain", "ORGANISM", 308, 314], ["BsiWI", "GENE_OR_GENE_PRODUCT", 421, 426], ["NheI", "GENE_OR_GENE_PRODUCT", 431, 435], ["clip, core, and flap regions", "DNA", 38, 66], ["glycoproteins", "PROTEIN", 74, 87], ["chimeric G", "PROTEIN", 102, 112], ["ectodomain regions", "PROTEIN", 175, 193], ["rRABV vector", "DNA", 242, 254], ["human codon", "DNA", 270, 281], ["BNSPDG vector", "DNA", 375, 388], ["BsiWI and NheI restriction sites", "DNA", 421, 453], ["human", "SPECIES", 270, 275], ["VSV", "SPECIES", 137, 140], ["human", "SPECIES", 270, 275], ["analysis", "TEST", 6, 14], ["the clip", "TEST", 34, 42], ["the glycoproteins", "TREATMENT", 70, 87], ["the proposed chimeric G", "TREATMENT", 89, 112], ["VSV G", "TREATMENT", 137, 142], ["the placement of the ectodomain regions", "TREATMENT", 154, 193], ["vaccine vectors", "TREATMENT", 215, 230], ["the rRABV vector", "TREATMENT", 238, 254], ["a human codon", "TREATMENT", 268, 281], ["optimized RABV G (SAD B19 strain", "TREATMENT", 282, 314], ["the BsiWI and NheI restriction sites", "TREATMENT", 417, 453], ["flap", "OBSERVATION", 54, 58]]], ["Human codon optimization was selected in anticipation of downstream vaccine production in primate cells.", [["cells", "ANATOMY", 98, 103], ["Human", "ORGANISM", 0, 5], ["primate", "ORGANISM", 90, 97], ["cells", "CELL", 98, 103], ["primate cells", "CELL_TYPE", 90, 103], ["Human", "SPECIES", 0, 5], ["Human codon optimization", "TREATMENT", 0, 24], ["downstream vaccine production", "TREATMENT", 57, 86]]], ["To make the BNSP333-coMOKVG vector, we inserted MOKV G (MOKV.NIG68-RV4 strain (Wright et al., 2010) , GenBank accession number HM623780, provided by Gene Tan) into the BNSP333 vector using the InFusion cloning kit (Clontech) and oligos CO-041 and CO-042.", [["oligos CO-041", "CHEMICAL", 229, 242], ["CO-042", "CHEMICAL", 247, 253], ["CO-041", "CHEMICAL", 236, 242], ["CO-042", "CHEMICAL", 247, 253], ["BNSP333", "GENE_OR_GENE_PRODUCT", 12, 19], ["MOKV G", "GENE_OR_GENE_PRODUCT", 48, 54], ["BNSP333", "GENE_OR_GENE_PRODUCT", 168, 175], ["Clontech", "GENE_OR_GENE_PRODUCT", 215, 223], ["oligos CO-041", "SIMPLE_CHEMICAL", 229, 242], ["CO-042", "SIMPLE_CHEMICAL", 247, 253], ["BNSP333-coMOKVG vector", "DNA", 12, 34], ["MOKV G", "DNA", 48, 54], ["MOKV", "DNA", 56, 60], ["BNSP333 vector", "DNA", 168, 182], ["the BNSP333-coMOKVG vector", "TREATMENT", 8, 34], ["the InFusion cloning kit", "TREATMENT", 189, 213], ["oligos CO", "TEST", 229, 238], ["CO", "TEST", 247, 249]]], ["To make the rMOKV vector, we inserted the human codon-optimized MOKV G sequence into the BNSPDG vector using the NotI and NheI restriction sites, the NotI site having been cloned into the vector previously.", [["rMOKV", "GENE_OR_GENE_PRODUCT", 12, 17], ["human", "ORGANISM", 42, 47], ["NotI", "GENE_OR_GENE_PRODUCT", 113, 117], ["NheI", "GENE_OR_GENE_PRODUCT", 122, 126], ["NotI", "GENE_OR_GENE_PRODUCT", 150, 154], ["rMOKV vector", "DNA", 12, 24], ["human codon", "DNA", 42, 53], ["MOKV G sequence", "DNA", 64, 79], ["BNSPDG vector", "DNA", 89, 102], ["NotI and NheI restriction sites", "DNA", 113, 144], ["NotI site", "DNA", 150, 159], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["the rMOKV vector", "TREATMENT", 8, 24], ["the human codon", "TREATMENT", 38, 53], ["optimized MOKV G sequence", "TREATMENT", 54, 79], ["the BNSPDG vector", "TREATMENT", 85, 102], ["the NotI and NheI restriction sites", "TREATMENT", 109, 144], ["the NotI site", "PROBLEM", 146, 159]]], ["To make the chimeric glycoproteins 1 and 2, fragments of codon optimized RABV G and MOKV G were first amplified by PCR using the primers listed in the table below and cloned into a pCAGGS expression vector via InFusion cloning (Clontech).", [["2", "GENE_OR_GENE_PRODUCT", 41, 42], ["RABV G", "GENE_OR_GENE_PRODUCT", 73, 79], ["MOKV G", "GENE_OR_GENE_PRODUCT", 84, 90], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 181, 187], ["Clontech", "GENE_OR_GENE_PRODUCT", 228, 236], ["chimeric glycoproteins 1 and 2", "PROTEIN", 12, 42], ["RABV G and MOKV G", "DNA", 73, 90], ["pCAGGS expression vector", "DNA", 181, 205], ["InFusion cloning", "DNA", 210, 226], ["RABV", "SPECIES", 73, 77], ["the chimeric glycoproteins", "TREATMENT", 8, 34], ["codon optimized RABV G", "TREATMENT", 57, 79], ["MOKV G", "TREATMENT", 84, 90], ["the primers", "TREATMENT", 125, 136], ["a pCAGGS expression vector", "TREATMENT", 179, 205], ["InFusion cloning (Clontech)", "TREATMENT", 210, 237]]], ["Three fragments were combined to make Chimeric G 1 (amplified using oligos CO-062 through CO-067) and four fragments were combined to make Chimeric G 2 (amplified using oligos CO-067 through CO-074).", [["fragments", "ANATOMY", 6, 15], ["CO-067", "CHEMICAL", 90, 96], ["CO-074", "CHEMICAL", 191, 197], ["CO-062", "CHEMICAL", 75, 81], ["CO-067", "CHEMICAL", 90, 96], ["CO-067", "CHEMICAL", 176, 182], ["CO-074", "CHEMICAL", 191, 197], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 38, 50], ["Chimeric G 2", "GENE_OR_GENE_PRODUCT", 139, 151], ["Chimeric G 1", "DNA", 38, 50], ["oligos CO-062", "DNA", 68, 81], ["CO-067", "DNA", 90, 96], ["Chimeric G 2", "DNA", 139, 151], ["CO-074", "DNA", 191, 197], ["Three fragments", "PROBLEM", 0, 15], ["Chimeric G", "TEST", 38, 48], ["oligos CO", "TEST", 68, 77], ["CO", "TEST", 90, 92], ["four fragments", "PROBLEM", 102, 116], ["Chimeric G 2", "TREATMENT", 139, 151], ["oligos CO", "TEST", 169, 178], ["CO", "TEST", 191, 193], ["fragments", "OBSERVATION", 6, 15]]], ["The chimeric Gs were then cloned into the BNSPDG vector using the NotI and NheI restriction sites to create rChimera1 (later termed LyssaVax) and rChimera2.", [["Gs", "GENE_OR_GENE_PRODUCT", 13, 15], ["NotI", "GENE_OR_GENE_PRODUCT", 66, 70], ["NheI", "GENE_OR_GENE_PRODUCT", 75, 79], ["rChimera1", "GENE_OR_GENE_PRODUCT", 108, 117], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 132, 140], ["rChimera2", "GENE_OR_GENE_PRODUCT", 146, 155], ["BNSPDG vector", "DNA", 42, 55], ["NotI and NheI restriction sites", "DNA", 66, 97], ["rChimera1", "PROTEIN", 108, 117], ["LyssaVax", "DNA", 132, 140], ["rChimera2", "DNA", 146, 155], ["the BNSPDG vector", "TREATMENT", 38, 55], ["the NotI and NheI restriction sites", "TREATMENT", 62, 97]]], ["The correct sequences of all four plasmids were confirmed by Sanger sequencing.Recovery of recombinant vectorsRecombinant RABV were recovered as described previously (Abreu-Mota et al., 2018; Kurup et al., 2015; Papaneri et al., 2013) .", [["plasmids", "ANATOMY", 34, 42], ["RABV", "ORGANISM", 122, 126], ["plasmids", "DNA", 34, 42], ["RABV", "SPECIES", 122, 126], ["all four plasmids", "TREATMENT", 25, 42], ["Sanger sequencing", "TEST", 61, 78], ["recombinant vectorsRecombinant RABV", "TREATMENT", 91, 126]]], ["Briefly, X-tremeGENE 9 transfection reagent (Millipore Sigma) in Opti-MEM reduced serum medium (Life Technologies) was used to co-transfect the respective full-length viral cDNA clones along with the plasmids encoding RABV N, P, and L and the T7 RNA polymerase into BSR cells in T25 flasks.", [["serum", "ANATOMY", 82, 87], ["plasmids", "ANATOMY", 200, 208], ["BSR cells", "ANATOMY", 266, 275], ["X-tremeGENE 9", "CHEMICAL", 9, 22], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["RABV", "ORGANISM", 218, 222], ["BSR cells", "CELL", 266, 275], ["full-length viral cDNA clones", "DNA", 155, 184], ["plasmids", "DNA", 200, 208], ["RABV N, P, and L", "DNA", 218, 234], ["T7 RNA polymerase", "PROTEIN", 243, 260], ["BSR cells", "CELL_LINE", 266, 275], ["RABV", "SPECIES", 218, 222], ["X-tremeGENE 9 transfection reagent (Millipore Sigma)", "TREATMENT", 9, 61], ["Opti-MEM reduced serum medium (Life Technologies", "TREATMENT", 65, 113], ["viral cDNA clones", "TREATMENT", 167, 184], ["the plasmids", "TREATMENT", 196, 208], ["P", "TEST", 226, 227], ["the T7 RNA polymerase", "TEST", 239, 260], ["T7", "ANATOMY", 243, 245], ["T25 flasks", "OBSERVATION", 279, 289]]], ["We harvested the supernatants of transfected cells after 7 days and analyzed the supernatants for the presence of infectious virus by infecting fresh BSR cell cultures and immunostaining with FITC-conjugated anti-RABV N mAb (Fujirebio).Recovery of recombinant vectorsCell Reports 32, 107920, July 21, 2020 e4 Article ll OPEN ACCESS To confirm the glycoprotein sequence in the recovered viruses, the viruses were sequenced by the following method: BSR cells were infected at an MOI of 1 then incubated for 2 days.", [["supernatants", "ANATOMY", 17, 29], ["cells", "ANATOMY", 45, 50], ["supernatants", "ANATOMY", 81, 93], ["BSR cell cultures", "ANATOMY", 150, 167], ["Cell", "ANATOMY", 267, 271], ["BSR cells", "ANATOMY", 447, 456], ["FITC", "CHEMICAL", 192, 196], ["cells", "CELL", 45, 50], ["BSR cell cultures", "CELL", 150, 167], ["FITC", "SIMPLE_CHEMICAL", 192, 196], ["anti-RABV N mAb", "SIMPLE_CHEMICAL", 208, 223], ["Fujirebio", "SIMPLE_CHEMICAL", 225, 234], ["Cell", "CELL", 267, 271], ["BSR cells", "CELL", 447, 456], ["transfected cells", "CELL_LINE", 33, 50], ["BSR cell cultures", "CELL_LINE", 150, 167], ["FITC-conjugated anti-RABV N mAb", "PROTEIN", 192, 223], ["Fujirebio", "PROTEIN", 225, 234], ["glycoprotein sequence", "DNA", 347, 368], ["BSR cells", "CELL_LINE", 447, 456], ["transfected cells", "TREATMENT", 33, 50], ["infectious virus", "PROBLEM", 114, 130], ["BSR cell cultures", "TEST", 150, 167], ["immunostaining", "TEST", 172, 186], ["FITC", "TEST", 192, 196], ["conjugated anti-RABV N mAb", "TREATMENT", 197, 223], ["the glycoprotein sequence", "TEST", 343, 368], ["the viruses", "PROBLEM", 395, 406], ["BSR cells", "PROBLEM", 447, 456], ["infectious", "OBSERVATION", 114, 124], ["viruses", "OBSERVATION", 386, 393]]], ["Media was removed and the PureLink RNA Mini Kit (Ambion) was used to lyse the cells and extract RNA.", [["cells", "ANATOMY", 78, 83], ["Ambion", "ORGANISM", 49, 55], ["cells", "CELL", 78, 83], ["extract RNA", "RNA", 88, 99], ["the PureLink RNA Mini Kit (Ambion)", "TREATMENT", 22, 56]]], ["Using the SuperScript II Reverse Transcriptase (Invitrogen), sections of the viral genomes containing G were amplified out of the total RNA (primers RP951 and RP952).", [["sections", "ANATOMY", 61, 69], ["SuperScript II Reverse Transcriptase", "GENE_OR_GENE_PRODUCT", 10, 46], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 48, 58], ["G", "GENE_OR_GENE_PRODUCT", 102, 103], ["SuperScript II Reverse Transcriptase", "PROTEIN", 10, 46], ["viral genomes", "DNA", 77, 90], ["primers RP951", "DNA", 141, 154], ["RP952", "DNA", 159, 164], ["the SuperScript II Reverse Transcriptase (Invitrogen)", "TREATMENT", 6, 59], ["the viral genomes", "TREATMENT", 73, 90], ["viral genomes", "OBSERVATION", 77, 90]]], ["RT-PCR products were run on an 1% agarose gel and bands were excised and analyzed by Sanger sequencing using the same primers.ImmunofluorescenceTo analyze broadened reactivity of the chimeric glycoproteins, VERO cells grown on 15 mm coverslips (Fisherbrand) were transfected with pCAGGS vectors containing either RABV G, MOKV G, Chimeric G 1 or Chimeric G 2 using XtremeGene 9.", [["VERO cells", "ANATOMY", 207, 217], ["coverslips", "ANATOMY", 233, 243], ["XtremeGene 9", "CHEMICAL", 364, 376], ["agarose", "SIMPLE_CHEMICAL", 34, 41], ["VERO cells", "CELL", 207, 217], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 280, 286], ["MOKV G", "GENE_OR_GENE_PRODUCT", 321, 327], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 329, 341], ["Chimeric G 2", "GENE_OR_GENE_PRODUCT", 345, 357], ["chimeric glycoproteins", "PROTEIN", 183, 205], ["VERO cells", "CELL_LINE", 207, 217], ["pCAGGS vectors", "DNA", 280, 294], ["RABV G", "DNA", 313, 319], ["MOKV G", "DNA", 321, 327], ["Chimeric G 1", "DNA", 329, 341], ["Chimeric G 2", "DNA", 345, 357], ["XtremeGene 9", "DNA", 364, 376], ["RABV", "SPECIES", 313, 317], ["RT-PCR products", "TREATMENT", 0, 15], ["an 1% agarose gel", "TREATMENT", 28, 45], ["bands", "TREATMENT", 50, 55], ["the same primers", "TREATMENT", 109, 125], ["the chimeric glycoproteins", "PROBLEM", 179, 205], ["VERO cells", "PROBLEM", 207, 217], ["15 mm coverslips (Fisherbrand)", "TREATMENT", 227, 257], ["pCAGGS vectors", "TREATMENT", 280, 294], ["RABV G", "TREATMENT", 313, 319], ["MOKV G", "TREATMENT", 321, 327], ["Chimeric G", "TREATMENT", 329, 339], ["Chimeric G", "TREATMENT", 345, 355], ["chimeric glycoproteins", "OBSERVATION", 183, 205], ["VERO cells", "OBSERVATION", 207, 217]]], ["Two days post-transfection, cells were fixed with 4% paraformaldehyde (PFA), blocked with PBS containing 5% FBS, and stained with either the human anti-RABV G mAb 4C12 conjugated to DyLight 488, mouse anti-MOKV G sera (from G. Tan), or mouse anti-RABV G sera (generated against BNSP333), each at 1:400 dilution and incubated for 2 h at RT.", [["cells", "ANATOMY", 28, 33], ["FBS", "ANATOMY", 108, 111], ["sera", "ANATOMY", 213, 217], ["sera", "ANATOMY", 254, 258], ["paraformaldehyde", "CHEMICAL", 53, 69], ["PFA", "CHEMICAL", 71, 74], ["cells", "CELL", 28, 33], ["paraformaldehyde", "SIMPLE_CHEMICAL", 53, 69], ["PFA", "SIMPLE_CHEMICAL", 71, 74], ["FBS", "ORGANISM_SUBSTANCE", 108, 111], ["human", "ORGANISM", 141, 146], ["DyLight 488", "SIMPLE_CHEMICAL", 182, 193], ["mouse", "ORGANISM", 195, 200], ["anti-MOKV G", "GENE_OR_GENE_PRODUCT", 201, 212], ["sera", "ORGANISM_SUBSTANCE", 213, 217], ["mouse", "ORGANISM", 236, 241], ["anti-RABV G", "ORGANISM", 242, 253], ["sera", "ORGANISM_SUBSTANCE", 254, 258], ["BNSP333", "SIMPLE_CHEMICAL", 278, 285], ["human anti-RABV G mAb 4C12", "PROTEIN", 141, 167], ["DyLight 488", "PROTEIN", 182, 193], ["human", "SPECIES", 141, 146], ["mouse", "SPECIES", 195, 200], ["mouse", "SPECIES", 236, 241], ["human", "SPECIES", 141, 146], ["mouse", "SPECIES", 195, 200], ["mouse", "SPECIES", 236, 241], ["anti-RABV", "SPECIES", 242, 251], ["cells", "TEST", 28, 33], ["4% paraformaldehyde (PFA", "TREATMENT", 50, 74], ["PBS", "TREATMENT", 90, 93], ["5% FBS", "TEST", 105, 111], ["the human anti-RABV G mAb", "TREATMENT", 137, 162], ["mouse anti-MOKV G sera", "TEST", 195, 217], ["mouse anti-RABV G sera", "TREATMENT", 236, 258]]], ["Coverslips were washed with PBS and samples stained with mouse sera were then stained with Cy3-conjugated goat anti-mouse IgG secondary at 1:200.", [["samples", "ANATOMY", 36, 43], ["sera", "ANATOMY", 63, 67], ["mouse", "ORGANISM", 57, 62], ["sera", "ORGANISM_SUBSTANCE", 63, 67], ["Cy3", "SIMPLE_CHEMICAL", 91, 94], ["Cy3-conjugated goat anti-mouse IgG", "PROTEIN", 91, 125], ["mouse", "SPECIES", 57, 62], ["goat", "SPECIES", 106, 110], ["anti-mouse", "SPECIES", 111, 121], ["mouse", "SPECIES", 57, 62], ["goat", "SPECIES", 106, 110], ["PBS", "TREATMENT", 28, 31], ["mouse sera", "TEST", 57, 67], ["Cy3", "TEST", 91, 94], ["conjugated goat anti-mouse IgG", "TREATMENT", 95, 125]]], ["After a 2 h incubation at RT, coverslips were washed and mounted onto glass slides with Vectashield Hard Set containing DAPI (Vector Laboratories).", [["DAPI", "CHEMICAL", 120, 124], ["DAPI", "SIMPLE_CHEMICAL", 120, 124], ["a 2 h incubation at RT", "TREATMENT", 6, 28], ["coverslips", "TREATMENT", 30, 40]]], ["Images of slides were analyzed in ProgRes (Jenoptic) and Fiji software (Schindelin et al., 2012) .ImmunofluorescenceImmunofluorescence assays on infected cells were carried out in a similar manner, with the following difference: VERO cells were infected at MOI 0.01 with live virus (rRABV, rMOKV or LyssaVax in Figure 2 ; rRABV, rMOKV, BNSP333-MOKVG or BNSP333-RABVG in Figure S1 ) then fixed with 4% PFA 2 days post-transfection.Viral growth curveRelated to Figure S1 .", [["cells", "ANATOMY", 154, 159], ["VERO cells", "ANATOMY", 229, 239], ["PFA", "CHEMICAL", 401, 404], ["cells", "CELL", 154, 159], ["VERO cells", "CELL", 229, 239], ["infected cells", "CELL_TYPE", 145, 159], ["VERO cells", "CELL_LINE", 229, 239], ["rRABV", "PROTEIN", 322, 327], ["BNSP333", "PROTEIN", 336, 343], ["MOKVG", "DNA", 344, 349], ["BNSP333", "DNA", 353, 360], ["RABVG", "DNA", 361, 366], ["rRABV", "SPECIES", 283, 288], ["rMOKV", "SPECIES", 290, 295], ["Images of slides", "TEST", 0, 16], ["ImmunofluorescenceImmunofluorescence assays", "TEST", 98, 141], ["infected cells", "PROBLEM", 145, 159], ["VERO cells", "PROBLEM", 229, 239], ["rMOKV", "TREATMENT", 290, 295], ["LyssaVax", "TREATMENT", 299, 307], ["rRABV", "TEST", 322, 327], ["rMOKV", "TEST", 329, 334], ["BNSP333", "TEST", 336, 343], ["MOKVG", "TEST", 344, 349], ["BNSP333", "TEST", 353, 360], ["4% PFA", "TREATMENT", 398, 404], ["Viral growth", "TEST", 430, 442], ["infected cells", "OBSERVATION", 145, 159]]], ["BSR cells were seeded in 6-well cell culture plates and incubated until 70% confluent.", [["BSR cells", "ANATOMY", 0, 9], ["cell", "ANATOMY", 32, 36], ["BSR cells", "CELL", 0, 9], ["cell", "CELL", 32, 36], ["BSR cells", "CELL_LINE", 0, 9], ["BSR cells", "TEST", 0, 9], ["well cell culture plates", "TEST", 27, 51], ["confluent", "OBSERVATION_MODIFIER", 76, 85]]], ["Cells were then infected at a MOI of 0.01 for 3 hours, washed 2x with PBS, and replenished with OptiPRO media (GIBCO).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PBS", "TREATMENT", 70, 73], ["OptiPRO media", "TREATMENT", 96, 109]]], ["Samples of each well were collected every 24 h, stored at 4 C, then titered in triplicate.Purification and inactivation of the virus particlesLarge volumes of rRABV-and LyssaVax-containing supernatants were concentrated in a stirred 300 mL ultrafiltration cell (Millipore) and then purified over a 20% sucrose cushion in an SW32 Ti rotor (Beckman, Inc.) at 25,000 rpm for 1.5 h ay 4 C. rMOKV was purified similarly but without prior concentration in ultrafiltration cells.", [["Samples", "ANATOMY", 0, 7], ["supernatants", "ANATOMY", 189, 201], ["cell", "ANATOMY", 256, 260], ["ultrafiltration cells", "ANATOMY", 450, 471], ["LyssaVax", "CHEMICAL", 169, 177], ["sucrose", "CHEMICAL", 302, 309], ["sucrose", "CHEMICAL", 302, 309], ["Ti", "CHEMICAL", 329, 331], ["rRABV", "GENE_OR_GENE_PRODUCT", 159, 164], ["LyssaVax", "SIMPLE_CHEMICAL", 169, 177], ["cell", "CELL", 256, 260], ["rMOKV", "GENE_OR_GENE_PRODUCT", 386, 391], ["cells", "CELL", 466, 471], ["rRABV", "PROTEIN", 159, 164], ["LyssaVax", "PROTEIN", 169, 177], ["ultrafiltration cells", "CELL_TYPE", 450, 471], ["Samples", "TEST", 0, 7], ["Purification", "TREATMENT", 90, 102], ["the virus particles", "TREATMENT", 123, 142], ["rRABV", "TEST", 159, 164], ["LyssaVax", "TREATMENT", 169, 177], ["supernatants", "TREATMENT", 189, 201], ["a stirred 300 mL ultrafiltration cell (Millipore", "TREATMENT", 223, 271], ["a 20% sucrose cushion", "TREATMENT", 296, 317], ["an SW32 Ti rotor (Beckman", "TREATMENT", 321, 346], ["prior concentration in ultrafiltration cells", "TREATMENT", 427, 471], ["Large", "OBSERVATION_MODIFIER", 142, 147], ["volumes", "OBSERVATION_MODIFIER", 148, 155], ["ultrafiltration cells", "OBSERVATION", 450, 471]]], ["Virion pellets were resuspended in phosphate-buffered saline (PBS), and protein concentrations were determined using a bicinchoninic acid (BCA) assay kit (Pierce).", [["phosphate", "CHEMICAL", 35, 44], ["bicinchoninic acid", "CHEMICAL", 119, 137], ["BCA", "CHEMICAL", 139, 142], ["phosphate", "CHEMICAL", 35, 44], ["bicinchoninic acid", "CHEMICAL", 119, 137], ["BCA", "CHEMICAL", 139, 142], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 35, 60], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 119, 137], ["BCA", "SIMPLE_CHEMICAL", 139, 142], ["Virion pellets", "TREATMENT", 0, 14], ["phosphate-buffered saline (PBS", "TREATMENT", 35, 65], ["protein concentrations", "TEST", 72, 94], ["a bicinchoninic acid (BCA", "TREATMENT", 117, 142]]], ["The virus particles were inactivated with 50 mL per mg of particles of a 1:100 dilution of b-propiolactone (BPL) in cold water.", [["b-propiolactone", "CHEMICAL", 91, 106], ["BPL", "CHEMICAL", 108, 111], ["b-propiolactone", "CHEMICAL", 91, 106], ["BPL", "CHEMICAL", 108, 111], ["b-propiolactone", "SIMPLE_CHEMICAL", 91, 106], ["BPL", "SIMPLE_CHEMICAL", 108, 111], ["The virus particles", "TREATMENT", 0, 19], ["a 1:100 dilution of b-propiolactone (BPL", "TREATMENT", 71, 111], ["virus particles", "OBSERVATION", 4, 19]]], ["The absence of infectivity was verified by inoculating BSR cells with 10 mg of BPL-inactivated viruses.", [["cells", "ANATOMY", 59, 64], ["BPL", "CHEMICAL", 79, 82], ["BSR cells", "CELL", 55, 64], ["BPL", "GENE_OR_GENE_PRODUCT", 79, 82], ["BSR cells", "CELL_LINE", 55, 64], ["infectivity", "PROBLEM", 15, 26], ["BPL", "TEST", 79, 82], ["infectivity", "OBSERVATION", 15, 26]]], ["After 4 days of incubation at 34 C, the cells were subcultured and 500 mL of supernatant was passaged on fresh BSR cells.", [["cells", "ANATOMY", 40, 45], ["supernatant", "ANATOMY", 77, 88], ["BSR cells", "ANATOMY", 111, 120], ["cells", "CELL", 40, 45], ["BSR cells", "CELL", 111, 120], ["BSR cells", "CELL_LINE", 111, 120], ["incubation", "TREATMENT", 16, 26], ["the cells", "TREATMENT", 36, 45], ["supernatant", "TREATMENT", 77, 88], ["BSR cells", "OBSERVATION", 111, 120]]], ["Cultures were split 3 times, every 3 days.", [["Cultures", "TEST", 0, 8]]], ["After the final growth period, cells were fixed and stained with a FITC-conjugated anti-RABV N mAb to confirm the absence of live virus.Protein gelTo examine their purity, inactivated virus particles were diluted 1:1 in urea buffer (200 mM Tris-HCl [pH 6.8], 8 M urea, 5% sodium dodecyl sulfate (SDS), 0.1 mM ethylenediaminetetraacetic acid [pH 8], 0.03% bromophenol blue, and 0.5 M dithiothreitol) and denatured at 95 C for 5 m.", [["cells", "ANATOMY", 31, 36], ["urea", "CHEMICAL", 220, 224], ["Tris-HCl", "CHEMICAL", 240, 248], ["urea", "CHEMICAL", 263, 267], ["sodium dodecyl sulfate", "CHEMICAL", 272, 294], ["ethylenediaminetetraacetic acid", "CHEMICAL", 309, 340], ["bromophenol blue", "CHEMICAL", 355, 371], ["dithiothreitol", "CHEMICAL", 383, 397], ["FITC", "CHEMICAL", 67, 71], ["urea", "CHEMICAL", 220, 224], ["Tris-HCl", "CHEMICAL", 240, 248], ["urea", "CHEMICAL", 263, 267], ["sodium dodecyl sulfate", "CHEMICAL", 272, 294], ["SDS", "CHEMICAL", 296, 299], ["ethylenediaminetetraacetic acid", "CHEMICAL", 309, 340], ["bromophenol blue", "CHEMICAL", 355, 371], ["dithiothreitol", "CHEMICAL", 383, 397], ["cells", "CELL", 31, 36], ["FITC", "SIMPLE_CHEMICAL", 67, 71], ["anti-RABV N mAb", "SIMPLE_CHEMICAL", 83, 98], ["urea", "SIMPLE_CHEMICAL", 220, 224], ["urea", "SIMPLE_CHEMICAL", 263, 267], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 272, 294], ["SDS", "SIMPLE_CHEMICAL", 296, 299], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 309, 340], ["bromophenol blue", "SIMPLE_CHEMICAL", 355, 371], ["dithiothreitol", "SIMPLE_CHEMICAL", 383, 397], ["FITC-conjugated anti-RABV N mAb", "PROTEIN", 67, 98], ["cells", "TEST", 31, 36], ["a FITC", "TEST", 65, 71], ["conjugated anti-RABV N mAb", "TREATMENT", 72, 98], ["live virus", "PROBLEM", 125, 135], ["Protein gelTo", "TEST", 136, 149], ["inactivated virus particles", "PROBLEM", 172, 199], ["urea buffer", "TREATMENT", 220, 231], ["Tris", "TEST", 240, 244], ["pH", "TEST", 250, 252], ["urea", "TEST", 263, 267], ["sodium dodecyl sulfate", "TREATMENT", 272, 294], ["SDS", "TEST", 296, 299], ["mM ethylenediaminetetraacetic acid", "TEST", 306, 340], ["pH", "TEST", 342, 344], ["bromophenol blue", "TREATMENT", 355, 371], ["0.5 M dithiothreitol", "TREATMENT", 377, 397]]], ["Three micrograms of protein were resolved on a 10% SDS-polyacrylamide gel and stained with SYPRO Ruby Protein Gel Stain (Invitrogen) according to the manufacturer's specifications.", [["SDS", "CHEMICAL", 51, 54], ["polyacrylamide", "CHEMICAL", 55, 69], ["protein", "TEST", 20, 27], ["a 10% SDS", "TREATMENT", 45, 54], ["polyacrylamide gel", "TREATMENT", 55, 73], ["SYPRO Ruby Protein Gel Stain", "TEST", 91, 119], ["Invitrogen", "TEST", 121, 131]]], ["The gel was then exposed under UV light for 430 ms.Protein gelPathogenicity experiments Related to Figure S4 .", [["The gel", "TREATMENT", 0, 7], ["Protein gelPathogenicity experiments", "PROBLEM", 51, 87], ["Figure S4", "PROBLEM", 99, 108], ["Figure S4", "OBSERVATION", 99, 108]]], ["Four groups of Swiss Webster mice (Charles River, 5 male and 5 female per group, age 6 to 10 weeks) were intranasally (i.n.) infected with 10 5 focus-forming units (FFU) of live virus diluted in 20 mL phosphate-buffered saline (PBS).", [["phosphate", "CHEMICAL", 201, 210], ["phosphate", "CHEMICAL", 201, 210], ["Swiss Webster mice", "ORGANISM", 15, 33], ["Charles River", "ORGANISM", 35, 48], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 201, 226], ["mice", "SPECIES", 29, 33], ["Swiss Webster mice", "SPECIES", 15, 33], ["live virus", "TREATMENT", 173, 183], ["buffered saline (PBS", "TREATMENT", 211, 231]]], ["The mice were weighed and monitored daily until day 21 post-infection and further monitored until day 30.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["Mice exhibiting signs of disease or that lost greater than 25% weight were euthanized.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["disease", "PROBLEM", 25, 32], ["disease", "OBSERVATION", 25, 32], ["lost", "OBSERVATION_MODIFIER", 41, 45], ["greater", "OBSERVATION_MODIFIER", 46, 53]]], ["To assess a peripheral route of infection, 4 groups of Swiss Webster mice were intramuscularly (i.m.) infected with 10 5 FFU of live virus diluted in 100 mL PBS, distributed equally to muscle of both hind limbs.", [["muscle", "ANATOMY", 185, 191], ["hind limbs", "ANATOMY", 200, 210], ["infection", "DISEASE", 32, 41], ["Swiss Webster mice", "ORGANISM", 55, 73], ["muscle", "ORGAN", 185, 191], ["hind limbs", "ORGANISM_SUBDIVISION", 200, 210], ["mice", "SPECIES", 69, 73], ["Swiss Webster", "SPECIES", 55, 68], ["mice", "SPECIES", 69, 73], ["infection", "PROBLEM", 32, 41], ["Swiss Webster mice", "TREATMENT", 55, 73], ["live virus", "TREATMENT", 128, 138], ["peripheral", "ANATOMY", 12, 22], ["infection", "OBSERVATION", 32, 41], ["muscle", "ANATOMY", 185, 191], ["both", "ANATOMY_MODIFIER", 195, 199], ["hind limbs", "ANATOMY", 200, 210]]], ["The mice were weighed and monitored daily until day 21 post-infection and further monitored until day 28.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["Mice exhibiting signs of disease or that lost greater than 25% weight were euthanized.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["disease", "PROBLEM", 25, 32], ["disease", "OBSERVATION", 25, 32], ["lost", "OBSERVATION_MODIFIER", 41, 45], ["greater", "OBSERVATION_MODIFIER", 46, 53]]], ["Survival was analyzed using the log-rank Mantel-Cox test in GraphPad Prism.Protein gelImmunization and challenge Swiss Webster mice (Charles River) were used in this study: groups of female mice, age 6 to 10 weeks, were immunized i.m. with 10 mg BPL-inactivated virus diluted in 100 mL phosphate-buffered saline (PBS) and distributed equally to muscle of both hind limbs.", [["muscle", "ANATOMY", 345, 351], ["hind limbs", "ANATOMY", 360, 370], ["BPL", "CHEMICAL", 246, 249], ["phosphate", "CHEMICAL", 286, 295], ["BPL", "CHEMICAL", 246, 249], ["phosphate", "CHEMICAL", 286, 295], ["Swiss Webster mice", "ORGANISM", 113, 131], ["Charles River", "ORGANISM", 133, 146], ["mice", "ORGANISM", 190, 194], ["BPL", "SIMPLE_CHEMICAL", 246, 249], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 286, 311], ["muscle", "ORGAN", 345, 351], ["hind limbs", "ORGANISM_SUBDIVISION", 360, 370], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 190, 194], ["Cox test", "TEST", 48, 56], ["Protein gelImmunization", "TREATMENT", 75, 98], ["10 mg BPL", "TREATMENT", 240, 249], ["phosphate", "TREATMENT", 286, 295], ["buffered saline (PBS", "TREATMENT", 296, 316], ["muscle", "ANATOMY", 345, 351], ["both", "ANATOMY_MODIFIER", 355, 359], ["hind limbs", "ANATOMY", 360, 370]]], ["In groups which received glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE, IDRI), 20 mL of 0.25 mg/ml adjuvant were included in the 100 mL total per mouse.", [["glucopyranosyl", "CHEMICAL", 25, 39], ["GLA-SE", "CHEMICAL", 72, 78], ["glucopyranosyl", "CHEMICAL", 25, 39], ["glucopyranosyl lipid", "SIMPLE_CHEMICAL", 25, 45], ["GLA", "SIMPLE_CHEMICAL", 72, 75], ["mouse", "ORGANISM", 154, 159], ["mouse", "SPECIES", 154, 159], ["mouse", "SPECIES", 154, 159], ["glucopyranosyl lipid adjuvant", "TREATMENT", 25, 54], ["GLA-SE, IDRI)", "TREATMENT", 72, 85], ["adjuvant", "TREATMENT", 107, 115], ["stable", "OBSERVATION_MODIFIER", 55, 61]]], ["Mice were immunized on days 0, 7, and 28.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["Blood was drawn (100 mL via the retro-orbital route) weekly and centrifuged at 10,000 rpm for 10 m for serum collection.", [["Blood", "ANATOMY", 0, 5], ["retro-orbital", "ANATOMY", 32, 45], ["serum", "ANATOMY", 103, 108], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["Blood", "TEST", 0, 5], ["serum collection", "TEST", 103, 119]]], ["Serum was analyzed from individual mice (unless noted).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["mice", "ORGANISM", 35, 39], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["Serum", "TEST", 0, 5]]], ["One set of mice (Figures 3, 4 , 5, and 6) was challenged on day 58 post-immunization (p.i.) with either SPNB or rMOKV.", [["SPNB", "CHEMICAL", 104, 108], ["mice", "ORGANISM", 11, 15], ["rMOKV", "PROTEIN", 112, 117], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["Figures", "TEST", 17, 24], ["immunization", "TREATMENT", 72, 84]]], ["10 5 FFU of live virus were e5 Cell Reports 32, 107920, July 21, 2020 Article ll OPEN ACCESS diluted in 20 mL PBS was administered i.n.", [["Cell", "ANATOMY", 31, 35], ["live virus", "PROBLEM", 12, 22], ["Article ll OPEN ACCESS", "TREATMENT", 70, 92], ["20 mL PBS", "TREATMENT", 104, 113]]], ["The mice were weighed and monitored daily until day 21 post-infection and further monitored until day 37.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["Mice exhibiting signs of disease or that lost greater than 25% weight were euthanized.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["disease", "PROBLEM", 25, 32], ["disease", "OBSERVATION", 25, 32], ["lost", "OBSERVATION_MODIFIER", 41, 45], ["greater", "OBSERVATION_MODIFIER", 46, 53]]], ["Survival was analyzed using the log-rank Mantel-Cox test in GraphPad Prism.", [["Cox test", "TEST", 48, 56]]], ["The other set of mice (Figure 7 ) was terminally bled via heart puncture on day 47 p.i. and euthanized.Protein gelProduction of soluble RABV and MOKV G To produce soluble RABV G, BEAS-2b cells were inoculated with VSVDG-GFP-RABVG at MOI 0.01.", [["heart", "ANATOMY", 58, 63], ["BEAS-2b cells", "ANATOMY", 179, 192], ["mice", "ORGANISM", 17, 21], ["heart", "ORGAN", 58, 63], ["RABV", "ORGANISM", 136, 140], ["MOKV G", "GENE_OR_GENE_PRODUCT", 145, 151], ["RABV", "ORGANISM", 171, 175], ["BEAS-2b cells", "CELL", 179, 192], ["GFP", "GENE_OR_GENE_PRODUCT", 220, 223], ["MOKV G", "PROTEIN", 145, 151], ["BEAS-2b cells", "CELL_LINE", 179, 192], ["VSVDG", "PROTEIN", 214, 219], ["GFP", "PROTEIN", 220, 223], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["RABV", "SPECIES", 136, 140], ["RABV", "SPECIES", 171, 175], ["heart puncture", "TEST", 58, 72], ["soluble RABV", "TREATMENT", 128, 140], ["MOKV G", "TREATMENT", 145, 151], ["soluble RABV G", "TEST", 163, 177], ["BEAS", "TEST", 179, 183], ["VSVDG", "TEST", 214, 219], ["GFP", "TEST", 220, 223], ["heart", "ANATOMY", 58, 63], ["puncture", "OBSERVATION", 64, 72]]], ["Three days post-infection, supernatant was collected, filtered through a 0.45 mm filter and concentrated by tangential flow filtration.", [["supernatant", "ANATOMY", 27, 38], ["a 0.45 mm filter", "TREATMENT", 71, 87], ["tangential flow filtration", "TREATMENT", 108, 134], ["tangential", "OBSERVATION_MODIFIER", 108, 118], ["flow filtration", "OBSERVATION", 119, 134]]], ["Concentrated virus was purified over 20% sucrose cushion in a SW 32 Ti rotor (Beckman) at 25,000 rpm for 2 h.", [["sucrose", "CHEMICAL", 41, 48], ["sucrose", "CHEMICAL", 41, 48], ["Ti", "CHEMICAL", 68, 70], ["Concentrated virus", "PROBLEM", 0, 18], ["a SW 32 Ti rotor (Beckman)", "TREATMENT", 60, 86], ["virus", "OBSERVATION", 13, 18]]], ["Pellets were resuspended in TEN buffer with 5% sucrose.", [["Pellets", "ANATOMY", 0, 7], ["sucrose", "CHEMICAL", 47, 54], ["sucrose", "CHEMICAL", 47, 54], ["sucrose", "SIMPLE_CHEMICAL", 47, 54], ["Pellets", "TREATMENT", 0, 7], ["5% sucrose", "TREATMENT", 44, 54]]], ["To solubilize the glycoprotein, octyglucopyranoside (OGP, Fisher) was added to 2% final concentration and solution was incubated at room temperature with constant mixing for 30 m.", [["octyglucopyranoside", "CHEMICAL", 32, 51], ["OGP", "CHEMICAL", 53, 56], ["octyglucopyranoside", "CHEMICAL", 32, 51], ["octyglucopyranoside", "SIMPLE_CHEMICAL", 32, 51], ["OGP", "SIMPLE_CHEMICAL", 53, 56], ["glycoprotein", "PROTEIN", 18, 30], ["the glycoprotein", "TREATMENT", 14, 30], ["octyglucopyranoside (OGP", "TREATMENT", 32, 56]]], ["The suspension was spun at max speed in a benchtop centrifuge for 3 m to pellet debris.", [["The suspension", "TREATMENT", 0, 14], ["a benchtop centrifuge", "TREATMENT", 40, 61], ["suspension", "OBSERVATION_MODIFIER", 4, 14], ["debris", "OBSERVATION", 80, 86]]], ["Pellets were treated with OGP in the same manner 2 more times.", [["Pellets", "ANATOMY", 0, 7], ["OGP", "CHEMICAL", 26, 29], ["OGP", "CHEMICAL", 26, 29], ["OGP", "SIMPLE_CHEMICAL", 26, 29], ["Pellets", "TREATMENT", 0, 7], ["OGP", "TREATMENT", 26, 29]]], ["Pooled supernatants from all 3 extractions were spun in a SW 55 Ti rotor (Beckman) at 45,000 rpm for 1.5 h.", [["supernatants", "ANATOMY", 7, 19], ["Ti", "CHEMICAL", 64, 66], ["Pooled supernatants", "PROBLEM", 0, 19], ["all 3 extractions", "TREATMENT", 25, 42]]], ["Supernatant containing soluble G was analyzed for protein concentration by BCA (Pierce), and for purity by SDS-PAGE and western blot.Protein gelTo produce soluble MOKV G, BEAS-2b cells were transfected with pCAGGS-coMOKVG using the XtremeGene 9 transfection reagent (Millipore-Sigma).", [["Supernatant", "ANATOMY", 0, 11], ["BEAS-2b cells", "ANATOMY", 171, 184], ["XtremeGene 9", "CHEMICAL", 232, 244], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["BCA", "SIMPLE_CHEMICAL", 75, 78], ["MOKV G", "GENE_OR_GENE_PRODUCT", 163, 169], ["BEAS-2b cells", "CELL", 171, 184], ["pCAGGS-coMOKVG", "GENE_OR_GENE_PRODUCT", 207, 221], ["soluble G", "PROTEIN", 23, 32], ["Protein gelTo", "PROTEIN", 133, 146], ["MOKV G", "PROTEIN", 163, 169], ["BEAS-2b cells", "CELL_LINE", 171, 184], ["pCAGGS", "PROTEIN", 207, 213], ["coMOKVG", "PROTEIN", 214, 221], ["XtremeGene 9 transfection reagent", "PROTEIN", 232, 265], ["Supernatant containing soluble G", "TREATMENT", 0, 32], ["Protein gelTo", "TEST", 133, 146], ["BEAS", "TEST", 171, 175], ["pCAGGS", "TEST", 207, 213], ["the XtremeGene 9 transfection reagent", "TREATMENT", 228, 265]]], ["Two days post-transfection, cells were infected with MOKV G PTVS (described below), and 2 days postinfection, supernatant containing MOKVG pseudotyped VSV was collected.", [["cells", "ANATOMY", 28, 33], ["supernatant", "ANATOMY", 110, 121], ["cells", "CELL", 28, 33], ["pseudotyped", "ORGANISM", 139, 150], ["VSV", "ORGANISM", 151, 154], ["pseudotyped", "SPECIES", 139, 150], ["VSV", "SPECIES", 151, 154], ["MOKV G PTVS", "TREATMENT", 53, 64], ["MOKVG pseudotyped VSV", "TREATMENT", 133, 154], ["pseudotyped VSV", "OBSERVATION", 139, 154]]], ["MOKV G was solubilized from the pseudotype virions in the same manner as RABV G.ELISATo assess vaccine immunogenicity, mouse sera were analyzed by enzyme-linked immunosorbent assay (ELISA), probing for reactivity against either soluble RABV G or MOKV G (production described above).", [["sera", "ANATOMY", 125, 129], ["G", "GENE_OR_GENE_PRODUCT", 5, 6], ["pseudotype", "ORGANISM", 32, 42], ["RABV", "ORGANISM", 73, 77], ["mouse", "ORGANISM", 119, 124], ["sera", "ORGANISM_SUBSTANCE", 125, 129], ["RABV G", "GENE_OR_GENE_PRODUCT", 236, 242], ["MOKV G", "GENE_OR_GENE_PRODUCT", 246, 252], ["RABV G", "PROTEIN", 236, 242], ["MOKV G", "PROTEIN", 246, 252], ["mouse", "SPECIES", 119, 124], ["MOKV", "SPECIES", 0, 4], ["RABV", "SPECIES", 73, 77], ["mouse", "SPECIES", 119, 124], ["RABV", "SPECIES", 236, 240], ["the pseudotype virions", "TREATMENT", 28, 50], ["RABV G.ELISATo", "TREATMENT", 73, 87], ["mouse sera", "TEST", 119, 129], ["enzyme", "TEST", 147, 153], ["immunosorbent assay", "TEST", 161, 180]]], ["Mouse sera from days 0, 7, 14, 35, and 56 were analyzed individually in triplicate, except mock infected sera which was pooled.", [["sera", "ANATOMY", 6, 10], ["sera", "ANATOMY", 105, 109], ["Mouse", "ORGANISM", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse sera", "TEST", 0, 10], ["mock infected sera", "PROBLEM", 91, 109]]], ["Immulon 96-well plates (Nunc) were coated with soluble G diluted in carbonate buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 [pH 9.5]).", [["Immulon", "CHEMICAL", 0, 7], ["Na", "CHEMICAL", 92, 94], ["carbonate", "CHEMICAL", 68, 77], ["Na 2 CO 3", "CHEMICAL", 92, 101], ["NaHCO 3", "CHEMICAL", 110, 117], ["carbonate", "SIMPLE_CHEMICAL", 68, 77], ["Na 2 CO 3", "SIMPLE_CHEMICAL", 92, 101], ["Immulon", "TEST", 0, 7], ["soluble G diluted in carbonate buffer", "TREATMENT", 47, 84], ["Na", "TEST", 92, 94], ["CO", "TEST", 97, 99], ["mM NaHCO", "TEST", 107, 115], ["pH", "TEST", 119, 121]]], ["For RABV G, 50 ng in 100 mL buffer was used per well and for MOKV G, 25 ng in 50 mL per well.", [["RABV", "ORGANISM", 4, 8], ["RABV", "SPECIES", 4, 8], ["RABV G", "TREATMENT", 4, 10]]], ["Plates were incubated overnight at 4 C. Plates were then washed 3 times with 300 mL per well of PBS containing 0.05% Tween 20 (PBST), then blocked with 5% milk in PBST (250 mL per well) for 2 h at RT, shaking.", [["milk", "ANATOMY", 155, 159], ["Tween 20", "CHEMICAL", 117, 125], ["milk", "ORGANISM_SUBSTANCE", 155, 159], ["Plates", "TEST", 0, 6], ["PBS", "TREATMENT", 96, 99], ["5% milk in PBST", "TREATMENT", 152, 167], ["shaking", "PROBLEM", 201, 208]]], ["Plates were washed again, then coated with primary buffer (PBS with 0.5% bovine serum albumen), either 100 mL per well (RABV G plates) or 50 mL per well (MOKV G plates).", [["serum", "ANATOMY", 80, 85], ["bovine", "ORGANISM", 73, 79], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["albumen", "ORGANISM_SUBSTANCE", 86, 93], ["bovine", "SPECIES", 73, 79], ["bovine", "SPECIES", 73, 79], ["RABV", "SPECIES", 120, 124], ["primary buffer (PBS", "TREATMENT", 43, 62], ["0.5% bovine serum albumen", "TREATMENT", 68, 93], ["RABV G plates", "TREATMENT", 120, 133], ["MOKV G plates", "TREATMENT", 154, 167]]], ["Serum was diluted 3-fold down the plate in triplicate, starting at either 1:100 or 1:300, then plates were incubated overnight at 4 C. Plates were then washed 3 times and coated with PBST containing HRP-conjugated Goat antimouse IgG (H+L) at 1:10,000.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["HRP", "SIMPLE_CHEMICAL", 199, 202], ["HRP", "PROTEIN", 199, 202], ["Goat antimouse IgG", "PROTEIN", 214, 232], ["H+L", "PROTEIN", 234, 237], ["Goat", "SPECIES", 214, 218], ["Goat", "SPECIES", 214, 218], ["Serum", "TEST", 0, 5], ["Plates", "TEST", 135, 141], ["PBST", "TEST", 183, 187], ["HRP", "TEST", 199, 202], ["conjugated Goat antimouse IgG", "TREATMENT", 203, 232]]], ["After incubation for 2 h at RT, plates were washed and 200 mL of o-phenylenediamine dihydrochloride (OPD) substrate (Sigma) was added to each well.", [["o-phenylenediamine dihydrochloride", "CHEMICAL", 65, 99], ["o-phenylenediamine dihydrochloride", "CHEMICAL", 65, 99], ["OPD", "CHEMICAL", 101, 104], ["o-phenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 65, 99], ["OPD", "SIMPLE_CHEMICAL", 101, 104], ["2 h at RT, plates", "TREATMENT", 21, 38], ["o-phenylenediamine dihydrochloride (OPD) substrate (Sigma)", "TREATMENT", 65, 123]]], ["After a 15 m incubation, the reaction was stopped by the addition of 50 mL 3M H 2 SO 4 per well.", [["H 2 SO 4", "CHEMICAL", 78, 86], ["a 15 m incubation", "TREATMENT", 6, 23], ["the reaction", "PROBLEM", 25, 37]]], ["Optical density was determined at 490 nm (OD490).", [["density", "OBSERVATION", 8, 15]]], ["Individual mouse data were analyzed in GraphPad Prism using a sigmoidal dose-response fit (variable slope) to determine 50% effective concentration [EC 50 ].", [["mouse", "ORGANISM", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["Individual mouse data", "TEST", 0, 21], ["a sigmoidal dose", "TREATMENT", 60, 76]]], ["Data from groups were also averaged (n = 10) and plotted.RFFIT neutralization assaysSerum was first heat inactivated at 56 C for 30 m.", [["RFFIT", "SIMPLE_CHEMICAL", 57, 62], ["assaysSerum", "SIMPLE_CHEMICAL", 78, 89], ["Data from groups", "TEST", 0, 16]]], ["Mouse sera from days 0, 7, 14, 21, 28, 35, 56 and at necropsy (surviving mice only) were analyzed individually in duplicate, except mock infected sera which was pooled.", [["sera", "ANATOMY", 6, 10], ["sera", "ANATOMY", 146, 150], ["Mouse", "ORGANISM", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["mice", "ORGANISM", 73, 77], ["sera", "ORGANISM_SUBSTANCE", 146, 150], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 73, 77], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 73, 77], ["Mouse sera", "TEST", 0, 10], ["mock infected sera", "PROBLEM", 132, 150]]], ["Rabies virus neutralizing activity was determined using the rapid fluorescent focus inhibition test assay (RFFIT) (Wunner and Jackson, 2010) .", [["Rabies virus", "ORGANISM", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus neutralizing activity", "PROBLEM", 0, 34], ["the rapid fluorescent focus inhibition test assay", "TEST", 56, 105]]], ["Mouse neuroblastoma (NA) cells were seeded in 96-well plates 2 days prior to the assay (30,000 cells per well).", [["neuroblastoma (NA) cells", "ANATOMY", 6, 30], ["cells", "ANATOMY", 95, 100], ["neuroblastoma", "DISEASE", 6, 19], ["Mouse", "ORGANISM", 0, 5], ["neuroblastoma (NA) cells", "CELL", 6, 30], ["cells", "CELL", 95, 100], ["Mouse neuroblastoma (NA) cells", "CELL_LINE", 0, 30], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse neuroblastoma (NA) cells", "PROBLEM", 0, 30], ["the assay", "TEST", 77, 86], ["neuroblastoma", "OBSERVATION", 6, 19]]], ["Serum samples were 2-fold serially diluted in duplicate in 96-well plates, starting from at a dilution of 1:50 (unless otherwise noted) in 50 mL Opti-MEM (Life Technologies).", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples", "TEST", 0, 13], ["well plates", "OBSERVATION_MODIFIER", 62, 73]]], ["The U.S. standard rabies immune globulin was used at 2 IU/ml.", [["rabies", "ORGANISM", 18, 24], ["globulin", "GENE_OR_GENE_PRODUCT", 32, 40], ["rabies", "SPECIES", 18, 24], ["The U.S. standard rabies immune globulin", "TREATMENT", 0, 40]]], ["Working dilutions of RABV strain CVS-11 were prepared in Opti-MEM, and 5 mL the working dilution was added to each well containing diluted serum.", [["serum", "ANATOMY", 139, 144], ["RABV", "ORGANISM", 21, 25], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["RABV strain CVS-11", "SPECIES", 21, 39], ["RABV strain CVS", "TEST", 21, 36], ["the working dilution", "TREATMENT", 76, 96]]], ["Plates were incubated for 1 h at 34 C. Medium was removed from NA cells and diluted serum/virus mixtures were transferred to the cell plates.", [["NA cells", "ANATOMY", 63, 71], ["serum", "ANATOMY", 84, 89], ["cell", "ANATOMY", 129, 133], ["NA cells", "CELL", 63, 71], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["cell", "CELL", 129, 133], ["NA cells", "CELL_LINE", 63, 71], ["NA cells", "TREATMENT", 63, 71], ["diluted serum/virus mixtures", "TREATMENT", 76, 104], ["cell plates", "OBSERVATION", 129, 140]]], ["After 2 h incubation at 34 C, media was aspirated, replaced with fresh Opti-MEM, and plates were incubated for 22 h at 34 C with 5% CO 2 .", [["CO 2", "CHEMICAL", 132, 136], ["fresh Opti-MEM", "TREATMENT", 65, 79]]], ["Plates were then fixed with 80% acetone and stained with FITC-conjugated anti-RABV N antibody.", [["acetone", "CHEMICAL", 32, 39], ["acetone", "CHEMICAL", 32, 39], ["FITC", "CHEMICAL", 57, 61], ["acetone", "SIMPLE_CHEMICAL", 32, 39], ["FITC", "SIMPLE_CHEMICAL", 57, 61], ["anti-RABV N antibody", "SIMPLE_CHEMICAL", 73, 93], ["FITC-conjugated anti-RABV N antibody", "PROTEIN", 57, 93], ["Plates", "TEST", 0, 6], ["80% acetone", "TREATMENT", 28, 39], ["FITC", "TEST", 57, 61]]], ["50% endpoint titers were calculated using the Reed-Muench method and converted to international units (IU) per milliliter by comparing to the standard.RFFIT neutralization assaysGeneration of MOKV G PTVs MOKV G pseudotype viruses (MOKV G PTVs) are single-round infectious particles comprised of MOKV Gs on the surface of the virion and a VSV genome lacking G and containing Nanoluciferase and EGFP (VSVDG-NanoLuc-EGFP) packaged within the virion (Figure S7) .", [["surface", "ANATOMY", 310, 317], ["MOKV G PTVs", "ORGANISM", 192, 203], ["MOKV G pseudotype viruses", "ORGANISM", 204, 229], ["MOKV G PTVs", "ORGANISM", 231, 242], ["Gs", "GENE_OR_GENE_PRODUCT", 300, 302], ["surface", "CELLULAR_COMPONENT", 310, 317], ["virion", "CELLULAR_COMPONENT", 325, 331], ["VSV", "ORGANISM", 338, 341], ["G", "GENE_OR_GENE_PRODUCT", 357, 358], ["Nanoluciferase", "GENE_OR_GENE_PRODUCT", 374, 388], ["EGFP", "GENE_OR_GENE_PRODUCT", 393, 397], ["VSVDG-NanoLuc-EGFP", "GENE_OR_GENE_PRODUCT", 399, 417], ["Gs", "PROTEIN", 300, 302], ["VSV genome", "DNA", 338, 348], ["Nanoluciferase", "PROTEIN", 374, 388], ["EGFP", "DNA", 393, 397], ["VSVDG", "PROTEIN", 399, 404], ["NanoLuc", "PROTEIN", 405, 412], ["EGFP", "PROTEIN", 413, 417], ["G pseudotype viruses", "SPECIES", 209, 229], ["MOKV", "SPECIES", 295, 299], ["VSV", "SPECIES", 338, 341], ["endpoint titers", "TEST", 4, 19], ["the Reed-Muench method", "TREATMENT", 42, 64], ["neutralization assays", "TEST", 157, 178], ["MOKV G PTVs", "TREATMENT", 192, 203], ["MOKV", "TEST", 204, 208], ["G pseudotype viruses", "PROBLEM", 209, 229], ["MOKV G PTVs", "TREATMENT", 231, 242], ["the virion", "TREATMENT", 321, 331], ["a VSV genome lacking G", "TREATMENT", 336, 358], ["Nanoluciferase", "TREATMENT", 374, 388], ["EGFP", "TEST", 393, 397], ["VSVDG", "TEST", 399, 404], ["NanoLuc-EGFP)", "TREATMENT", 405, 418], ["infectious", "OBSERVATION", 261, 271]]], ["To generate MOKV G PTVs, the human lung cell line BEAS-2B was first transfected with an expression vector containing human codon-optimized MOKV G (pCAGGS-coMOKVG) using X-tremeGENE 9 transfection reagent (Millipore Sigma).", [["lung cell line BEAS-2B", "ANATOMY", 35, 57], ["MOKV G PTVs", "GENE_OR_GENE_PRODUCT", 12, 23], ["human", "ORGANISM", 29, 34], ["lung cell line BEAS-2B", "CELL", 35, 57], ["human", "ORGANISM", 117, 122], ["MOKV G", "GENE_OR_GENE_PRODUCT", 139, 145], ["MOKV G PTVs", "CELL_LINE", 12, 23], ["human lung cell line", "CELL_LINE", 29, 49], ["BEAS-2B", "CELL_LINE", 50, 57], ["expression vector", "DNA", 88, 105], ["human codon", "DNA", 117, 128], ["MOKV G", "DNA", 139, 145], ["pCAGGS", "DNA", 147, 153], ["coMOKVG", "DNA", 154, 161], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 117, 122], ["MOKV G PTVs", "TREATMENT", 12, 23], ["the human lung cell line BEAS", "TEST", 25, 54], ["an expression vector", "TREATMENT", 85, 105], ["human codon", "TREATMENT", 117, 128], ["optimized MOKV G (pCAGGS-coMOKVG)", "TREATMENT", 129, 162], ["X-tremeGENE 9 transfection reagent", "TREATMENT", 169, 203], ["lung", "ANATOMY", 35, 39], ["cell line", "OBSERVATION", 40, 49]]], ["Two days post-transfection, cells were infected at an MOI of 1 with VSVDG-NanoLuc-EGFP pseudotyped with an irrelevant glycoprotein (Lassa fever virus glycoprotein complex) for initial infection (Abreu-Mota et al., 2018) .", [["cells", "ANATOMY", 28, 33], ["Lassa fever", "DISEASE", 132, 143], ["infection", "DISEASE", 184, 193], ["cells", "CELL", 28, 33], ["VSVDG", "GENE_OR_GENE_PRODUCT", 68, 73], ["NanoLuc", "GENE_OR_GENE_PRODUCT", 74, 81], ["EGFP", "GENE_OR_GENE_PRODUCT", 82, 86], ["Lassa fever virus", "ORGANISM", 132, 149], ["NanoLuc", "DNA", 74, 81], ["glycoprotein", "PROTEIN", 118, 130], ["Lassa fever virus glycoprotein complex", "PROTEIN", 132, 170], ["Lassa fever virus", "SPECIES", 132, 149], ["Lassa fever virus", "SPECIES", 132, 149], ["an MOI", "TEST", 51, 57], ["VSVDG", "TEST", 68, 73], ["NanoLuc", "TREATMENT", 74, 81], ["EGFP pseudotyped", "PROBLEM", 82, 98], ["an irrelevant glycoprotein", "PROBLEM", 104, 130], ["Lassa fever virus glycoprotein complex", "TREATMENT", 132, 170], ["initial infection", "PROBLEM", 176, 193], ["infection", "OBSERVATION", 184, 193]]], ["Two h post-infection, the inoculum was removed and cells were washed 3 times with PBS before media was replaced.", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["the inoculum", "TREATMENT", 22, 34], ["cells", "TREATMENT", 51, 56], ["PBS before media", "TREATMENT", 82, 98], ["post-infection", "OBSERVATION", 6, 20], ["inoculum", "OBSERVATION_MODIFIER", 26, 34]]], ["Two days post-infection, cells were inspected for GFP expression under a fluorescent microscope and supernatant containing MOKV G PTVs was collected.", [["cells", "ANATOMY", 25, 30], ["supernatant", "ANATOMY", 100, 111], ["cells", "CELL", 25, 30], ["GFP", "GENE_OR_GENE_PRODUCT", 50, 53], ["MOKV G PTVs", "SIMPLE_CHEMICAL", 123, 134], ["GFP", "PROTEIN", 50, 53], ["cells", "PROBLEM", 25, 30], ["GFP expression", "PROBLEM", 50, 64], ["a fluorescent microscope", "TEST", 71, 95], ["MOKV G PTVs", "TREATMENT", 123, 134]]], ["MOKV G PTVs were passaged 3 times prior to use in the neutralization assay to ensure a pure population of virions.RFFIT neutralization assaysCell Reports 32, 107920, July 21, 2020 e6 MOKV G RABV G Chimeric G 1 Chimeric G 2 Figure S3 .", [["virions", "ANATOMY", 106, 113], ["Cell", "ANATOMY", 141, 145], ["Cell", "CELL", 141, 145], ["MOKV", "SPECIES", 0, 4], ["MOKV G PTVs", "TREATMENT", 0, 11], ["the neutralization assay", "TEST", 50, 74], ["a pure population of virions", "PROBLEM", 85, 113], ["MOKV", "TEST", 183, 187], ["RABV", "TEST", 190, 194], ["Chimeric", "TEST", 197, 205], ["G", "TEST", 206, 207], ["virions", "OBSERVATION", 106, 113], ["S3", "ANATOMY", 230, 232]]], ["Immunofluorescence of transfected chimeric lyssavirus glycoproteins.", [["lyssavirus glycoproteins", "GENE_OR_GENE_PRODUCT", 43, 67], ["transfected chimeric lyssavirus glycoproteins", "PROTEIN", 22, 67], ["Immunofluorescence", "TEST", 0, 18], ["transfected chimeric lyssavirus glycoproteins", "PROBLEM", 22, 67], ["transfected chimeric lyssavirus glycoproteins", "OBSERVATION", 22, 67]]], ["VERO cells transfected with pCAGGS expression plasmids containing the genes of either Chimeric G 1 (left column), Chimeric G 2 (second column), MOKV G (third column), or RABV G (fourth column).", [["VERO cells", "ANATOMY", 0, 10], ["VERO cells", "CELL", 0, 10], ["pCAGGS", "GENE_OR_GENE_PRODUCT", 28, 34], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 86, 98], ["Chimeric G 2", "GENE_OR_GENE_PRODUCT", 114, 126], ["MOKV G", "GENE_OR_GENE_PRODUCT", 144, 150], ["RABV G", "GENE_OR_GENE_PRODUCT", 170, 176], ["VERO cells", "CELL_LINE", 0, 10], ["pCAGGS expression plasmids", "DNA", 28, 54], ["Chimeric G 1", "DNA", 86, 98], ["Chimeric G 2", "DNA", 114, 126], ["MOKV G", "DNA", 144, 150], ["RABV G", "DNA", 170, 176], ["RABV", "SPECIES", 170, 174], ["VERO cells", "PROBLEM", 0, 10], ["pCAGGS expression plasmids", "TREATMENT", 28, 54], ["Chimeric G 2 (second column", "TEST", 114, 141], ["MOKV G (third column)", "PROBLEM", 144, 165], ["left", "ANATOMY_MODIFIER", 100, 104], ["column", "ANATOMY", 105, 111]]], ["Two days post-transfection, cells were fixed with 4% paraformaldehyde and stained with a DyLight 488-conjugated human anti-RABV G mAb 4C12 (top row), mouse anti-MOKV G sera (middle row) or mouse anti-RABV G sera (bottom row).", [["cells", "ANATOMY", 28, 33], ["sera", "ANATOMY", 168, 172], ["sera", "ANATOMY", 207, 211], ["paraformaldehyde", "CHEMICAL", 53, 69], ["DyLight 488", "CHEMICAL", 89, 100], ["cells", "CELL", 28, 33], ["paraformaldehyde", "SIMPLE_CHEMICAL", 53, 69], ["human", "ORGANISM", 112, 117], ["mouse", "ORGANISM", 150, 155], ["anti-MOKV G sera", "GENE_OR_GENE_PRODUCT", 156, 172], ["mouse", "ORGANISM", 189, 194], ["anti-RABV G sera", "GENE_OR_GENE_PRODUCT", 195, 211], ["DyLight 488-conjugated human anti-RABV G mAb 4C12", "PROTEIN", 89, 138], ["top row", "PROTEIN", 140, 147], ["human", "SPECIES", 112, 117], ["mouse", "SPECIES", 150, 155], ["mouse", "SPECIES", 189, 194], ["human", "SPECIES", 112, 117], ["mouse", "SPECIES", 150, 155], ["mouse", "SPECIES", 189, 194], ["cells", "TEST", 28, 33], ["4% paraformaldehyde", "TREATMENT", 50, 69], ["conjugated human anti-RABV G mAb", "TREATMENT", 101, 133], ["mouse anti-MOKV G sera (middle row)", "TREATMENT", 150, 185], ["mouse anti-RABV G sera (bottom row", "TREATMENT", 189, 223]]], ["Sera specific to RABV G and MOKV G both bind to Chimeric Gs 1 and 2, whereas they are not otherwise cross-reactive with the other glycoprotein.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["RABV G", "ORGANISM", 17, 23], ["MOKV G", "GENE_OR_GENE_PRODUCT", 28, 34], ["Chimeric Gs 1", "GENE_OR_GENE_PRODUCT", 48, 61], ["2", "GENE_OR_GENE_PRODUCT", 66, 67], ["RABV G and MOKV G", "DNA", 17, 34], ["Chimeric Gs 1 and 2", "DNA", 48, 67], ["glycoprotein", "PROTEIN", 130, 142], ["RABV", "SPECIES", 17, 21], ["Sera", "TREATMENT", 0, 4], ["RABV G", "TREATMENT", 17, 23], ["Chimeric Gs", "TEST", 48, 59]]], ["4C12 binds only to Chimeric G 1.", [["4C12", "SIMPLE_CHEMICAL", 0, 4], ["Chimeric G 1", "GENE_OR_GENE_PRODUCT", 19, 31], ["4C12", "PROTEIN", 0, 4], ["Chimeric G 1", "PROTEIN", 19, 31]]], ["Brightness adjusted with sets transfected with the same glycoprotein and stained with the same antibody.", [["glycoprotein", "PROTEIN", 56, 68]]], ["Scale bars represent 100 \u03bcm.", [["100 \u03bcm", "OBSERVATION_MODIFIER", 21, 27]]], ["Table S1 .", [["S1", "ANATOMY", 6, 8]]], ["RABV neutralizing titers.", [["RABV", "ORGANISM", 0, 4], ["RABV", "SPECIES", 0, 4], ["RABV neutralizing titers", "TEST", 0, 24], ["neutralizing titers", "OBSERVATION", 5, 24]]], ["RABV neutralizing titers in IU/ml as determined by RFFIT.", [["RABV", "ORGANISM", 0, 4], ["RABV", "SPECIES", 0, 4], ["RABV neutralizing titers", "TREATMENT", 0, 24]]], ["The 4 immunogen groups are labeled in the first column: mock immunization with PBS, and immunization with rRABV, rMOKV, and LyssaVax.", [["rRABV", "GENE_OR_GENE_PRODUCT", 106, 111], ["rMOKV", "GENE_OR_GENE_PRODUCT", 113, 118], ["LyssaVax", "GENE_OR_GENE_PRODUCT", 124, 132], ["rRABV", "PROTEIN", 106, 111], ["rMOKV", "PROTEIN", 113, 118], ["LyssaVax", "PROTEIN", 124, 132], ["rRABV", "SPECIES", 106, 111], ["The 4 immunogen groups", "TREATMENT", 0, 22], ["mock immunization", "TREATMENT", 56, 73], ["PBS", "TREATMENT", 79, 82], ["immunization", "TREATMENT", 88, 100], ["rRABV", "TREATMENT", 106, 111], ["rMOKV", "TREATMENT", 113, 118], ["LyssaVax", "TREATMENT", 124, 132]]], ["On day 58 after the start of immunizations, 5 mice from each group were challenged with either live SPBN or live rMOKV.", [["SPBN", "CHEMICAL", 100, 104], ["mice", "ORGANISM", 46, 50], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["immunizations", "TREATMENT", 29, 42]]], ["Level of detection (LOD) ranged from 0.2 IU/ml to 4 IU/ml based on starting serum dilution (1:5 to 1:50, respectively).", [["serum", "ANATOMY", 76, 81], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["detection", "TEST", 9, 18], ["LOD", "TEST", 20, 23], ["serum dilution", "TEST", 76, 90]]], ["All samples tested in duplicate except individual serum samples tested 1:5, which were tested in singlet.", [["samples", "ANATOMY", 4, 11], ["serum samples", "ANATOMY", 50, 63], ["serum samples", "ORGANISM_SUBSTANCE", 50, 63], ["All samples", "TEST", 0, 11], ["individual serum samples", "TEST", 39, 63]]]], "PMC7292903": [], "PMC7205639": [["IntroductionThe genetic code is degenerate.", [["degenerate", "PROBLEM", 32, 42]]], ["There are 61 triplet codons coding for 20 amino acids and 3 stop codons [1].", [["amino acids", "CHEMICAL", 42, 53], ["amino acids", "CHEMICAL", 42, 53], ["amino acids", "AMINO_ACID", 42, 53], ["61 triplet codons coding", "TREATMENT", 10, 34], ["20 amino acids", "TREATMENT", 39, 53]]], ["Therefore, each amino acid is encoded by several codons, with the exception of two amino acids (methionine and tryptophan).", [["amino acid", "CHEMICAL", 16, 26], ["amino acids", "CHEMICAL", 83, 94], ["methionine", "CHEMICAL", 96, 106], ["tryptophan", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 16, 26], ["amino acids", "CHEMICAL", 83, 94], ["methionine", "CHEMICAL", 96, 106], ["tryptophan", "CHEMICAL", 111, 121], ["amino acid", "AMINO_ACID", 16, 26], ["amino acids", "AMINO_ACID", 83, 94], ["methionine", "SIMPLE_CHEMICAL", 96, 106], ["tryptophan", "AMINO_ACID", 111, 121], ["each amino acid", "TEST", 11, 26], ["two amino acids", "TREATMENT", 79, 94], ["methionine and tryptophan)", "TREATMENT", 96, 122]]], ["This codon redundancy results in synonymous codon usage, whereby one amino acid is encoded by 2, 4, or 6 codons [2].", [["amino acid", "CHEMICAL", 69, 79], ["amino acid", "CHEMICAL", 69, 79], ["amino acid", "AMINO_ACID", 69, 79], ["This codon redundancy", "PROBLEM", 0, 21], ["synonymous codon usage", "TREATMENT", 33, 55], ["one amino acid", "TEST", 65, 79], ["synonymous codon", "OBSERVATION", 33, 49]]], ["Several previous studies have revealed that synonymous codons are utilized with different frequencies and are not randomly used by different genomes or genes.", [["Several previous studies", "TEST", 0, 24], ["synonymous codons", "PROBLEM", 44, 61], ["synonymous codons", "OBSERVATION", 44, 61]]], ["Each species preferentially uses different synonymous codons [5].", [["Each species", "PROBLEM", 0, 12], ["different synonymous codons", "TREATMENT", 33, 60]]], ["This results in a species-specific codon usage bias.IntroductionSimilarly, there are several tRNA species that carry the same amino acid.", [["amino acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 126, 136], ["amino acid", "AMINO_ACID", 126, 136], ["a species", "TEST", 16, 25], ["several tRNA species", "PROBLEM", 85, 105], ["the same amino acid", "TREATMENT", 117, 136], ["tRNA species", "OBSERVATION", 93, 105]]], ["These tRNA species are called isoacceptors [6].", [["These tRNA species", "PROBLEM", 0, 18]]], ["Codons and anti-codons in tRNA do not interact in a one-to-one fashion [7].", [["anti-codons", "PROTEIN", 11, 22], ["Codons and anti-codons in tRNA", "TREATMENT", 0, 30]]], ["Base pairing at the third codon position is wobble; for example, G can pair with both cytosine (C) and uracil (U) [8].", [["cytosine", "CHEMICAL", 86, 94], ["uracil", "CHEMICAL", 103, 109], ["cytosine", "CHEMICAL", 86, 94], ["C", "CHEMICAL", 96, 97], ["uracil", "CHEMICAL", 103, 109], ["cytosine", "SIMPLE_CHEMICAL", 86, 94], ["C", "SIMPLE_CHEMICAL", 96, 97], ["uracil", "SIMPLE_CHEMICAL", 103, 109], ["third codon position", "DNA", 20, 40], ["both cytosine (C) and uracil (U)", "TEST", 81, 113], ["wobble", "OBSERVATION_MODIFIER", 44, 50]]], ["It has been demonstrated that tRNA modification directly affects tRNA and mRNA wobble base pairing [9, 10].", [["tRNA", "CELLULAR_COMPONENT", 65, 69], ["tRNA modification", "TREATMENT", 30, 47], ["mRNA wobble base pairing", "TEST", 74, 98], ["tRNA modification", "OBSERVATION", 30, 47]]], ["Both the available tRNA isoacceptors and tRNA modification change with the cell cycle, and they can be altered by cellular stresses [11, 12].", [["cell", "ANATOMY", 75, 79], ["cellular", "ANATOMY", 114, 122], ["cell", "CELL", 75, 79], ["cellular", "CELL", 114, 122], ["tRNA isoacceptors", "PROTEIN", 19, 36], ["tRNA isoacceptors", "TREATMENT", 19, 36], ["tRNA modification change", "TREATMENT", 41, 65], ["the cell cycle", "TREATMENT", 71, 85], ["tRNA modification", "OBSERVATION", 41, 58]]], ["For efficient protein translation, the codon usage pattern should correlate with the population of available tRNA isoacceptors [13].", [["efficient protein translation", "TREATMENT", 4, 33], ["the codon usage pattern", "TREATMENT", 35, 58]]], ["In the cellular stress-response, the alteration could enhance the expression of stress-response genes, with the codon usage patterns compatible with the changed tRNA modifications.", [["cellular", "ANATOMY", 7, 15], ["cellular", "CELL", 7, 15], ["stress-response genes", "DNA", 80, 101], ["stress-response genes", "PROBLEM", 80, 101], ["the changed tRNA modifications", "TREATMENT", 149, 179], ["cellular stress", "OBSERVATION", 7, 22], ["tRNA modifications", "OBSERVATION", 161, 179]]], ["Those genes shown to be regulated by this codon-specific manner are called Modification Tunable Transcripts (MoTTs) [12, 14].IntroductionTwo major models have been proposed to explain the causes of codon usage bias: mutation pressure, and translational selection [15].", [["Modification Tunable Transcripts", "DNA", 75, 107], ["mutation pressure", "TEST", 216, 233], ["translational selection", "TREATMENT", 239, 262]]], ["As to mutation pressure, it is believed that GC content is the major factor driving codon usage bias [16, 17].", [["mutation pressure", "TEST", 6, 23], ["GC content", "PROBLEM", 45, 55]]], ["The high mutation rates of some nucleotides or codons result in nucleotide substitution that might contribute to lower frequencies of some nucleotides and codons [15].", [["nucleotide", "CHEMICAL", 64, 74], ["nucleotides", "CHEMICAL", 32, 43], ["nucleotide", "CHEMICAL", 64, 74], ["nucleotides", "CHEMICAL", 139, 150], ["The high mutation rates", "PROBLEM", 0, 23], ["some nucleotides", "PROBLEM", 27, 43], ["codons", "PROBLEM", 47, 53], ["nucleotide substitution", "PROBLEM", 64, 87], ["some nucleotides and codons", "TREATMENT", 134, 161], ["high mutation", "OBSERVATION", 4, 17]]], ["Mutation pressure has been suggested to be the most important factor determining the codon usage bias in human RNA viruses [18, 19, 20].", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["Mutation pressure", "TEST", 0, 17]]], ["However, there are correlations between the codon usage bias and other factors related to translation efficiency (such as available tRNAs, mRNA secondary structure, translation elongation rate, and the intragenic and intergenic codon bias) that cannot be explained by mutation pressure.", [["tRNAs", "RNA", 132, 137], ["mRNA", "RNA", 139, 143], ["other factors", "PROBLEM", 65, 78], ["translation efficiency", "PROBLEM", 90, 112], ["available tRNAs", "TREATMENT", 122, 137], ["mRNA secondary structure", "PROBLEM", 139, 163], ["translation elongation rate", "PROBLEM", 165, 192], ["the intragenic and intergenic codon bias", "PROBLEM", 198, 238], ["mutation pressure", "TEST", 268, 285], ["translation efficiency", "OBSERVATION", 90, 112], ["elongation", "OBSERVATION_MODIFIER", 177, 187], ["cannot be explained", "UNCERTAINTY", 245, 264]]], ["This suggests that translational selection also influences codon usage bias [15].", [["translational selection", "TREATMENT", 19, 42]]], ["The translational selection acts on codon usage bias to achieve efficient and accurate translation.", [["codon usage bias", "TREATMENT", 36, 52]]], ["The use of codons correlates with abundant tRNAs, resulting in a higher translation rate [21, 22, 23].", [["abundant tRNAs", "RNA", 34, 48], ["abundant tRNAs", "TREATMENT", 34, 48]]], ["A correlation between codon usage bias and abundant tRNAs has been found in prokaryotes (such as E. coli [24]) and in some eukaryotes (such as S. cerevisiae [25], C. elegans [22], Drosophila [23], and human [26]).", [["E. coli", "ORGANISM", 97, 104], ["S. cerevisiae", "ORGANISM", 143, 156], ["C. elegans", "ORGANISM", 163, 173], ["human", "ORGANISM", 201, 206], ["abundant tRNAs", "RNA", 43, 57], ["E. coli", "SPECIES", 97, 104], ["S. cerevisiae", "SPECIES", 143, 156], ["C. elegans", "SPECIES", 163, 173], ["Drosophila", "SPECIES", 180, 190], ["human", "SPECIES", 201, 206], ["E. coli", "SPECIES", 97, 104], ["S. cerevisiae", "SPECIES", 143, 156], ["C. elegans", "SPECIES", 163, 173], ["human", "SPECIES", 201, 206], ["codon usage bias", "TREATMENT", 22, 38], ["abundant tRNAs", "PROBLEM", 43, 57], ["E. coli", "PROBLEM", 97, 104], ["C. elegans", "TEST", 163, 173], ["Drosophila", "TEST", 180, 190]]], ["However, rare codons are preferred to encode some specific sets of genes or regions of genes, for instance, to enable protein oscillation in different phases of the cell cycle, slow down protein translation across the membrane, and reduce ribosome jamming and mRNA secondary structure at the 5\u2032end of coding sequences [11, 27, 28, 29].", [["cell", "ANATOMY", 165, 169], ["membrane", "ANATOMY", 218, 226], ["ribosome", "ANATOMY", 239, 247], ["cell", "CELL", 165, 169], ["membrane", "CELLULAR_COMPONENT", 218, 226], ["rare codons", "PROBLEM", 9, 20], ["the cell cycle", "TEST", 161, 175], ["slow down protein translation", "PROBLEM", 177, 206], ["ribosome jamming and mRNA secondary structure", "PROBLEM", 239, 284], ["rare", "OBSERVATION_MODIFIER", 9, 13], ["codons", "OBSERVATION", 14, 20], ["cell cycle", "OBSERVATION", 165, 175], ["ribosome jamming", "OBSERVATION", 239, 255]]], ["Therefore, the translational selection acting on the optimization of frequent and rare codon utilization is important in appropriate gene translation.IntroductionViral replication is dependent on the cellular machineries of the host cells.", [["cellular", "ANATOMY", 200, 208], ["cells", "ANATOMY", 233, 238], ["cellular", "CELL", 200, 208], ["host cells", "CELL", 228, 238], ["host cells", "CELL_TYPE", 228, 238], ["frequent and rare codon utilization", "TREATMENT", 69, 104], ["IntroductionViral replication", "TREATMENT", 150, 179], ["dependent", "OBSERVATION_MODIFIER", 183, 192], ["host cells", "OBSERVATION", 228, 238]]], ["Thus, one would intuitively think that the codon usage of a viral genome should match that of its host in order to be efficiently expressed.", [["viral genome", "DNA", 60, 72], ["a viral genome", "TREATMENT", 58, 72]]], ["A previous study indicated an alteration in the cellular tRNA level after the infection of human immunodeficiency virus type 1 (HIV-1) [34].", [["cellular", "ANATOMY", 48, 56], ["infection", "DISEASE", 78, 87], ["human immunodeficiency virus", "DISEASE", 91, 119], ["cellular", "CELL", 48, 56], ["human immunodeficiency virus type 1", "ORGANISM", 91, 126], ["HIV-1", "ORGANISM", 128, 133], ["human immunodeficiency virus type 1", "SPECIES", 91, 126], ["HIV-1", "SPECIES", 128, 133], ["human immunodeficiency virus type 1", "SPECIES", 91, 126], ["HIV-1", "SPECIES", 128, 133], ["A previous study", "TEST", 0, 16], ["an alteration in the cellular tRNA level", "PROBLEM", 27, 67], ["the infection of human immunodeficiency virus type", "PROBLEM", 74, 124], ["alteration", "OBSERVATION", 30, 40], ["cellular tRNA", "OBSERVATION", 48, 61], ["infection", "OBSERVATION", 78, 87]]], ["In contrast, the cellular tRNA level was found to be unchanged following vaccinia and influenza A virus (IAV) infection, whereas an alteration in the polysome-associated tRNA population was observed, particularly the population of polysome tRNA isoacceptors correlated with viral codon usage [35].", [["cellular", "ANATOMY", 17, 25], ["polysome", "ANATOMY", 150, 158], ["influenza A virus (IAV) infection", "DISEASE", 86, 119], ["cellular", "CELL", 17, 25], ["vaccinia", "ORGANISM", 73, 81], ["influenza A virus", "ORGANISM", 86, 103], ["IAV", "ORGANISM", 105, 108], ["polysome", "GENE_OR_GENE_PRODUCT", 150, 158], ["polysome tRNA isoacceptors", "GENE_OR_GENE_PRODUCT", 231, 257], ["polysome tRNA isoacceptors", "RNA", 231, 257], ["influenza A virus", "SPECIES", 86, 103], ["influenza A virus", "SPECIES", 86, 103], ["IAV", "SPECIES", 105, 108], ["the cellular tRNA level", "TEST", 13, 36], ["vaccinia", "PROBLEM", 73, 81], ["influenza A virus (IAV) infection", "PROBLEM", 86, 119], ["an alteration", "PROBLEM", 129, 142], ["the polysome", "PROBLEM", 146, 158], ["tRNA population", "PROBLEM", 170, 185], ["polysome tRNA isoacceptors", "TREATMENT", 231, 257], ["viral codon usage", "TREATMENT", 274, 291], ["cellular tRNA", "OBSERVATION", 17, 30], ["unchanged", "OBSERVATION_MODIFIER", 53, 62], ["tRNA population", "OBSERVATION", 170, 185], ["polysome tRNA", "OBSERVATION", 231, 244]]], ["These findings suggest that the codon usage pattern and the regulation of translational machineries may influence gene expression in some viruses.IntroductionIn this study, we investigated the relationship between the codon usage bias of human genes and human RNA viruses.", [["human", "ORGANISM", 238, 243], ["human", "ORGANISM", 254, 259], ["human genes", "DNA", 238, 249], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 254, 259], ["the codon usage pattern", "PROBLEM", 28, 51], ["translational machineries", "TREATMENT", 74, 99], ["some viruses", "PROBLEM", 133, 145], ["this study", "TEST", 161, 171], ["human RNA viruses", "PROBLEM", 254, 271], ["RNA viruses", "OBSERVATION", 260, 271]]], ["It is generally believed that the codon usage bias of viruses differs from that of human genes; however, various human genes possess various codon usage patterns [19, 26].", [["human", "ORGANISM", 83, 88], ["human", "ORGANISM", 113, 118], ["human genes", "DNA", 83, 94], ["human genes", "DNA", 113, 124], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 113, 118], ["viruses", "PROBLEM", 54, 61]]], ["In addition, intragenic codon biases had previously been reported in humans and mice [36].", [["humans", "ORGANISM", 69, 75], ["mice", "ORGANISM", 80, 84], ["humans", "SPECIES", 69, 75], ["mice", "SPECIES", 80, 84], ["humans", "SPECIES", 69, 75], ["mice", "SPECIES", 80, 84], ["intragenic codon biases", "PROBLEM", 13, 36]]], ["A comparison of the codon usage at the genome level is therefore too generalized; a more precise comparison at the single-gene level may provide a better insight into the viral codon usage bias.Principal component analysis of the relative synonymous codon usage (PCA of RSCU) ::: ResultsA total of 20,190 major transcript variants of human protein coding sequences were recruited from the GENCODE database (version 26).", [["human", "ORGANISM", 334, 339], ["human protein coding sequences", "DNA", 334, 364], ["human", "SPECIES", 334, 339], ["human", "SPECIES", 334, 339], ["the codon usage", "TREATMENT", 16, 31], ["human protein coding sequences", "TEST", 334, 364], ["too generalized", "OBSERVATION_MODIFIER", 65, 80], ["viral codon", "OBSERVATION", 171, 182], ["synonymous codon", "OBSERVATION", 239, 255]]], ["The protein coding sequences of 77 human RNA viruses were downloaded from the NCBI database.", [["human", "ORGANISM", 35, 40], ["protein coding sequences", "DNA", 4, 28], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["The protein coding sequences", "TEST", 0, 28], ["human RNA viruses", "PROBLEM", 35, 52], ["the NCBI database", "TEST", 74, 91]]], ["The open reading frames (ORFs) of the protein coding sequences were rechecked by ORFfinder (NCBI) before performing the RSCU calculation.", [["open reading frames", "DNA", 4, 23], ["ORFs", "DNA", 25, 29], ["protein coding sequences", "DNA", 38, 62], ["ORFfinder", "DNA", 81, 90], ["RSCU", "DNA", 120, 124], ["the protein coding sequences", "TEST", 34, 62], ["the RSCU calculation", "TEST", 116, 136]]], ["The RSCU is a simple parameter that represents the codon usage bias of synonymous codons in a coding sequence.", [["RSCU", "DNA", 4, 8], ["coding sequence", "DNA", 94, 109], ["synonymous codons", "PROBLEM", 71, 88], ["synonymous codons", "OBSERVATION", 71, 88]]], ["In our analysis, the RSCU was calculated from the protein coding sequences of the human and RNA viruses.", [["human", "ORGANISM", 82, 87], ["RSCU", "DNA", 21, 25], ["protein coding sequences", "DNA", 50, 74], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["our analysis", "TEST", 3, 15], ["RNA viruses", "OBSERVATION", 92, 103]]], ["The RSCU of each gene consists of 59 values corresponding to 59 synonymous codons; thus, the PCA was performed to simplify the data to a smaller number of principal factors as a summary feature of the codon usage pattern of each gene.", [["RSCU", "DNA", 4, 8], ["59 synonymous codons", "PROBLEM", 61, 81], ["the PCA", "TREATMENT", 89, 96], ["synonymous codons", "OBSERVATION", 64, 81]]], ["The PCA successfully reduced the 59 values of each RSCU into two significant components.", [["The PCA", "TREATMENT", 0, 7], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["components", "OBSERVATION_MODIFIER", 77, 87]]], ["The RSCUs of the human genes and RNA viruses were represented by the coordinates of principal component 1 (PC1, x-axis) and principal component 2 (PC2, y-axis) plotted on the PCA of an RSCU graph (Figure 1).", [["human", "ORGANISM", 17, 22], ["RSCUs", "DNA", 4, 9], ["human genes", "DNA", 17, 28], ["PC1", "PROTEIN", 107, 110], ["PC2", "PROTEIN", 147, 150], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["RNA viruses", "PROBLEM", 33, 44], ["PC1", "TEST", 107, 110], ["PC2", "TEST", 147, 150], ["human genes", "ANATOMY", 17, 28], ["RNA viruses", "OBSERVATION", 33, 44]]], ["The RSCU and PCA of the RSCUs of the human genes and human RNA viruses are shown in Supplementary File 1.Principal component analysis of the relative synonymous codon usage (PCA of RSCU) ::: ResultsIn Figure 1, the PCAs of the RSCUs of the human genes were represented with a transparent black dot; genes with a similar RSCU were located in the same area of the graph.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 53, 58], ["PCAs", "CANCER", 215, 219], ["RSCUs", "CANCER", 227, 232], ["human", "ORGANISM", 240, 245], ["RSCU", "CANCER", 320, 324], ["RSCU", "DNA", 4, 8], ["human genes", "DNA", 37, 48], ["PCAs", "DNA", 215, 219], ["RSCUs", "DNA", 227, 232], ["human genes", "DNA", 240, 251], ["RSCU", "DNA", 320, 324], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 240, 245], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 240, 245], ["human RNA viruses", "PROBLEM", 53, 70], ["a transparent black dot", "PROBLEM", 274, 297], ["a similar RSCU", "PROBLEM", 310, 324], ["PCA", "OBSERVATION", 13, 16], ["human genes", "ANATOMY", 37, 48], ["RNA viruses", "OBSERVATION", 59, 70], ["synonymous codon", "OBSERVATION", 150, 166], ["human genes", "ANATOMY", 240, 251]]], ["The number of human gene located in each quadrant was counted: upper left, 6,020 genes; lower left, 4,227 genes; upper right, 4,664 genes; and lower right, 5,281 genes.", [["human", "ORGANISM", 14, 19], ["human gene", "DNA", 14, 24], ["6,020 genes", "DNA", 75, 86], ["4,227 genes", "DNA", 100, 111], ["upper right", "DNA", 113, 124], ["4,664 genes", "DNA", 126, 137], ["5,281 genes", "DNA", 156, 167], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["quadrant", "ANATOMY", 41, 49], ["upper", "ANATOMY_MODIFIER", 63, 68], ["left", "ANATOMY_MODIFIER", 69, 73], ["lower", "ANATOMY_MODIFIER", 88, 93], ["left", "ANATOMY_MODIFIER", 94, 98], ["upper", "ANATOMY_MODIFIER", 113, 118], ["right", "ANATOMY_MODIFIER", 119, 124], ["lower", "ANATOMY_MODIFIER", 143, 148], ["right", "ANATOMY_MODIFIER", 149, 154]]], ["Interestingly, many human genes were located densely in the right quadrants, specifically, between (x = 0.95 to 1.7) and (y = -0.7 to 0.6).", [["right quadrants", "ANATOMY", 60, 75], ["human", "ORGANISM", 20, 25], ["human genes", "DNA", 20, 31], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["human genes", "OBSERVATION", 20, 31], ["right", "ANATOMY_MODIFIER", 60, 65], ["quadrants", "ANATOMY_MODIFIER", 66, 75]]], ["Most RNA viruses were also located in the right quadrants.", [["right quadrants", "ANATOMY", 42, 57], ["Most RNA viruses", "PROBLEM", 0, 16], ["viruses", "OBSERVATION", 9, 16], ["right", "ANATOMY_MODIFIER", 42, 47], ["quadrants", "ANATOMY_MODIFIER", 48, 57]]], ["Additionally, negative sense-single strand RNA viruses (-ssRNA), ambisense RNA viruses (Ambi), and HIV-1 viruses were located in the area of the right quadrants where the human genes were densely located.", [["right quadrants", "ANATOMY", 145, 160], ["HIV-1 viruses", "ORGANISM", 99, 112], ["human", "ORGANISM", 171, 176], ["human genes", "DNA", 171, 182], ["HIV-1", "SPECIES", 99, 104], ["human", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 99, 104], ["human", "SPECIES", 171, 176], ["single strand RNA viruses", "PROBLEM", 29, 54], ["ssRNA", "PROBLEM", 57, 62], ["ambisense RNA viruses", "PROBLEM", 65, 86], ["HIV-1 viruses", "TREATMENT", 99, 112], ["RNA viruses", "OBSERVATION", 43, 54], ["area", "ANATOMY_MODIFIER", 133, 137], ["right", "ANATOMY_MODIFIER", 145, 150], ["quadrants", "ANATOMY_MODIFIER", 151, 160], ["human genes", "ANATOMY", 171, 182]]], ["However, a great variation was observed in some groups of RNA viruses, especially positive-sense single strand RNA viruses (+ssRNA), doubled strand RNA viruses (dsRNA), and retroviruses (Retro).Principal component analysis of the relative synonymous codon usage (PCA of RSCU) ::: ResultsThe relationship between the PCA of the RSCU analysis and the codon adaptive index (CAI) was investigated.", [["retroviruses", "ORGANISM", 173, 185], ["RSCU", "DNA", 327, 331], ["a great variation", "PROBLEM", 9, 26], ["RNA viruses", "PROBLEM", 58, 69], ["sense single strand RNA viruses", "PROBLEM", 91, 122], ["ssRNA", "PROBLEM", 125, 130], ["doubled strand RNA viruses (dsRNA)", "PROBLEM", 133, 167], ["the RSCU analysis", "TEST", 323, 340], ["great variation", "OBSERVATION", 11, 26], ["RNA viruses", "OBSERVATION", 58, 69], ["RNA viruses", "OBSERVATION", 111, 122], ["RNA viruses", "OBSERVATION", 148, 159], ["synonymous codon", "OBSERVATION", 239, 255]]], ["CAI is a common parameter used to assess the codon usage bias of a gene.", [["CAI", "DNA", 0, 3]]], ["It is calculated from the frequency of the overall codons in a given protein coding sequence with respect to a reference set of genes [37].", [["protein coding sequence", "DNA", 69, 92], ["a given protein coding sequence", "TREATMENT", 61, 92]]], ["In our analysis, the human codon usage table, which is the average codon frequency of a human genome, was used as the reference set.", [["human", "ORGANISM", 21, 26], ["human", "ORGANISM", 88, 93], ["human codon usage table", "DNA", 21, 44], ["human genome", "DNA", 88, 100], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 88, 93], ["our analysis", "TEST", 3, 15], ["the human codon usage table", "TREATMENT", 17, 44], ["a human genome", "TREATMENT", 86, 100]]], ["From the results (Figure 1), the PCA of the RSCU of the human codon usage table was plotted near the x and y intercepts, showing the average codon usage pattern of all human genes.", [["RSCU", "CANCER", 44, 48], ["human", "ORGANISM", 56, 61], ["human", "ORGANISM", 168, 173], ["RSCU", "DNA", 44, 48], ["human codon usage table", "DNA", 56, 79], ["human genes", "DNA", 168, 179], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 168, 173], ["average codon", "OBSERVATION", 133, 146], ["all human genes", "OBSERVATION", 164, 179]]], ["A number of human genes in the PCA of the RSCU graph were selected and subjected to the CAI calculation.", [["human", "ORGANISM", 12, 17], ["human genes", "DNA", 12, 23], ["RSCU graph", "DNA", 42, 52], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["the CAI calculation", "TEST", 84, 103], ["human genes", "OBSERVATION", 12, 23], ["PCA", "ANATOMY", 31, 34]]], ["The graphs of PC1 and CAI, of PC2 and CAI, were plotted; the linear regression and Pearson correlation coefficient (PCC) were subsequently analyzed.", [["PC1", "GENE_OR_GENE_PRODUCT", 14, 17], ["PC2", "GENE_OR_GENE_PRODUCT", 30, 33], ["PC1", "DNA", 14, 17], ["CAI", "DNA", 22, 25], ["PC2", "PROTEIN", 30, 33], ["PC1", "TEST", 14, 17], ["CAI", "TEST", 22, 25], ["PC2", "TEST", 30, 33], ["CAI", "TEST", 38, 41], ["the linear regression", "PROBLEM", 57, 78]]], ["From Figure 2A, it was found that the CAI of genes gradually decreased with an increase in PC1 (R2 = 0.7958, PCC = -0.8921, p-value <0.0001), while a positive correlation was observed between CAI and PC2 (R2 = 0.5824, PCC = 0.7631, p-value < 0.0001).", [["CAI", "DNA", 38, 41], ["the CAI of genes", "PROBLEM", 34, 50], ["PC1", "TEST", 91, 94], ["R2", "TEST", 96, 98], ["PCC", "TEST", 109, 112], ["p-value", "TEST", 124, 131], ["CAI", "TEST", 192, 195], ["PC2", "TEST", 200, 203], ["R2", "TEST", 205, 207], ["PCC", "TEST", 218, 221], ["p-value", "TEST", 232, 239], ["gradually", "OBSERVATION_MODIFIER", 51, 60], ["decreased", "OBSERVATION_MODIFIER", 61, 70], ["increase", "OBSERVATION_MODIFIER", 79, 87]]], ["The percentages of the GC content at the third position of the codon (%G+C(3)) of the human genes were also determined.", [["G+C(3)", "GENE_OR_GENE_PRODUCT", 71, 77], ["human", "ORGANISM", 86, 91], ["human genes", "DNA", 86, 97], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["the GC content", "TEST", 19, 33], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["GC content", "OBSERVATION", 23, 33]]], ["In a similar way to CAI (Figure 2B), %G+C(3) gradually decreased with an increase in PC1 (R2 = 0.9459, PCC = -0.9726, p-value < 0.0001).", [["CAI", "TEST", 20, 23], ["%G+C", "TEST", 37, 41], ["PC1", "TEST", 85, 88], ["R2", "TEST", 90, 92], ["PCC", "TEST", 103, 106], ["p-value", "TEST", 118, 125], ["increase", "OBSERVATION_MODIFIER", 73, 81]]], ["A weak correlation between PC2 and %G+C(3) was observed (R2 = 0.4373, PCC = 0.6613, p-value < 0.0001).", [["PC2", "GENE_OR_GENE_PRODUCT", 27, 30], ["PC2", "PROTEIN", 27, 30], ["PC2", "TEST", 27, 30], ["G+C", "TEST", 36, 39], ["R2", "TEST", 57, 59], ["PCC", "TEST", 70, 73], ["p-value", "TEST", 84, 91]]], ["Thus, the PCA of the RSCU analysis could be used to characterize the heterogeneity of the codon usage bias in the human genome, in which genes in the left-upper quadrant contain more optimal codon usage for high expression, whereas those in the right quadrants near or below the x-axis have less optimal codon usage.Principal component analysis of the relative synonymous codon usage (PCA of RSCU) ::: ResultsThe PCAs of RSCUs of the human genes that coded for highly expressed proteins were plotted on a graph.", [["left-upper quadrant", "ANATOMY", 150, 169], ["right quadrants", "ANATOMY", 245, 260], ["human", "ORGANISM", 114, 119], ["upper quadrant", "ORGANISM_SUBDIVISION", 155, 169], ["human", "ORGANISM", 434, 439], ["RSCU", "DNA", 21, 25], ["human genome", "DNA", 114, 126], ["RSCUs", "DNA", 421, 426], ["human genes", "DNA", 434, 445], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 434, 439], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 434, 439], ["the RSCU analysis", "TEST", 17, 34], ["high expression", "PROBLEM", 207, 222], ["codon usage", "OBSERVATION", 90, 101], ["human genome", "OBSERVATION", 114, 126], ["left", "ANATOMY_MODIFIER", 150, 154], ["upper", "ANATOMY_MODIFIER", 155, 160], ["quadrant", "ANATOMY", 161, 169], ["more optimal", "OBSERVATION_MODIFIER", 178, 190], ["codon usage", "OBSERVATION", 191, 202], ["right", "ANATOMY_MODIFIER", 245, 250], ["quadrants", "ANATOMY_MODIFIER", 251, 260], ["less optimal", "OBSERVATION_MODIFIER", 291, 303], ["codon usage", "OBSERVATION", 304, 315], ["synonymous codon", "OBSERVATION", 361, 377]]], ["The highly expressed proteins of humans had been previously identified using the proteomic approach (Figure 1; see the gene list in Supplementary Table 1).", [["humans", "ORGANISM", 33, 39], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["the proteomic approach", "TREATMENT", 77, 99]]], ["From Figure 1, most of the highly expressed proteins were located in the left quadrants.", [["left quadrants", "ANATOMY", 73, 87], ["proteins", "OBSERVATION", 44, 52], ["left", "ANATOMY_MODIFIER", 73, 77], ["quadrants", "ANATOMY_MODIFIER", 78, 87]]], ["This is in agreement with our analysis showing the relationship between PCA and CAI, and it supports the validity of using PCA to predict CAI.Human genes with codon usage bias similar to RNA viruses ::: ResultsFrom the PCA of the RSCU graph (Figure 1), it was demonstrated that most of the human RNA viruses were located in the right quadrants.", [["right quadrants", "ANATOMY", 328, 343], ["Human", "ORGANISM", 142, 147], ["human", "ORGANISM", 290, 295], ["Human genes", "DNA", 142, 153], ["RSCU graph", "DNA", 230, 240], ["Human", "SPECIES", 142, 147], ["human", "SPECIES", 290, 295], ["Human", "SPECIES", 142, 147], ["human", "SPECIES", 290, 295], ["our analysis", "TEST", 26, 38], ["PCA and CAI", "TREATMENT", 72, 83], ["PCA", "TREATMENT", 123, 126], ["codon usage", "TREATMENT", 159, 170], ["the RSCU graph", "TEST", 226, 240], ["the human RNA viruses", "PROBLEM", 286, 307], ["right", "ANATOMY_MODIFIER", 328, 333], ["quadrants", "ANATOMY_MODIFIER", 334, 343]]], ["The degree of difference in the codon usage pattern varied among the groups of viruses.", [["the codon usage pattern", "PROBLEM", 28, 51], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["difference", "OBSERVATION_MODIFIER", 14, 24], ["codon usage", "OBSERVATION", 32, 43], ["viruses", "OBSERVATION", 79, 86]]], ["The highest PC1 (x) belonged to rotavirus, indicating a high degree of difference in codon usage pattern compared to human genes and other RNA viruses.", [["rotavirus", "DISEASE", 32, 41], ["PC1", "GENE_OR_GENE_PRODUCT", 12, 15], ["rotavirus", "ORGANISM", 32, 41], ["human", "ORGANISM", 117, 122], ["PC1", "DNA", 12, 15], ["human genes", "DNA", 117, 128], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["The highest PC1", "TEST", 0, 15], ["rotavirus", "PROBLEM", 32, 41], ["a high degree of difference in codon usage pattern", "PROBLEM", 54, 104], ["other RNA viruses", "PROBLEM", 133, 150], ["rotavirus", "OBSERVATION", 32, 41], ["high degree", "OBSERVATION_MODIFIER", 56, 67], ["codon usage", "OBSERVATION", 85, 96], ["RNA viruses", "OBSERVATION", 139, 150]]], ["In particular, there were a number of human genes with RSCUs similar to RNA viruses (Figure 1), especially -ssRNA, Ambi, and HIV viruses, which were located in the right quadrants, where human genes were also located densely.", [["right quadrants", "ANATOMY", 164, 179], ["HIV viruses", "DISEASE", 125, 136], ["human", "ORGANISM", 38, 43], ["RSCUs", "GENE_OR_GENE_PRODUCT", 55, 60], ["Ambi", "GENE_OR_GENE_PRODUCT", 115, 119], ["HIV viruses", "ORGANISM", 125, 136], ["human", "ORGANISM", 187, 192], ["human genes", "DNA", 38, 49], ["human genes", "DNA", 187, 198], ["human", "SPECIES", 38, 43], ["HIV", "SPECIES", 125, 128], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 38, 43], ["HIV viruses", "SPECIES", 125, 136], ["human", "SPECIES", 187, 192], ["RSCUs", "PROBLEM", 55, 60], ["RNA viruses", "PROBLEM", 72, 83], ["ssRNA", "PROBLEM", 108, 113], ["Ambi", "PROBLEM", 115, 119], ["HIV viruses", "PROBLEM", 125, 136], ["HIV viruses", "OBSERVATION", 125, 136], ["right", "ANATOMY_MODIFIER", 164, 169], ["quadrants", "ANATOMY_MODIFIER", 170, 179], ["human genes", "ANATOMY", 187, 198]]], ["To investigate the kinds of human genes with codon usage patterns similar to RNA viruses and the contributions of those genes in important biological processes, the human genes plotted in the same area with each subgroup of RNA viruses were retrieved.", [["human", "ORGANISM", 28, 33], ["human", "ORGANISM", 165, 170], ["human genes", "DNA", 28, 39], ["human genes", "DNA", 165, 176], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 165, 170], ["codon usage patterns", "TREATMENT", 45, 65], ["RNA viruses", "PROBLEM", 77, 88], ["the human genes", "PROBLEM", 161, 176], ["RNA viruses", "PROBLEM", 224, 235], ["RNA viruses", "OBSERVATION", 77, 88], ["RNA viruses", "OBSERVATION", 224, 235]]], ["The criteria for selection of the human genes with RSCUs similar to RNA viruses are described in the methods section.Human genes with codon usage bias similar to RNA viruses ::: Results", [["human", "ORGANISM", 34, 39], ["RSCUs", "GENE_OR_GENE_PRODUCT", 51, 56], ["Human", "ORGANISM", 117, 122], ["human genes", "DNA", 34, 45], ["Human genes", "DNA", 117, 128], ["human", "SPECIES", 34, 39], ["Human", "SPECIES", 117, 122], ["human", "SPECIES", 34, 39], ["Human", "SPECIES", 117, 122], ["RSCUs", "PROBLEM", 51, 56], ["RNA viruses", "PROBLEM", 68, 79], ["codon usage", "TREATMENT", 134, 145], ["RNA viruses", "OBSERVATION", 68, 79]]]], "PMC6941262": [["BackgroundHuman metapneumovirus (HMPV) is a single-stranded RNA virus in the family Paramyxoviridae and closely related to human respiratory syncytial virus (RSV) [1].", [["BackgroundHuman metapneumovirus", "DISEASE", 0, 31], ["respiratory syncytial virus", "DISEASE", 129, 156], ["BackgroundHuman metapneumovirus", "ORGANISM", 0, 31], ["HMPV", "ORGANISM", 33, 37], ["human", "ORGANISM", 123, 128], ["respiratory syncytial virus", "ORGANISM", 129, 156], ["RSV", "ORGANISM", 158, 161], ["BackgroundHuman metapneumovirus", "SPECIES", 0, 31], ["human", "SPECIES", 123, 128], ["respiratory syncytial virus", "SPECIES", 129, 156], ["BackgroundHuman metapneumovirus", "SPECIES", 0, 31], ["HMPV", "SPECIES", 33, 37], ["human respiratory syncytial virus", "SPECIES", 123, 156], ["RSV", "SPECIES", 158, 161], ["BackgroundHuman metapneumovirus (HMPV", "PROBLEM", 0, 37], ["a single-stranded RNA virus", "PROBLEM", 42, 69], ["the family Paramyxoviridae", "TREATMENT", 73, 99], ["human respiratory syncytial virus", "PROBLEM", 123, 156], ["metapneumovirus", "OBSERVATION", 16, 31], ["respiratory syncytial", "ANATOMY", 129, 150]]], ["HMPV causes respiratory disease similar to RSV, ranging from mild upper respiratory infection to bronchiolitis and pneumonia [2].", [["respiratory", "ANATOMY", 12, 23], ["respiratory", "ANATOMY", 72, 83], ["HMPV", "DISEASE", 0, 4], ["respiratory disease", "DISEASE", 12, 31], ["RSV", "DISEASE", 43, 46], ["respiratory infection", "DISEASE", 72, 93], ["bronchiolitis", "DISEASE", 97, 110], ["pneumonia", "DISEASE", 115, 124], ["HMPV", "ORGANISM", 0, 4], ["RSV", "ORGANISM", 43, 46], ["HMPV", "SPECIES", 0, 4], ["RSV", "SPECIES", 43, 46], ["HMPV", "PROBLEM", 0, 4], ["respiratory disease", "PROBLEM", 12, 31], ["RSV", "PROBLEM", 43, 46], ["mild upper respiratory infection", "PROBLEM", 61, 93], ["bronchiolitis", "PROBLEM", 97, 110], ["pneumonia", "PROBLEM", 115, 124], ["respiratory disease", "OBSERVATION", 12, 31], ["RSV", "OBSERVATION", 43, 46], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["upper", "ANATOMY_MODIFIER", 66, 71], ["respiratory", "ANATOMY", 72, 83], ["infection", "OBSERVATION", 84, 93], ["bronchiolitis", "OBSERVATION", 97, 110], ["pneumonia", "OBSERVATION", 115, 124]]], ["HMPV infections are seasonal and co-infection with other respiratory pathogens is common [1].", [["HMPV infections", "DISEASE", 0, 15], ["respiratory pathogens", "DISEASE", 57, 78], ["HMPV", "ORGANISM", 0, 4], ["HMPV", "SPECIES", 0, 4], ["HMPV infections", "PROBLEM", 0, 15], ["co-infection", "PROBLEM", 33, 45], ["other respiratory pathogens", "PROBLEM", 51, 78], ["infections", "OBSERVATION", 5, 15], ["co-infection", "OBSERVATION", 33, 45]]], ["The HMPV genome is approximately 13 kb and comprises eight open reading frames (ORFs) encoding nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion glycoprotein (F), transcription enhancer protein (M2), small hydrophobic protein (SH), attachment glycoprotein (G), and large polymerase protein (L) [3].", [["HMPV", "ORGANISM", 4, 8], ["nucleoprotein (N)", "GENE_OR_GENE_PRODUCT", 95, 112], ["matrix protein", "GENE_OR_GENE_PRODUCT", 134, 148], ["fusion glycoprotein (F)", "GENE_OR_GENE_PRODUCT", 154, 177], ["M2", "GENE_OR_GENE_PRODUCT", 211, 213], ["small hydrophobic protein", "GENE_OR_GENE_PRODUCT", 216, 241], ["attachment glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 248, 275], ["large polymerase protein (L) [3", "GENE_OR_GENE_PRODUCT", 281, 312], ["HMPV genome", "DNA", 4, 15], ["open reading frames", "DNA", 59, 78], ["ORFs", "DNA", 80, 84], ["nucleoprotein (N), phosphoprotein (P)", "PROTEIN", 95, 132], ["matrix protein", "PROTEIN", 134, 148], ["M", "PROTEIN", 150, 151], ["fusion glycoprotein", "PROTEIN", 154, 173], ["F", "PROTEIN", 175, 176], ["transcription enhancer protein", "PROTEIN", 179, 209], ["M2", "PROTEIN", 211, 213], ["small hydrophobic protein", "PROTEIN", 216, 241], ["SH", "PROTEIN", 243, 245], ["attachment glycoprotein", "PROTEIN", 248, 271], ["G", "PROTEIN", 273, 274], ["large polymerase protein", "PROTEIN", 281, 305], ["L", "PROTEIN", 307, 308], ["HMPV", "SPECIES", 4, 8], ["The HMPV genome", "PROBLEM", 0, 15], ["phosphoprotein (P), matrix protein (M), fusion glycoprotein", "TREATMENT", 114, 173], ["transcription enhancer protein", "TEST", 179, 209], ["small hydrophobic protein", "PROBLEM", 216, 241], ["attachment glycoprotein", "TEST", 248, 271], ["large polymerase protein", "TEST", 281, 305], ["HMPV genome", "OBSERVATION", 4, 15], ["13 kb", "OBSERVATION_MODIFIER", 33, 38], ["small", "OBSERVATION_MODIFIER", 216, 221], ["hydrophobic protein", "OBSERVATION", 222, 241]]], ["The membrane glycoproteins F and G sequences are used to define two major genotypes or groups, A and B, which are further classified into four subgroups (A1, A2, B1, and B2).", [["membrane", "ANATOMY", 4, 12], ["B", "GENE_OR_GENE_PRODUCT", 101, 102], ["B1", "GENE_OR_GENE_PRODUCT", 162, 164], ["B2", "GENE_OR_GENE_PRODUCT", 170, 172], ["membrane glycoproteins F and G sequences", "DNA", 4, 44], ["A1", "PROTEIN", 154, 156], ["A2", "PROTEIN", 158, 160], ["B1", "PROTEIN", 162, 164], ["B2", "PROTEIN", 170, 172], ["The membrane glycoproteins F and G sequences", "TREATMENT", 0, 44]]], ["HMPV A2, the most frequently observed subgroup, is further divided into two proposed sub-lineages (A2a and A2b) [3].BackgroundHMPV is reported to have an important contribution to acute respiratory infections (ARI) in Africa.", [["respiratory", "ANATOMY", 186, 197], ["BackgroundHMPV", "CHEMICAL", 116, 130], ["acute respiratory infections", "DISEASE", 180, 208], ["ARI", "DISEASE", 210, 213], ["HMPV A2", "ORGANISM", 0, 7], ["HMPV A2", "PROTEIN", 0, 7], ["HMPV", "SPECIES", 0, 4], ["acute respiratory infections (ARI)", "PROBLEM", 180, 214], ["important contribution to", "UNCERTAINTY", 154, 179], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["respiratory", "ANATOMY", 186, 197], ["infections", "OBSERVATION", 198, 208]]], ["For instance, HMPV-associated hospitalization was estimated at 6.5 per 1000 person years in infants in Soweto, South Africa [4]; at 4% in hospitalized children with severe ARI during a 2-year period in Cameroon [5]; and in rural western Kenya, incidence of HMPV associated with ARI cases in outpatient clinic visits was estimated at 0.43 per 100 person-years among outpatients [6].", [["ARI", "DISEASE", 172, 175], ["HMPV", "DISEASE", 257, 261], ["ARI", "DISEASE", 278, 281], ["HMPV", "ORGANISM", 14, 18], ["infants", "ORGANISM", 92, 99], ["children", "ORGANISM", 151, 159], ["HMPV", "ORGANISM", 257, 261], ["person", "SPECIES", 76, 82], ["infants", "SPECIES", 92, 99], ["children", "SPECIES", 151, 159], ["HMPV", "SPECIES", 14, 18], ["HMPV", "SPECIES", 257, 261], ["HMPV", "PROBLEM", 14, 18], ["severe ARI", "PROBLEM", 165, 175], ["HMPV", "PROBLEM", 257, 261]]], ["In Kilifi coastal Kenya, between January 2007 to December 2011, children under 6 months of age accounted for 44% of HMPV positive cases, while 74% were children under 1 year, and 1.3% (2/160) were children > 36 months [7].", [["children", "ORGANISM", 64, 72], ["HMPV", "ORGANISM", 116, 120], ["children", "ORGANISM", 152, 160], ["children", "ORGANISM", 197, 205], ["children", "SPECIES", 64, 72], ["children", "SPECIES", 152, 160], ["children", "SPECIES", 197, 205], ["HMPV", "SPECIES", 116, 120], ["HMPV positive cases", "PROBLEM", 116, 135]]], ["In Dadaab and Kakuma refugee camps in Kenya, HMPV was detected in 5.7% hospitalizations, and virus-positive crude hospitalization rate (per 1000 children < 5 years old) was 4 for HMPV [8].", [["HMPV", "ORGANISM", 45, 49], ["children", "SPECIES", 145, 153], ["HMPV", "SPECIES", 45, 49], ["HMPV", "SPECIES", 179, 183], ["HMPV", "PROBLEM", 45, 49], ["virus", "PROBLEM", 93, 98], ["HMPV", "PROBLEM", 179, 183]]], ["In Mali, contribution of HMPV to pneumonia had a population attributable fraction of 9% (95% CI: 7\u201311%) [9]; while in Morocco [10], 8.9% of children < 5 years admitted with severe pneumonia were infected with HMPV.", [["HMPV", "DISEASE", 25, 29], ["pneumonia", "DISEASE", 33, 42], ["pneumonia", "DISEASE", 180, 189], ["HMPV", "DISEASE", 209, 213], ["HMPV", "ORGANISM", 25, 29], ["children", "ORGANISM", 140, 148], ["HMPV", "ORGANISM", 209, 213], ["children", "SPECIES", 140, 148], ["HMPV", "SPECIES", 25, 29], ["HMPV", "SPECIES", 209, 213], ["HMPV", "PROBLEM", 25, 29], ["pneumonia", "PROBLEM", 33, 42], ["CI", "TEST", 93, 95], ["severe pneumonia", "PROBLEM", 173, 189], ["HMPV", "PROBLEM", 209, 213], ["HMPV", "OBSERVATION", 25, 29], ["pneumonia", "OBSERVATION", 33, 42], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["pneumonia", "OBSERVATION", 180, 189], ["infected", "OBSERVATION", 195, 203]]], ["HMPV prevalence and incidence elsewhere globally, is indicated in Additional file 4: Table S1.", [["HMPV", "SPECIES", 0, 4]]], ["Of note is that the variations in incidence rates could be attributed to study population, seasonality and even detection methods.", [["the variations in incidence rates", "PROBLEM", 16, 49], ["study population", "PROBLEM", 73, 89]]], ["Nonetheless, genomic epidemiology of HMPV in Africa is inadequately reported, and comparison of genetic similarity and differences between African and global strains is not documented.BackgroundGenome sequences provide valuable resources for characterizing viral evolution and disease epidemiology, and for identifying transmission events and outbreaks, which is not always possible with sub-genomic fragments [11\u201313].", [["HMPV", "DISEASE", 37, 41], ["HMPV", "ORGANISM", 37, 41], ["Genome sequences", "DNA", 194, 210], ["sub-genomic fragments", "DNA", 388, 409], ["HMPV", "SPECIES", 37, 41], ["HMPV", "PROBLEM", 37, 41], ["African and global strains", "PROBLEM", 139, 165], ["outbreaks", "PROBLEM", 343, 352], ["sub-genomic fragments", "PROBLEM", 388, 409], ["HMPV", "OBSERVATION", 37, 41], ["not always possible", "UNCERTAINTY", 363, 382]]], ["The increased number of phylogenetically informative variant sites obtained from full genomes may allow better linking of cases and aid public health interventions in real time during epidemics [14, 15].", [["phylogenetically informative variant sites", "PROBLEM", 24, 66], ["public health interventions", "TREATMENT", 136, 163], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["PCR approaches for targeted whole genome sequencing, in contrast to random amplification, can preferentially amplify the target virus over host or environmental nucleic acids [16, 17] potentially focusing sequencing on the virus of interest.", [["nucleic acids", "CHEMICAL", 161, 174], ["PCR approaches", "TEST", 0, 14], ["targeted whole genome sequencing", "TREATMENT", 19, 51], ["environmental nucleic acids", "TEST", 147, 174]]], ["To date, the largest dataset of HMPV whole genomes (n = 61) sequenced from any tropical country is from three Peruvian cities, Lima, Piura and Iquitos [18].", [["HMPV", "ORGANISM", 32, 36], ["HMPV whole genomes", "DNA", 32, 50], ["HMPV", "SPECIES", 32, 36], ["HMPV", "PROBLEM", 32, 36], ["Lima", "ANATOMY", 127, 131]]], ["In Africa, apart from one metapneumovirus genome identified from a wild mountain gorilla in Rwanda (GenBank accession number HM197719), there are no HMPV genomes reported according to the NIAID Virus Pathogen Database and Analysis Resource (ViPR, http://www.viprbrc.org/, accessed April 30, 2019).", [["metapneumovirus", "ORGANISM", 26, 41], ["mountain gorilla", "ORGANISM", 72, 88], ["HMPV", "ORGANISM", 149, 153], ["metapneumovirus genome", "DNA", 26, 48], ["HMPV genomes", "DNA", 149, 161], ["mountain gorilla", "SPECIES", 72, 88], ["mountain gorilla", "SPECIES", 72, 88], ["HMPV", "SPECIES", 149, 153], ["one metapneumovirus genome", "PROBLEM", 22, 48], ["HMPV genomes", "PROBLEM", 149, 161], ["metapneumovirus genome", "OBSERVATION", 26, 48], ["no", "UNCERTAINTY", 146, 148], ["HMPV genomes", "OBSERVATION", 149, 161]]], ["This has led to limited understanding of the genetic and genomic diversity of HMPV in the continent.BackgroundThis work describes a whole genome sequencing (WGS) approach for HMPV from a small number of HMPV positive clinical samples collected at Kilifi County Hospital in Kilifi, Kenya and University Teaching Hospital in Lusaka, Zambia.", [["samples", "ANATOMY", 226, 233], ["HMPV", "ORGANISM", 78, 82], ["HMPV", "ORGANISM", 175, 179], ["HMPV", "ORGANISM", 203, 207], ["HMPV", "SPECIES", 78, 82], ["HMPV", "SPECIES", 175, 179], ["HMPV", "SPECIES", 203, 207], ["HMPV", "PROBLEM", 78, 82], ["a whole genome sequencing (WGS) approach", "TREATMENT", 130, 170], ["HMPV", "PROBLEM", 175, 179], ["HMPV positive clinical samples", "PROBLEM", 203, 233], ["HMPV", "OBSERVATION", 78, 82], ["small", "OBSERVATION_MODIFIER", 187, 192]]], ["The genomes were generated by sequencing overlapping PCR amplicons spanning the entire genome.", [["PCR amplicons", "DNA", 53, 66], ["sequencing overlapping PCR amplicons", "TREATMENT", 30, 66]]], ["These are the first reported complete genome sequences of locally circulating HMPV strains obtained directly from clinical samples in Africa.", [["samples", "ANATOMY", 123, 130], ["HMPV", "ORGANISM", 78, 82], ["HMPV", "SPECIES", 78, 82], ["locally circulating HMPV strains", "PROBLEM", 58, 90], ["HMPV strains", "OBSERVATION", 78, 90]]], ["We also combined the new genomes with publicly available sequences to examine patterns in global HMPV genetic diversity.Genome characteristics ::: ResultsWhole genome sequencing was successful for all 5 clinical samples that were attempted.", [["samples", "ANATOMY", 212, 219], ["samples", "CANCER", 212, 219], ["HMPV", "SPECIES", 97, 101], ["publicly available sequences", "TEST", 38, 66], ["Whole genome sequencing", "TREATMENT", 154, 177], ["HMPV", "OBSERVATION", 97, 101]]], ["A single genomic sequence was obtained from each sample, and the length of the 5 new HMPV genomes ranged from 13,097 to 13,134 nt (> 95% length coverage).", [["sample", "ANATOMY", 49, 55], ["HMPV", "ORGANISM", 85, 89], ["5 new HMPV genomes", "DNA", 79, 97], ["A single genomic sequence", "TEST", 0, 25], ["new HMPV genomes", "TEST", 81, 97], ["nt", "TEST", 127, 129], ["HMPV", "OBSERVATION", 85, 89]]], ["Sequencing and data assembly parameters, including coverage depth are shown in Table 1.", [["Sequencing and data assembly parameters", "TEST", 0, 39]]]], "PMC7243237": [["Sir, I write further to the letter by Holmes et al.1 with regard to management of broken jaws in the wake of the COVID pandemic using closed reduction protocols such as intermaxillary fixation with the post-operative follow up of patients by GDPs.", [["jaws", "ANATOMY", 89, 93], ["COVID", "DISEASE", 113, 118], ["jaws", "ORGAN", 89, 93], ["patients", "ORGANISM", 230, 238], ["GDPs", "SIMPLE_CHEMICAL", 242, 246], ["patients", "SPECIES", 230, 238], ["management", "TREATMENT", 68, 78], ["broken jaws", "PROBLEM", 82, 93], ["closed reduction protocols", "TREATMENT", 134, 160], ["intermaxillary fixation", "TREATMENT", 169, 192], ["broken jaws", "OBSERVATION", 82, 93], ["intermaxillary fixation", "OBSERVATION", 169, 192]]]], "PMC7450918": [["Heroes Work HereIt is difficult to describe the debt of gratitude that is owed to our first responders, the emergency room teams, and those at Hospital for Special Surgery (HSS) who stepped out of their comfort zone to care for the sickest-of-the-sick COVID-19 patients as HSS transitioned from a specialty hospital to a general hospital.", [["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269], ["Special Surgery", "TREATMENT", 156, 171]]], ["And as with all highly functioning teams, there are many others who labored tirelessly behind the scenes (and at times side-by-side) to support the mission.Heroes Work HereHere we describe the work of one such team at HSS: Information Technology (IT).", [["labored", "PROBLEM", 68, 75]]], ["A bit like air and water, IT is hardly noticeable, until the supply is disrupted.", [["A bit like air and water", "PROBLEM", 0, 24], ["air", "OBSERVATION", 11, 14], ["disrupted", "OBSERVATION", 71, 80]]], ["And as with air and water, IT is crucial to the survival of an organization in times of stability, and even more so in times of crisis [1, 3, 6].Heroes Work HereAfter COVID-19 swept through China and Europe, and then arrived on the West Coast of the USA, it became clear that the New York City area was likely to become the epicenter of the pandemic.", [["crisis", "PROBLEM", 128, 134], ["COVID", "TEST", 167, 172], ["stability", "OBSERVATION", 88, 97], ["pandemic", "OBSERVATION", 341, 349]]], ["Predictions became increasingly dire.", [["increasingly", "OBSERVATION_MODIFIER", 19, 31], ["dire", "OBSERVATION", 32, 36]]], ["In response, in late March 2020, New York State Governor Andrew Cuomo ordered hospitals to increase their bed capacity by 50 to 100% and to submit a surge plan.Heroes Work HereFounded in 1863 as the Hospital for the Ruptured and the Crippled, HSS has been in continuous operation ever since, with a singular focus on the treatment of musculoskeletal diseases.", [["musculoskeletal", "ANATOMY", 334, 349], ["musculoskeletal diseases", "DISEASE", 334, 358], ["musculoskeletal diseases", "PROBLEM", 334, 358], ["Ruptured", "OBSERVATION", 216, 224], ["musculoskeletal", "ANATOMY", 334, 349], ["diseases", "OBSERVATION", 350, 358]]], ["Yet this was the scene that HSS was facing when by order of Governor Cuomo all elective surgery was halted.", [["Governor Cuomo all elective surgery", "TREATMENT", 60, 95]]], ["HSS had already taken critical steps to ensure its ability to respond to the oncoming catastrophe.", [["critical steps", "TREATMENT", 22, 36], ["the oncoming catastrophe", "PROBLEM", 73, 97], ["catastrophe", "OBSERVATION", 86, 97]]], ["This team provided crucial guidance as the crisis unfolded.", [["crucial guidance", "TREATMENT", 19, 35], ["the crisis unfolded", "PROBLEM", 39, 58], ["crisis unfolded", "OBSERVATION", 43, 58]]], ["The infection prevention and emergency support teams were located in nearby rooms.", [["infection", "DISEASE", 4, 13], ["The infection prevention", "PROBLEM", 0, 24], ["infection", "OBSERVATION", 4, 13]]], ["These included deployment of a customer relationship management (CRM) tool (Salesforce), which enabled centralized issue management, as well as large screen monitors and other videoconferencing and teleconferencing tools.", [["a customer relationship management", "TREATMENT", 29, 63], ["centralized issue management", "TREATMENT", 103, 131], ["large screen monitors", "TEST", 144, 165]]], ["Existing livestream capabilities were scaled-up, with regular sessions broadcast.", [["Existing livestream capabilities", "PROBLEM", 0, 32]]], ["These broadcasts were recorded and saved online for later viewing as well.Leadership Lessons in Interconnectivity and CommunicationThe use of well-known video conferencing tools such as Skype for Business, Zoom, and Microsoft Teams were critical, not only for leadership but also for the entire organization as appropriate social distancing was maintained.", [["These broadcasts", "TEST", 0, 16], ["Interconnectivity", "OBSERVATION_MODIFIER", 96, 113]]], ["Each of these tools had unique requirements regarding enterprise-wide licensing, security analysis, contracting, and training.Work from HomeIn March, it was decided that any employee who could perform their work remotely should do so.", [["security analysis", "TEST", 81, 98]]], ["Prior to the pandemic, approximately 200 people worked from home on any given day.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47]]], ["To accommodate this increase, several structural changes were made: the internet bandwidth was increased tenfold, from 1 gigabit per second (GBPS) to 10 GBPS.", [["increased tenfold", "PROBLEM", 95, 112], ["GBPS", "TEST", 153, 157], ["increase", "OBSERVATION_MODIFIER", 20, 28]]], ["Citrix infrastructure (myaccess.hss.edu) was increased 80%, to permit more than 3500 users.", [["Citrix", "CHEMICAL", 0, 6], ["Citrix", "CHEMICAL", 0, 6], ["Citrix", "SIMPLE_CHEMICAL", 0, 6], ["Citrix infrastructure", "TREATMENT", 0, 21]]], ["Virtual private network (VPN) user licenses were doubled.", [["network", "MULTI-TISSUE_STRUCTURE", 16, 23]]], ["Changes were made to Kronos to allow time-stamping from home.", [["Kronos", "TREATMENT", 21, 27]]], ["Over 400 laptops or tablets were deployed with sophisticated software to allow staff to access specialized tools required for their job functions (e.g., softphones for call center staff).", [["tablets", "TREATMENT", 20, 27]]], ["Technology was acquired to allow internal and external PDFs to be filled and signed online.", [["internal and external PDFs", "TREATMENT", 33, 59]]], ["Digital check requests and paperless purchasing and tracking were also implemented.", [["Digital check requests", "TEST", 0, 22]]], ["The ability to use videoconferencing technology was key to the success of work from home (WFH).", [["videoconferencing technology", "TREATMENT", 19, 47]]], ["The press was replete with tech advice on how to WFH successfully [7].TelehealthAs mentioned, 1 week before elective surgery was banned in New York State, HSS made the decision to stop performing all but \u201cessential services.\u201d", [["elective surgery", "TREATMENT", 108, 124]]], ["All other patients were offered telehealth (TH) visits (Fig. 2).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Telehealth has long been a part of a pandemic response, and its role in managing this pandemic is clear [2].", [["clear", "OBSERVATION", 98, 103]]], ["Although HSS had established a TH strategy and implemented TH tools available in the electronic medical record system (Epic) more than a year prior, the pandemic offered an exceptional opportunity to accelerate those efforts.TelehealthThe Epic TH workflows and functionalities were quickly scaled-up to accommodate hundreds of providers.", [["a TH strategy", "TREATMENT", 29, 42], ["The Epic TH workflows", "TREATMENT", 235, 256]]], ["This work included the addition of TH visit types and templates, new MyHSS (patient portal) questionnaires, icons to patient schedules indicating the patient was connected to Zoom, patient location, start/stop time, and level of service buttons.", [["TH", "SIMPLE_CHEMICAL", 35, 37], ["patient", "ORGANISM", 76, 83], ["portal", "MULTI-TISSUE_STRUCTURE", 84, 90], ["patient", "ORGANISM", 117, 124], ["patient", "ORGANISM", 150, 157], ["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 76, 83], ["patient", "SPECIES", 117, 124], ["patient", "SPECIES", 150, 157], ["patient", "SPECIES", 181, 188], ["icons to patient schedules", "TREATMENT", 108, 134], ["portal", "ANATOMY", 84, 90]]], ["Updates were made to billing to accommodate changing payor requirements.", [["changing payor requirements", "TREATMENT", 44, 71]]], ["Dashboards were created to monitor TH usage.", [["TH", "GENE_OR_GENE_PRODUCT", 35, 37]]], ["Twenty new tip sheets were created for providers and office staff.", [["Twenty new tip sheets", "TREATMENT", 0, 21], ["tip", "OBSERVATION_MODIFIER", 11, 14]]], ["At-the-elbow support and an analyst-led command center were established.", [["elbow", "ANATOMY", 7, 12]]], ["Changes in security settings were made to Zoom, which was the platform used with Epic for TH.", [["Epic for TH", "TREATMENT", 81, 92]]], ["Ambra, software for sharing images (X-ray, magnetic resonance imaging, for example), was integrated with Epic, allowing patients to download outside images to be reviewed during the visit.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["sharing images", "TEST", 20, 34], ["X-ray", "TEST", 36, 41], ["magnetic resonance imaging", "TEST", 43, 69], ["Epic", "TREATMENT", 105, 109], ["download outside images", "TEST", 132, 155]]], ["The IT service desk was scaled to accommodate a dramatic increase in calls, and revised scenario scripting was provided to educate service desk analysts as to the issues patients and providers may encounter.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["dramatic", "OBSERVATION_MODIFIER", 48, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65]]], ["Virtual visits increased from a few hundred in March to over 20,000 by early May!Ambulatory Essential ServicesAlthough TH was able to accommodate large numbers of patients, significant numbers still required essential services onsite.", [["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171]]], ["Outpatient areas were consolidated into a few locations.", [["consolidated", "OBSERVATION", 22, 34], ["few", "OBSERVATION_MODIFIER", 42, 45]]], ["Controlling patient flow in order to properly screen and socially distance was also more easily accomplished with fewer locations.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["The consolidation required a large IT contribution.", [["The consolidation", "PROBLEM", 0, 17], ["consolidation", "OBSERVATION", 4, 17], ["large", "OBSERVATION_MODIFIER", 29, 34]]], ["New offices and departments had to be created within Epic, along with decision-tree logic to ensure that correct forms were completed electronically by the patient prior to arrival.", [["patient", "ORGANISM", 156, 163], ["patient", "SPECIES", 156, 163]]], ["Automated telephone calls were re-scripted and used to communicate important COVID-19-related information to patients prior to arrival.", [["patients", "ORGANISM", 109, 117], ["COVID-19", "DNA", 77, 85], ["patients", "SPECIES", 109, 117]]], ["Electronic COVID-19 screening questionnaires, as well as other instructions that were needed before in-person visits, were created and implemented in Epic.", [["Electronic COVID", "TEST", 0, 16], ["screening questionnaires", "TEST", 20, 44]]], ["Additional automated text messages were created to send to patients.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["Hardware, such as wrist-band printers, was acquired, formatted, and installed at these locations.", [["Hardware", "TREATMENT", 0, 8], ["wrist", "ANATOMY", 18, 23]]], ["IT security and access team members provisioned over 2500 users to be able to schedule patients into the new departments.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["As always, training and analytics were involved to support the education for, and real-time analysis of, these new workflows.Building a New Ambulatory Orthopedic Triage CenterOur initial focus was to serve our community by doing what we do best, providing comprehensive musculoskeletal care.", [["comprehensive musculoskeletal care", "TREATMENT", 256, 290], ["New", "OBSERVATION_MODIFIER", 136, 139]]], ["We therefore converted the first floor of our hospital from a foot and ankle specialty ambulatory surgery unit to an \u201corthopedic triage center\u201d (OTC).", [["foot", "ANATOMY", 62, 66], ["foot", "ORGANISM_SUBDIVISION", 62, 66], ["ankle", "ORGANISM_SUBDIVISION", 71, 76], ["foot", "ANATOMY", 62, 66], ["ankle", "ANATOMY", 71, 76]]], ["The intent was to offload all emergent orthopedic care from the NewYork-Presbyterian (NYP) system to allow them to focus on the surge of COVID-19 patients.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154]]], ["This required a large \u201clift\u201d by IT to support this transition.", [["a large \u201clift\u201d", "TREATMENT", 14, 28], ["large", "OBSERVATION_MODIFIER", 16, 21]]], ["Modification of the physical space required changes in computer, monitor, and printer locations and device mapping within Epic.", [["the physical space", "PROBLEM", 16, 34], ["device mapping", "TREATMENT", 100, 114]]], ["Point-of-care glucose monitors, medication dispensing machines, and mobile workstations had to be configured.", [["glucose", "CHEMICAL", 14, 21], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["glucose monitors", "TREATMENT", 14, 30], ["medication dispensing machines", "TREATMENT", 32, 62], ["mobile workstations", "TREATMENT", 68, 87]]], ["Security and Epic access rights were provided to a large number of NYP residents and HSS nurses, who in their new role were considered outpatient nurses.", [["Epic access rights", "TREATMENT", 13, 31]]], ["Support was provided for their new roles through at-the-elbow support and a newly established local command center.Critical Care ::: Building a New HospitalCaring for critically ill patients requires an order of magnitude more complicated workflow and content than the orthopedic content in the HSS electronic medical record.", [["critically ill", "DISEASE", 167, 181], ["elbow", "ORGANISM_SUBDIVISION", 56, 61], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["elbow", "ANATOMY", 56, 61], ["New", "OBSERVATION_MODIFIER", 144, 147]]], ["New and complex order sets were developed to care for these patients.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["complex", "OBSERVATION_MODIFIER", 8, 15]]], ["These included ICU admission, tracheostomy, ventilation, and nursing items.", [["tracheostomy", "TREATMENT", 30, 42], ["ventilation", "TREATMENT", 44, 55], ["tracheostomy", "OBSERVATION", 30, 42]]], ["Prior to the COVID-19 crisis, this process would have taken many weeks.", [["the COVID", "TEST", 9, 18]]], ["In addition to content, these patients required new telemetry, ventilation, and tracheostomy workflows.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["new telemetry", "TEST", 48, 61], ["ventilation", "TREATMENT", 63, 74], ["tracheostomy workflows", "TREATMENT", 80, 102]]], ["Many order sets for the med-surg floors were built to accommodate patients we typically do not care for.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["med", "ANATOMY", 24, 27]]], ["These sets included general medical admission, pediatric admission, and infection isolations sets.", [["infection", "DISEASE", 72, 81], ["infection isolations sets", "PROBLEM", 72, 97]]], ["Medications not previously used at HSS but needed for the care of these patients were built into the system.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Medications", "TREATMENT", 0, 11]]], ["Isolation status and COVID-19 polymerase chain reaction (PCR) test result were added to the \u201cstoryboard\u201d (a banner visible in a patient\u2019s chart).", [["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["Isolation status", "TEST", 0, 16], ["COVID", "TEST", 21, 26], ["polymerase chain reaction", "TEST", 30, 55], ["PCR) test", "TEST", 57, 66]]], ["Discharge instructions for COVID-19 and hospice patients were created.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 27, 32], ["hospice", "TREATMENT", 40, 47]]], ["In addition, the ethics committee, spiritual care, do not resuscitate, and advanced directives required IT build.Staff and Patient Safety ::: Cross-Cutting FundamentalsPatient and staff safety are of the utmost importance, even more so in a pandemic.", [["Patient", "SPECIES", 123, 130], ["Patient", "SPECIES", 168, 175], ["spiritual care", "TREATMENT", 35, 49]]], ["Key to keeping patients and staff safe was the creation and implementation of several screening tools created to assess patients for COVID-19 before they enter the institution.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 120, 128], ["several screening tools", "TEST", 78, 101], ["COVID", "TEST", 133, 138]]], ["Thermal cameras were evaluated to monitor body temperature of those entering the building.", [["body", "ANATOMY", 42, 46], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["Thermal cameras", "TREATMENT", 0, 15]]], ["Patients were required to complete a screening questionnaire (built into Epic) to assess for symptoms and other risk factors of COVID-19.", [["COVID-19", "CHEMICAL", 128, 136], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a screening questionnaire", "TEST", 35, 60], ["symptoms", "PROBLEM", 93, 101], ["COVID", "TEST", 128, 133]]], ["But as the situation evolved, multiple versions of the questionnaire reflected new risk factors.", [["new risk factors", "PROBLEM", 79, 95]]], ["When PCR and antibody testing started to be performed on both patients and visitors, they were built into the lab system (with required regulatory verbiage, different for each manufacturer).", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["PCR", "TEST", 5, 8], ["antibody testing", "TEST", 13, 29], ["regulatory verbiage", "TREATMENT", 136, 155]]], ["Knowing a patient\u2019s isolation status is critical to safety.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17]]], ["New statuses indicating that COVID-19 test results were positive, negative, or pending were added and highlighted in the Epic chart, with additional alerts presented to clinicians in their workflow (clinical decision support).", [["COVID", "TEST", 29, 34]]], ["Previously done face-to-face, because of the need for social distancing, nursing devices (Rover) were configured to allow second signing at an appropriate distance.", [["nursing devices", "TREATMENT", 73, 88]]], ["Similarly, Vocera (an auditory communication device) was upgraded to allow hands-free communication for clinicians.", [["an auditory communication device", "TREATMENT", 19, 51]]], ["Over 100 iPads were deployed so that patient-family, patient-clinician, and clinician-clinician communication could occur without physical proximity.", [["patient", "ORGANISM", 37, 44], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 37, 44], ["patient", "SPECIES", 53, 60]]], ["Contact tracing, a key element used to contain pandemics [2], relies on both automated and manual processes.", [["Contact tracing", "TEST", 0, 15]]], ["IT is working intensively with operations to explore options and develop a contact tracing approach \u201cright-sized\u201d to HSS [9].Cybersecurity ::: Cross-Cutting FundamentalsCyberthreats have increased dramatically since the beginning of the pandemic [4].", [["a contact tracing approach", "TEST", 73, 99], ["Cross-Cutting FundamentalsCyberthreats", "TREATMENT", 143, 181], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["dramatically", "OBSERVATION_MODIFIER", 197, 209]]], ["At HSS, there has been a 25% increase in the number of attacks.", [["attacks", "PROBLEM", 55, 62], ["25%", "OBSERVATION_MODIFIER", 25, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["Every day, over 10,000 COVID-19-related phishing attacks occur.", [["phishing attacks", "PROBLEM", 40, 56]]], ["Furthermore, there has been a 70% worsening of \u201cphishing resilience\u201d (a metric we measure monthly, it is the ratio of those who report vs. those of who open and click links in phishing emails) among HSS staff members.", [["a 70% worsening of \u201cphishing resilience", "PROBLEM", 28, 67], ["worsening", "OBSERVATION_MODIFIER", 34, 43]]], ["These facts highlighted the need to increase our cybersecurity vigilance.", [["our cybersecurity vigilance", "TREATMENT", 45, 72]]], ["All new solutions, as well as all vendors, undergo security assessments.", [["All new solutions", "TREATMENT", 0, 17], ["security assessments", "TEST", 51, 71], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Nine such assessments have occurred since the beginning of the pandemic.", [["Nine such assessments", "TEST", 0, 21]]], ["In addition, increased end-user training regarding phishing attacks and the appropriate use of video streaming has been implemented.Analytics ::: Cross-Cutting FundamentalsData, its availability, presentation, and interpretation are crucial for baseline institutional function and even more important at times of crisis.", [["phishing attacks", "PROBLEM", 51, 67], ["video streaming", "TREATMENT", 95, 110], ["crisis", "PROBLEM", 313, 319], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["During the pandemic, the analytics team has produced large numbers of new dashboards, Epic reports, and items to support research.", [["large", "OBSERVATION_MODIFIER", 53, 58], ["numbers", "OBSERVATION_MODIFIER", 59, 66], ["new", "OBSERVATION_MODIFIER", 70, 73]]], ["The need for real-time vs. near-time automation was recognized and the IT analytics team quickly built this capability.Training ::: Cross-Cutting FundamentalsNew workflows such as WFH-remote access, live video streams, and new Epic configurations required augmented training.", [["augmented training", "TREATMENT", 256, 274], ["new", "OBSERVATION_MODIFIER", 223, 226]]], ["Additional in-person support was also provided.Service Desk ::: Cross-Cutting FundamentalsCalls in March and April to the service desk rose from approximately 10,000 for that period in 2019 to over 17,000 in 2020.", [["Additional in-person support", "TREATMENT", 0, 28]]], ["Without proper scripting and an increase in the number of agents available to answer calls, there could have been significant disruption to care.", [["agents", "TREATMENT", 58, 64], ["significant disruption to care", "PROBLEM", 114, 144], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["disruption", "OBSERVATION", 126, 136]]], ["The number of calls from patients regarding MyHSS (our online patient portal) more than doubled from 3170 (January and February) to 7431 (March and April).", [["patients", "ORGANISM", 25, 33], ["patient", "ORGANISM", 62, 69], ["patients", "SPECIES", 25, 33], ["patient", "SPECIES", 62, 69], ["portal", "ANATOMY", 70, 76]]], ["This was largely attributable to the need for assistance to access telemedicine visits via the portal.Lessons LearnedThe culture and spirit of our institution that has placed us in the forefront of musculoskeletal medicine for over a century and a half allowed us to succeed in responding to this crisis.", [["The culture", "TEST", 117, 128], ["this crisis", "PROBLEM", 292, 303], ["portal", "ANATOMY", 95, 101]]], ["IT teams quickly realized that their efforts would be critical to ensuring that our clinicians would be able to treat COVID-19 patients in a safe manner.", [["COVID", "DISEASE", 118, 123], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["COVID", "TREATMENT", 118, 123]]], ["While most staff members we able to work remotely, many IT staff came into the hospital during the worst of the crisis to implement various technology solutions previously mentioned.", [["various technology solutions", "TREATMENT", 132, 160]]], ["The entire HSS IT team was grateful to be able to contribute in a meaningful way during this time of crisis.Lessons LearnedAt the beginning of the crisis, HSS leadership established and clearly communicated the guiding principles of protecting our staff, protecting our patients, and protecting the community.", [["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["crisis", "PROBLEM", 101, 107]]], ["The result was focused decision-making and an acceptance by end users of technology solutions that were rapidly deployed and then improved as required (a \u201cminimum viable product\u201d).", [["technology solutions", "TREATMENT", 73, 93]]], ["We were able to implement technologies in a matter of hours and days, versus the weeks and months before COVID-19.", [["COVID", "TEST", 105, 110]]], ["HSS spent the last 8 years investing in a modern, scalable, and flexible technical and software infrastructure.", [["software infrastructure", "OBSERVATION", 87, 110]]], ["We also were extra-vigilant in cybersecurity monitoring since it was clear from the outset of the pandemic that cyber criminals would take advantage of personal and technical vulnerabilities that were created.Lessons LearnedThe acceptance and growth of telemedicine by both patients and clinicians was much higher than expected.", [["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 274, 282], ["cybersecurity monitoring", "TEST", 31, 55]]], ["Operationalizing TH was labor intensive and required a great deal of communication with patients to have them successfully join the visit.", [["TH", "GENE_OR_GENE_PRODUCT", 17, 19], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["labor", "PROBLEM", 24, 29]]], ["Critical success factors were having staff reach out to patients in advance of the visit to provide technical assistance and training the physician office staff so that they were familiar with the technology and able to troubleshoot.Lessons LearnedCommunication methods used by IT leadership including weekly all-hands Skype meetings, continued updates through the established weekly chief information officer blog, daily operational huddles, and leadership stand-ups all helped with the rapid dissemination of information and fostering a feeling of connectedness among remote and on-site staff.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Critical success factors", "PROBLEM", 0, 24]]], ["HSS immediately used the best practice of all COVID-19 communications coming from a single, recognizable email address that assured the validity of the content.Lessons LearnedIt is fair to say that the most important lesson learned was that in every crisis, lies opportunity.", [["all COVID", "TREATMENT", 42, 51]]], ["As the crisis unfolded, every segment of HSS played its role in supporting the following guiding principles and priorities:Lessons Learned", [["the crisis unfolded", "PROBLEM", 3, 22]]]]}